Characterisation of lipoproteins in staphylococcus aureus by Elgallali, A
1 
 
 
 
 
 
CHARACTERISATION OF LIPOPROTEINS IN 
STAPHYLOCOCCUS AUREUS 
 
 
ASHRAF ELGALLALI 
 
 
Centre for Parasitology and Disease Research, 
School of Environment and Life Sciences, 
University of Salford,  
Salford, UK 
 
 
 
Submitted In Partial Fulfilment of the Requirement of the Degree of 
Doctor of Philosophy, 2016 
I 
 
Table of Contents 
List of tables .................................................................................................................... III 
List of figures .................................................................................................................. VI 
Acknowledgements ...................................................................................................... VIII 
Declaration....................................................................................................................... IX 
List of abbreviations ......................................................................................................... X 
Abstract ......................................................................................................................... XIII 
Chapter one ............................................................................................................................ 1 
1. Introduction ................................................................................................................... 2 
1.1 Staphylococcus aureus ............................................................................................ 2 
1.2 Lipoproteins ........................................................................................................... 18 
1.3 S. aureus genome ................................................................................................... 26 
1.5 The Nematode Caenorhabditis elegans ................................................................ 37 
1.6 Whole transcriptome shotgun sequencing technology (RNA-Seq) ....................... 47 
2.7 Project aims and objectives ................................................................................... 51 
Chapter two ......................................................................................................................... 52 
2. Material and methods .................................................................................................. 53 
2.1 Bacterial strains and growth conditions................................................................. 53 
2.2 Oxacillin/cefoxitin disc diffusion test.................................................................... 53 
2.3 Proteomic analysis of S. aureus lipoproteins ........................................................ 54 
2.4 In-gel Trypsin digestion ........................................................................................ 56 
2.5 Protein identification by LC/MS/MS .................................................................... 57 
2.6 Bioinformatics of S. aureus genomic DNA........................................................... 60 
2.7 Isolation of RNA and assessment quality/concentration ....................................... 69 
2.8 Caenorhabditis elegans as a model of bacterial infection ..................................... 74 
2.9 Differential expression analysis for S. aureus 8325-4 lipoprotein genes with RNA 
sequencing ................................................................................................................... 80 
II 
 
Chapter three........................................................................................................................ 82 
3. Genetic analysis of Staphylococcus aureus lipoproteins ............................................. 83 
3.1 Introduction ........................................................................................................... 83 
3.2 Results ................................................................................................................... 85 
3.3 Discussion ............................................................................................................ 116 
Chapter four ....................................................................................................................... 120 
4. Proteomics identification of S. aureus lipoproteins under different growth conditions
 ....................................................................................................................................... 121 
4.1 Introduction ......................................................................................................... 121 
4.2 Results ................................................................................................................. 124 
4.3 Discussion ............................................................................................................ 133 
Chapter five ....................................................................................................................... 136 
5. Transcription of S. aureus lipoprotein genes studied using quantitative RT-PCR, RNA 
sequencing and during pathogenesis in C. elegans ....................................................... 137 
5.1 Introduction ......................................................................................................... 137 
5.2 Results ................................................................................................................. 139 
5.3 Discussion ............................................................................................................ 206 
Chapter six ......................................................................................................................... 215 
6. General summary and discussion .............................................................................. 216 
7. References ................................................................................................................. 221 
Appendices ........................................................................................................................ 254 
Appendix 1 .................................................................................................................... 255 
Appendix 2. ................................................................................................................... 280 
 
 
 
 
III 
 
List of tables 
Table 1. SDS-PAGE loading gel concentrations ................................................................. 55 
Table 2. Mixture of 20 μM stock solutions made up of 4 peptides of known sizes used as 
internal calibration ............................................................................................................... 58 
Table 3. S. aureus strains used in BLAST comparative analysis ........................................ 62 
Table 4. Oligonucleotide primers, base sequences, genes locations, and predicted sizes of 
PCR products for S. aureus lipoproteins ............................................................................. 63 
Table 5. Primers/probes, genes base sequences and predicted sizes of qPCR products for S. 
aureus lipoprotein genes ...................................................................................................... 73 
Table 6. Details of RNA samples from three independent experiment of treated and control 
cells ...................................................................................................................................... 77 
Table 7. List of 50 lipoprotein genes tested by PCR in three S. aureus strains (MRSA252, 
RN4282 and T1) .................................................................................................................. 90 
Table 8. Phylogenetic analysis of 44 lipoprotein genes for 20 S. aureus strains, calculated 
by DnaSP program .............................................................................................................. 91 
Table 9. Comparison of lipoprotein function in S. aureus MRSA252 and other S. aureus 
strains according to the UniProt database............................................................................ 94 
Table 10. An overview of genes encoding S. aureus lipoprotein and their regulating 
operons description, the promoter sequences and 4 binding sites were predicted using the 
BPROM web-based software (Solovyev and Salamov, 2011). Operons were predicted 
using Genome 2D (genome2D.molgenrig.nl) and Artemis 
(http://www.sanger.ac.uk/science/tools/artemis) (Rutherford et al., 2000). ....................... 99 
Table 11. Promoter sequences of S. aureus MRSA252 lipoproteins ................................ 102 
Table 12. List of S. aureus MRSA252 lipoproteins including details of their genes and 
lipoprotein signal peptides, the carboxy-terminal region (C-region or lipobox), the 
hydrophobic (H-) region and amino-terminal (N-) region. ............................................... 107 
Table 13. Zone diameter and MIC interpretive for S. aureus tested with 30 μg of cefoxitin
 ........................................................................................................................................... 115 
Table 14. List of identified lipoprotein of S. aureus MRSA252 in 1D SDS-PAGE 1D ... 126 
Table 15. List of identified lipoprotein of S. aureus MRSA252 in 2-DE ......................... 126 
Table 16. List of S. aureus MRSA252 lipoproteins identified in gel-free in-solution 
proteins digestion method and analysed by LC-MS/MS ................................................... 128 
Table 17. Comparison of the lipoprotein expression in S. aureus MRSA252 .................. 131 
IV 
 
Table 18. Expression fold level of 5 lipoprotein genes in 3 S. aureus strains examined by 
quantitative real-time PCR ................................................................................................ 140 
Table 19. Transcriptome comparison of lipoprotein genes in S. aureus 8325-4 at different 
phases of growth ................................................................................................................ 145 
Table 20. Comparison of S. aureus MRSA252 lipoprotein genes transcriptome in the C. 
elegans infection model at 16 and 40 h ............................................................................. 154 
Table 21. Major groups of up-regulated genes in S. aureus at 16 h of C. elegans infection 
model and their predicted function .................................................................................... 160 
Table 22. Top 100 up-regulated genes in S. aureus infection of C. elegans at 16 h 
comparing to 16 h control sample ..................................................................................... 160 
Table 23. Major groups of down-regulated genes in S. aureus at 16 h of C. elegans 
infection compared to non-infected control sample and their predicted function ............. 163 
Table 24. Top 100 down-regulated genes in S. aureus infection of C. elegans at 16 h 
comparing to to non-infected control sample .................................................................... 163 
Table 25. Major groups of up-regulated genes of S. aureus at 40 h of C. elegans infection 
comparing to non-infected control sample and their predicted function ........................... 166 
Table 26. List of the most up-regulated genes of S. aureus at 40 h after infection of C. 
elegans comparing to 16 h control sample ........................................................................ 166 
Table 27. Major groups of down-regulated genes in S. aureus at 40 h of C. elegans 
infection comparing to 16 h control sample model and their predicted function .............. 169 
Table 28. The most down-regulated genes in S. aureus at 40h of C. elegans infection 
comparing to 16 h control sample ..................................................................................... 169 
Table 29. Major groups of up-regulated genes in S. aureus at 40 h of C. elegans infection 
compared to 16 h of infection sample and their predicted function .................................. 172 
Table 30. Top 100 up-regulated genes in S. aureus infection of C. elegans at 40 h 
comparing to 16 h of infection sample .............................................................................. 172 
Table 31. Major groups of down-regulated genes in S. aureus at 40 h of C. elegans 
infection comparing to 16 h of infection sample and their predicted function.................. 175 
Table 32. Top 100 down-regulated genes in S. aureus infection of C. elegans at 40 h 
comparing to 16 h of infection sample .............................................................................. 175 
Table 33. Number of Differentially Expressed genes of S. aureus MRSA252 during the C. 
elegans infection model ..................................................................................................... 178 
Table 34. Number of Differentially Expressed genes of C. elegans ................................. 180 
V 
 
Table 35. Major groups of up-regulated genes in C. elegans at 16 h of infection model 
compared with the non-infected 16 h control sample their predicted function ................. 183 
Table 36. Top 100 C. elegans genes up-regulated after 16 h of infection compared with the 
non-infected 16 h control sample ...................................................................................... 183 
Table 37. Major groups of up-regulated genes in C. elegans at 40 h of infection model 
compared with the non-infected 16 h control sample and their predicted function .......... 186 
Table 38. Top 100 C. elegans genes up-regulated after 40 h of infection compared with the 
non-infected 16 h control sample ...................................................................................... 186 
Table 39. Major groups of up-regulated genes in C. elegans at 40 h of infection model 
comparing to 16 h of infection sample and their predicted function ................................. 189 
Table 40. Top 100 C. elegans genes up-regulated after 40 h of infection comparing with 16 
h of infected sample ........................................................................................................... 189 
Table 41. Major groups of down-regulated genes in C. elegans at 16 h of infection model 
comparing to 16 h control sample and their predicted function ........................................ 192 
Table 42. Top 100 C. elegans genes down-regulated after 16 h of infection compared with 
the non-infected 16 h control sample ................................................................................ 192 
Table 43. Major groups of down-regulated genes in C. elegans at 40 h of infection model 
comparing to 16 h control sample and their predicted function ........................................ 195 
Table 44. Top 100 C. elegans genes down-regulated after 40 h of infection compared with 
the non-infected 16 h control sample ................................................................................ 195 
Table 45. Major groups of down-regulated genes in C. elegans at 40 h of infection model 
comparing to 16 h of infection sample and their predicted function ................................. 198 
Table 46. Top 100 C. elegans genes down-regulated after 40 h of infection compared with 
the 16 h of infection samples ............................................................................................. 198 
Table 47. Top 100 up and down-regulated genes of C. elegans at different times during the 
infection model .................................................................................................................. 201 
 
 
 
 
 
 
 
VI 
 
List of figures  
Figure 1. S. aureus survival strategies during infection stages ........................................... 11 
Figure 2. (A) S. aureus cell surface and secreted proteins in a different bacterial growth 
phases. (B) Shows a cross section of the bacterial cell envelope ........................................ 14 
Figure 3. The structure of the lipid modification in lipoproteins ........................................ 18 
Figure 4. Tripartite structure of lipoprotein signal sequence............................................... 21 
Figure 5. Biosynthesis pathway of bacterial lipoprotein in Gram-positive (two-step) and (A 
to D) biosynthesis pathway of Gram-negative bacteria (three-step) ................................... 24 
Figure 6. Life cycle of C. elegans at 22°C .......................................................................... 39 
Figure 7. Workflows of in-gel and in-solution protein digestion procedures ..................... 59 
Figure 8. RT-PCR assay amplification efficiency of gene SAR0216 .................................. 72 
Figure 9. Schematic diagram illustrating an overview of C. elegans killing assay ............. 79 
Figure 10. A 1.5% agarose gel image showing PCR products of 6 lipoprotein genes 
fragments ............................................................................................................................. 87 
Figure 11. A 1.5% agarose gel image showing PCR products of 4 lipoprotein genes 
fragments ............................................................................................................................. 87 
Figure 12. The distribution and location of lipoprotein genes mapped on the reference 
circular genome of S. aureus MRSA252 and labeled according to their position of the 
strands. ................................................................................................................................. 98 
Figure 13. Amino acid numbers and position in lipobox of lipoproteins in 20 S. aureus 
strains ................................................................................................................................. 106 
Figure 14. Phylogenetic relationships of lipoprotein among 20 S. aureus strain .............. 114 
Figure 15. The growth curves of S. aureus MRSA252 at 37°C in Tryptone soya broth .. 130 
Figure 16. Comparisons of differential expression fold patterns of lipoprotein genes as 
determined by real-time quantitative PCR assay ............................................................... 142 
Figure 17. Comparisons of differential expression patterns of lipoprotein genes as 
determined by real-time quantitative PCR assay ............................................................... 143 
Figure 18. C. elegans survival in TS agar at 20°C with S. aureus MRSA252 .................. 147 
Figure 19. N2 Bristol wild-type (WT) C. elegans survival in NGM agar at 20°C with E. 
coli OP50 ........................................................................................................................... 148 
Figure 20. Images of C. elegans fed on S. aureus ............................................................. 149 
Figure 21. Images of healthy C. elegans fed on E. coli OP50 .......................................... 150 
Figure 22. Correlation heatmap matrix for RNA-seq samples .......................................... 153 
VII 
 
Figure 23. Correlation heatmap matrix for RNA-seq C. elegans samples ........................ 153 
Figure 24. Proportional Venn diagram summarizing common differentially expressed 
genes of S. aureus MRSA252 during the infection model of C. elegans .......................... 179 
Figure 25. Proportional Venn diagram summarizing common differentially expressed 
genes of C. elegans during the infection model ................................................................ 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VIII 
 
Acknowledgements 
I am extremely indebted to Allah for the good health and wellbeing that were necessary to 
complete this thesis.  
I would sincerely like to express my special appreciation and thanks to my supervisor, 
Prof. Howard Foster for his incredible endless support and his continuous willingness and 
assistance to finish my PhD, for his patience, motivation and enormous knowledge, 
without his guidance and encouragement this thesis would not be completed. 
Very special thanks to my family: my parents, brother and sisters for supporting me, 
without their motivation and encouragement I would not complete this thesis.  
I would especially like to thank my friends, I am extremely grateful and indebted to them 
for sharing expertise, and valuable guidance and encouragement extended to me. 
I would also thank all of my friends and colleagues in the lab for maintaining a good and 
nice work atmosphere. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IX 
 
Declaration 
No portion of this work referred to in this report has been submitted in support of an 
application for another degree or qualification of this or any other university or other 
institute of learning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
List of abbreviations  
aa   …………………….…. amino acid 
Agr ………………………. Accessory gene regulator  
CA-MRSA……….…….… Community-acquired methicillin-resistant S. aureus 
CHIP………………….…. Chemotaxis inhibitory protein 
CPM ……………………... Counts Per million Mapped reads 
DE ……………………….. Differentially Expressed 
DOLOP ………………….. Database of Bacterial Lipoproteins  
DNase ……………………. Deoxyribonuclease  
DTT ……………………… Dithiotreitol  
EAp…………………….… Extracellular Adherence protein 
E-value ……………………Expect value  
FC …………………………Fold Change 
FDR ……………………… False Discovery Rate 
FPKM ……………………. Fragments per Kilobase Transcript per Million mapped reads 
Fur ……………………….  Ferric uptake regulator  
GFP …………………….... Green fluorescent protein 
HA-MRSA…………….…. Hospital-acquired methicillin-resistant Staphylococcus aureus 
IM lipoproteins ……..……. Inner-Membrane lipoproteins 
IAA ………………………. Iodoacetamide  
ICU ….…………………… Intensive Care Units  
ISA ………………..………Iso-Sensitest agar  
Isd…………………....…… Iron-regulated surface determinant 
pro-IL-1β ………………….pro-Interleukin-1β  
LC …………………..……. Liquid Chromatography  
LGT..………….………….. Lateral Gene Transfer 
Lpp …………………...….. Lipoproteins  
XI 
 
LPXTG motif ………….. (Leu-Pro-any-Thr-Gly)  
Lsp ……………………... Lipoprotein signal peptidase  
MALP-2 ………………... Macrophage activating lipopeptide-2  
MRSA ……………...…... Methicillin-resistant Staphylococcus aureus  
MSCRAMM…….............. Microbial surface components recognizing adhesive matrix 
molecules 
NJ ………………...…….. Neighbor joining tree  
NOD………………..…… Nucleotide-binding oligomerization domain 
OM lipoproteins ……....... Outer Membrane lipoproteins 
ORFs ……………..…..… Open reading frames  
OTU …………..………... Operational taxonomic unit  
PAMP…………..……….. Pathogen-associated molecular pattern 
PBP……………………… Penicillin-binding protein 
PMNs cells….………..….. Poly morphonuclear leukocyte  
PRR……………………… Pattern recognition receptor 
PSM…………………..…. Phenol Soluble Modulin 
PV …………………..…... P-value 
PVL ………………..….…Panton-Valentin leucocidin 
RNase ……………….…...ribonuclease   
SAB …………………...… Staphylococcus aureus bacteraemia 
SBPs ……………………. Substrate Binding Proteins  
SCCmec ……………….... Staphylococcal chromosomal cassette mec 
SDS ….……….……...….. Sodium Dodecyl Sulfate  
SAR …………………...…Staphylococcal Accessory Regulator  
SNPs ………………......... Single-nucleotide polymorphism  
SP………………………...Signal peptide 
SOD………………....…… Superoxide dismutase 
XII 
 
srtA ……………………... surface protein sorting A  
Tat …………………..….. Twin arginine translocation pathway  
TCR……………….…..….T cell receptor 
TMED …..…….…….….. Tetramethylethylenediamine  
TLR….…..…………….…Toll-like receptor  
TSB….………...…….….. Tryptic Soy Broth  
TST ……………………... Toxic Shock Toxin-1 
VRSA ........................…... vancomycin resistant Staphylococcus aureus  
VISA ……………….…… vancomycin intermediate Staphylococcus aureus  
WT…………………….… Wild type 
2-DE ….…………………..Two-dimensional gel electrophoresis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XIII 
 
Abstract 
The Gram-positive bacterium Staphylococcus aureus is an extremely successful 
opportunistic bacterium capable of causing a wide range of hospital-acquired and 
community-acquired infections, and is becoming increasingly virulent and resistant to 
antibiotics. In order to investigate this pathogen, various methods have been used to 
analyse the pathogenic behaviour including genomics, transcriptomics and proteomics. S. 
aureus expresses approximately 55-70 lipoproteins with only about half with known 
functions. Little is known about the biochemical functions of many individual lipoproteins 
and their proteomics has not been investigated in detail. Lipoproteins have a broad ranging 
functionality and perform various roles in bacterial activity and attract a particular interest 
to investigate their virulence and survival influences in the course of host infection. The 
initial part of this study was to find out whether the lipoproteins of S. aureus have similar 
genetic characteristics among all strains. PCR and Quantitative Real-Time PCR 
experiments were performed to analyse the genetic and the expression levels for some 
lipoprotein genes. The majority of PCR results showed high similarity in lipoprotein 
genetic structure among the examined strains. Phylogenetic trees from concatenated 
lipoprotein genes alignment were generated to represent the lipoprotein genes distribution 
of S. aureus strains. To identify and characterise proteomic of S. aureus lipoproteins a 
comprehensive quantitative proteome profiling of S. aureus lipoproteins using gel-free /in-
solution trypsin digestion system followed by LC-MS/MS quantification identified 38 
lipoproteins that represent two-thirds of the S. aureus MRSA252 lipoprotein. In addition, 
S. aureus-mediated infections with live C. elegans were performed on solid assays to 
investigate the host-pathogen relationships. S. aureus MRSA252 exhibited a high level of 
nematocidal activity with average time for half of the worms to die of ~ 2 d and infected C. 
elegans showed visible signs of illness. To evaluate lipoprotein transcripts expression level 
and microbe/host-specific pathogenic factors RNA of both S. aureus and C. elegans were 
characterised after isolation from the infected C. elegans and subjected to RNA 
Sequencing, the large-scale data has provided useful information on pathogen and host 
activities during infection. RNA sequencing analysis showed different types of regulations 
and interactions of lipoprotein transcripts during host exposures to indicate 3 transcripts 
significantly were up-regulated and 11 down-regulated. RNA sequencing analysis showed 
that 62 lipoprotein transcripts were expressed during C. elegans infection model. 
Proteomic analysis using the application of gel-free proteomic technique identified 38 
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lipoproteins that were expressed in the non-infection condition representing approx. two-
thirds of the S. aureus MRSA252 lipoproteins. The results suggest that some lipoproteins 
were involved in pathogenesis of C. elegans but their function were not clear. More 
research is needed for explore the roles of lipoproteins in pathogenesis and the interactions 
of S. aureus with the host immune responses.
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Introduction and the aims of this thesis 
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1. Introduction  
1.1 Staphylococcus aureus 
1.1.1 General introduction 
Staphylococcus aureus has been recognized as one of the most common pathogenic Gram-
positive bacteria around the world with a serious prevalence of hospital- and community-
associated (CA) infections. It causes a range of infectious diseases such as sepsis, 
endocarditis and pneumonia. In addition, it can cause uncomplicated skin infections 
impetigo, also soft tissue infections, with or without abscess formation (Noguchi et al., 
2006). Furthermore, S. aureus can cause toxin-mediated diseases such as toxic shock 
syndrome, scalded skin syndrome and food poisoning (Dinges et al., 2000). S. aureus are 
pathogenic bacteria that have become a great public health concern in recent years due to 
their ability to produce an array of virulence factors and drug-resistant variants. Before the 
availability of antibiotics, S. aureus infections were most often non-fatal but after the 
discovery and use of penicillin the prognosis of staphylococcal infections significantly 
improved. The first reported isolation of methicillin-resistant staphylococcus aureus in 
1961 in the United Kingdom was shortly after methicillin introduced into clinical use 
(Barber, 1961). Since that time infections caused by methicillin resistant S. aureus 
(MRSA) have become causes of predominantly hospital-acquired and community-acquired 
infections with emergence of various antimicrobial resistances over the past years and 
causing high morbidity and mortality rates. Both epidemic potential strains EMRSA-15 
and EMRSA-16 emerged in the United Kingdom in the early 1990s and causing life 
threatening infections (Johnson et al., 2001). The ability of S. aureus to evolve new 
virulent strains and acquire resistance to a number of antibiotics including methicillin 
(methicillin-resistant Staphylococcus aureus; MRSA) has increased dramatically. 
However, these strains started to spread rapidly in the late 1980s to the mid-1990s, and 
have been known to be endemic in some hospitals and become more difficult to eradicate 
(Lindsay and Holden, 2004). MRSA prevalence in United Kingdom: <1% of patients 
living at home, 22% of care home residents and 40% of positive S. aureus blood cultures, 
82% of those with MRSA infection are ≥ 60 years (Health Protection Agency, 2009 ). The 
surveillance on the cases of methicillin-resistant S. aureus blood stream infections (BSIs) 
recorded in England between 2003 and 2013, the numbers of reported MRSA BSIs in 
2003-2004 was 7700 cases and such infections showed a notable decline after the 
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introduction of legislation and introduction of healthcare-associated improvement 
programmes in 2006 was significantly associated with the reduction of MRSA BSIs 
(Duerden et al., 2015). The MRSA BSI rates per 100, 000 population have slightly 
decreased from 1.8 to 1.7 to 1.4 and to 1.5 in 2012, 2013, 2014 and 2015, respectively 
(Health Protection Agency, 2015). S. aureus related infections include skin and soft tissue 
infections, pneumonia, infective endocarditis and bloodstream infections in United States 
are over half a million cases and more than 10,000 deaths per year (Klevens et al., 2007, 
Otto, 2010). Methicillin resistance in S. aureus is due to the acquisition of a mobile genetic 
element, their size ranging from 21/67 kb in size, termed the staphylococcal cassette 
chromosome mec (SCCmec) (Katayama et al., 2000).   
Glycopeptide antibiotics including vancomycin prevent maturation of bacterial cell wall by 
binding to the terminal D-alanyl-D-alanine residues of peptidoglycan precursors, 
consequently blocking the bacterial enzymes involved in the late steps of peptidoglycan 
synthesis (Anderson et al., 1965). Infections with MRSA strains are usually treated with 
vancomycin, but the first vancomycin intermediate-level resistant isolates (VISA) were 
discovered in 1997 (Hiramatsu et al., 1997). There are early reports of high-level 
vancomycin resistant isolates (VRSA) that have acquired the vanA resistance gene from 
vancomycin resistant enterococci (Control and Prevention, 1997, Hierholzer et al., 1995). 
Reports revealed that 40%-60% of all hospital S. aureus infections in Europe, United 
States and Japan were resistant to methicillin (Lindsay and Holden, 2006). Resistant 
MRSA strains express a special enzyme known as penicillin-binding protein 2a (PBP2a) 
which is not inactivated by β-lactams and keeps generating the cross-linked peptidoglycan 
in their presence (Ubukata et al., 1985). Platensimycin antibiotic has been shown to be 
effective against some strains of MRSA and VRSA (Wang et al., 2007). There are some 
limited effective antibiotics that cure MRSA infections and some are to be developed in 
the near future (Dryden, 2014).  
1.1.2 S. aureus microbiology and taxonomy 
S. aureus is a member of the family Micrococcaceae and on microscopic examination the 
organisms appear as Gram-positive spherical bacteria (cocci) non-motile and non-spore 
forming with a diameter of 0.5–1.5 μm, appearing in clusters on the Gram’s stain (Wesley 
and Bannerman, 1994). It is distinguished from other staphylococcal species with the gold 
pigmentation of their colonies when grown on solid media (β-haemolytic colonies), and 
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positive results of coagulase (Willis et al., 1966), mannitol-fermentation and 
deoxyribonuclease tests (Raymond and Traub, 1970). It is catalase positive (unlike 
streptococci), a facultative anaerobic organism. S. aureus is extremely heat sensitive and is 
inactivated at a temperature > 46ºC while their enterotoxins are heat-stable proteins which 
survive heat treatment and low pH conditions (Evenson et al., 1988). Both MRSA and 
methicillin-susceptible S. aureus have been found to survive for many weeks in a 
completely dry environment (Beard-Pegler et al., 1988). 
The S. aureus cell wall is a strong protective coat and relatively amorphous form, about 
20-50nm in thickness (Shockman and Barren, 1983), composed from repeating 
disaccharide N-acetylmuramic acid-(β1–4)-N-acetylglucosamine, cross-linking is via a 
pentglycine interpeptide bridge (Ghuysen and Strominger, 1963). The staphylococcal cell 
wall also contains secondary polymers (proteins, carbohydrates and teichoic acids) that are 
immobilised in the peptidoglycan scaffold (Navarre and Schneewind, 1999). 
Peptidoglycan is the major component of the cell wall and comprises up to 50% of the cell 
wall mass (Waldvogel, 1995). However, there is another essential component group of 
phosphate containing polymers known as teichoic acids. S. aureus has two types of 
teichoic acids, cell wall teichoic acid and cell membrane associated lipoteichoic acid, both 
of them make up about 40% of cell wall mass (Knox and Wicken, 1973), which give a 
negative charge to the bacterial cell surface and take part in the acquisition and localisation 
of metal ions especially in divalent cations and the activities of autolytic enzymes 
(Wilkinson, 1997). Over 90% of S. aureus clinical isolated strains have been shown to 
possess capsular polysaccharides; production of this capsule is reported to decrease 
phagocytosis in vitro and to increase S. aureus virulence in a mouse bacteraemia model 
(Thakker et al., 1998). S. aureus is typically an extracellular pathogen able to survival and 
persist in different host tissues (Brouillette et al., 2003), it is also capable of internalising 
within non-professional phagocytic cells such as epithelial and endothelial cells for a short 
time, this strategy helps the pathogen to evade host defence mechanisms and the action of 
antimicrobial agents that mainly act in the extracellular space (Sinha et al., 1999).  
1.1.3 Transmission of S. aureus 
About thirty percent of the human population are natural reservoirs for S. aureus by 
carrying the organism in their nose (in the anterior nares) (Wertheim et al., 2005), 58% on 
their throat (Nilsson and Ripa, 2006) and hand carriage was found in 24.9% (David et al., 
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2014), with asymptomatic colonisation being more frequent than infection. Throat 
colonization was more common than nasal colonization (Marshall and Spelman, 2007). 
Between 25% -50% of healthy persons may be persistently or transiently colonised, 
however, colonisation rate is higher amongst individuals who are immuno-compromised, 
for example diabetic patients, HIV-infected patients, patients who require haemodialysis 
and people with skin diseases (Sydnor and Perl, 2011). S. aureus also colonises and infects 
many mammals including domestic animals such as dogs and cats, some birds e.g. 
chickens and turkeys, and farm animals such as cows, pigs and goats (Baptiste et al., 
2005). Infection with S. aureus is a common cause of dairy cow mastitis with significant 
economic impact; moreover these animals may act as good reservoirs for human 
colonisation (McCarthy and Lindsay, 2010).  
The majority of S. aureus patients with symptomatic infections are invaded with their own 
colonising strains (Kluytmans et al., 1997). Infection might be also acquired from another 
person or from environmental exposure. S. aureus transmission in the community sector is 
associated with skin-to-skin contact and contaminated household environment (Desai et 
al., 2011), bacteria can survive for long periods on household fomites for up to 2 months 
(Baggett et al., 2004). Reports on MRSA environmental contamination have shown that 
5%-8% among households without CA-MRSA disease however in households with a CA-
MRSA-infected person or a healthcare labourer were 26%-32% (Scott et al., 2008, 
Uhlemann et al., 2011). Airborne spread and transmission through contacts with 
contaminated materials may also be involved (Cooper et al., 2004).  
Hospital transmission (patient to patient) is the most likely outcome from transient 
colonisation of the hands of hospital workers, who then transfer strains between patients. 
Spread of bacteria in aerosols from the respiratory or nasal discharges from heavily 
colonised individuals has been reported (David and Daum, 2010). S. aureus host switching 
is an important mechanism in the evolution of pathogenicity, for instance, transmission 
from bovine to human and from human to poultry host switches have been observed 
(Lowder et al., 2009, Sakwinska et al., 2011). The considered human commensal pathogen 
S. aureus has been isolated from numerous vertebrate species (Kloos, 1980). The main 
reservoir of S. aureus in the home is colonized or infected individuals and domestic 
animals (Bloomfield et al., 2007).  
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Hygiene and medical interventions in United Kingdom have led to a significant reduction 
in incidence of health care-associated methicillin resistant S. aureus MRSA related 
infections (Mandatory Surveillance MRSA). S. aureus MRSA shows attributes that are not 
always found in most clinically isolated bacteria, it has the ability to express a range of 
virulence factors and therefore is always considered medically relevant when encountered 
in clinical specimens. S. aureus is able to develop and expand resistance to a wide range of 
antimicrobial treatments and it is a major pathogen in both hospital and community 
infections (Styers et al., 2006).  
1.1.4 Epidemiology of S. aureus infections 
Development of new molecular typing approaches has allowed the study of population 
structure and epidemiology of bacterial pathogens, but these approaches are variable in 
practical for large population samples. The evolution of methicillin-resistant 
Staphylococcus aureus (MRSA) has changed the clinical and molecular epidemiology of 
S. aureus infections in the past three decades, these observations have showed the 
importance of epidemiological variations of S. aureus infections and the molecular 
characterisation of pathogenic resistant strains. Bacterial adaptability and the significant 
speed of bacterial evolution together with environmental challenges give this bacterium an 
ability to create genetic variation for their survival. Little information is available about the 
epidemiology of S. aureus in the non-western parts of the world; due to the increasing 
number of people traveling worldwide this epidemiology has changed.    
In general, numbers of both community-acquired and hospital-acquired staphylococcal 
infection has increased with increasing levels of antibiotic resistance and the emergence of 
epidemic strains (Chatterjee and Otto, 2013). S. aureus pathogenicity indicates that 
virulence is a multi-factorial process as single gene inactivation experiments could not 
prevent S. aureus pathogenic ability (Fedtke et al., 2004). The national data on 
hospitalizations and antibiotic resistance in S. aureus MRSA infections in the United 
States in 2010, the records show 4,476 MRSA colonized/infected patients in 67,412 
inpatients with prevalence rate is 66.4 per 1,000 inpatients, 25.3 infections and 41.1 
colonisations per 1,000 inpatients (Jarvis et al., 2012). Attempts to reduce the prevalence 
of MRSA in hospital have achieved some success, in the period between 2001 and 2007, 
MRSA central line-associated blood stream infections within ICU cases in US were 
decreased by almost 50% (Burton et al., 2009). Investigated study in hospitalized patients 
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between 2005 and 2008 confirmed a 34 % decreased of MRSA-related bloodstream 
infections incidence (Kallen et al., 2010). S. aureus bacteraemia (SAB) infection overall 
rates may have stabilized over the past two decades, with incidence of SAB vary from 10 
to 30 cases per 100,000 person per a year in industrialized community (Laupland et al., 
2013). A little is known about the incidence of SAB in the nonindustrialized, in contrast, 
incidence of community-acquired SAB between 2004 and 2010 in northeast Thailand was 
approx. 3 per 100,000 people-years (Kanoksil et al., 2013). The incidence of MRSA cases 
among 3,662 S. aureus isolated in four hospitals in Siberian Russia between 2007 and 
2011, prevalence of HA-MRSA was 22% while the CA-MRSA was 2.9% (Khokhlova et 
al., 2015). 
From a clinical point of view, new approaches to reduce the S. aureus infections include 
minimizing the duration of hospital stay, improved surveillance systems, use of antibiotic 
to eliminate nasal carriage before elective surgery and more strict hand hygiene regulations 
(Skov et al., 2012). English National Point Prevalence Survey on Healthcare-associated 
Infections and Antimicrobial Use indicated a sharp decrease of healthcare-associated 
MRSA bacteraemia from 1.8% of cases with MRSA bacteraemia in 2006 to 0.1% in 2011 
(Mandatory Surveillance MRSA). Over time, CA-MRSA epidemic became more 
complicated in various geographic locations and urgently need to improve the 
understanding of S. aureus epidemiology. Schaumburg et al. investigated the 
epidemiology of S. aureus isolates in the African continent in both rural communities and 
developed urban populations were found to contain the Panton-Valentine leukocidin gene 
that encodes the potent leukotoxin in 17% to 74% of isolates, the majority of these PVL-
positive strains were methicillin-susceptible, suggested that PVL epidemiology in Africa 
was different from that in Europe where the prevalence of S. aureus PVL-positive strains 
was <2% (Schaumburg et al., 2014). However, MRSA as a prevalent pathogen in Middle 
East region has MRSA prevalence for 45% of S. aureus nasal colonised patients, most of 
these isolates were related to sequence type (ST) 22 and PVL-negative (Tokajian, 2014). 
Disruption of MRSA strains in Asian countries are similar to those observed in Europe and 
north American countries, to accounts for >50% of S. aureus isolates in some countries 
(Chen and Huang, 2014). S. aureus epidemiology in Australian indigenous communities 
indicated considerable changes in CA-MRSA clones over the past twenty years with high 
emergence and spreading rate, this spread was accompanied by a considerable increase in 
the prevalence of staphylococcal infections from 2000 to 2011(Williamson et al., 2014).  
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Since S. aureus toxic shock syndrome (TSS) was first described by Todd et al. in 1978, 
TSS was linked with superabsorbent tampons in menstruating women (Herzer, 2001), with 
highest annual infection rate of 13.7 per 100,000 menstruating women (Osterholm and 
Forfang, 1982). Introduction of more hygienic advice to all susceptible women to use 
suitable tampons reduced the annual incidences of S. aureus TSS to 1 per 100,000 
menstruating women and 0.3 per nonmenstruating women (Hajjeh et al., 1999), after that, 
the incidence of S. aureus TSS has stayed stable with the annual incidences around 0.69 
per 100,000 menstruating women and 0.32 per 100,000 of total populations (DeVries et 
al., 2011). 
Vaccine candidates for S. aureus have been tested in clinical trials using both active and 
passive immunization modalities, but in attempts to develop a vaccine in future there are 
several issues should be considered, firstly, antigens used should be expressed by a 
majority of S. aureus strains, second, these antigens have been proved to stimulate the 
immune response of preclinical animal models of infection, finally, in passive 
immunization animal experiments the produced antibodies against these antigens must be 
protective (Kuklin et al., 2006). Four cell wall-anchored surface proteins of S. aureus as 
antigens in a murine model were assembled into a combined vaccine has given high levels 
of protection against invasive infections (Stranger-Jones et al., 2006). The majority of 
antibacterial subunit-based vaccines components have two categories, either a secreted 
toxins or abundantly expressed surface exposed molecules (Grandi, 2010). IsdA and IsdH 
S. aureus  surface proteins that are expressed during infection were used in cotton rat 
model of nasal colonisation, rats vaccinated with IsdA or IsdH developed protection 
against nasal carriage (Clarke et al., 2006).  
A number of excellent strategies to developing an effective S. aureus vaccine, including 
(1) a sensible fund needed to be invested in clinical trials. (2) A multiple mixed bacterial 
antigens will be preferable to become the main scientific approach for new vaccines. (3) 
Cell-mediated immune response biological function during infection should be evaluated 
in an appropriate patient population (Patti, 2011). An effective combined vaccine provided 
stable protection against S. aureus contains five conserved antigens known to have 
different roles in S. aureus pathogenesis including two lipoproteins, ferric hydroxamate 
binding lipoprotein FhuD2 and putative lipoprotein conserved staphylococcal antigen 1A 
(Csa1A) (Bagnoli et al., 2015). It is very important to detect new vaccines and to find out 
new strategies to treat S. aureus infections. 
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1.1.5 Pathogenesis of S. aureus 
Staphylococcus aureus is an adaptable microbe that can express a range of virulence 
factors, including adhesins, enzymes, toxins and capsular polysaccharides. These virulence 
factors are controlled by a set of staphylococcal regulatory networks, including eight main 
accessory gene regulators system (Bien et al., 2011).  
S. aureus is one of the pyogenic pathogenic bacteria with an ability to induce abscess in 
both local and metastatic infections. There are five stages in the pathogenesis of S. aureus 
infections; (1) colonisation, (2) local infection, (3) systemic dissemination and/or sepsis, 
(4) metastatic infection, and (5) toxinosis. Once the organism breach skin or mucous 
membranes and reach underlying host tissues, they can cause an illness in any part of the 
infected tissue, causing a range of diseases varying from minor skin infections to life- 
threatening systemic infections, such as endocarditis and haemolytic pneumonia. 
Adherence is the first step for bacterial colonisation of a new host, this process mediated 
by several adhesins. By expressing a range of surface bound proteins known as microbial 
surface components recognising adhesive matrix molecules (MSCRAMMs), these 
molecules recognize the most prominent components of the extracellular matrix and blood 
plasma including, collagen-binding protein, fibrinogen, fibronectin-binding proteins A and 
B, elastin binding protein, prothrombin binding protein and von Willebrand factor binding 
protein have been well characterised (Clarke and Foster, 2006, Foster and Höök, 1998). S. 
aureus has characteristic survival strategies during infection as shown in figure 1.  
S. aureus produces various toxins that are classified on the basis of their mechanisms of 
action; it has three well known types of toxin: (i) cytotoxins, with main functions to lyse 
host cells to provide nutrients required for bacterial growth, (ii) leukotoxins (Luk), (iii)  
pyrogenic-toxin superantigens and (v) exfoliative toxins (Fueyo et al., 2005). The 
pyrogenic-toxin superantigens are small sized proteins related and sharing some degrees of 
amino acid sequence homology, binding to major histocompatibility complex (MHC) class 
II proteins and produce an extensive T-cell proliferation and cytokine release (Marrack and 
Kappler, 1990). Different forms of enterotoxin molecule are responsible for the illness 
caused by these proteins such as toxic shock syndrome and food poisoning.  
Even with limited amino acid sequence homology, toxic shock syndrome toxin 1 structure 
is similar to enterotoxins B and C, while the gene for toxic shock syndrome toxin 1 was 
present in 20% of S. aureus isolates (Marrack and Kappler, 1990). S. aureus produces a 
10 
 
range of exoproteins such as exotoxins and enzymes, the main function of these 
exoproteins may be to convert host tissue cells into nutrients required for bacterial growth 
(Dinges et al., 2000). These cytolytic proteins form β-barrel pores in host cell plasma 
membrane and lyse the target cells cause leakage of cellular content (Foster, 2005). One of 
these important controversial virulence factor is PVL a cytotoxin bicomponent β-pore-
forming toxin which produced by 2–3% of clinical S. aureus isolate (Kuehnert et al., 
2006), this factor was universally found in all CA-MRSA clones (David and Daum, 2010), 
clinical data linked the bicomponent cytolysin PVL with necrotising skin infections and 
pneumonia (Gillet et al., 2002). Pathogenic strains differ in post-invasion strategies to give 
different disease signs, for example, the extremely pathogenic S. aureus strains 6850 and 
ST239 invade host cells and release different toxins and virulence factors regulated by agr 
global regulator system, while, other strains persist within intact cells without causing 
inﬂammatory affects and failed to express agr system virulence factors (Grundmeier et al., 
2010). Additional sets of exotoxins produced S. aureus which include the pyrogenic toxin 
superantigens (PTSAgs) toxic shock syndrome toxin-1 (TSST-1) and staphylococcal 
enterotoxins are able to stimulate proliferation of T-lymphocytes (Holtfreter and Broker, 
2005). In toxin-mediated staphylococcal disease, since bacterial toxin (in this case one of 
several enterotoxins) has been elaborated, food poisoning can occur even in the absence of 
viable bacteria, however, in staphylococcal toxic shock syndrome (TSS) if toxin is 
elaborated at colonised sites, for example, in the presence of a superabsorbent tampons, 
this is sufficient to produce this syndrome (in this case menstrual TSS). Staphylococcal 
Scalded Skin Toxin SSS causes a skin disease mainly affecting children and 
immunocompromised patients. SSS toxin consists of two serotypes, exfoliatin A and B, 
which have superantigenic activity and therefore induce selective polyclonal expansion of 
T-cells restricted to certain Vβs T-cell receptors (Ladhani, 2003). 
Infections with S. aureus occur often as a consequence of inoculation into an uncovered 
wound; however, in the upper respiratory tracts, viral infection damages mucosal layer and 
predisposes host to S. aureus pneumonia (McCullers, 2006). Early stages of S. aureus 
contact with host tissues without the mucosal layer or damaged skin triggers up-regulation 
of virulence genes (Novick, 2003). S. aureus main component peptidoglycan and 
lipoprotein are sensed by host pattern recognition molecules (Fournier and Philpott, 2005), 
also various endogenous Toll like receptor ligands released by necrotic tissues start to 
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trigger the pro-inflammatory signalling leading to different immune cell activation 
(Pisetsky, 2007). 
A recent murine infection model study to determine the surface proteome of USA300 
MRSA S. aureus found that the majority of in vivo expressed surface associated proteins 
were lipoproteins, which were part of ABC-type transport systems involved in nutrient 
acquisition especially metal ion uptake proteins (Diep et al., 2014a). 
 
 
 
 
Figure 1. S. aureus survival strategies during infection stages  
(adopted from Liu, 2004). 
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1.1.6 Detection of methicillin/oxacillin/cefoxitin resistance in S. aureus by using 
cefoxitin as test agent 
Molecular and non-molecular methods are currently available to detect the presence of 
MRSA in clinical samples, correct detection of MRSA strains is very importance to ensure 
effective treatment and to prevent further transmission, methicillin/oxacillin-resistant 
staphylococci are heterogeneous in their showing a resistance to β-lactam antibiotics, 
while experimental conditions play a major role as well on the expression of these genes 
and altering the detection of resistance. 
S. aureus susceptible and resistant strains produce four major penicillin-binding proteins 
(PBP 1, 2, 3 and 4) (Georgopapadakou and Liu, 1980), the fundamental cause of most 
methicillin resistance is production of an extra penicillin-binding protein PBP2a (PBP2') 
which determines the methicillin resistance strains (Hartman and Tomasz, 1984, Reynolds 
and Brown, 1985). PBP2a is a high molecular weight class B PBP (Ghuysen, 1994), 
PBP2a is located in the bacterial cell wall and has a low binding affinity for most of the 
semi-synthetic penicillins such as methicillin and oxacillin (Appelbaum, 2007), but the 
structural basis for this low affinity is not fully understood. PBPs proteins are mediated by 
the mecA gene, however, mecA homologous genes with 80% nucleotide similarity were 
found in Staphylococcus sciuri (Hanssen and Ericson Sollid, 2006), also homologous 
genes with 91% nucleotide similarity were detected in Staphylococcus vitulinus 
(Schnellmann et al., 2006). There are some other genes that may affect expression of 
methicillin resistance in S. aureus but these genes were detected in both susceptible and 
resistant strains (Labischinskia et al., 1998). Also some strains appear to have a low level 
of resistance with variations to existing of PBPs (Bignardi et al., 1996). Strains that 
produce extra penicillinase have shown low level of resistance in some conditions 
(Mcdougal and Thornsberry, 1986). Cross resistance between methicillin and other β-
lactam antibiotics was identified in MRSA strains (Chambers, 1997).   
Cefoxitin disk diffusion test has been used to predict the presence of mecA-mediated 
oxacillin resistance in S. aureus strains which encodes PBPs that related to oxacillin 
resistance of Coagulase-negative staphylococci CoNS (Chambers, 1997). Cefoxitin disk 
diffusion test results are easier to interpret and more sensitive for the detection of mecA-
mediated resistance strains than oxacillin disks (Pottumarthy et al., 2005, Witte et al., 
2007a). In 2007, the Clinical and Laboratory Standards Institute (CLSI) modified the 
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recommended resistance and susceptibility breakpoints for the 30 μg cefoxitin disk test to 
detect mecA-mediated resistance in S. aureus from ≤19 mm and ≥20 mm to ≤ 21 mm and ≥ 
22 mm, respectively (Broekema et al., 2009). The international guidelines for using 
oxacillin to deﬁne methicillin resistance strains as resistance ≥4 mg/L and susceptible ≤ 2 
mg/L (Howe and Andrews, 2012). 
1.1.7 Cell envelope proteins of staphylococcal and their functions 
Staphylococci have a number of unique apparatuses to immobilise proteins on their 
surface, either via covalently linked by their C-terminal to cell wall peptidoglycan or with 
non-covalent binding of proteins to either the peptidoglycan or secondary wall polymers 
e.g. teichoic acids (Navarre and Schneewind, 1999). These proteins play a role in bacterial 
pathogenicity by establishing successful colonisation, invasion of host tissue and surviving 
in the host environment including; adhesion, antiphagocytic influence, destruction of host 
cell surface components and hydrolysis of molecules for nutrient utilisation (Lee and 
Fischetti, 2006). Some of these proteins are shown in figure 2. Staphylococci have no pili 
or fimbrial structures and employ surface protein-mediated adhesion to host cells as a 
mechanism to escape from immune defenses also to survive within the infected host 
(Telford et al., 2006). Many cell wall proteins are also responsible to organise synthesis 
and maturation of bacterial peptidoglycan at particular sites during cell growth and 
division (Höltje, 1998). 
Surface proteins of staphylococci that are anchored in the cell wall surface consist of at 
least two topogenic sequences, i.e., an N-terminal signal peptide and C-terminal cell wall 
sorting signal (Abrahmsen et al., 1985). Sortases enzymes promote the covalent anchoring 
of surface proteins to the cell wall envelope, this enzyme catalyse transpeptidation reaction 
within the first cleaving surface protein substrate at the cell wall sorting signal, the 
outcome of this reaction a surface protein linked to peptidoglycan which combined into 
cell envelope and displayed on the bacterial surface (Schneewind et al., 1993). Generally, 
all bacterial proteins destined for translocation across the cytoplasmic membrane consist of 
an N-terminal signal recognition sequence, but through the translocation process signal 
peptides are removed proteolytically via signal peptidases then these proteins are either 
secreted into the extracellular matrix or attached to the cell wall (Dalbey et al., 1997). 
Covalently linked proteins to peptidoglycan layer possess a C-terminal sorting signal 
containing a conserved LPXTG sequence motif (Navarre and Schneewind, 1999). Because 
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of their extracellular localization another class of in-vivo expressed surface-associated 
proteins of S. aureus are lipoproteins (Diep et al., 2014a, Sutcliffe and Harrington, 2002). 
A new bioinformatics experimental tool can be used to predict bacterial proteins exposed 
on the surface of the organism that commonly involved in host-pathogen interaction to 
identify antibacterial targets for both therapy and vaccination (Giombini et al., 2010). 
 
 
 
Figure 2. (A) S. aureus cell surface and secreted proteins in a different bacterial 
growth phases. (B) Shows a cross section of the bacterial cell envelope 
(Lowy, 1998) 
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1.1.8 LPXTG motif (Leu-Pro-any-Thr-Gly) 
Cell wall associated surface proteins have many common structures to enable them to 
anchor to the cell wall peptidoglycan. These features consists an N-terminal signal peptide 
required for Sec pathway secretion and a conserved the C-terminal cell wall sorting signal 
that helps in attachment of a protein to the cell wall by sortase (SrtA) (Mazmanian et al., 
1999). One prevalent feature of peptidoglycan linked surface proteins is the presence of 
the LPXTG-motif at the C-terminal, during surface translocation. For example, protein A 
of S. aureus is produced as a precursor bearing an N-terminal signal peptide and a C-
terminal sorting signal with an invariant LPXTG motif, attached to a series of hydrophobic 
amino acids and a short tail of positively charged residues (Mazmanian et al., 2001). 
A specific transpeptidase enzyme srtA cleaves the peptide bond between the threonine and 
glycine residues of LPXTG motif, then covalently links them to the peptidoglycan via the 
carboxyl group of threonine, subsequently tethering the C-terminus of protein A to the 
bacterial peptidoglycan (Jonsson et al., 2002). Mutant S. aureus strains lacking srtA gene 
failed to anchor and display some surface proteins and showed less ability to cause  
infections (Mazmanian et al., 2000). S. aureus surface has been reported to display up to 
21 different LPXTG proteins (Roche et al., 2003). However, according to an online 
database on (http://www.uniprot.org), which provides the scientific community with a 
comprehensive high quality and freely accessible resource of protein sequence and 
functional information, S. aureus has about 32 LPXTG proteins after analyses of 14 
complete genome sequences, whereas only 21 genes encoding LPXTG proteins were 
originally identified (Roche et al., 2003). LPXTG include the surface proteins, Bap 
(biofilm associated protein) and Aap/SasG (S. epidermidis accumulation-associated 
protein/ S. aureus surface protein G), these proteins are mediators of staphylococcal 
biofilm development (O'Neill et al., 2008). S. aureus mutant strains, lacking the srtA gene, 
failed to anchor all surface proteins examined due to a defect in processing of sorting 
signals at the LPXTG motif (Mazmanian et al., 2000). Most of these polypeptides were 
found to react with human tissues, serum proteins and polypeptides of the extracellular 
matrix (Foster and Höök, 1998). 
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1.1.9 Host responses to S. aureus infection   
Different bacterial subcellular components have been reported to activate the host cells 
response, such as bacterial envelope elements e.g. lipoproteins, peptidoglycan, teichoic 
acids or secreted compounds such as enterotoxins or toxic shock syndrome toxin (Stoll et 
al., 2005). Invading bacteria replicate in infected tissues and induce proinflammatory 
responses with the release of cytokines and chemokines which are necessary for recruiting 
immune cells to the site of infection. Invasions of host immune cells occurs together with 
partial liquefaction and necrosis of tissue and production of peripheral fibrin walls to avoid 
microbial spread and preparation to eliminate the necrotic tissue (Jonsson et al., 1985).  
Detection of the invading pathogen is the first step of host immune system, the innate 
immune response is capable of recognising pathogens and provides a relative first line of 
defence. This recognition requires pattern recognition receptors (PRRs), including Toll-
like receptors (TLRs) and intracellular nucleotide-binding oligomerization domain 
receptors (NLRs) (Akira et al., 2006). S. aureus virulence is related to different bacterial 
surface components (e.g., polysaccharide capsule and protein A), as well as surface bound 
proteins for example, clumping factor and fibronectin binding proteins and also 
extracellular proteins (e.g. coagulase, hemolysins, enterotoxins, TSST-1, exfoliatins and 
Panton-Valentine leukocidin (PVL) (Archer, 1998). 
The ability of bacteria to cause disease is due to evasion of host defence; this includes 
resistance to antimicrobial peptides and killing by phagocytic cells (Levy, 1996). In the 
lungs, defences include mucociliary clearance of the respiratory system epithelium and 
increasing the production of antimicrobial peptides, surfactant proteins, chemokines and 
cytokines mediating immune cells which help to prevent colonisation by pathogens (Bals 
and Hiemstra, 2004). Host epithelial cells forms the initial line of defence against 
microbial pathogens via activation of various intracellular signalling pathways, S. aureus 
evokes an intense host response to trigger the poly morphonuclear leukocyte (PMNs) cells 
to the site of infection by chemotactic signaling pathways, these immense numbers of 
leukocytes are considered the primary cellular defence against S. aureus invasion and the 
subsequent infiltration of macrophages and fibroblasts (DeLeo et al., 2009). Bacterial 
Lipoproteins (Lpp) as a pathogen-associated molecular patterns (PAMP’s) are sensed by 
host immune cells by TLR2 (Toll-like receptor 2) together with TLR1 or TLR6, depending 
on this signals the innate immunity will induce and activate the necessary pathways to 
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control adaptive immunity (Iwasaki and Medzhitov, 2004). Eleven human TLRs and 13 
mouse TLRs have been identified so far, each TLR is able to identify pathogen associated 
molecular patterns derived from different microbes (Akira et al., 2006). Bacterial 
lipoprotein act as trigger molecules to activate the host innate immune responses via TLR2 
and subsequently TLR signals participate in direct regulation of adaptive immunity 
(Iwasaki and Medzhitov, 2010). Synthetic lipoprotein analogs such as Pam3Cys 
lipopeptides, Pam3CSK4 from Escherichia coli and dipalmitoyl MALP-2 from 
Mycoplasma fermentans have shown similar proinflammatory properties of bacterial 
lipoproteins (Takeuchi et al., 2000). Further experiments led to clear evidence in which 
triacylated lipopeptides recognise through TLR2/TLR1, while diacylated lipopeptides 
recognise through TLR2/TLR6 (Akira, 2003).  
Lipoproteins are the dominant immunobiologically active compound in S. aureus by their 
influence to induce cytokine release (Hashimoto et al., 2006b). An evidence shows that 
released lipoprotein were important for induction of pro-inflammatory cytokine 
interleukin-1β (IL-1β) and the activation of Nlrp3 inflammasome the member of 
intracellular nucleotide-binding oligomerization domain receptors (NLRs) and involved in 
immune defence against infection (Muñoz-Planillo et al., 2009). Impact of lipoprotein on 
the inflammation in vitro and immunocompetent cases in vivo was dependent on mature 
lipoprotein through releasing a strong cytokine and chemokine response by activating 
TLR2 (Schmaler et al., 2009). Meanwhile, lipoprotein deficient S. aureus RN4220 strain 
did not induce TLR2 activation (Kim et al., 2015). Lipoproteins were able to stimulate the 
activity of various immune cells types via TLR2 to release cytokines and chemokines 
products, such as monocytes and osteoclasts (Kang et al., 2011, Kim et al., 2013b). S. 
aureus deleted νSaα specific lipoprotein like cluster genes (lpl) showed that mutant 
bacterium was lacking in the stimulation of pro-inflammatory cytokines of host 
monocytes, macrophages and keratinocytes (Nguyen et al., 2015).  
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1.2 Lipoproteins 
1.2.1 Lipoprotein biosynthesis and localisation 
In general, cellular proteins can exist in different forms, either in soluble form in the 
cellular spaces (cytoplasm in both monoderm and diderm bacteria or periplasm in diderms 
only), or anchored to cell membranes (cytoplasm membrane in monoderms, inner- or outer 
membrane in diderms), some are anchored to cell wall (in monoderms), whereas, other 
proteins can be translocated into host cells or released into the extracellular spaces 
(Desvaux et al., 2009). The attachment of lipids to cellular proteins is an important post- 
translational modification occurring in both prokaryotes and eukaryotes. In 1969, some 
modifications were discovered in the major outer membrane protein of E. coli within the 
lipid N-acyl-S-diacylglyceryl cysteine at the N-terminal (Braun and Rehn, 1969). 
Afterwards, many related and unrelated bacterial proteins with the same lipid modification 
were discovered and are generally known as lipoproteins. The attached lipid to the outer 
membrane protein was later known as a diacylglyceryl group, this moiety attached by 
thioether linkage to the sulfhydryl group of N-terminal cysteine and the α-amino group of 
diacylglyceryl modified cysteine is fatty acylated as in figure 3 (Hantke and Braun, 1973). 
Another study in the Gram-positive bacterium  Acholeplasma laidlawii have established a 
major class of membrane lipoproteins which share type II signal peptide sequences with a 
conserved lipid-modified cysteine residue at the N-terminus to enable this protein to 
anchor onto the periplasmic leaflet of the plasma membrane or outer membrane in Gram-
negative bacteria (Dahl et al., 1985). Bioinformatic studies on the available bacterial 
genomes sequences indicated that lipoprotein genes constitute approximately 1–3% of 
their total genes (Babu et al., 2006). 
 
Figure 3. The structure of the lipid modification in lipoproteins 
The N-terminal cysteine modified with a diacylglyceryl group attached by a thioether 
linkage, the amino group is acylated with a fatty acid.  
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Bacterial cellular activities required a diverse class of membrane proteins that can work 
well in aqueous medium, whilst anchored to the hydrophobic membrane of the cell 
envelope. Bacteria have evolved several strategies for their various membrane proteins: 
e.g. (1) proteins with a hydrophobic surface, which along with other noncovalent and even 
ionic interactions, associate with the membrane; (2) transmembrane proteins carrying 
peptide segments in their helical or beta sheeted structure cross the membrane to provide 
anchorage and help the parts of the transmembrane segments perform the relevant roles; 
(3) some proteins have lipid modification with exo or endo fatty acids, as well as other 
lipid moieties, that provide a hydrophobic anchor either at one end or on the surface of 
such proteins (Babu et al., 2006). Bacterial lipoproteins have been classified according to 
their functional nature as antigens, adhesins, binding proteins, enzymes, transporters, 
toxin, structural proteins and hypothetical lipoproteins (Babu and Sankaran, 2002).  
Cell envelope lipoproteins of Gram-positive bacteria are anchored into the outer leaflet of 
the plasma membranes, a lipid modification takes place by covalent addition of a 
diacylglyceride to an indispensable cysteine residue located in the C-terminal region of a 
signal peptide as described for the prototypical Braun’s lipoprotein of E. coli (Braun and 
Wu, 1994). lipoprotein are effective within a subcellular part located between the inner 
aspect of plasma membrane and outer aspect of the peptidoglycan and other layers of the 
cell wall (Hutchings et al., 2009). In the absence of an outer membrane in Gram-positive 
bacteria, proteins must be attached to the plasma membrane to be retained within the cell 
envelope. For this reason, several lipoprotein have functions similar to the periplasmic or 
surface proteins of Gram-negative bacteria (Rahman et al., 2008).  
Consequently, it is suggested that at least some lipoproteins of Gram-positive bacteria are 
functionally similar to periplasmic proteins of Gram-negative bacteria, a comparison most 
directly sustained by the fact that, in Gram-positive bacteria, substrate binding proteins 
(SBPs) of ATP-binding cassette (ABC) transporters are classically lipoproteins (Sutcliffe 
and Russell, 1995). Functionally, many bacterial lipoprotein have a role in substrate 
binding action, which is a part of ABC transport systems (Tam and Saier, 1993), these 
proteins are also involved in sensing environmental signals (Sutcliffe and Russell, 1995), 
protein secretion and folding of exoproteins (Kontinen and Sarvas, 1993), adherence to 
various surfaces (Kolenbrander et al., 1998), invasion of host cells (Réglier-Poupet et al., 
2003), bacterial coaggregation (Kolenbrander, 1993), antibiotic resistance (Jousselin et al., 
2012), respiration (Bengtsson et al., 1999). A little is known about the biochemical 
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functions of individual lipoprotein but their proteomics has not been investigated as much 
in Gram-positive bacteria as they have in Gram-negative bacteria. Determination of the 
accurate lipidated structures of lipoprotein is crucial for elucidating the molecular basis of 
interactions between the host and microorganism. 
1.2.2 Lipobox of S. aureus lipoproteins and their modification  
Most bacterial proteins that are synthesised within the cell and transferred to extra 
cytoplasmic space or growth medium have an N-terminal signal peptide or signal 
sequence. Analysis of the signal sequences of several lipoproteins revealed common 
structural features that are recognised prior to lipid modification. The signal sequence is 
divided into three regions: secretory signal peptides structures contain a short positively 
charged N-region, a hydrophobic H-region that spans the membrane and a C-region has 
small and uncharged residues around the cleavage site which is recognised by the 
peptidase to cleave the peptide and produce a mature protein (Heijne, 1983). Signal 
peptides are mainly divided into secretory signal peptides that are cleaved by Signal 
Peptidase I and others cleaved by Signal Peptidase II, which is characteristic of the 
membrane-bound lipoproteins (Sankaran and Wu, 1995). Lipoproteins are initially 
translated as preprolipoproteins in both Gram-negative and Gram-positive bacteria, which 
have an N-terminal signal peptide, containing ~ 20 amino acids with distinctive 
characteristic elements of the signal peptides of secreted proteins (Inouye et al., 1977). The 
C-region of lipoprotein signal peptides contain a four-amino-acid motif called the lipobox 
(Sankaran and Wu, 1993). Proteins intended to be lipidated carry a conserved sequence at 
the C-region end of signal peptides with Cysteine (+1 position) to which the lipid-
modification linked is invariant and the (-3 position) mainly Leu, referred to as the 
lipobox, with consensus of lipobox amino acid sequence of [LVI] [ASTVI][GAS]C, this 
directs them to the lipoprotein biogenesis maturation. The N-region contains from 5 to 7 
residues with two positively charged Lys or Arg residues and the H-region length varies 
between 7 and 22 residues, with a modal value of 12 residues (figure 4). The C-region 
motif forms the molecular basis for many in silico algorithms that have been used to 
predict lipoprotein genes in bacterial genomes (Babu et al., 2006, Setubal et al., 2006). 
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Figure 4. Tripartite structure of lipoprotein signal sequence 
Modified from Babu et al. (2006). 
 
The sequence of the C-region of signal peptides (lipobox) with sequences [LVI] 
[ASTVI][GAS]C, is modified through the covalent attachment of a diacylglycerol moiety 
to the thiol group on the side chain of the essential cysteine residue, including a regular 
four amino-acid sequence at the C-terminal end of signal peptide sequence –Leu_3–
Ser/Ala_2–Ala/Gly_1–Cys_1 ending with the modifiable cysteine (Babu and Sankaran, 
2002). A statistical survey on amino acids of lipobox predicted lipoproteins from 234 
completely sequence of different bacterial genomes preceding the lipid-modifiable Cys (+1 
position) shows that these are well conserved, about 70% of the models showed that the -3 
position was Leu (71%), Val (9%) and Ile (6%). Also, occasionally Ala, Phe, Gly, Cys, or 
Met residues were found in the -3 position but with low frequencies (<5%). The -2 
position was more variable and could contain uncharged polar and nonpolar residues Ala 
(30%), Ser (28%), Thr (12%), Val (10%) and Ile (8%). Gly, Leu and Met were observed 
with low frequencies in this position, usually, the -1 position was occupied equally by Gly 
(45%) or Ala (39%); but Ser was found in 16% of all results (Babu et al., 2006). 
Predictions of lipoprotein in silico and structure information indicate that the amino acid 
following +1 cysteine lack any predicted or observed secondary structure (Zückert, 2014). 
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1.2.3 Post-translational lipid modification of lipoproteins 
Sec-associated YidC appears to assist preprolipoproteins pass the cytoplasmic membrane 
as unfolded proteins via the general secretory (Sec) pathway (Fröderberg et al., 2004), or 
with the help of a SecA1 and SecA2 (Feltcher et al., 2013), however, other secretion 
pathways are used to transport lipoprotein across the membrane in some high GC Gram-
positive bacteria via the twin-arginine translocation pathway (Sheldon and Heinrichs, 
2012). The biosynthetic pathway of bacterial lipoprotein involves three sequentially acting 
enzymes: preprolipoprotein diacylglyceryl transferase (Lgt), prolipoprotein signal 
peptidase (Lsp) and apolipoprotein N-acyltransferase (Lnt). The first step of biosynthetic 
pathway involves the lipoprotein diacylglyceryl transferase (Lgt), which attaches the 
diacylglyceryl group from phosphatidylglycerol to the thiol of Cys, (first amino acid after 
the signal peptide) via a thioether linkage resulting in a prolipoprotein. The second enzyme 
Lsp (lipoprotein signal peptidase), recognises the diacylglyceryl modification and cleaves 
between the amino acid at position -1 and the lipid-modified cysteine residue, and leaves 
cysteine of the lipobox shown as new amino-terminal residue (Tokunaga et al., 1982). 
Lipoproteins from Gram-negative bacteria are further modified by lipoprotein N 
acyltransferase (Lnt) which adds an N-acyl group to the diacylglyceryl cysteine and 
produces a mature triacylated lipoprotein triacylated lipoprotein (Sankaran and Wu, 1994). 
These enzymes are important in lipoprotein biosynthesis in Gram-negative bacteria, but, in 
Gram-positive bacteria Lgt and Lsp have been found to be essential in some of the high 
GC-content species tested, but not in low GC-content species such as S. aureus (Nakayama 
et al., 2012). Bacterial lipoproteins are structurally split into two types; diacylated 
lipoproteins and triacylated lipoproteins, this classification depends on the absence or 
presence of particular enzymes involved in lipoprotein maturation as shown in figure 5.  
N-acylation modification in Escherichia coli is essential for sorting lipoproteins from the 
inner membrane to the outer membrane by localization of lipoprotein via (Lol) system 
(Tanaka et al., 2001). E. coli type Lnt enzyme is conserved in most Gram-negatives and in 
high GC-content Gram-positive bacteria, has been shown to contain triacyl lipoproteins 
(Thompson et al., 2010). Lnt homolog was not found in the genome of some S. aureus 
strains suggesting that lipoproteins are diacylated (Stoll et al., 2005). However, Kurokawa 
et al. reported a purified triacylated 33kDa lipoprotein S. aureus was able to stimulate 
TLR2 and was confirmed as a triacylated SitC lipoprotein (Kurokawa et al., 2009). In 
addition, genomic analysis has revealed that some members of high-GC-content Gram-
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positive bacteria (actinomycetes) contain homologues of Lnt the ﬁnal enzyme involved in 
the maturation of a lipoprotein (Vidal-Ingigliardi et al., 2007). Triacylated lipoproteins 
were detected in low-GC Gram-positive S. aureus (Asanuma et al., 2011, Kurokawa et al., 
2009). Also, putative Lnt genes were identified in Gram-positive mycobacteria (Tschumi 
et al., 2009). Recent biochemical evidence that N-acylation-free diacyl lipoprotein 
accumulated when bacteria were grown in acidic or high salt concentration media 
(Kurokawa. et al., 2012), all these results suggest that bacterial lipoprotein biosynthesis is 
changeable in response to growth conditions and variable between bacterial strains. 
Both Lgt and Lsp enzymes are extensively conserved in eubacteria, but Lnt has not been 
confirmed in all low G-C content Gram-positive bacteria (Asanuma et al., 2011, Stoll et 
al., 2005). Consequently, whether lipoproteins of S. aureus are di- or triacylated is still not 
confirmed. Lipoprotein in low GC-content bacteria such as Firmicutes and Tenericutes had 
been considered as diacylated with the absence of E. coli Lnt gene in their genome 
(Kovacs-Simon et al., 2011, Tschumi et al., 2009, Zückert, 2014), and lipoprotein in 
Tenericutes was shown to have diacyl form (Shibata et al., 2000), also contained the N-
acylated triacyl form (Serebryakova et al., 2011). MS/MS analysis on lipoprotein 
structures of two related low G-C Gram-positive bacteria M. genitalium and M. 
pneumoniae were found in N-acylated triacyl form (Kurokawa et al., 2012), these uneven 
results predict that unidentified Lnt similar enzyme are involved in the biosynthetic 
pathways of the N-acylated triacyl and N-acetyl lipoprotein forms. 
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Figure 5. Biosynthesis pathway of bacterial lipoprotein in Gram-positive (two-step) 
and (A to D) biosynthesis pathway of Gram-negative bacteria (three-step)  
(A) The precursor of lipoprotein is preprolipoprotein translocated by the Sec or Tat 
machinery into the outer leaflet of the plasma membrane, (B) thiol group of invariant 
cysteine in lipobox is modified by a diacylglyceryl moiety by Lpp Lgt transfers a 
diacylglyceryl, generating a thioether linkage. (C) Lsp cleaves the signal peptide at N-
terminus leaving the cysteine as new amino-terminal residue forming the mature 
lipoprotein in Gram-positive. (D) In Gram-negative and some Gram-positive bacteria Lnt 
enzyme, transfers an acyl group from another phospholipid to the newly-generated a-
amino group of the S-diacylglyceryl cysteine of the apolipoprotein, to form mature 
triacylated lipoprotein. Modified from Kovacs-Simon et al., 2011. 
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Preprolipoproteins are transported across the cytoplasmic membrane by one of two 
different pathways. Firstly; the general secretory pathway (Sec), which is the predominant 
route of protein transport for those proteins carrying a secretory signal peptide by the 
action of Sec translocase which recognises proteins bearing N-terminal signal peptides and 
transfers them across the membrane in an unfolded conformation (Driessen and Nouwen, 
2008). The Sec pathway exports unfolded proteins using the energy generated by ATP 
hydrolysis (Natale et al., 2008). The majority of preprolipoproteins in Gram-negative 
Escherichia coli are exported by Sec machinery (Sugai and Wu, 1992), Sec was shown to 
influence the Lsp mediated mechanism of lipid modified prolipoprotein that are formed by 
Lgt (Kosic et al., 1993). 
Secondly; via the twin arginine protein translocase pathway (Tat), this recognises signal 
peptides that carry a distinctive form of two consecutive Arginines (R-R) in the N-region 
(Lee et al., 2006). Tat translocase exports folded proteins possessing a twin-arginine motif 
and is reliant on the proton motive force (Natale et al., 2008). Translocation of lipoproteins 
by the (Tat) system in the high-GC Gram-positive bacteria Actinomycetes has been 
demonstrated (Kovacs-Simon et al., 2011). Also further modification has been reported on 
lipoprotein for attachment to the cell wall or anchoring in the cytoplasmic membrane 
(Schmaler et al., 2010). Bioinformatic analysis study in high-GC-content Gram-positive 
Streptomyces species has indicated that a significant fraction of preprolipoproteins were 
exported via Tat with up to 20% of putative lipoprotein (Zückert, 2014). Meanwhile no 
information are available on Tat dependent lipoproteins in the low-GC-content Gram 
positive bacteria, even some Firmicutes genomes shown lack of Tat pathway (Dilks et al., 
2003), it has not been proved that lipoproteins can be transported via the Tat pathway, 
therefore mature lipoproteins in the membrane appear to be exported via the Sec pathway.  
1.2.4 Roles of lipoproteins in bacterial pathogenesis 
The significance of lipoproteins from the point of their roles in bacterial pathogenesis is of 
interest, as these lipid-modified proteins play a variety of roles in host-pathogen 
interactions. S. aureus Lgt mutant strains were measured for production of 
proinflammatory cytokines and found to produce lower levels of TNF-α and IL-6 than 
wild-type strains (Wardenburg et al., 2006). In the same manner, Lsp mutant strains of 
Listeria monocytogenes were found to be ineffective in phagosomal escape of bacteria 
during invasion (Réglier-Poupet et al., 2003). The antibiotic globomycin acts as a specific 
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inhibitor to SPase II; bacteria were treated with globomycin and SPase II deficient mutant 
strains showed accumulation of lipid-modified prolipoproteins (Hayashi and Wu, 1990). 
Also, lipoproteins released from gram-negative Enterobacteriaceae played a role in 
activating the inflammatory response and avoiding the host defence by inducing cytokine 
production in the macrophage (Zhang et al., 1998). Moreover, a 19 kDa lipoprotein of 
Mycobacteria that elicits antibody and T cell responses in humans and mice, induced 
innate immune response in dendritic cells and neutrophils (Neufert et al., 2001). Modified 
antigens of lipoproteins are good candidates in vaccine development, for instance, 
lipoprotein 20 is an outer membrane lipoprotein that is an excellent vaccine candidate 
antigen against Helicobacter pylori (Keenan et al., 2000), while the vaccine of Lyme 
disease was generated from OspA and DbpA lipoproteins of the spirochete Borrelia 
burgdorferi, which was found to be effective in several animal models (Chang et al., 1995, 
Hanson et al., 1998). Expression of PPIase PrsA lipoprotein in S. aureus affects both 
glycopeptide and oxacillin resistance in MSSA and MRSA strains (Jousselin et al., 2012). 
Five lipoproteins were involved in nutrient acquisition in murine identified model (Diep et 
al., 2014a). Lipoprotein FhuD2 immunisations has shown protective immunity against S. 
aureus in murine infection model and proved as an effective vaccine candidate (Mishra et 
al., 2012). Mariotti, et al. confirmed the efficiency of apo-FhuD2 as a protective antigen, 
vaccination with FhuD2 or FhuD2 formulated with hydroxamate siderophores were 
protective in a murine S. aureus infection model (Mariotti et al., 2013). 
1.3 S. aureus genome  
Staphylococcal genomes are approximately 2.8 Mbp in size with relatively low G-C 
content. S. aureus genome sequencing was an essential step for future development against 
this pathogen. The ﬁrst sequenced S. aureus strains N315 and Mu50 (Kuroda et al., 2001) 
were determined by shot gun random sequencing and this has been followed by many 
other additional strains (Bartels et al., 2014, Nair et al., 2011, Schijffelen et al., 2013). 
Identification of genes associated with pathogenic strains would help in investigation of S. 
aureus variation, evolution, pathogenicity and epidemiology. Hence, to understand the 
roles of ecological and genetic features, especially host-pathogen molecular interactions, 
involved in host-to-host transmission and colonisation, it is important to expose new 
strategies to control the pathogen. A very complicated regulatory network is responsible 
for many differential gene expressions. S. aureus carry genes encoding toxins, cell surface 
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proteins and antimicrobial resistance that may increase its virulence and give resistance to 
all antibiotics families; expression of all these genes is regulated by specific and very 
sensitive mechanisms (Fitzgerald et al., 2001). Different methods such as: (i) multilocus 
enzyme electrophoresis (MLEE); (ii) random amplified polymorphic DNA polymerase 
chain reaction (RAPD-PCR); (iii) restriction fragment length polymorphism (RFLP); (iv) 
pulsed-field gel electrophoresis (PFGE); (v) staphylococcal protein A (spa) typing ;and 
(vi) multi-locus sequence typing (MLST) have been used to investigate the molecular 
epidemiology of staphylococci (Ben Nejma et al., 2014, Qu et al., 2014).  
The completed genome sequences of numerous strains of S. aureus suggested that there 
was: (i) a high degree of nucleotide sequence similarity among the different strains; (ii) 
acquisition of genetic information by horizontal transfer between bacterial species had 
occurred and (iii) there was a unique number of pathogenicity or genomic islands and 
mobile genetic elements that contain clusters of enterotoxin and exotoxin genes or 
antimicrobial resistance determinants (Baba et al., 2008). The first microarray comparative 
genomics studies to characterise S. aureus genomic diversity and virulence gene 
distribution among 36 strains covered 92% of genes in S. aureus COL genome, identified 
that 22% of S. aureus compared genomes was variable (Fitzgerald et al., 2001).  
Whole genome comparative analytical study of 12 S. aureus strains revealed unique 
features, among all of the sequenced strains 32.8 to 33% G-C contents did not vary 
significantly, with chromosome lengths range from 2.74 to 2.91 Mbp, genomic islands 
found included prophages (range of 1 to 4) and pathogenicity islands (PI) were found in 
different numbers (Baba et al., 2008). Genome comparative studies on S. aureus revealed 
that the genome was composed of a complex combination of genes, many of them have 
been acquired by lateral genetic transfer (LGT) determine virulence important properties 
and antimicrobial resistance, but insufficient information is known about transfer 
mechanisms (Hiramatsu et al., 2004). The common and unique genomic island νSaα in S. 
aureus encode tandem paralog referred to as lipoproteins cluster (lipoprotein-like [lpl]) 
comprises 10 lipoprotein genes with a lipo-box containing signal sequence (Babu et al., 
2006). The νSaα mobile genetic elements suggested to be acquired independently through 
intra-species genetic transfer between S. aureus strains (Baba et al., 2008). 
Lindsay et al.(2006) used multi-strains whole genome microarrays to compare 61 
community-acquired invasive isolates of S. aureus and 100 carriage isolates from healthy 
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individuals, 10 human lineages were found to dominate and some minor lineages, each 
lineage possessed a unique combination of surface proteins and regulators called core-
variable (CV) genes, which match to the clonal complexes (CCs) specified by MLST 
typing, this lineage has not evolved independently, but as a consequence of multiple 
recombinations of CV genes between them, also, all strains hold a range of mobile genetic 
elements (MGE) and make up approximately 15% to 20% of the genome and include 
bacteriophages, integrated plasmids, pathogenicity islands, staphylococcal cassette 
chromosomes (SCC), genomic islands and transposons (Lindsay et al., 2006). All of these 
emerge to play a role as putative virulence genes and resistance, but variations within 
lineages indicate regular horizontal transfer (Witney et al., 2005). A few extant clones are 
linked with the majority of infections and some of lineages are non-randomly related with 
distinct human and animal infections, whether a limited number of lineages are responsible 
for a large part of S. aureus infections implies that interclone variance in relative virulence 
is large and raises the possibility that difference in genome content can lead to significant 
roles in pathogenicity (Fitzgerald et al., 2001). 
A total of 56 UK isolates of animal associated S. aureus and 161 human S. aureus isolates 
from healthy individuals and community acquired infections in UK, determine that animal-
associated S. aureus group was related to ten lineages, with approximately 60% of them 
assigned to only four lineages, most mastitis cases were caused by bovine strains, however 
a few human lineages caused mastitis, nearly 54% of horse-associated S. aureus isolates 
belonged to human associated lineages clusters (Sung et al., 2008).  
S. aureus has many well characterised global regulators of virulence determinant 
production; such as accessory gene regulator agr (Peng et al., 1988), staphylococcal 
accessory regulator sarA (Cheung and Projan, 1994), sae (Giraudo et al., 1994), sigB 
(Bischoff et al., 2001), arl (Fournier and Hooper, 2000), and some Sar proteins repress one 
or more of sarA homologues genes (Arvidson and Tegmark, 2001), each of these 
regulators are parts of an important network involved in control and expression of 
virulence factors including surface proteins expression, exoproteins and many other 
proteins essential for bacterial activity (Harris et al., 2002). One virulence gene can be 
under the control of many regulators to ensure that the speciﬁc gene is expressed under 
favourable conditions. For example, agr regulator negatively regulates the expression of 
spa, encoding protein A (Projan and Novick, 1997), although SarS activates its expression 
via binding to spa promoter (Tegmark et al., 2000). In the same time, agr down-regulates 
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sarS expression level (Cheung et al., 2001). This indication suggests that agr down-
regulates spa expression when down-regulating expression of sarS activator (Tegmark et 
al., 2000). Virulence gene regulators can affect the expression of target genes directly or 
indirectly.  
Between 45 and 66 genes encoding S. aureus lipoproteins were predicted out of almost 
2,500 open reading frames of S. aureus genome (Babu et al., 2006, Sibbald et al., 2006), 
but most of the lipoprotein remained as predicted lipoprotein or with unknown functions 
(Schmaler et al., 2010). One of the problems in determining gene functions in 
pathogenesis is that inactivation of limited genes does not completely remove the S. aureus 
pathogenicity, suggesting that virulence is a multi-factorial process (Said-Salim et al., 
2003).   
1.3.1 Staphylococcus aureus global regulation genes 
Virulence genes expression in general tends to be influenced by a different factors 
including, the concentration of autoinducing peptides and by bacterial density, pH and 
CO2, and each of these signals controls diﬀerent regulatory systems. The ability of S. 
aureus to produce a number of virulence factors including those related to life threatening 
infections, antibiotic resistance and survival in distinct adverse environments and antibiotic 
resistance genes is controlled either by two component systems (e.g., agr, saeRS, srrAB, 
arlRS, lytSR) and/or by transcriptional regulators (e.g., sarA, sigB, sar family genes, 
tcaRA) (Ballal et al., 2009, Gordon et al., 2013). 
1.3.2 Agr (accessory gene regulator) 
A huge effort has been directed toward identifying genes and regulatory mechanisms 
associated with S. aureus virulence factors as previously explained in section 1.1.5.  
Expression of virulence genes is highly coordinated and is generally controlled by global 
regulatory elements (Chien et al., 1999). The dual action of agr global regulator, which 
acts during the post-exponential phase, has been shown to inhibit the transcription of some 
cell wall-associated proteins e.g. coagulase, protein A and ﬁbronectin binding protein 
(Tseng et al., 2004). In contrast, agr activates many exoproteins such as beta-hemolysin, 
alpha-toxin, TSST-1 and leucotoxins (Dinges et al., 2000). Agr mutation identiﬁed 104 
genes including 20 putative virulence genes that were up-regulated and 34 genes were 
down-regulated by agr, in the same experiments a sarA mutation altered expression of 
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~120 genes, to show 76 genes up-regulated and 44 were down-regulated (Dunman et al., 
2001). The eﬀector of agr at the transcriptional and translational levels is a RNA molecule, 
RNAIII-agr intergenic region, which modulates virulence factor expression (Novick et al., 
1993).  
The agr locus consists of 5 genes, agrA, agrC, agrD, agrB and hld, however its consist of 
two divergent transcripts RNAII and RNAIII with sizes of 3 kb and 0.8 kb, respectively, 
which are under the control of two main promoters P2 and P3 (Peng et al., 1988). RNAII 
transcript driven by P2 promoter and encodes four gene operons, agrBDCA, RNAIII 
effective molecule is responsible for up-regulation of extracellular protein synthesis and 
down-regulation of cell wall associated protein production during post exponential phase 
(Chien et al., 1999). 
The consistent regulation of extracellular and cell wall virulence factors during growth has 
hinted at the contribution of global regulatory system in S. aureus, e.g. in the exponential 
phase, cell-wall adhesive functions proteins are actively synthesized to correspond with the 
tissue binding and colonization stage of infection, these proteins known as MSCRAMMs 
(microbial surface components recognizing adhesive matrix molecules), while post-
exponential phase, the expression of cell wall proteins is decreased and the synthesis of 
extracellular toxins and enzymes is increased (Cheung et al., 2004). Both agr and sarA 
global regulators have been shown to co-ordinately regulate the transition from 
exponential to post exponential bacterial protein expression (Novick, 2003). 
Some virulence gene can be under the influence of several regulators or regulatory 
systems, which influence each other to ensure expression of the target gene within 
appropriate conditions. Expression of these factors is controlled by multiple regulatory 
systems such as the accessory gene regulator (agr) and staphylococcal accessory regulator 
(sarA) loci, S. aureus accessory regulatory protein (SarA) influencing both exoprotein and 
cell surface protein expression (Cheung et al., 1992).  
1.3.3 Sar protein family structure 
Sar locus encoded within a 1.2-kb DNA fragment, encompasses three overlapping 
transcripts (sarA, sarB and sarC) each of which terminates at the same site and encodes for 
the SarA protein, these transcripts, designated sarA (0.58 kb), sarB (0.8 kb) and sarC (1.2 
kb), have similar 3’ ends but within three distinct promoters (Manna et al., 1998). SarA 
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has been shown to promote production of many extracellular and cell wall-associated 
proteins, while inhibiting the transcription of protein A and protease genes, also it is 
required for full agr expression in S. aureus (Cheung et al., 1997). SarA in S. aureus is 
constitutively produced during cell growth phase, meanwhile expression of each Sar 
transcript occurs in a growth phase dependent manner; the highest expression level of sarA 
and sarB are mainly transcribed during the log phase, in contrast, sarC is predominantly 
expressed during stationary phase of growth (Bayer et al., 1996). SarA protein regulate 
some target genes by directly binding to gene promoters or indirectly by downstream 
effects on regulons e.g. binding to agr promoter or by stabilising mRNA during 
exponential phase (Roberts et al., 2006) . SarA is the major regulatory molecule of this 
locus and mediates its elect both directly by binding to target gene promoters (e.g. agr, hla 
and spa) and indirectly via the downstream elect on other regulons that sarA locus controls 
the expression of over 100 target genes (Dunman et al., 2001). 
Locus sarA encodes a 372 bp open reading frame with three upstream promoters (P2, P3, 
and P1) driving three overlapping transcripts, each of them coding for the 14.5 kDa SarA 
protein (Cheung. et al., 1997). The 372 bp ORF sarA together with extensive 800 bp 
upstream sequence is present within the main transcript sarB (Chien and Cheung, 1998). 
The crystal structure of a SarA DNA complex has been explained and indicates that SarA 
mediates DNA supercoiling form (Roberts et al., 2006). SarA similar to SarR structures, it 
is diametric winged helix character including each monomer consisting of 5 α-helices, 3 β-
strands and several loops (α1α2-β1α3α4-β2β3-α5), SarA dimer possesses a central helical 
core and two winged helix motifs, each winged helix motif has a helix-turn-helix motif 
(α3α4) and a β-hairpin turn wing (β2β3), both of them employed as putative DNA binding 
domains (Schumacher et al., 2001). 
1.3.4 Staphylococcal mechanisms and genes encoding lipoproteins for iron and 
manganese uptake 
Uptake of nutrients from the environment by bacteria is an essential process that supplies 
bacteria with different elements and allows them to recognise the environmental 
conditions. Determining the complete genome sequences for some strains has allowed 
detection of those genes encoding a number of iron transporters, searching within genome 
database using amino acid sequences of known iron transporters. Iron depletion conditions 
in host body ﬂuids serve as a most important environmental signal to bacteria to express 
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virulence factors (Trivier and Courcol, 1996). Iron uptake system network usually based 
on a member of the ATP-binding cassette (ABC) family of transporters for importing iron 
or complexed-iron across the membrane, this multi subunit complex structure contains; (i) 
integral membrane proteins, which act as a permease; (ii) peripheral membrane ATP 
binding proteins that hydrolyse ATP; and (iii) extracellular substrate binding proteins 
(SBPs) that work as receptors (Williams et al., 2004).  
Structure of SBP systems is slightly different between Gram-negative and Gram positive 
bacteria, in Gram-negative bacteria, SBPs are secreted into the periplasm and are retained 
in this space by the outer membrane, but in Gram-positive bacteria, with the absence of 
outer membrane, are required to tether these proteins to the plasma membrane via a lipid 
anchor or by incorporating with a specific integral membrane element of the transporter 
(Tam and Saier, 1993). Two different mechanisms of iron uptake in Staphylococcus spp 
have been described, siderophore or non-siderophore based pathways to use a range of 
available iron substrates including a release of low molecular-weight high-affinity iron 
scavenging molecules known as siderophores, which can bind to specific receptors if 
combined with iron molecules including staphyloferrin A and B, and in addition S. aureus 
produces a siderophore called aurochelin (Brown and Holden, 2002).  
Different studies have identified nine iron regulated lipoproteins (IRLPs) from approx. 55-
70 total lipoproteins expressed by S. aureus, SirA, HtsA, SstD, FhuD1, FhuD2, IsdE, 
FepA, SitC and Opp1A, and their important functions in bacterial pathogenesis and 
immune stimulation (Sheldon and Heinrichs, 2012, Wright and Nair, 2012). Ferric uptake 
regulator (Fur) gene is a homodimeric metalloprotein which acts as a transcriptional 
regulator of iron homeostasis in various bacteria (Andrews et al., 2003). Other IRLPs 
staphylococcal iron transporter, SitABC/MntABC proved to play a role in iron uptake and 
homeostasis (Sheldon and Heinrichs, 2012). 
Well distinguished system of iron uptake in S. aureus is the ferric hydroxamate uptake 
(Fhu) system, encoded by up to 5 genes including fhuC (ATPase), fhuB and fhuG (to 
assemble membrane embedded permease) located in an operon that encodes an ATP-
binding cassette (ABC) transporter, FhuC gene is a predicted ATPase, while FhuB and 
FhuG (high-affinity receptors) are membrane spanning proteins (Sebulsky et al., 2000).  
Lipoprotein FhuD2 (ferric hydroxamate uptake) was first discovered as a ferric 
hydroxamate siderophore binding protein that involved iron uptake via a dedicated ATP 
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binding cassette (ABC) transporter (Sebulsky and Heinrichs, 2001). S. aureus RN6390 
strain carries at least 5 iron regulatory genes, their products regulating the ferric 
hydroxamate uptake mechanism, three gene operon fhuCBG encodes the ATPase, 
however fhuD2 codes lipoprotein fhuD are the fifth gene involved in this transport scheme 
(Sebulsky et al., 2004). 
S. aureus can also consume a range of siderophores produced by other bacteria such as 
enterobactin, a catechol type siderophore and some hydroxamate siderophores e.g. 
ferrichrome and aerobactin (Sebulsky and Heinrichs, 2001, Sebulsky et al., 2004). 
Predominant lipoprotein SitC one of staphylococcal iron transporters; SitABC (Cockayne 
et al., 1998), PrsA, peptidyl-prolyl cis-trans-isomerase a part of protein folding system and 
OppA, oligopeptide permease (Stoll et al., 2005).  
Manganese (Mn) uptake has been shown to be essential for the growth and survival of 
many living organisms and play speciﬁc cellular roles in vivo pathogenicity as a cofactor 
in enzymes for metabolism, catabolism and photosynthesis (Jakubovics and Jenkinson, 
2001). In S. aureus Mn has non-enzymatic role in the protection of the cell from oxidative 
stress factors (Clements et al., 1999). Control of iron, zinc and Mn uptake are mediated by 
members of Fur and DtxR protein families (Hantke, 2001). ABC permeases transport 
binding protein in Gram-positive bacteria has lipoprotein modification (Sutcliffe and 
Russell, 1995). The MntABC operon is composed of three genes, MntA the ATP-binding 
protein, MntB the integral membrane transporter and MntC metal binding lipoprotein 
(Nielsen et al., 2011). The MntC lipoprotein a part of the MntABC operon is involved in 
the uptake of manganese and/or zinc in Staphylococcus spp for cellular processes and host-
bacteria interactions (Claverys, 2001). Horsburgh, et al. showed that MntABC operon 
mutant S. aureus had lowered intracellular manganese concentration (Horsburgh et al., 
2002). MntC gene was highly expressed early during S. aureus infection stages of murine 
bacteraemia model, active immunization with MntC mutant strain was shown a signiﬁcant 
reduction of S. aureus acute bacteraemia in vivo (Anderson et al., 2012). 
1.4 A Database of Bacterial Lipoproteins (DOLOP) 
A Database with a various features based on bioinformatics analysis tools are available to 
predict bacterial lipoproteins using predicted features of an N-terminus lipobox and 
lipoprotein signal peptides and comparison of different predictive algorithms has been 
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developed (Babu et al., 2006). Each organism has a set of different numbers of 
lipoproteins and to identify their various bioinformatics features in a large data set a proper 
algorithm are needed to predict the lipoproteins based on their amino acid compositions by 
using available updated database of sequenced genomes with a higher degree of 
confidence. The best predictive rules on Gram-positive bacteria lipoproteins were 
suggested algorithm G+Lpp (Sutcliffe and Harrington, 2002), in contrast, another trained 
set of predictive rules suggested algorithm for Gram-negative bacteria to predict 
lipoproteins by looking at the signal sequence features and proposed as LipoP (Juncker et 
al., 2009). The comparative analysis of DOLOP database for bacterial lipoproteins 
information, based on the data of molecular bioinformatics of different functional 
lipoproteins, these predicted lipoproteins from about 234 completely sequenced bacterial 
genomes, as a result of all these works, the numbers of bacterial lipoproteins that have 
been identified would exceed several thousand from a variety of bacterial sources (Babu et 
al., 2006). Database of bacterial lipoproteins (DOLOP) is available at (http://www.mrc-
lmb. cam.ac.uk/genomes/dolop). However, unfortunately this database was not kept up to 
date as it was last modified in April 2005, but it is provided a useful starting point to study 
staphylococcal lipoproteins as data from 6 strains of S. aureus were included. 
The availability of complete genome sequences for some S. aureus strains can provide 
reliable information to discover lipoproteins sequences, depending on the predictive 
basics. Also, provide some evidence about possible functions by identifying protein 
domains predicted lipoproteins. Furthermore, by using protein sequences database with the 
advantage of a combination of keywords, limits research results to only one species 
(Bairoch and Apweiler, 2000). Some S. aureus lipoproteins were not detected by DOLOP 
precomputed features-tools because the regular expression pattern allowing detection of 
lipidation sequence ([LVI] [ASTVI] [GAS] [C] lipobox) is too stringent. The LipoP 
method to predict lipoprotein signal peptides in Gram-positive is more permissive, 
however using a single tool may result in errors (Bagos et al., 2008). This suggests the best 
approach is to combine the various features-based methods available and compare the final 
results. Determination of outer membrane localization machinery (LOL) for lipoproteins 
and the effect of amino acids in the modifiable cysteine in the mature sequence in their 
recognition and amino acid residues at +3 and +4 positions were found to affect the 
membrane localization of native lipoproteins (Terada et al., 2001). Another method to 
assign lipoprotein predictions is the Prosite position-specific matrix PS51257, this system 
35 
 
has been used to predict lipoproteins encoded by Gram-negative bacterial genomes (Hulo 
et al., 2008). 
1.4.1 Proteome analysis of S. aureus 
Proteomics allows a better understanding of biological and pharmacological structure of 
bacterial lipoproteins. proteomics provide a perfect complement to comparative genomics 
analyses, by giving a large view of protein profiling and their ability to visualise changes 
in protein expression in S. aureus (Gatlin et al., 2006, Kohler et al., 2005). Classical 
proteomics techniques have shown changes of the metabolism and pathogenic by 
visualisation of main metabolic pathways in a simple proteomics procedures. Proteomes 
are characterized in the past by two ways (i) protein microarrays and (ii) protein staining of 
two-dimensional gel electrophoresis (2DE) which resolves the complex protein sample in 
two dimensions based on molecular weight and pI (isoelectric point). Both methods were 
has variable reproducibility and low characterization of the less abundant proteins (Janini 
and Veenstra, 2002, MacBeath, 2002).  
It is a highly recommended technique for separation and quantitation of lipoproteins, and 
has much to contribute to the experimental analysis of bacterial cell proteins (Brady et al., 
2006). However, after gel-free and mass spectrometry techniques have been introduced to 
proteomics experiments, 2-DE has become the second choice in proteomics approach. Gel-
based techniques have some limitations including a poor reproducibility, limited dynamic 
range, sensitivity, and its time consuming and there are many technical problems that can 
occur (Janini and Veenstra, 2002).  
A different proteomics strategy coupled gel electrophoresis with mass spectrometry, 
proteins spots resulting from gel separated by 2-DE, subsequently analysed by mass 
spectrometry machines (MALDI-TOF-MS or by LC-MS/MS), nevertheless, the drawback 
of protein analysis by mass spectrometry is the limited molecular information for the intact 
secreted proteins (Ravipaty and Reilly, 2010). In S. aureus 2-DE/MS proteome mapping 
has been used successfully to investigate hundreds of proteins in both, intracellular 
(cytoplasmic) (Kohler et al., 2005) and extracellular (secreted) proteins (Kohler et al., 
2003). The physico-chemical properties of proteins and analytical window of 2-D gels can 
affect the abundance of individual proteins on the gel, in quantitative proteomics study on 
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S. aureus COL, 683 proteins were found to be different between proteome patterns of 
analytical windows of pI 4-7 and in the pI range of 6-11 (Becher et al., 2009b).  
The introduction of mass spectrometry (MS) techniques with high resolution and mass 
accuracy, and using gel-free sample preparation methods, has achieved significant 
analytical improvements. Gel-free MS-based proteomics approaches need smaller samples, 
in 2D gel-based proteomics μg quantities of sample proteins are needed, but with modern 
gel-free proteomic approaches ng of samples can be used (Schmidt et al., 2010). Within a 
short time, the new approaches of LC/MS allow identifying a hundreds of peptides within 
a single run providing significantly more information (Thakur et al., 2011).  
The three major components of mass spectrometry instruments are an ionisation device, a 
mass analyser, and a detector, all ions generated by the ionisation source are separated by 
the analyser that separates them according to their mass-to-charge (M/Z) ratios, then the 
selected ions passed towards the detector where they are finally registered (Ravipaty and 
Reilly, 2010). The whole genome sequencing of important microbial pathogens unlocked 
the codes to identify different proteins via mass spectrometry as theoretical masses can be 
calculated and found in an available database. To analyse proteins by mass spectrometry, 
the size and polarity are impediment for some of them, but with some site specific 
proteases can overcome this issue by cutting proteins into small peptides (Mann et al., 
2001). 
In S. aureus relatively quantitative combination strategy has been used effectively for 
proteomics identification and has characterised the features of extracellular proteins, in 
order to find out the regulatory network involved in pathogenicity (Ziebandt et al., 2004). 
Meanwhile, Cordwell, et al. mapped the cytoplasmic proteins of two strains (COL and 
8325) and covered about 12% of S. aureus proteome (Cordwell et al., 2002). Most of the 
hydrophobic proteins remain undetected, either because they precipitated during isoelectric 
focusing, or due to their low abundance (Nandakumar et al., 2005). Transcriptional 
analyses of S. aureus showed the main regulation process of virulence factors expression 
under different environmental conditions but the proteome during host infection are variant 
due to protein production can be regulated post translationally (Cordwell et al., 2002). 
Most of proteomics studies on S. aureus virulence in infected tissues have been performed 
by applying culture stress conditions that challenges that the microbe encounters during 
infection, these studies do not  show the pathogen activities during infection challenges 
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and limitations imposed by host interference (Bumann, 2010). Proteomics revolution in 
biotechnology has led to discovering of many important proteins involved in different 
approaches of bacterial infection and diseases, this advance technology allowed the 
scientists to find out wide proteome for a number of pathogenic organisms.  
1.5 The Nematode Caenorhabditis elegans 
Caenorhabditis elegans (Caeno, recent; rhabditis, rod; elegans, nice), is a free-living, soil-
dwelling and self-fertilizing non-parasitic nematode, microbivore where it feeds on a wide 
range of bacteria and fungi, microbes passed into the pharynx and crushed by a cuticular 
(grinder), and pumped through to the intestine (Nicholas and Hodgkin, 2004b), some of 
these microorganisms are identified pathogens, capable of infecting and even fatal to C. 
elegans. From a practical standpoint, it is easily maintained and manipulated in basic 
laboratories, can be propagated on agar plates or in liquid media and can live up to 3 
weeks at room temperature. C. elegans transparent body facilitate visualizing and 
dissecting internal features using simple dissecting microscopes. Their small in size (1.5 
mm long), short generation time (produce 300 genetically identical progeny in a 3 days life 
cycle at 25°C), ease of handling, powerful genetics, invariant developmental lineage, small 
and completely sequenced genome (100 Mb) give it an abundant advantage to use as 
valuable effective model host of research (Powell and Ausubel, 2008). 
Biological data and entire genomic sequence for C. elegans are assembled in freely 
accessible public databases and numerous strains including mutant strains are available 
through scientific resources, also its small size, ease of handling, short generation time and 
powerful genetics give it great advantage to be employed as host model (Schulenburg et 
al., 2004). Their use does not raise ethical issue related to use of animals as biological 
models. Various features of interaction of C. elegans with pathogens have been described 
in immunogenetic studies, also many model host organisms provide a number of useful 
experimental advantages for discovering genes and genetic pathways involved in 
biological processes (Millet and Ewbank, 2004, Nicholas and Hodgkin, 2004a). 
Transgenic C. elegans strains were easily created using microinjection DNA and worms 
transparency renders the use of fluorescent reporter genes in vivo (Aballay et al., 2000). 
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1.5.1 Life cycle of C. elegans 
Well-fed C. elegans can develop and reproduce at a wide range of temperatures, however 
development stops at temperature below 8°C and the worms become sterile above at 27°C, 
it has a life cycle approx. 3 d under ideal conditions and their average life span is 3 weeks 
at 20°C (Félix and Braendle, 2010). C. elegans life cycle has six stages: consists of 
embryonic stage, four postembryonic larval stages and a reproductive mature stage with 
optional reversible, developmental arrest at some larval stages, the life cycle of C. elegans 
shown in figure 6.  
Hermaphrodites, C. elegans produce both oocytes and sperm and reproduce in the absence 
of males by self-fertilization. In favourable conditions, males arise infrequently (0.1%) by 
spontaneous non-disjunction in the hermaphrodite germ line and at higher frequency (up to 
50%) through mating (Hodgkin, 1986). Hermaphrodite worm produces larger number of 
oocytes and approximately 300 sperm, to generate about 300 progeny by self-fertilization 
in 4-5 days and more than 1000 progeny by a male fertilization (Ward and Lamunyon, 
1995). Embryonic stage divided into two phases, the first phase requires cells proliferation 
and organogenesis, however elongation, morphogenesis and cuticle synthesize occur in the 
second phase, finally the animal hatches into an L1 larva (Edgar et al., 1994).  
When environmental conditions are favourable L1 larvae develops through 4 larval stages 
(L1 to L4) to adult within 3 to 5 d when conditions are favourable e.g. food, temperature 
and crowdedness. During post-embryonic maturation stage the structures of sexual 
reproduction (gonad, vulva and sex muscles) also the neurons and epidermal tissues are 
completed in this stage. In unfavourable conditions C. elegans larvae are capable of 
interrupting their reproductive growth by arresting at an alternative L3 stage termed dauer 
which is characterized by developmental quiescence, stress resistance and more adapted 
for long-term survival (Wang and Kim, 2003). Sexual immature, starved and non-aging 
dauer larvae can survive for up to three months in unfavourable conditions, then resume 
development when conditions and environmental factors changed (Wood, 1988). 
Availability of food after hatching triggers post-embryonic development and cell divisions 
resume, post-embryonic growth begins after 3 h of hatching, but in the absence of nutrition 
L1 larvae arrest development until food becomes available (Sulston and Horvitz, 1977).  
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C. elegans has two sexes, hermaphrodites and males, hermaphrodites can self-fertilize or 
mate with males but cannot fertilize each other (Fischer, 1988). C. elegans genome has 
five pairs of autosomes chromosomes and one pair of X chromosome, worm sex 
determination is defined by the copy number of X chromosome; hermaphrodites have two 
copies (XX) and whereas males have one (XO) (Riddle et al., 1997).  
 
 
Figure 6. Life cycle of C. elegans at 22°C                                                                   
Starting with fertilization time followed by each name and length of time that animal 
spends at different stages. Worm Atlas, Altun. 
(http://www.wormatlas.org/ver1/handbook/anatomyintro/anatomyintro.htm). 
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As C. elegans feeds on bacterial lawns, this attribute the model host in two ways; it 
provides a convenient route for infection by microbial pathogens, and bacterial feeding can 
be used for the application of RNA interference (RNAi) based gene silencing, by using E. 
coli strains expressing dsRNA (Kamath and Ahringer, 2003). 
C. elegans is exposed to various bacterial and fungal pathogens in their surrounding 
environment and expected to have evolved effective defense mechanisms to face this 
infection. C. elegans is the most attractive model host in many biological researches, 
especially in developmental biology and neurobiology, these researches rely on the fact 
that virulence factors relevant for infection of mammals are similar for full pathogenicity 
during infection of nematodes (Schulenburg et al., 2004). It is well suited parasite for 
mutagenesis and forward genetic analysis and has a fully sequenced genome (Strange, 
2003). C. elegans is a simple nematode model host for studying the relationship between 
the animal innate immune system and many bacterial and fungal pathogenesis (Powell and 
Ausubel, 2008).  
When C. elegans feeds on the standard laboratory diet E. coli OP50 strain, the pharyngeal 
grinder crushes all food and no live bacteria were found in the worm intestine (Aballay et 
al., 2000, Garsin et al., 2001), however, if the pathogenic microbes pass intact through the 
pharynx and accumulate in the intestine, this can cause infection. A large number of 
different microbial pathogens have been revealed to infect C. elegans, including Gram-
positive bacterial pathogens Staphylococcus aureus (Sifri et al., 2003), Microbacterium 
nematophilum (Hodgkin et al., 2000) and Enterococcus faecalis (Garsin et al., 2001); 
Gram negative bacterial pathogens Pseudomonas aeruginosa which was the first 
bacterium shown to be able to infect and kill C. elegans; (Tan et al., 1999), Salmonella 
enterica, Salmonella typhimurium (Aballay et al., 2000), Serratia marcescens (Kurz and 
Ewbank, 2000), and Yersinia pestis (Darby et al., 2002); and the pathogenic yeast 
Cryptococcus neoformans (Mylonakis et al., 2002), moreover, some putative fungal 
pathogens to C. elegans have been recognised, including Drechmeria coniospora (Jansson 
et al., 1985). C. elegans has shown many ways to survive from the harmful effects of these 
infections by sensing and distinguishing between bacterial compounds in their 
environments (Pradel et al., 2007). 
Infected C. elegans show visible signs of illness e.g. bacterial biofilm formation, tail 
swelling and massive internal accumulation of microbes or die more quickly with mean 
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lifespan between 1.5-7 days. In contrast, with non-pathogenic E. coli OP50 the mean 
lifespan time is 15-17 days (Powell and Ausubel, 2008). S. aureus was amongst the first 
models used in C. elegans immunity research experiments and S. aureus A003 strain was 
shown to exhibit a high level of nematocidal activity with average time for half of the 
worms to die of ~ 2 days (Garsin et al., 2001). A significant killing activity of 23 clinical 
S. aureus isolates were examined and revealed to kill more than 70% of nematodes during 
the course of ~ 5 days, also all C. elegans larval stages were killed by S. aureus. The main 
molecular mechanisms of pathogenicity are not fully understood but accumulation of 
bacteria in infected nematodes digestive tract was observed (Sifri et al., 2003). Worms fed 
on S .aureus appeared normal for the first 16 to 20 h including nematode locomotion 
detected visually, pharyngeal pumping and foraging, however after 24 to 48 h all of these 
activities gradually decreased until the worms became immobile and died (Sifri et al., 
2003). Adult worms proved to be more susceptible to S. aureus infection than all larval 
stages (Bae et al., 2004). Various bacterial virulence genes required for the nematode were 
also important in other model hosts (Tan et al., 1999).  
The dead worms lost all cellular appearance architecture and appeared as ghosts in 
bacterial lawn, furthermore, “bag of worms” phenomena were observed in the infected 
death nematodes, when eggs of a gravid hermaphrodite hatched internally and the resulting 
L1 larvae consumed their parents. This matricide might be occur because infected 
nematodes become too weak to lay eggs normally (Garsin et al., 2001, O'quinn et al., 
2001). Examination of infected worms under Nomarski differential interference contrast 
microscopy showed clear distention of the intestinal lumen with visible intact bacteria, 
although worms fed E. coli OP50 had slender intestinal lumen with no visible intact 
bacteria (Sifri et al., 2003). P. aeruginosa PA14 strain expressing Aequorea victoria GFP 
was able to kill worms after 48 h of infection, clear green fluorescence pigments was 
observed within the lumen of worm intestines, indicating the accumulation of bacteria 
(Tan et al., 1999). 
1.5.2 Infection routes of C. elegans 
Microbial pathogens can harm C. elegans either by colonizing the intestine or adhere to 
nematode cuticle and decrease its lifespan, while other pathogens produce toxins that kill 
C. elegans without any directly contact with the worms. The main two routes of infection 
of C. elegans through pharynx or the epidermis. Some organisms cause the pathogenic 
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effect after ingestion by worms, often exerting their effect in the anterior part of the 
intestine where they may establish an intestinal infection (Gravato‐Nobre and Hodgkin, 
2005). Intact microbes must manage to pass through upper digestive tracts and surviving 
any disruption by pharyngeal grinder action, start to proliferate within the gut, causing 
distension and damaging the intestinal epithelium cells, leading to mortality associated 
with epithelial disruption (Köthe et al., 2003, Mylonakis et al., 2002), Gram-negative 
bacteria Salmonella typhimurium have been shown to establish intracellular infection in 
the intestinal cells (Jia et al., 2009), other important pathogens was found to have 
significantly detrimental activity by their production of bacterial toxins, this was reported 
with P. aeruginosa PAO1 (Gallagher and Manoil, 2001) and Bacillus thuringiensis 010 
strain (Zhang et al., 2014).  
It is relatively simple to substitute non-pathogenic food source of C. elegans with 
pathogenic bacterial strains, this allow analysing the involved virulence mechanisms and 
host defences. C. elegans are able to distinguish metabolites, autoinducers, odours and 
pathogenic bacteria (Beale et al., 2006). Due to chemical and mechanical features of C. 
elegans skin, only limited bacteria and fungi were proved to bind to or degrade the 
extracellular exoskeleton of worm. A few pathogenic microbes have been shown to adhere 
to and then penetrate the cuticle and grow into the epidermis, for example the fungus 
Drechmeria coniospora were capable of adhering and causing mouth and vulval infections 
(Jansson, 1994). The bacteria Yersinia pestis and Yersinia pseudotuberculosis formed 
biofilms on the heads of the nematodes, the dense mass of bacteria prevented feeding 
(Joshua et al., 2003). 
According to JebaMercy and Balamurugan, virulence of pathogen can be influenced by 
preinfection of C. elegans with other microbes, this immune challenge was shown when 
preinfected C. elegans with pathogenic S. aureus increased the vulnerability of host by 
significantly reducing the life span and increasing the chance for opportunistic pathogen 
Proteus mirabilis to be more pathogenic (JebaMercy and Balamurugan, 2012). 
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1.5.3 C. elegans immunity system 
Many conserved innate immune defence have been revealed by investigate host/microbes 
interactions using vertebrate and invertebrate models. The discovery that the innate 
defence mechanisms of invertebrates, vertebrates and some plants shared similarities was a 
major development in immunological studies. All vertebrates have employed complex 
immunity system used to repel against pathogenic microbes, this complex immune 
mediated by two highly co-dependent immune systems known as innate and adaptive, 
whilst, adaptive immune system seems to be absent from all invertebrates and 
consequently its rely on their innate immune mechanisms in their response against 
infections (Aballay, 2013, Gravato‐Nobre and Hodgkin, 2005).  
Innate immune defence is the early barrier to infectious agents and acts immediately, 
innate immune responses are generally initiated via host recognition the conserved 
structures of pathogens as foreign body known as pathogen associated molecular patterns 
(PAMPs) e.g. lipopolysaccharide, peptidoglycan or modified nucleic acids, PAMPs 
sometimes known as microbe associated molecular patterns (MAMPs), moreover, 
recognition of damage-associated molecular patterns (DAMPs), for example ATP and 
monsodium urate crystals can enhance activation by PAMPs, but also may be enough to 
initiate the innate immune activities (Twumasi-Boateng and Shapira, 2012). Different 
classes of pattern recognition receptors (PRRs) responsible for recognizing PAMPs or 
DAMPs molecules including many proteins such as NOD-like receptors (NLRs), 
Toll/Toll-like receptors (TLRs) and RIG-I-like nucleotide recognition receptors (RLRs) 
leading to the activation of intracellular signalling pathways (Kumar et al., 2011). These 
pathways can mediate upregulation of expression of specific defensive genes, the effector 
molecules product serve to limit infection or destroy invading pathogens. 
Non-vertebrate, Drosophila melanogaster (fruit fly) was an important host model to 
discover Toll family receptors the most widely distributed molecules involved in 
mammalian defence, non-vertebrate host model D. melanogaster become a model to study 
host/ microbe interactions (Lemaitre et al., 1996). NLRs take part in antimicrobial action 
in both animals and plants (Ting et al., 2008). In vertebrates, TLRs prominent class of 
PRRs, can sense the outer membrane components of bacteria (Akira et al., 2006). C. 
elegans avoid pathogenic elements through a process mediated by a Toll receptor (Pujol et 
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al., 2001). Triggering of long lasting adaptive immunity which has immunological 
memory against infectious agents is usually initiated via the innate immune system.  
1.5.4 C. elegans defence strategies 
C. elegans has three important tactics of defences against microbial pathogens, the first 
strategy is the avoidance behaviour against certain pathogens, worms are able to 
differentiate between different bacterial lawns and then they can evade possibly pathogenic 
strains (Andrew and Nicholas, 1976). Olfactory sense, G protein coupled receptors and 
Toll‑like receptor (TOL‑1) were involved in triggering the avoidance behaviour against 
Serratia marcescens pathogen (Pradel et al., 2007). Many soil bacteria have employed the 
defense strategy of releasing toxic materials, e.g. Pseudomonas fluorescens produces 
extracellular secondary metabolites to act as a defense mechanism against bacterivorous 
nematodes (Neidig et al., 2011). 
The second line of protection against any microbial attacks is a strong cuticle which 
constitutes the exoskeleton of worm, when a pathogen cannot be avoided. The third 
mechanisms of C. elegans defence is the complex inducible defence system including 
many signalling cascades that regulate the production of antimicrobial peptides and 
proteins in a pathogen and tissue specific way (Engelmann and Pujol, 2010). Mechanisms 
of pathogenesis and infection among different microbes models would be also carefully 
observe the differences in the immune response that been used in C. elegans, these 
differences should relative to the disease process as it is associated with toxins and/ or 
infection (e.g. P. aeruginosa and S. aureus) or by establishing an infection (e.g. M. 
nematophilum) (Schulenburg et al., 2004). Osanai, et al. demonstrated that TSST-1 and 
SEC toxins produced by S. aureus were playing a role in C. elegans avoidance which is 
mediated by 5-HT signalling pathway (Osanai et al., 2012). Avoidance of Pseudomonas 
aeruginosa by C. elegans was subsequent to activation of TIR-1-NSY-1-SEK-1 signalling 
pathway in ADF neurons which neighbour pharyngeal pumps and are responsible for the 
avoidance behaviour of C. elegans (Shivers et al., 2009). The scaffold protein 
Toll/interleukin-1 receptor (TIR-1) was also important for identify pathogenic microbes 
and pathogen-associated molecular patterns (Couillault et al., 2004). 
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1.5.5 The specific requirements for pathogenesis 
There are significant differences in the genetic requirements of S. aureus to infect 
nematodes and humans, one of these significant difference is the temperature during 
infection, as the worms optimum growth temperature is 25°C, however temperature of 
mammals before infection is 37°C and during the later stages of infection is between 32°C 
and 43°C, these temperature changes indicating changes in genes expression and their 
virulence affects (Vlach et al., 2000). Another study proved that some genes required for 
pathogenesis of one staphylococcal infection were unnecessary in a different disease 
model (Schwan et al., 1998). Lack of an adaptive immune system in C. elegans is another 
drawback to use it as a model host, also C. elegans seems to have less or no specialized 
cells similar to scavenging phagocytic neutrophils and macrophages (Gravato‐Nobre and 
Hodgkin, 2005).  
1.5.6 C. elegans antimicrobial peptides and proteins 
Generally C. elegans produces a set of antimicrobial peptides and proteins to defend itself 
against microbes. C. elegans has a numerous candidates of antimicrobial effector 
molecules, some of them were equivalent to known antimicrobial factors in nematode 
species while others were transcriptionally regulated upon infection models, which seem to 
be produced rapidly and do not have similar structures even in other nematodes (Ewbank 
and Zugasti, 2011).  
1.5.6.1 Caenopores 
Saposin like proteins (SPPs) also known as caenopores, is a large family, with 28 coding 
genes constitutes at least 33 different C. elegans antimicrobial proteins, caenopores 
structure belong to SAPLIP (saposin like protein) superfamily as exemplified by the 
structure of caenopore-5 (SPP-5) (Aylin et al., 2012). Caenopores have a similar structure 
and function characteristics with a range of organisms from amoebae to mammals such as 
the pore-forming cytotoxic proteins that can kill bacteria (Roeder et al., 2010). These 
proteins are generally expressed in C. elegans intestine and their expression can be 
triggered by specific pathogenic bacteria but their mode of action has not been fully 
studied (Ewbank and Zugasti, 2011). 
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1.5.6.2 Lysozymes 
Lysozymes are another class of molecules show a significant role in both vertebrate and 
invertebrate immunity. Lysozymes are a group of important putative antimicrobial proteins 
in C. elegans, their expressions in the intestine was reported to be induced by specific 
infections (Alper et al., 2007). The function of enzyme is attacking the peptidoglycans 
layer of bacterial cell walls mainly the Gram-positive bacteria. The immune system of C. 
elegans has a set of lysozyme genes playing an important role against the invading 
pathogen (Shapira et al., 2006). C. elegans lack C‑type lysozymes, but possesses 15 
lysozyme genes divided into 3 classes, two of them related to protist lysozymes and one 
specific to invertebrates (Schulenburg and Boehnisch, 2008). Some of these lysozyme 
activities have been observed to be important in C. elegans resistance to many Gram 
positive and Gram negative bacteria (O’Rourke et al., 2006). Lys‑7 lysozyme was induced 
via bacterial challenge and their inactivation has render worms to be more susceptible 
against M. nematophilum and P. aeruginosa (Mallo et al., 2002, O’Rourke et al., 2006). 
The exact immune defence functions of all these lysozymes remains to be determined. 
1.5.6.3 Lectins 
The large family of lectins also involved in innate defence mechanism in many species, C. 
elegans show a complex patterns of genes regulation of lectin, expression of some lec and 
clec genes was up-regulated by several pathogens, however their activation relatively to 
defence against different pathogenic infections (Mallo et al., 2002, O’Rourke et al., 2006, 
Wong et al., 2007). Lectins were involved in microbe recognition via binding to pathogen 
surface sugars, others were act as opsonizing factors and/or possess antimicrobial activity, 
whilst others seem to play a role in masking host epitopes the targets for some specific 
microbial effectors (Schulenburg et al., 2008). 
1.5.6.4 Reactive Oxygen Species  
C. elegans also has the ability to release bactericidal Reactive Oxygen Species (ROS) in 
response in host defence to attacking pathogens e.g. the Gram-positive bacteria 
Enterococcus faecalis which induce ROS production as an antimicrobial defense by the 
action of the dual oxidase BLI-3 (Chávez et al., 2009). The antimicrobial activities of ROS 
is not specific in their action to attack the invaded microbe, this may lead to accumulation 
of ROS and damage some of host tissue, subsequently increasing the chance of triggering a 
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protective stress response in worms (Chávez et al., 2007). Another evidence is that C. 
elegans can avoid cultures and culture supernatants of pathogenic bacteria S. aureus by 
rapid recognition of secretory products including staphylococcal enterotoxin C (SEC) and 
toxic shock syndrome toxin 1 (TSST-1), avoidance of this molecules was dependent on 
Toll/interleukin-1 receptor (TIR-1) and generation of 5-hydroxytryptamine (5-HT) (Osanai 
et al., 2012). 
1.6 Whole transcriptome shotgun sequencing technology (RNA-Seq) 
There are thousands of genes and their products in bacterial cells that act in a complex and 
coordinated system to allow microbes to survive in a different environment. Traditional 
molecular biology methods usually work on a limited basis, which means the general 
depiction of whole genes function is very limited. To achieve a useful comprehensive 
interaction for all genes in the living organism and the expression levels of specific genes 
during normal growth or pathogenic processes of certain microorganism a reliable and 
effective tool are required to complete these aims. The advanced next-generation RNA 
sequencing (RNA-seq) is a modern technique that has been widely used for transcriptomic 
researches to provide excellent genome coverage to almost all of the expressed transcripts 
of an organism.  
It is a process that consists in sequencing all cDNA obtained from an RNA sample to 
identifying and quantifying RNA molecules that are expressed at a certain time-point and 
under a specific set of conditions. RNA-seq was first introduced in 2008, which involves 
high sequencing of cDNA generated from RNA preparations to alter the general view of 
extent and complexity of transcriptomes and overcome some of disadvantages of existing 
sequencing approaches (Wang et al., 2009). Next generation sequencing technology offer 
an enormous throughput of billions of bases per run to obtain a whole transcriptome by a 
single sequencing run with high coverage to randomly reveal all that can be sequenced 
without previous information on what has to be discovered, this high sequencing output is 
the key point in the sensitivity and comprehensiveness of RNA-seq analysis (Marie et al., 
2010). RNA-sequencing method has been used to identify and quantify molecules of non-
coding short RNA (sRNA) (Vogel and Sharma, 2005). Quantitative sequencing must show 
relative abundance of individual RNA molecules, this abundance depends on RNA 
preparation and on the sequencing method, some RNA molecules tend to form secondary 
structures leading to less efficiently sequence which could significantly alter the 
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quantitative analysis (Marie et al., 2010). RNA-seq can detect a different transcriptional 
feature including the 5′end of total RNAs (Wurtzel et al., 2010).  
This sensitive ultra-sequencing approach makes it possible to investigate unculturable 
microbes or that cannot be isolated e.g. endosymbionts (Güell et al., 2011). RNA-seq has a 
number of advantages over microarrays, including single base pair high resolution, 
minimum background signal, a wide range of expression levels, enormous levels of 
throughput, smaller RNA material requirements and it can detect transcripts that do not 
match to a past sequenced genome (McClure et al., 2013). Previous transcriptional 
analysis approaches were based on hybridization of specific oligonucleotides to particular 
loci for their sequence specificity by using selective primers binding to target cDNA in 
qRT-PCR, hybridization of cDNA to probes on microarray chips or labeled specific probes 
binding to RNA in Northern blotting. However, RNA-seq is various in principle through 
matching data to genes by sequence alignment instead, no probe sequences are specified, 
experimental design are similar in genome sequence and determines all transcription in an 
equal manner. Sequence data mapping is also more accurate than hybridization between 
oligonucleotides and give sequencing with high resolution, these advantages help to 
determine the bacterial genetic features and genetic variation between strains (Croucher 
and Thomson, 2010). RNA-seq quantification of genes expression is not affected by 
interference between the genes due to non-specific hybridization of cDNA to probes 
(Cloonan and Grimmond, 2008). Hybridization techniques measure genes expression 
levels by detection of fluorescence or radioactivity, RNA-seq has a better dynamic range 
for measuring variable data through revealing the amount of data matching to coding 
sequence, then quantified as reads per kilobase CDS length per million reads analysed 
(Mortazavi et al., 2008). The ribosomal RNA consist the majority of total isolated RNA, 
depletion of rRNA molecules has been used to intensify the coverage and productivity of 
mRNA and non-coding RNA (Sharma et al., 2010). However, quantity of RNA-seq data 
by abundant transcripts will need more research in some points; for example, analysing 
bacterial genes expression in vivo where host tissue RNA will be more abundant than that 
of the bacteria (Conway, 2003). Interestingly, it has been shown even with analysing only 
one RNA sample, RNA-Seq can be very useful (Meyer et al., 2009). To prove highly 
appropriate RNA-seq datasets it should compare either technical or biological replicates to 
make them fit for expression studies. RNA-seq in S. aureus was firstly used to study small 
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non-coding RNAs (Beaume et al., 2010), and to find the role of anti-sense transcription 
(Lasa et al., 2011).   
1.6.1 Characteristics of bacterial transcriptomes 
Bacterial transcription and regulation of gene expression has been a topic of interest for 
many years, with different discoveries being made with the combination of modern 
genetics assays and highly quantitative methods. The considerable number of microbial 
genomes available in databanks has given the opportunity for more in depth studies of 
pathogenic microbes, including the post-genomics investigations and relevant biological 
processes. Advent of next generation sequencing technology including bacterial RNA-
Sequencing has made the progress in discoveries bacterial transcriptomics and improves 
functional genomics experiments. RNA-Sequencing has changed the scientific view of the 
extent and complexity of microbial transcriptomes and provides more detailed 
measurement of levels for transcripts than other approaches. Bacterial transcriptomes have 
different characteristics than eukaryotic transcriptomes, in bacterial genome, the neighbour 
genes frequently overlap and consequently disturbing to differentiate between the start of 
individual genes transcript from the end of another (McClure et al., 2013). Thus bacterial 
RNA-seq data analysis has different aspects of eukaryotic RNA-seq data. 
Many technologies have been used successfully to infer and quantify the transcriptome, 
including hybridization and sequence based methods, the hybridization based technologies 
usually employed fluorescent labelled cDNA and custom-made microarrays or commercial 
high-density oligo microarrays (Wang et al., 2009). Bacterial transcriptomes have different 
features from the eukaryotic transcriptomes, in bacterial genomes the neighbouring genes 
usually overlap; consequently, interfering between the start of one gene transcript from the 
end of neighbour gene adds complexity to transcriptome analysis, this complexity of 
starting synthesis of protein which require many other proteins and regulatory elements, 
RNAP-associated proteins generality affect the processivity of RNAP (McClure et al., 
2013). The most complicated challenge to investigate proteome of microbe within a host 
model is how to recover a sufﬁcient number of bacterial cells from infected tissue 
(Bumann, 2010, Windle et al., 2010). 
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1.6.2 Bacterial proteins transcription: genes, promoters and regulatory factors 
Different promoters may control expression of genes or operons under specific conditions, 
and gene models for eukaryotic RNA genes are not similar for bacterial small regulatory 
RNAs (McClure et al., 2013). Bacterial genes are arranged in operons, which are defined 
as group of adjoining genes regulated through a single operator (Jacob and Monod, 1961), 
nevertheless this definition no longer convenient to different gene regulation aspects, it has 
been thought that this organization leads to an equal level of expression for all genes, 
however irregular gene expression level within the same operons was proved due to the 
failure of expression downstream genes in an operon because of the mutation in upstream 
of the operon and that lead to operon polarity (Güell et al., 2009). Bacterial transcription 
performed by single RNA polymerase (RNAP) holoenzyme complexes which employ a set 
of enzymes and σ-factors, the RNAP holoenzyme binds to various σ-factors that recognize 
different promoters and lead to control specific sets of genes, bacteria have varied numbers 
of σ-factors, while most of them have at least one of the housekeeping σ-factor family 
(Paget and Helmann, 2003). The start of protein translation usually requires a short 
sequence Shine-Dalgarno motif, which is located close to the start codon that recruits the 
ribosome to the mRNA (Güell et al., 2011). 
1.6.3 Transcriptional regulators in S. aureus 
Proteomics and transcriptomics are powerful combination to investigate genes expression. 
The relatively small size of S. aureus genome and their adaptability for evolution suggests 
that this bacterium has a high level of genome flexibility, depending on their environment 
(Holden et al., 2004). Many S. aureus strains have been extensively studied, however, the 
function of great number of their genes is still unidentified. S. aureus produces a numerous 
of virulence factors in a response to environmental changes, this successful behaviour 
strongly correlated with the regulation of genes expression, RNAs are known as the main 
regulatory molecules for the physiological and virulence factors of prokaryotes in response 
to various environmental and stress changes (Beaume et al., 2011). Almost 200 transcripts 
and antisense RNA molecules were identified and characterized to act as regulatory RNAs 
by showing that 10% of the intergenic regions in the genome of S. aureus contain 
expressed transcripts (Marie et al., 2010). S. aureus encodes 135 transcriptional factors 
(TFs) and sigma factors were identified and classified into 36 regulatory families, 43% of 
them have been experimentally characterized (Ibarra et al., 2013). 
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2.7 Project aims and objectives 
The investigations were undertaken with the following aims: 
The medical impact of S. aureus has led to the development of many concepts about their 
virulence features. The main aim of this research was to characterise the genetic features of 
S. aureus lipoproteins and examine their expression under different conditions to 
determine whether they may play a role in the virulence of the bacterium.   
 A bioinformatics analysis would be performed to investigate the total number of 
lipoproteins in S. aureus and identify their common molecular features between 
different strains that had their DNA sequenced. The initial part of this study would 
be to sequence lipoprotein genes to confirm that those genes were actually present 
in the examined strains.  
 A second aim was to evaluate and identify of lipoprotein genes of S. aureus and 
their expression in vitro and in vivo conditions, also whether they may play roles in 
pathogenicity by real-time PCR assay and RNA-Sequencing. 
Finally, the impact of proteomics and transcriptomics tools would be examined 
which would be used to follow the changes in lipoprotein gene expression proﬁles 
in response to S. aureus infection in a model system and explore new information 
on the pathogen physiology and pathogenicity. The host model C. elegans would 
be used to determine the changes in expression of lipoprotein genes and genes 
encoding different virulence factors that are regulated at different times during the 
infection process. 
 It was hoped that identification of different S. aureus lipoproteins and 
characterising them would clarify their importance for future studies that aim to 
clarify the molecular basis of the interaction between the invading bacteria and the 
host, in the field of inflammation, host innate immunity, infectious diseases and 
development of novel antibiotics and vaccines.   
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Material and methods 
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2. Material and methods  
2.1 Bacterial strains and growth conditions  
The highly successful epidemic hospital-acquired methicillin-resistant S. aureus strain 
EMRSA-16 clone (MRSA252) that was used in these experiments was obtained from the 
Health Protection Agency culture collections, UK; NCTC13277. S. aureus 8325-4 was 
taken from Professor Howard Foster culture collection. The clinical isolates T1 and 
RN4282 were taken from our culture collection and were originally supplied by Professor 
Valerie Edwards-Jones. T1 (FRI189S) was isolated from a case of menstrual TSS (MTSS) 
and was originally supplied by MS Bergdoll. Strain RN4282 was supplied by T.J. Foster, 
University of Dublin, Republic of Ireland, and originally obtained from Professor R.P. 
Novick. All strains were grown in tryptone soya broth media (Oxoid, Basingstoke, UK). 
Methicillin-resistant S. aureus NCTC 12493 was included as methicillin resistant quality 
control organisms obtained from Culture Collections Public Health England, UK. 
2.2 Oxacillin/cefoxitin disc diffusion test 
Bacterial sensitivity test was carried out on pure cultures of S. aureus strains to determine 
susceptibility and resistance to methicillin resistance in S. aureus, zones of inhibition were 
measured after incubation for 18-20 h. 
2.2.1 Photometric standardization of turbidity of suspensions (Moosdeen et al., 1988) 
A few colonies of each tested strain were mixed with 3 ml sterile distilled water to make   
a bacterial suspension with visible turbidity in a range >0.3-0.6 according to absorbance 
reading at 500 nm, this suspension was used within 15 min of preparation, 20 μl of 
bacterial suspension mixed with 5 ml sterile distilled water was used for inoculation of Iso-
Sensitest agar plates.  
2.2.2 Medium and inoculum preparation 
Inoculum was spread evenly over the entire surface of Iso-Sensitest agar (Oxoid, 
Basingstoke, UK), plates were allowed to dry for 10 min before applying discs of 30 μg 
cefoxitin, plates were incubated at 35°C in air for 18-20 h. MecA positive and methicillin-
resistant S. aureus NCTC 12493 was included as methicillin resistant control organisms. 
Cefoxitin test results interpretation were analysed according to the breakpoints of Clinical 
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& Laboratory Standards Institute, cefoxitin MIC breakpoints for determined inhibition 
zone was: susceptible = ≥ 22 mm diameter, resistant = ≤ 21 mm diameter. 
2.3 Proteomic analysis of S. aureus lipoproteins 
2.3.1 Lipoprotein extraction  
Lipoprotein isolation and fractionation of bacterial cell wall was performed according to 
the method described by Hashimoto et al. (2005). Bacterial growth was monitored 
spectrophotometrically by measuring at OD600 using Camspec M330 UV Visible 
Photospectrometer (Spectronic Camspec Ltd, UK). Briefly, 1 ml of bacterial cultures 
OD600 of 0.5 was diluted into 100 ml of tryptone soya broth (Oxoid, Basingstoke, UK) in a 
250 ml conical flask and incubated at 37°C with constant shaking at 150 rpm. Cultures of 
late exponential growth phase were harvested after 15 h (Kurokawa. et al., 2012). Bacteria 
were harvested by centrifugation at 12,000xg for 30 min, final pellets were resuspended in 
10 ml of TS buffer (NaCl, 50 mM, Tris HCL10 mM) supplemented with 1 mM protease 
inhibitor Pefabloc SC (Sigma-Aldrich, UK) to prevent protein degradation. Bacterial 
suspension was sonicated five times using a tip-probe sonicator for 10 sec and kept in ice 
to avoid extra heating, the mixture was centrifuged at 10,000xg for 10 min at 4°C to 
remove insoluble materials then 0.9 ml of bacterial suspension was mixed with 0.1 ml of 
20% non-ionic detergent Triton X-114 (Fisher Scientific, UK) and incubated for 2 h at 4°C 
on a rotator. Phases were allowed to separate at 37°C for 15 min in a water bath followed 
by centrifugation at 10,000g for 5 min for phase separation (upper aqueous phase and 
lower detergent phase). The lower detergent phase was collected and washed 3 x with TS 
buffer and the lipoproteins were recovered by adding 9 times the sample volume of 
acetone and storing at -20°C overnight. Final pellets were recovered by centrifugation at 
13,000xg for 10 min at 4°C. Proteins were quantified by NanoDrop 1000 
spectrophotometer (Thermo Scientific) with absorbance at 280nm. 
2.3.2 Lipoprotein separation  
2.3.2.1 Analytical and preparative 1-D/2-D PAGE 
In order to examine the extracted proteins by SDS-PAGE, samples were suspended in 
Laemmli buffer x 2 (0.5 M Tris-HCl, pH 6.8, glycerol, 12% (w/v) SDS, 0.1% (w/v) 
bromophenol blue), then loaded in separating gel 12% and stacking gel 4% as in table 1, 
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by loading 12 μl of each sample and 5 μl of unstained protein molecular weight marker, 
gels run at 180 V for 2h with SDS-PAGE running buffer (0.192 M glycine, 25 mM Tris-
base and 0.1% SDS), the gels were run in mini-protein III gel electrophoresis equipment 
(Bio-Rad, UK).  
Gels were stained for 2h in 45 ml of methanol, 0.1 g coomassie brilliant blue, 100 ml 
acetic acid and 70% distilled water, then gels were destained in a solution of 100 ml 
methanol, 35 ml acetic acid in 1L distilled water, with shaking for 3h. 
 
Table 1. SDS-PAGE loading gel concentrations 
Solution Separating gel 12% Stacking gel 4% 
Sterile deionised water 9.6 ml 4.96 ml 
30% acrylamide mix 8 ml 0.74 ml 
0.4% SDS in 1.5 M Tris-base pH 8.8 6 ml - 
0.4% SDS in 0.5 M Tris-base pH 6.8 - 1.86 ml 
10% ammonium persulphate 90 μl 75 μl 
Tetramethylethylenediamine 9 μl 9 μl 
 
2.3.2.2 Protein separation in 2-D gels  
Complex proteins samples from bacterial cells can be separated to produce an individual 
protein spots to give clear 2-D maps of the proteome. First dimension was carried out 
using two different sizes pH 3-10 18-cm I and pH 3-5.6 7 cm PG non-linear Immobiline 
DryStrip gel strips (Amersham Pharmacia Biotech, Sweden). Approx. 100 μg proteins 
prior to analysis were rehydrated in 340 μl of rehydration buffer [7 M urea (Sigma-
Aldrich, UK), 2 M thiourea (Sigma-Aldrich, UK), 2% CHAPS (Sigma-Aldrich, UK), 0.5% 
Bio-Lyte pH 3-10 carrier ampholytes, 0.2% DTT and 0.1% bromophenol blue solution]. 
Amersham Ettan™ IPGphor II isoelectric focusing system (GE Healthcare, UK) was used. 
IPG gel strips were isoelectrically focused for a total of 85000 Vh, running conditions 
were as follows: 500 V for 500 Vh, followed by two gradients of 1000 V for 800 Vh and 
8000 V for 13 500 Vh and finally 8000 V for 20 000 Vh. IPG gel strips were equilibrated 
in 75 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS and 0.1% bromophenol blue 
solution, including 1% DTT in the reduction step (15 min) and 2.5% iodoacetamide in the 
alkylation step (15 min). The second dimension was performed on 12.5% SDS-
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polyacrylamide slab gel (25 x 19.5 x 0.15 cm) was prepared in Multi-Casting Chamber 
(Bio-Rad), strips were embedded in 0.5% agarose in cathode buffer (0.192M glycine, 25 
mM Tris-base and 0.1% SDS). Separation was carried out at room temperature, gels were 
run by electrophoresis in a Protean II xi 2-D Cell (Bio-Rad) at 110 V for the first 20 min 
and then at 180 V until the bromophenol blue reached the bottom of the gel. Protein spots 
in all gels were stained for 1 h with coomassie brilliant blue solution, gel was destained in 
a solution of 100 ml methanol plus 35 ml acetic acid in 1L distilled water for 3 h, stained 
gels were scanned using a Quantity One scanner (Bio-Rad). Individual spots were excised 
from gels and subjected to trypsin digestion.  
2.4 In-gel Trypsin digestion  
Stained proteins spots and bands containing target proteins were subjected to series of 
reduction and alkylation reaction in Eppendorf tubes, the alkylation reaction results in 
carbamidomethyl modified cysteine residues. The first step was reduction of the gel spots 
with 50 mM ammonium bicarbonate NH4 HCO3 ( Fisher Scientific, UK), 150 μl of NH4 
HCO3 was added to each gel spot and incubated for 15 min then the ammonium 
bicarbonate was discarded and replaced with 150 μl of 50% acetonitrile for each tube to 
remove coomassie dye and incubated for 15 min, this process was repeated for three times 
to remove all stain, 5 mM of dithiothreitol (Fisher Scientific, UK) was added to each tube 
and incubated for 1 h in a heating block at 60°C, in this step proteins were subjected to 
denaturation and alkylation of disulfide bonds at the cysteine residues. After removing the 
supernatant, 15 mM iodoacetamide (Fisher Scientific, UK) was added to each tube and 
incubated for 1 h in the dark, this step prevent proteins to form disulfide bonds by binding 
iodoacetamide which act as irreversible inhibitor of all cysteine peptidases. Supernatant 
was removed and replaced with 50 mM NH4 HCO3 and incubated for 15 min at room 
temperature, liquid was discarded and 150 μl of 50% acetonitrile added and left for another 
15 min, after this step as much liquid as possible was removed. Trypsin Sequencing Grade 
enzyme (Promega, Madison, WI, USA) which specifically hydrolyzes peptide bonds at the 
carboxylic sides of lysine and arginine residues, solution at a ratio of 1:100 (20 μg was 
mixed with 20 μl of a stability-optimized resuspension buffer solution and 400 μl of 50 
mM NH4 HCO3, this mixture were added to gel spots tubes and incubated at 37°C for at 
least 8 h then the liquid was collected and kept in new tubes labelled with final peptide 
digested tube, while 100 μl of acetonitrile TFA solution was added to gel spots and  
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incubated at room temperature for 1 h and the final supernatant were added to final peptide 
digested tubes, extra extraction of liquid from the digest gel was extracted by addition of 
40 μl of water, extracted tryptic peptides were analysis by mass spectrometry.  
2.5 Protein identification by LC/MS/MS  
Tryptic peptides were desalted and purified by using an in-house manufactured C18 
purification tip, briefly, C18 Zip-Tip (10 μl pipette tip with 0.5 μl bed of C18 silica based 
medium fixed at its tip) was wetted with 15 μl of 50% acetonitrile and 0.1% TFA, C18 tip 
was equilibrated with 15 μl of 0.1% TFA, material was slowly aspirated and dispensed, 
desalting was performed by aspirating and dispensing 10 μl of 0.1% TFA, then peptides 
were eluted with 20 μl of 50% acetonitrile and 0.1% TFA, then peptides were analysed on 
Thermo QExactive mass spectrometer coupled to a Dionex RSLC nano system (Dionex), 
samples were resolved on a Nano EASY (Thermo Scientific, UK) C18 reverse-phase 
column fitted with a 50 cm long, 75 µm internal diameter, reverse-phase column and 
resolved using a 60 min gradient. Liquid chromatography and mass spectrometry was 
performed at Central Proteomics Facility, Sir William Dunn Pathology School, Oxford 
University. A nano-spray injection was employed to introduce samples into a Brucker 
Esquire 3000 plus ion trap mass spectrometer. Generated raw data file (.dat) was analysed 
by data processing MaxQuant software package to create peak lists mascot generic file 
(.mgf) based on the acquired MS/MS spectra, proteins were identified by Mascot server 
(version 2.4; Matrix Science, London, UK), outcome data were searched against the 
UniProt KB/Swiss-Prot of S. aureus MRSA252 proteins sequence database.  
2.5.1 Protein identification by peptide mass fingerprinting/MALDI TOF-MS  
Tryptic peptides obtained from gel spots digestion were mixed with a solution of 50% 
acetonitrile, 0.1% trifluoroacetic acid (Sigma-Aldrich, UK) and 10 mg α-cyano-4-
hydroxycinnamic acid /ml (Sigma-Aldrich, UK) and then placed onto 96 well 1/4 
microtitre stainless steel plate and incubated  for 10 min to crystallize. Samples were 
analysed by MALDI-TOF MS operated in positive linear mode, internal calibration 
containing mixed of four peptides are summarized in table 2, were used to calibrate results. 
A brief summary in figure 7 shows the proteomic outline for all methods used to 
investigate lipoprotein in S. aureus including gel based and gel-free peptide digestion 
procedures.   
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Table 2. Mixture of 20 μM stock solutions made up of 4 peptides of known sizes used 
as internal calibration 
Peptides Size of peptide 70 μl solutions contain 
Bradykinin fragment 2-9 904.02 g/mol 10 μl 
Bombesin (acetate salt hydrate) 1,619.8 g/mol 10 μl 
Angiotensin II (acetate) 1,032.1 g/mol 20 μl 
ACTH (adrenocorticotropic hormone 
fragment 18-39 human) 
2,465.6 g/mol 30 μl 
 
 
2.5.2 Quantitative proteomics techniques  
2.5.2.1 In-solution digestion, Liquid Chromatography and Mass Spectrometry 
(LC/MS/MS) 
One hundred micrograms of protein mixtures from each sample were trypsin digested as 
described in section 2.4 section and the resulting digest was analysed by the LC/MS/MS, 
analysis performed using a Dionex RSLC nano ultrahigh pressure HPLC system fitted 
with a 50cm long and 75 micron internal diameter reverse-phase column and resolved 
using a 60 min gradient and coupled with high-resolution Thermo Q-Exactive Orbitrap 
Mass Spectrometer Liquid chromatography, the mass spectrometry and proteins identified 
by Mascot were performed at Central Proteomics Facility, Sir William Dunn Pathology 
School, Oxford University.  
The raw data files were analysed by data processing quantitation MaxQuant software 
package, version 1.2.2.5 (Cox and Mann, 2008), to create peak lists mascot generic file, 
then proteins identified by Mascot (version 2.4; Matrix Science, London, UK), tryptic 
digested peptides generated from mass spectrometric were searched against proteins 
database followed by matching with relatively corresponding proteins list of UniProt 
KB/Swiss-Prot of S. aureus MRSA252 proteins sequence. Spectra were normalised by the 
method of spectral abundance factor (NSAF) to calculate samples variations of expression 
changes (Zybailov et al., 2006). 
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In-gel (left) and in-solution (right) protein digestion procedures and subsequent LC-
MS/MS analysis of lipoprotein samples. 
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Figure 7. Workflows of in-gel and in-solution protein digestion procedures 
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2.6 Bioinformatics of S. aureus genomic DNA 
2.6.1 Bacterial genomic DNA extraction 
Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany) as in the manufacturer’s protocol. Briefly, harvested bacterial pellets were 
washed twice with 0.15 M NaCl, 10 mM EDTA (pH 8.0) and resuspended in lysozyme 
solution (10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA, 10 mg/ml lysozyme and 1mg/ml 
lysostaphin) and incubated for 30 min at 37°C, lysed cells were added to 25 μl proteinase 
K (Qiagen) and 200 μl AL buffer, samples were mixed and incubated at 56°C for 30 min, 
followed by adding 200 μl 100% ethanol and vortexed to homogenise the solution which 
was transferred into DNeasy Mini spin columns and centrifuged for 1 min at 6,000 x g. 
Columns were placed in new 2 ml collection tubes, 500 μl AW1 buffer were added and 
centrifuged for 1 min at 6000 x g, finally 500 μl AW2 buffer were add and centrifuged for 
3 min at 17,000 x g prior to eluting DNA with 100 μl TE buffer (10 mM Tris-HCl, pH 8.0; 
1 mM EDTA), DNA was verified by 1.5% agarose gel electrophoresis, isolated DNA 
stored at -20°C till further use.  
2.6.2 Polymerase Chain Reaction (PCR)  
All primer pairs were designed by Primer-BLAST (Ye et al., 2012), on the basis of 
published S. aureus genome MRSA252 (GenBank accession no NC_002952), by 
alignment of published DNA sequences of target lipoprotein genes at 
http://www.ncbi.nlm.nih.gov/ tools/primer blast/ index. S. aureus MRSA252 strain list of 
lipoprotein genes examined in this experiment with the accession numbers, oligonucleotide 
primers, nucleotide location and size of PCR product for each gene fragments are given in 
table 4.  
PCR amplification was performed in a thermal cycler (Stratagene Robocycler Gradient 96 
Thermal Cycler), VELOCITY DNA Polymerase (Bioline, UK) was used, reaction mixture 
consisted of 25 μl, 5 μl 5x Hi-Fi reaction buffer, 1 μl 10 mM dNTP Mix, 1 μl 10 μM each 
primers, 1.5 μl DMSO, 1 μl polymerase enzyme, 20 ng DNA template and 15 μl of 
nuclease free water. PCR reaction mixtures were heated for initial denaturation at 94°C for 
2 min; followed by 35 cycles of amplification; denaturing, annealing and extension at 
94°C (30 s), 58°C (1 min) and 72°C (1 min); with one final extension cycle at 72°C for 10 
min. PCR products were separated by 1.5%  agarose gel electrophoresis in 1x TBE buffer 
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(pH 8; 0.09 M Tris, 0.09 M boric acid, 2 mM EDTA) and 0.03% (wt/vol) GelRed               
( Biotium, UK), incorporated for DNA staining. Five microliters of PCR products were 
mixed with 5 μl of loading buffer and applied to each gel well; gels were run in 1x TBE 
buffer at 100 V for 1 h then visualized and photographed on a UV transilluminator. A 50 
bp Hyperladder II (Bioline, UK) was used as molecular size markers in all gels. 
2.6.3 S. aureus genes sequencing, annotation and comparative analysis  
PCR products were purified by using the QIAquick PCR purification kit (Qiagen) and 
subjected to Sanger sequencing technology (Sanger et al., 1977) at Eurofins MWG 
Operon. Sequencing was performed using either of the primers used for PCR, forward and 
reverse reads were generated for all amplicons and analysed using FinchTV viewer 
(Version 1.4.0, Geospiza, Inc., Seattle, WA, USA; http://www.geospiza.com). Each 
chromatogram file of nucleotide sequences for complete sequenced lipoprotein genes of 
RN4282 and T1 S. aureus strains were individually checked for final use by using 
FinchTV viewer, while translated predicted lipoprotein DNA sequences for other 18 
strains were obtained from publicly available databases the National Centre for 
Biotechnology Information (NCBI), http:// www. ncbi.nlm.nih.gov. Table 3 shows the S. 
aureus strains used in BLAST comparative analysis. Sequence homology of each target 
gene in a genome was first identified using BLAST function of GenBank database 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM =blastn &PAGE_TYPE= BlastSearch 
& LINK_LOC=blasthome, a list of predicted lipoprotein and their amino acids sequences 
of S. aureus MRSA252 is available at http://www.mrc-lmb.cam.ac.uk/ genomes /dolop 
/predicted/a.shtml, and included in section 3.2.4 (table 12). All sequence reads were 
aligned against S. aureus MRSA252 strain, 50 lipoprotein selected genes were sequences 
and aligned to identify SNPs and large regions of difference, nucleotides sequences were 
trimmed with Proseq 3.5 (Filatov, 2002).  
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Table 3. S. aureus strains used in BLAST comparative analysis 
S. aureus strain Pathogenicity Host Reference 
S. aureus MRSA252 HA-MRSA Human (Holden et al., 2004) 
S. aureus RN4282 MSSA Human 
(Edwards-Jones and Foster, 
2002) 
S. aureus T1 MSSA Human 
(Edwards-Jones and Foster, 
2002) 
S. aureus COL HA-MRSA Human and animals (Gill et al., 2005) 
S. aureus MSSA476 MSSA Human and animals (Holden et al., 2010) 
S. aureus MW2 CA-MRSA Human (Baba et al., 2002) 
S. aureus N315 HA-MRSA Human (Kuroda et al., 2001) 
S. aureus Mu50 HA-MRSA Human (Kuroda et al., 2001) 
S. aureus T0131 HA-MRSA Human (Li et al., 2011) 
S. aureus TW20 HA-MRSA Human (Holden et al., 2010) 
S. aureus BMB9393 HA-MRSA Human (Costa et al., 2013) 
S. aureus LGA251 MRSA Human and animals 
(García-Álvarez et al., 
2011) 
S. aureus RF122 MSSA animals (Herron-Olson et al., 2007) 
S. aureus ST398 MRSA Human and animals (Witte et al., 2007b) 
S. aureus M013 CA-MRSA Human (Huang et al., 2012) 
S. aureus M1 MRSA Human 
(Larner-Svensson et al., 
2013) 
S. aureus Mu3 HA-MRSA Human (Neoh et al., 2008) 
S. aureus str. 
Newman 
MSSA Human (Baba et al., 2008) 
S. aureus 
NCTC8325 
MSSA Human (Iandolo et al., 2002) 
S. aureus VC40 VRSA Human (Sass et al., 2012) 
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 Table 4. Oligonucleotide primers, base sequences, genes locations, and predicted sizes of PCR products for S. aureus lipoproteins 
ORF indicates the gene locus in MRSA252 strain (http://www.genedb.org/Query/geneType?taxons=Saureus_MRSA252&type=mRNA) 
Gene ORF 
Gene 
accession 
No 
Primers Oligonucleotide sequence (5’→3’) 
Nucleotide location 
within genome (bp) 
Size of PCR 
product (bp) 
SAR0118 YP_039582 
Forward 
 
TGTTTTTCAATATTTAACTTTTCATA 
128,926..129,918 993 bp 
Reverse 
 
GAATAAAGTAATTAAAATGCTTGTTGTTA 
SAR0174 YP_039639 
Forward 
 
ATGAAAAGGTTAAGCATAATCGTCA 
191,762..192,736 975 bp 
Reverse 
 
TCATGAACGTGATGCCTCCT 
SAR0201 YP_039666 
Forward 
 
GTGAAGAAAATCATTAGTATCGCA 
231,906..233,681 1776 bp 
Reverse 
 
TTATTGATTAATGGCTTTTTCTACT 
SAR0206 YP_039671 
Forward 
 
TAAAATATATCACGTTAGCCGTGGTAATG 
239,168..240,439 1272 bp 
Reverse 
 
TTTTGTGACGGATGAAGAATCTTAA 
SAR0216 YP_039681 
Forward 
 
TCATTGAATCATCTCCAAAAA 
251,020..251,988 969 bp 
Reverse 
 
GAAATCAAAAATTTATATCTTGCTA 
SAR0230 YP_039695 
Forward 
 
AGTTCGATAATCGATTAAATAGATACCT 
271,601..273,076 1476 bp 
Reverse 
 
TGAAGTTTAAAAGACTAGCAACTATATT 
SAR0340 YP_039797 
Forward 
 
ATGAAAAAGTTAACAACGCT 
385,032..385,886 855 bp 
Reverse 
 
TCATTCAGTAATCACAGCCA 
SAR0201 YP_039666 
Forward 
 
GTGAAGAAAATCATTAGTATCGCA 
231,906..233,681 1776 bp 
Reverse 
 
TTATTGATTAATGGCTTTTTCTACT 
SAR0340 YP_039797 
Forward 
 
ATGAAAAAGTTAACAACGCT 
385,032..385,886 855 bp 
Reverse 
 
TCATTCAGTAATCACAGCCA 
SAR0390 YP_039845 
Forward 
 
ATGAAATTAAAATCATTAGCAGTGT 
426,962..427,534 573 bp 
Reverse 
 
TTATTGATCTTGCTCACTCT 
SAR0396 YP_039852 
Forward 
 
TTATTTATCGATAACATCACTCTTGA 
430,210..430,836 627 bp 
Reverse 
 
AGAGATTACTACTAAGTACATTTTTAGCA 
SAR0438 YP_039889 
Forward 
 
ATGATGGGAAATATAAAAAGTT 
467,513..468,295 786 bp 
Reverse 
 
TTAGCTATCTTCATCAGACG 
SAR0439 YP_039890 
Forward 
 
AGGTTTGCATTGTACATAAGCG 
468,343..469,116 774 bp 
Reverse 
 
TGGTTTATAACTTAAAAATTCAATGA 
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Table 4-continued 
Gene ORF 
Gene 
accession No 
Primers Oligonucleotide sequence (5’→3’) 
Nucleotide location 
within genome (bp) 
Size of PCR 
product 
(bp) 
SAR0442 YP_039891 
Forward 
 
ATGGGATATTTAAAAAGGATTG 
469,987..470,757 771 bp 
Reverse 
 
CTATTTTTTCGCTGGCTTAT 
SAR0443 YP_039892 
Forward 
 
ATGAGATATTTAAATAGAGTTGTACTGTAC 
470,789..471,589 801 bp 
Reverse 
 
TCATTCATCATCTTCATTCACC 
SAR0444 YP_039893 
Forward 
 
TGAAGTCTATAAAAAGGATTGGAT 
471,608..472,402 794 bp 
Reverse 
 
TTAGTAATTATATTTATCCTCGCTT 
SAR0463 YP_039912 
Forward 
 
ATGAAAAGATTGATTGGGTTAGTTATC 
491,739..492,581 842 bp 
Reverse 
 
TTATTTTGCTAATGACGTTTCTATTGCC 
SAR0618 YP_040063 
Forward 
 
GTGAAGAAATCGTTAATTGCT 
666,806..667,693 888 bp 
Reverse 
 
TTATTTTCTATAAATTGCATCTCT 
SAR0641 YP_040083 
Forward 
 
TTATTTCATGCTTCCGTGTA 
687,790..688,719 930 bp 
Reverse 
 
AAAAATTAGTACCTTTATTATTAGC 
SAR0706 YP_040140 
Forward 
 
TTATTTTTTATCACGTTTATGGAGCC 
746,977..747,084 105 bp 
Reverse 
 
GTGCGATTTATGAATGAAATTCTTGTT 
SAR0730 YP_040157 
Forward 
 
ATGAAGAAATTAATCATCAGC 
766,363..766,752 390 bp 
Reverse 
 
TTATGATTGGTGTTTGTCATTA 
SAR0790 YP_040217 
Forward 
 
ATGAAGAAAACAGTCTTATATTTAGTA 
828,218..829,246 1029 bp 
Reverse 
 
TTATTTTACAACTTTTTCAAGTTC 
SAR0794 YP_040221 
Forward 
 
ATGAAAAAAATTGTTATTATCGC 
831,583..832,461 879 bp 
Reverse 
 
TTATTTTTCTTCTAATTTTTCAAGC 
SAR0872 YP_040295 
Forward 
 
AATTATTTGGTCTTATTTTAGTATTA 
910,328..911,149 822 bp 
Reverse 
 
CACCGTTGTATTTTTCATTAA 
SAR0953 YP_040375 
Forward 
 
ATGACAAGAAAGTTAAAAACGCTGAT 
995,948..997,603 1656 bp 
Reverse 
 
TTATTTTTTCTTCTTACCTGTTTCTTTA 
SAR1011 YP_040427 
Forward 
 
GTGAATAGGAATATCGTTAAATTAGTTGT 
1,054,214..1,055,173 960 bp 
Reverse 
 
TAAATCTTCTGCCATACTTTCACTTG 
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Table 4-continued 
Gene 
ORF 
Gene 
accession No 
Primers Oligonucleotide sequence (5’→3’) 
Nucleotide location 
within genome (bp) 
Size of PCR 
product (bp) 
SAR1034 YP_040449 
Forward 
 
TTAATGTCCACCTCCATGA 
1,079,932..1,081,032 1101 bp 
Reverse 
 
GTGTCAAAATTTAAGTCTTTGCTT 
SAR1066 YP_040479 
Forward 
 
ATGAAATTTGGAAAAACAATCGCA 
1,112,113..1,112,739 627 bp 
Reverse 
 
TTATTTAAATTGATCAACGTCTTGC 
SAR1106 YP_040519 
Forward 
 
TTGAGAATCATAAAGTATTTAACCATTT 
1,152,065..1,152,943 879 bp 
Reverse 
 
AATCATATAATTGAGTCATTGCCTTATC 
SAR1189 YP_040600 
Forward 
 
ATGAAAAAGACACTGGGATGT 
1,238,170..1,239,123 954 bp 
Reverse 
 
TATTTTAAAGAATCATCTGACGCTG 
SAR1288 YP_040698 
Forward 
 
TCATATTATTTTCTTCATAAACTGG 
1,352,458..1,352,814 357 bp 
Reverse 
 
TGAGGCGATGGTTTGTATT 
SAR1494 YP_040896 
Forward 
 
GTCAAACACACCATATTCTGA 
1,589,460..1,590,368 905 bp 
Reverse 
 
TGTTTAAAAGAACTAAACTAATCTT 
SAR1495 YP_040897 
Forward 
 
TCATTCGACCTCAATCCTTATAGAC 
1,590,426..1,591,331 906 bp 
Reverse 
 
GGCAAAATTAATCTTAATAGCAACG 
SAR1558 YP_040960 
Forward 
 
AAAAAGTAATCGGACTGCTAC 
1,634,418..1,634,852 427 bp 
Reverse 
 
TTAATATTGGCTCCTGGTACTG 
SAR1608 YP_041004 
Forward 
 
ATGAAAAAATTGGTTTCAATTGTTGGC 
1,681,001..1,681,582 582 bp 
Reverse 
 
TCATGATTTTGCATTTAAGTTTAATTTTG 
SAR1831 YP_041217 
Forward 
 
AGTTAATATTTTTAATTGTAATTGCTTTA 
1,913,827..1,914,672 846 bp 
Reverse 
 
AATTCCTTCATTACACTCTTGGC 
SAR1879 YP_041264 
Forward 
 
ATGTTAAAAGGATGCGGCGG 
1,966,068..1,966,682 555 bp 
Reverse 
 
ATTTATCAGGTTCACATGCACGTTT 
SAR1881 YP_041266 
Forward 
 
AATTCAAAGCTATCGTTGCAATCAC 
1,967,834..1,968,460 627 bp 
Reverse 
 
TAGTTTCTGCTGAATTATTTTCACG 
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Table 4-continued 
Gene ORF 
Gene 
accession No 
Primers Oligonucleotide sequence (5’→3’) 
Nucleotide location 
within genome (bp) 
Size of PCR 
product (bp) 
SAR1995 YP_041368 
Forward 
 
TTAATTACTGTAAATATGAACTTGCGG 
2,084,777..2,085,976 1200 bp 
Reverse 
 
ATGAAGCGTACATTAGTATTATTGATTA 
SAR2104 YP_041470 
Forward 
 
AGATTGTTAGGTTTATTATTAGTGAGCAC 
2,166,873..2,167,337 460bp 
Reverse 
 
TCAATTATCATTATTTATAATTTCAGAAA 
SAR2179 YP_041538 
Forward 
 
TTATTTCTTTTTCTTTTTAGACACTACT 
2,249,989..2,250,861 873 bp 
Reverse 
 
ATGAAGAAAAAAACGTTACTACCATTAT 
SAR2268 YP_041621 
Forward 
 
TTACTTTTGTTCTTTTTTTGATAAT 
2,349,338..2,350,321 984 bp 
Reverse 
 
ATGAGAGGTCTAAAAACTTTTAGTATAT 
SAR2363 YP_041718 
Forward 
 
TTATGCTGTAAAGTGGTATTCTT 
2,433,026..2,433,808 783 bp 
Reverse 
 
ATGAAAATGAAACGTTTTATAGCT 
SAR2368 YP_041723 
Forward 
 
TTGCAGCTTTAATTAATTTTTCTT 
2,437,923..2,438,831 904 bp 
Reverse 
 
ATGAAAAAACTATTATTACCATTAATAA 
SAR2457 YP_041810 
Forward 
 
TTATTGTTGGTAGTTTGGATCAG 
2,528,101..2,528,730 630 bp 
Reverse 
 
AAAATTAGTTACAGGGTTATTAGC 
SAR2496 YP_041846 
Forward 
 
TTAATGCGCTAACATTTCTTCT 
2,569,326..2,570,873 1548 bp 
Reverse 
 
ATGAAAAAGAAATTAGGTATGTTACTT 
SAR2499 YP_041849 
Forward 
 
TTGATTTTATCTTTTAATAATTTTTCATA 
2,571,954..2,572,553 600 bp 
Reverse 
 
AATTACTAACATTATTTATAGTGAGCATG 
SAR2500 YP_041850 
Forward 
 
CTAGTTCGTCATATTTTCTTCAT 
2,572,572..2,572,934 363 bp 
Reverse 
 
TTTGTGGCGACGGTATTATT 
SAR2504 YP_041854 
Forward 
 
AGATTTAGAAACATCTTGACCAAAC 
2,575,960..2,576,739 780 bp 
Reverse 
 
AAAGACTTTTATTTGTGGTGATAGC 
SAR2536 YP_041887 
Forward 
 
TTACTTATGACCACCTTTCTGTTTAT 
2,615,364..2,616,305 942 bp 
Reverse 
 
AATATATACTTGTCGTGCTTGTCTTA 
SAR2546 YP_041897 
Forward 
 
GAAAAAATTATGTTCATTAATTGTAGTAG 
2,627,660..2,628,115 456 bp 
Reverse 
 
CTATTTGTCGTCCATTTTATCTTTT 
SAR2554 YP_041905 
Forward 
 
CATTTCATTGAATGGTAATTCATACTGT 
2,635,602..2,637,200 1599 bp 
Reverse 
 
ATGAGAAAACTAACTAAAATGAGTGCAAT 
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2.6.4 Computation of sequence parameters 
Ratios of synonymous and nonsynonymous nucleotide substitutions were calculated using 
the method of Nei & Gojobori, 1986, which is implemented in MEGA version 6 (Tamura 
et al., 2013). Nucleotide diversity (π) the mean percentage of polymorphic sites over all 
pairwise comparisons was calculated by MEGA version 6. The ORF (Open Reading 
Frame) were identified by using ORF finder http://www.ncbi. nlm.nih.gov/gorf, to display 
evidence of frame shifts or mutations leading to a premature stop codon, nucleotide 
diversities and species divergence calculations were performed using MEGA 6 and DnaSP 
v5 (Librado and Rozas, 2009). Calculations of nucleotide (n) diversities for each gene 
were determined by MEGA 6 and DnaSP v5 software. Nucleotide diversity in 
synonymous, nonsynonymous and silent sites (synonymous sites are those sites in a codon 
where nucleotide changes result in synonymous substitutions) were computed using 
method of Nei and Gojobori 1986.  
2.6.5 Phylogenetic analysis and the concatenation approach  
There are various ways to construct phylogenetic trees from multiple genes for the same 
set of species. The most recent phylogenetic tree reconstruction is the genes concatenated 
head-to-tail to form a super-gene alignment. The statistical advantage of this method gives 
more phylogenetic accuracy by increasing the sample size. 
Reconstruction of evolutionary relationships was carried out by using two different 
software packages, Seaview 4 (Gouy et al., 2010), and MEGA version 6 (Tamura, et al 
2013) to confirm the phylogenetic results. Bayesian phylogeny was reconstructed from the 
concatenated sequences, 44 genes varying in sequence and in length from 105 to 1776 bp 
were used for the phylogenetic analysis (six genes were not present in all strains), 
representing 37670 bp were used to construct trees using the neighbour-joining tree 
method (Saitou and Nei, 1987), using default parameters except where specified. 
Nucleotide sequences were aligned using Clustal W2 (Larkin et al., 2007), with a manual 
adjustment. In order to root all created trees, the mid-point rooting (MPR) method were 
employed, the root of an unrooted tree is placed at the mid-point of the longest distance 
between the two most divergent operational taxonomic units (Hess and De Moraes Russo, 
2007).  
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Nucleotide homologous sequences were aligned with clustalW2 software (Larkin et al., 
2007), however, phylogenetic analyses were applied to the concatenated nucleotide 
sequence of 44 lipoprotein genes ( the most commen lipoprotein genes) for each S. aureus 
strain, the phylogenetic reconstruction method used neighbor-joining (NJ) method 
implemented in MEGA 6 software, the main advantages of this method is fast, suited for 
large datasets and for bootstrap analysis (Felsenstein, 1997). NJ tree was based on the 
gamma-corrected nucleotide distance, with parameter (a = 0.01) estimated by MrModeltest 
2.3 program (Posada and Crandall, 1998). In NJ trees, the reliability of internal branches 
was assessed by bootstrapping method for estimating the standard error (Efron and 
Tibshirani, 1986), which is installed in MEGA 6, 1,000 bootstrapping consensus 
pseudosamples were used. Tree drawing was managed with FigTree application (FigTree, 
2014). 
2.6.6 Nucleotide substitution and SNP analysis 
The generated nucleotide sequences for all genes were analysed to calculate the number of 
synonymous nucleotide substitutions (dS) and nonsynonymous nucleotide substitutions 
(dN) by a maximum-likelihood method using the DnaSP program, the outcome values 
were consistent with the phylogenetic analysis results. In order to investigate the single 
nucleotide polymorphisms SNPs, lipoprotein genes sequence of all strains were aligned 
against MRSA252 S. aureus reference genome.  
2.6.7 Lipobox features  
The publicly available complete genome sequences for S. aureus strains provided a useful 
starting point to research for lipoprotein with the improved multiple sequence alignment 
programs. The translated protein sequence of 50 predicted lipoprotein genes for two 
sequenced S. aureus and 18 other previously sequences strains available at the National 
Centre for Biotechnology Information NCBI http:// www. ncbi.nlm.nih.gov, were chosen 
to examine lipobox features, the first 45 amino acids sequences from each lipoprotein 
genes were aligned using MEGA 6 software to identify the consensus sequence. 
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2.7 Isolation of RNA and assessment quality/concentration  
2.7.1 RNA extraction  
Total RNA was isolated from S. aureus using PureLink RNA Mini Kit (Ambion) as in the 
manufacturer’s protocol, with slight modifications as outlined below. Briefly, 3 ml of 
bacterial culture cells ( ≤1 ×109 cells) at two times of exponential phase (4 and 8 h) were 
harvested and suspended with 6 ml RNAprotect Bacteria Reagent (Qiagen, Hilden, 
Germany), vortexed for 30 sec and incubated at ambient temperature for 10 min. The 
mixture was then centrifuged for 10 min at 5,000 x g. Pelleted cells were resuspended in 
lysozyme solution 10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA, 10 mg/ml lysozyme, 1 
mg/ml lysostaphin and Proteinase K, samples were incubated for 30 min at 37°C with 
shaking, 350 μl lysis buffer prepared with β-mercaptoethanol (10 μl β-mercaptoethanol per 
1 ml) was added and vortexed for 1 min. Samples were then homogenized in high-speed 
homogenizer (Invitrogen) and the supernatant was diluted with 100% ethanol. Binding, 
washing and elution steps were carried out in a Mini Spin column as in the manufacturer’s 
instruction. Eluted RNA was treated with DNase I, Amplification Grade (Invitrogen, UK), 
1 U/ 1 μg of total RNA at 37°C for 60 min to digest single and double stranded DNA, 
DNase I was inactivated by addition of 1 μl of 25 mM EDTA and the reaction mixture was 
incubated for 10 min at 65°C, removal of genomic DNA was confirmed by PCR. Integrity 
of total RNA was carried out at 70 V for 1 h using a 1% (w/v) agarose gel and stained with 
Gel Red (Biotium, UK), RNA concentrations were measured by NanoDrop 1000 
spectrophotometer (Thermo Scientific), three independent measurements of the same 
sample were performed, all RNA isolations resulted in acceptably low levels of protein 
contamination (A260/A280 ≥1.95), ratio of sample absorbance at 260 and 280 nm of ~2.0, 
samples stored at - 80°C for further use.  
2.7.2 cDNA synthesis  
cDNA was synthesized using Superscript III reverse transcriptase (Invitrogen). One 
microgram of total purified RNA was combined with 100 ng of random hexamers primers 
and 1ul 10 mM dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP) at neutral pH, 
then the mixture was heated at 65°C for 5 min and incubated on ice for 2 min. cDNA 
synthesis reaction volume consisted of 4 μl 5X first-strand buffer, 1 μl 0.1M DTT, 1 μl 
RNaseOUT 40U / μl (Ambion) and 1 μl of SuperScript III RT 200U/ μl, 1 μg RNA and 1ul 
10 mM of random hexamers primers, tubes was centrifuged briefly and incubated at 25°C 
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for 5 min, 55°C for 60 min, and reaction inactivated by heating at 70°C for 15 min, prior to 
degrading RNA with RNase H (Biolabs) for 20 min at 37°C, cDNA purified using a 
QIAquick PCR purification kit (Qiagen).  
2.7.3 Quantitative RT-PCR using dual labelled probes  
Lipoprotein gene expressions were determined by TaqMan quantitative RT-PCR to find 
out the relative expression levels of each gene under investigation within the same growth 
conditions. High purified salt-free oligonucleotide primers and dual labeled TaqMan 
probes were designed by using software provided by Eurofins Genetics Services, UK, 
http://ecom2.mwgdna.com/services/webgist/dual probe_design.tcl?ot=OLIGO DLPD& 
itemid=new, also synthesized by Eurofins Genetics services are listed in table 5. TaqMan 
probes were labeled with FAM on the 5’ end and TAMARA on the 3’ end. Predicted 
qPCR product sizes were in 100-150 bp range, while all experiments were performed in 
triplicate. Three independent experiments were conducted for 4 h and 8 h of grown culture, 
optimized PCR reactions were conducted in a total volume of 25 μl containing 2 μl of 
cDNA (1 μg of RNA), 12 μl 2 x QuantiTect Probe PCR Master Mix (QuantiTect Probe 
PCR Kit Qiagen) containing HotStarTaq DNA Polymerase, 1x PCR buffer (Tris Cl, KCl, 
(NH4)2SO4, 8 mM MgCl2, pH 8.7), 0.4 mM each deoxynucleoside triphosphate (dATP, 
dCTP, dGTP, and dTTP) and ROX Fluorescent dye, 10 pmol of each forward/reverse 
primers and 1 pmol of dual labeled probe and RNase-free water up to the final volume, 
reaction mixture was loaded onto semi-skirted PCR plates and snap-sealed by a plastic 
cap, PCR light cycler reactions were amplified and quantified using DNA Engine Opticon 
2 System. Cycling conditions used for all genes were: 1 cycle of initial denaturation at 
95°C for 15 min followed by 39 cycles of amplification at 94°C for 15 s, combined 
annealing, extension at 60°C for 1 min and reading fluorescence at regular intervals after 
the annealing and extension phases. Alongside a negative control (RNA) a non-template 
control (NTC) was performed in order to ensure amplification the negative samples was 
implemented, relative amounts of cDNA were normalized to S. aureus 16S rRNA gene as 
an endogenous control (GenBank accession no. Y15856). Gene expression levels ratio was 
approximated by two relative quantification normalized to reference gene equations to 
confirm all results, (i) The Pfaffl method: where ∆Ct = Ct (calibrator) – Ct (test) (Pfaffl, 
2001). 
 
71 
 
Ratio = (E target) ΔCT, target (calibrator – test)        
               (E ref) ΔCT, ref (calibrator – test) 
 
(ii) Livak method: 2-∆∆Ct where ∆∆Ct = ∆Ct (test) – ∆Ct (calibrator) (Schmittgen and 
Livak, 2008). MRSA252 4 h sample was chosen as calibrator for all samples, thus 
expression of the tested genes in other samples is expressed as an increase or decrease 
relative to the calibrator. Error bars represented the standard deviation of the mean 
expression values.   
2.7.4 Quantitative RT-PCR amplification efficiency (E) 
One of the main concerns regarding any real-time PCR assay product is the amplification 
efficiency (E) of RT-PCR experiment, amplification efficiency values of examined genes 
were measure by a evaluating the doubling of the reaction product at every RT-PCR cycle, 
Ct slope method (Pfaffl, 2004), by generating a serial dilutions (10 fold dilution) of target 
template and measuring the Ct value for each dilution. A standard curve for each gene was 
obtained by plotting threshold cycle Ct on the Y-axis and the log of cDNA concentrations 
(ng/μl) on X-axis. Amplification efficiency for the tested genes was calculated from the 
slopes of standard curve using the formula (E = 10–1/slope) when the expected slope value 
for a 10 fold serial dilution of template is -3.32. The ΔΔCt method was used to calculate 
RT-PCRs assay results with efficiencies close to 100%, amount of internal reference gene 
relative to a calibrator (fold change between two Ct values). The amplification efficiency 
(E) for gene SAR0216 as example is shown in figure 8. 
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Figure 8. RT-PCR assay amplification efficiency of gene SAR0216 
cDNA template and internal reference gene 16S rRNA, 100 ng were used to make 10 fold 
dilution series and using Ct slope method within 5 data points (concentrations) and 5 log 
dilution value, calculated efficiency for target gene assay was 98% and amplification 
factor 1.98. 
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Table 5. Primers/probes, genes base sequences and predicted sizes of qPCR products for S. aureus lipoprotein genes 
Gene 
Symbol 
Primers/probe Oligonucleotide sequence (5’→3’) 
Nucleotide location 
within genome (bp) 
Size of qPCR 
product (bp) 
SAR0444 
Forward ATAACCCAGAAGCACCAATATAC 
472145 to 472287 
143 bp Reverse GCCTTTTAGATTACCTGACCC 
Probe CCGACGCAAAAAGCGCCTAAA  
SAR0730 
Forward GAAATTAATCATCAGCATTATGGCG 
766367 to 766454 
88 bp Reverse GATATCCTTTTCCAGAGTGGC 
Probe AACAGGTTGTGGTAAAAGCCAAGAG  
SAR0390 
Forward AGTGTTATCAATGTCAGCGG 
426981 to 427147 
167 bp Reverse CAGCTTTTTTCACAGCATCTTC 
Probe TGCATGTGGCAATGATACTCCAAAAGA  
SAR0216 
Forward GCGGAATGTCCGGTA ATT TAG 
251048 to 251189 
142 bp Reverse AGCCGCTCAGTACAACAAC 
Probe AATTGACTTGGCATCGAACTCTGCAAC  
SAR0340 
Forward GCAAAAGCGTTATATCCAAAAGTTC 
385262 to 385379 
118 bp Reverse TCTCTTCTTTCATATCTGCAAGAC 
Probe AACGCTCTGAACCAGTTGCAGAA  
16S rRNA 
(endogenous 
control) 
Forward GGCAAGCGTTATCCGGAATT 
514800 to 514900 111 bp Reverse GTTTCCAATGACCCTCCACG 
Probe CCACGCGCGCTTTACGCCCA 
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2.8 Caenorhabditis elegans as a model of bacterial infection  
2.8.1 C. elegans, bacterial strains and growth conditions  
Wild type C. elegans (Bristol N2), E. coli OP50 was cultured in Luria broth and incubated 
at 37°C overnight, nematode strain N2 and E. coli strain OP50 used in this work were 
obtained from Dr Darren Brooks, University of Salford. 
2.8.2 Nematode Growth Medium (NGM) agar 
The following were prepared in double distilled H2O, 0.25% (w/v) Bacto Peptone (Sigma-
Aldrich, UK), 0.3% (w/v) NaCl and 2% (w/v) Bacto Agar (Sigma-Aldrich, UK), 
autoclaved at 121°C for 30 min and cooled to 55°C. Media was supplemented with filter 
sterilized 5 µg/ml cholesterol in ethanol, 1 mM calcium chloride, 1 mM magnesium 
sulphate, 25 mM potassium phosphate buffer (pH 6) and 0.1% of nystatin (10,000 units 
/ml; Sigma-Aldrich, UK).  
2.8.3 Nematode synchronization 
It is important to synchronize nematode cultures in order to obtain large numbers of gravid 
adult animals within the same age timing for subsequent experiments of host infection. To 
synchronize C. elegans eggs via the hypochlorite method as described by Lewis and 
Fleming, 1995 (Lewis and Fleming, 1995), plates of a lawn of E. coli OP50 containing 
gravid hermaphrodites nematodes carrying many fertilized eggs visible in their uterus, 
plates were washed with 5 ml sterile ddH2O into a 15 ml Falcon tube, 1 ml of 5% sodium 
hypochlorite and 500 µl of 5N NaOH were added and tubes were shaken vigorously for 30 
s to lyse the worms and release their eggs which are protected from the sodium 
hypochlorite by their shells, tubes were shaken for 5 min to dissolve all adult worms. 
Tubes were then centrifuged at 1500 x g for 30 sec to pellet released eggs, supernatant was 
discarded until approx. 500 µl of worms and liquid remained, 14 ml of sterile ddH2O were 
add to dilute the bleach, eggs were centrifuged at 1500 x g for 30s, supernatant was 
discarded again and wash process was repeated twice, after three washes, the pellet 
containing eggs was resuspend in 100 µl of ddH2O and transferred to the edge of a clean 
NGM plate seeded with non-pathogenic strain E. coli OP50 lawn for ~ 52 h of growth at 
25°C to use for killing assay. 
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2.8.4 Assay of C. elegans killing by S. aureus 
C. elegans killing assay was carried out as previously reported (Garsin et al., 2001, Sifri et 
al., 2003), as follow. S. aureus plates were prepared as follows, S. aureus MRSA252 were 
incubated aerobically overnight with aeration at 37°C in tryptone soya broth supplemented 
with 5 µg/ml of nalidixic acid (Sigma-Aldrich, UK), 1:10 dilution of overnight culture was 
prepared in fresh media, 10 µl of diluted culture spread on 6-cm-diameter plates containing 
TS agar supplemented with 5 µg/ml of nalidixic acid. Inoculated plates were incubated at 
37°C for 6 h and then allowed to equilibrate to room temperature for 30 min before being 
seeded with C. elegans. In each assay, between 30-40 L4 or young adult hermaphrodite 
nematodes were transferred from a lawn of E. coli OP50 to the prepared killing plates of S. 
aureus on the agar, just outside the lawn of bacteria and each assay experiment was 
repeated on five independent occasions and thus ~ 175 nematodes were followed. Plates 
were incubated at 20°C and examined at 24 h intervals under the dissecting microscope for 
viability, visually inspection of nematodes for movement and nematodes were considered 
dead when they failed to respond to gentle touch with a platinum wire pick. Nematodes 
that died as a result of getting stuck to the wall of the plate or been embedded under the 
agar were not included in the analysis data. C. elegans with food source E. coli OP50 
incubated at 20°C and monitored every 12 h served as control equal numbers of 
synchronized worms were picked and fed on E. coli OP50 for 28 days, survival rate 
indicated that lifespan of control animals was 28 days. Nematode survival was plotted with 
the non-parametric analysis by Kaplan-Meier method using Minitab software, Kaplan-
Meier estimate is the best method to measure the fraction of subjects living for a certain 
period of time after treatment (Bland and Altman, 1998).  
2.8.5 Total RNA isolation  
Total RNA was obtained from cells at late-log phase growth for the control samples and 
from each growth condition of C. elegans that had been infected with S. aureus MRSA252 
using RNeasy kit (Qiagen), approx. 100 nematodes were transferred to 1.5 ml micro-
centrifuge tube and volume made up to 1 ml with M9 buffer containing 1mM sodium azide 
to inhibit infected animals movement, nematodes were washed three times with M9 buffer 
and vortexed at 2000 ×g for 2 min, nematodes were lysed in buffer of (20 mM Tris-HCl 
pH 8 (Sigma-Aldrich, UK), 0.5% Triton X-100 (Fisher Scientific, UK), 0.5% Tween-20 
(Bio-Rad), 2 mM EDTA (Sigma-Aldrich, UK) 10 mg/ml lysozyme, 1 mg/ml lysostaphin 
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and 1 mg/ml proteinase K (Qiagen) in 0.5 ml PCR tube, tubes were briefly centrifuged to 
bring nematodes to the bottom and incubated at 37°C for 30 min, 500 μl of RLT buffer 
were add to homogenize the lysate nematodes and centrifuged at 12000 ×g for 2 min at 
room temperature in homogenizer (Invitrogen, UK). RNA isolation was performed 
according to the manufacturer's instructions Qiagen RNeasy Mini Kit. Extracted RNA 
were treated with TURBO DNase (Ambion), 1 µl DNase (2 U) for up to 10 µg of RNA in 
a 50 µl reaction, DNase enzyme was inactivated by adding 0.1 volume of inactivation 
reagent and incubated for 5 min at room temperature. RNA was quantified by using highly 
sensitive and accurate fluorescence-based Qubit quantitation assays Qubit 2.0 Fluorometer 
(Invitrogen, UK). Total RNA was checked for DNA contamination via PCR, samples of 
high quality were used for cDNA library construction. Ribo-Zero Magnetic Gold Kit 
(Epidemiology), Low-Input (Epicentre Technologies) was used to remove unwanted 5S, 
16S and 23S rRNAs from ~ 500 ng of starting material prior to sequencing analysis and 
creation of a sequencing library, rRNA depletion, quantity and quality assessment of each 
sample were carried out at Centre for Genomic Research (CGR)/ Liverpool University, 
UK. Final libraries were pooled in equimolar amounts using the Qubit and Bioanalyzer 
data, RNA was evaluated by Bioanalyzer and subsequently by qPCR using the Illumina 
Library Quantification Kit from Kapa (KK4854) on a Roche Light Cycler LC480II 
according to manufacturer's instructions. Ribo-Zero treated RNA samples were converted 
to cDNA libraries using the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre 
Technologies) and sequenced on an Illumina HiSeq 2500 system, libraries were purified 
using AMPure XP beads, reads of each organism were mapped to the corresponding 
genome assembly to calculate expression level of each gene. A brief overview of C. 
elegans killing assay and RNA library preparation are shown in figure 9. The experiment 
aimed to detect differentially expressed transcripts in contrasting samples of three 
conditions: C16 (control at 16h), T16 (treated for 16h) and T40 (treated for 40h). Samples 
are a mixture of RNA collected from S. aureus MASA252 and C. elegans Bristol N2, 
sample names and associated conditions are listed in table 6.  
 
 
 
77 
 
Table 6. Details of RNA samples from three independent experiment of treated and 
control cells 
Sample No Group Time point Condition 
1 Control 16h Not treated 
2 Control 16h Not treated 
3 Control 16h Not treated 
4 Test 16h S. aureus treated 
5 Test 16h S. aureus treated 
6 Test 16h S. aureus treated 
7 Test 40h S. aureus treated 
8 Test 40h S. aureus treated 
9 Test 40h S. aureus treated 
 
 
2.8.6 Alignment of reads to reference sequences 
The reference genome used for alignment was combination of the genome references for 
S. aureus MASA252 and C. elegans Bristol N2, S. aureus MRSA252 genome reference 
sequences was obtained from the NCBI genome database, the sequence FASTA file was 
downloaded from: 
ftp://ftp.ncbi.nlm.nih.gov/genbank/genomes/Bacteria/Staphylococcus_aureus_aureus_MR
SA252_uid265/BX571856.fna. The C. elegans Bristol N2 genome reference sequences 
and annotations were downloaded from url: ftp://ftp.ensembl.org/pub/release-81/fasta/ 
caenorhabditis_elegans/dna/Caenorhabditis_elegans.WBcel235.dna_ sm.toplevel.fa.gz. 
Reads were aligned to the combined genome sequences using Tophat (version 2.1.0) (Kim 
et al., 2013a), invoked the short read mapper Bowtie2 (version 2.2.5) (Langmead and 
Salzberg, 2012). The default mapping setting was used. Such an alignment setup informs 
the software of the read pair orientation and instructs it to report up to 1 alignment per 
read, if the number of available alignments is greater than 1, the alignment with the highest 
mapping quality is reported, when two or more alignments are mapped with equal quality, 
one of them is randomly selected and reported, read alignment statistics generated from 
samtools (Li, 2011).  
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2.8.7 Differential expression analysis 
Gene expressions levels of individual transcripts were estimated from reads alignment files 
by using Cufflinks (Trapnell et al., 2012), corresponding FPKM values were converted 
from count numbers and reported in this analysis. The number of fragment per kilobase per 
million base (FPKM) was used to show the gene expression levels and an FPKM value ≥1 
was used as a threshold (P-value <0.05). The count data were split into two sub-sets: one 
containing genes belong to S. aureus, other containing genes for C. elegans. The two sub-
data sets were analysed separately. The differential gene expression analyses were applied 
to the two sub-count data sets, respectively. The main processes of the analysis include 
data variation assessment, data modelling, model fitting, testing and the detection of 
differentially-expressed (DE) transcripts. DGE (Differential Gene Expression) analyses 
were performed in the R environment using the edgeR package (Robinson et al., 2010). P-
values associated with Fold Changec (FC) were adjusted for multiple testing using the 
False Discovery Rate (FDR) approach (Benjamini and Hochberg, 1995). Significantly 
differentially expressed genes were defined as those with FDR-adjusted P-value < 5%. 
Family-wise error rate (FWER) correction which controls the probability of committing of 
errors for any of tests, the concept of false discovery rate (FDR) allows to tolerate a certain 
number of tests to be incorrectly discovered by using threshold that can be declare tests as 
significant or not, all these analysis were carried out at Centre for Genomic Research 
(CGR)/ Liverpool University, UK. 
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Figure 9. Schematic diagram illustrating an overview of C. elegans killing assay 
S. aureus and total RNA isolation, starting from nematodes synchronization via 
hypochlorite bleaching and seeding nematodes in non-pathogenic E.coli OP50 for 48h 
before moving nematodes to plates seeded with pathogenic S. aureus MRSA252. 
Homogenized cells lyses were subjected to RNA extraction and followed by DNase 
treatment. rRNA was first removed from samples and cDNA libraries created using 
ScriptSeq Complete Gold Kit, Low-Input. 
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2.9 Differential expression analysis for S. aureus 8325-4 lipoprotein genes with RNA 
sequencing   
All steps were performed by Dr Sari Al-Houfie  
2.9.1 Bacterial culture 
S. aureus 8325-4 was inoculated into 20 ml Iso-sensitest broth (Oxoid, Basingstoke, UK) 
and incubated with constant shaking at 37°C and 200 r.p.m. When the cells reached mid 
exponentially phase (OD 0.5) cells were harvested after 1, 12 and 24 h and their OD were 
1.2, 6.7 and 10.4 respectively.   
2.9.2 RNA extraction, RNA library preparation and sequencing  
RNAprotect Bacteria Reagent and RNeasy Mini Kit (Qiagen) reagents were used to extract 
total RNA. DNase I (Qiagen) was included in the RNA extraction procedures to avoid 
DNA contamination. Purity of RNA was verified by NanoDrop spectrophotometer 2000 
(Thermo Scientific) and accurate RNA concentration measurements were obtained via 
Qubit RNA Assay Kits with a Qubit 2.0 Fluorometer (Life Technologies, Paisley, UK).  
RNA-seq and data analysis were performed at the Centre for Genomic Research Centre for 
Genomic Research (CGR) at Liverpool University, UK. Ribosomal RNAs were depleted 
from the samples by RiboZero Magnetic kit Bacteria (Epicentre Technologies), 2 μg of 
starting material was used. RNA-seq libraries were prepared from 20-25 ng of the enriched 
material using Epicentre ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre 
Technologies) and the libraries were purified using AMPure XP beads after 13 cycles of 
amplification. The final libraries were pooled in equimolar amounts and quantity and 
quality of each pool was assessed by Bioanalyzer and subsequently by qPCR using the 
Illumina KAPA Library Quantification Kits (Kapa Biosystems, UK) on a Roche Light 
Cycler LC480II according to the manufacturer's instructions. All pools were sequenced on 
3 lanes of the HiSeq 2000 using 2x100 bp paired-end sequencing with v3 chemistry. The 
mapping tools were Mapper Bowtie 2.1.0 using paired-end mapping mode. Analysis 
software was R version 3.0.1 and edgeR package version 3.0.4.  
2.9.3 Data analysis 
The results were based on analyses of three biological replicates, based on fold changes 
count, sample correlation analysis was performed to examine the variation within sample 
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replicates and between samples groups in order to evaluate differential expression of genes 
at the three time-points based on a cut off level of ≤5% for False Discovery Rate (FDR) 
values and 2-fold change in expression (FDR = ≤5% PLUS 2-fold change), the same 
criteria. Data for the 43 lipoproteins was extracted from this data. 
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Chapter three 
Genetic analysis of 
Staphylococcus aureus lipoproteins 
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3. Genetic analysis of Staphylococcus aureus lipoproteins 
3.1 Introduction  
Staphylococcus aureus strains have shown host specialization and different phenotypic and 
genotypic characters, such as production of toxins, cell surface proteins and antibiotic 
resistance, may differ between populations of S. aureus. This genetic flexibility has led to 
the evolution of many virulent and drug-resistant strains (Holden et al., 2004). Many 
complete S. aureus genome sequences are freely available to scientific researchers, these 
genomic sequence data have opened the doors to understand bacterial evolution and 
comparative genomics approaches to evaluate the relatedness and diversity of gene 
composition across different strains. Genetic diversity and population structure of S. 
aureus has been studied with different molecular techniques such as protein A gene (spa) 
typing (Frénay et al., 1996), multilocus sequence typing (MLST) (Sakwinska et al., 2009), 
pulse-field gel electrophoresis (PFGE) (David et al., 2013) and whole-genome sequencing 
(WGS) which provide all sequence data required to predict S. aureus phenotype (Gordon 
et al., 2014).  
Sequencing of disease-causing epidemic methicillin-resistant S. aureus EMRSA-16 clone 
strain (MRSA252) with a genome size ~ 2.8 Mbp isolated from clinical cases has a clinical 
importance and globally prevalent lineage. MRSA252 strain has genetically diverse ~ 6% 
of their genome with a novel unique genetic components compared with the available 
sequenced strains at that time (Holden et al., 2004). The simple approach to quantify genes 
relatedness is to compare certain DNA sequences for a group of genes, this method is 
relatively quick and inexpensive, while, it is very reproducible and available to almost any 
research group working in molecular centres. The availability of free databases of various 
bacterial genomes and computer software to compare sequences, allow comparative 
genomics techniques to play a role for evaluating relatedness and taxonomic studies in 
different aspects of molecular researches. Sequence of individual genes can provide some 
information about the differences between related strains within a given gene, such as 
random mutations and horizontal transfer. This study will show some comparative 
analyses of lipoprotein genes by using previously published lipoprotein genes of S. aureus 
strains and sequence of lipoprotein genes from two clinical isolate S. aureus with 
homologous lipoprotein genes of S. aureus MRSA252. One purpose of this study was to 
examine and compare the genetic features of lipoprotein genes in group of S. aureus 
84 
 
strains. More knowledge about the genotypic variation of S. aureus lipoprotein could help 
to investigate whether S. aureus lipoprotein of different strains genotypes are similar to 
each other, this statistical evidence for individual gene sequence divergence can help to 
reﬂect the general level of genome divergence. The goal of this experiment to determine 
how was the different S. aureus lipoprotein encoding genes are related to each other and 
whether the lipoprotein were common to all strains and whether some lipoproteins are 
specific to particular strains. Bioinformatics is also used to determine the random 
mutations within the genes. Moreover, single nucleotide polymorphism (SNP) analysis is 
used to compare relatedness and genetic variation of S. aureus lipoproteins.  
Furthermore, understanding S. aureus phylogeny and in particular the virulence factors 
distribution is very important to understand the diversity of virulent lineages between 
strains. Phylogeny trees data have been generated for these strains allowing comparison of 
the sequenced lipoprotein data, comparison of the genes sequences was facilitated by using 
different software packages which enabled the visualization of generated data. Tajima’s D 
is a widely used statistical genetics comparison test by comparing between the average 
number of pairwise differences and the number of segregating sites in a sample. This test 
distinguish between DNA sequence evolving randomly and one evolving under a non-
random process, also to detect natural selection in nucleotide sequences (Tajima, 1989). 
The randomly evolving DNA sequence contains mutations that do not affect the function 
of the genes, these mutations called neutral mutations. However, the non-neutral mutations 
may causes cellular disorders and malfunction e.g. loss of pathogenicity (Li et al., 2002). 
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3.2 Results 
3.2.1 Detection of lipoprotein genes and its homologues in S. aureus strains 
To examine the presence of predicted lipoprotein genes in S. aureus strains, three S. aureus 
strains (MRSA252, T1 and RN4282) were examined with PCR using designed primers for 
lipoprotein genes sequences taken from the NCBI database for S. aureus MRSA252 to 
amplify the target coding region of 50 lipoprotein genes in each strain under the same 
conditions. Examples of agarose gel electrophoresis results are shown in figures 10 and 11. 
The results of PCR work conducted are summarized in Table 7. PCR reactions were 
successful for most of the 50 tested lipoprotein genes which showed clear bands of the 
predicted sizes (e.g. see figures 10 and 11). Most genes were present in all strains and only 
a few genes were not detected in some strains. The genes were sequenced by Sanger 
sequencing technology to perform further BLAST multiple alignments and phylogenetic 
analysis. Four genes among the examined strains were variable in presence, SAR1881 
(putative lipoprotein) was not detected in strains RN4282 and T1, SAR2104 (putative 
lipoprotein) was not found in RN4282, SAR0953 (transport system extracellular binding 
lipoprotein) and SAR1494 (putative lipoprotein) were not detected in RN4282 strain.  
Standard BLAST tools were used for alignment of 50 lipoprotein genes sequence of S. 
aureus MRSA252 based against another 19 S. aureus strains were performed as an 
individual basis. The high alignment score gives an indication of high similarity between 
the aligned sequences, also the low E-value was generally close to zero, signifying the 
statistical significance of the pairwise alignment and reflecting the size of the database 
searched. Sequencing coverage results demonstrated that the analysis by BLAST search of 
the sequenced genes revealed that the nucleotide identities of 28 lipoprotein genes detected 
in all strains were well conserved in all 20 strains showing high similarity scores between 
them with at least 98% and 100% of sequence query coverage. A further 11 genes showed 
minor changes of nucleotide residues with a similarity ranging between 100-96% and the 
non-synonyms mutation were more frequent than the synonyms mutation. Further, among 
the examined genes 11 lipoprotein genes had strong nucleotides changes leading to large 
amino acid residues variations, any sequences pairwise alignment with E-value less than 
1e
-04
 can be considered related with an error rate of less than 0.01%. BLAST alignments 
search results are presented in appendix tables 1-44.  
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SAR0442, SAR0444 and SAR0443 genes despite their quite a small size (771bp, 782bp and 
699bp respectively) were shown to have very changeable sequences with a high rate of 
synonymous and non-synonymous substitutions sites, the total number of mutations within 
the strains MRSA252, T1 and RN4282 were 343, 190 and 272 sites respectively. These 
SNPs were present in a range of sites, as indicated in table 8. SAR0439 gene was extremely 
variable among all strains and shown the highest number of mutations sites in most strains, 
the total mutation sites 354 with 126 synonymous sites and the remaining 98 SNPs were 
non-synonymous. SAR0730 gene was relatively conserved in the amino acids structure 
between the strains except 4 strains (RF122, M013, ST398 and LGA251) were found to be 
slightly modified and showed considerable mutation sites compared to the other strains as 
shown in table 8. SAR1189 had a different pattern of amino acid diversity, four strains 
(LGA251, RF122, ST398 and M013) had an altered truncated gene sequences and 
revealed strong modification in their structure, while other strains had very slight 
nucleotide changes. Although, SAR0438 gene was found relatively to be variable between 
the examined strains sequences as lowest nucleotide similarities among the sequences were 
up to 83%, while, SAR1558 gene was found in 5 out of 20 strains with similarity 
percentage between 96-100% (appendix 1, table 8 and 48). In the other hand, the small 
sized 357bp SAR1288 gene was detected in 7 strains of all tested strains, but this gene was 
very unchanged and showed very minor amino acids variation (appendix 1, table 47). The 
smallest lipoprotein gene SAR0706 was detected in 4 strains only but with no nucleotide 
alteration in any strain (appendix 1, table 46).  
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Figure 10. A 1.5% agarose gel image showing PCR products of 6 lipoprotein genes 
fragments 
PCR products were stained with GelRed. (M) 50 bp Hyperladder II was used as molecular 
weight marker (Bioline), lane 1, 2, 3: SAR0641 gene (930 bp), lane 4, 5, 6: SAR0618 gene 
(888 bp), lane 7, 8, 9: SAR0463 gene (843 bp), lane 10, 11, 12: SAR0444 gene (795 bp), 
lane 13, 14, 15: SAR0340 gene (855 bp), lane 16, 17, 18: SAR0216 gene (969 bp), 
fragments for S. aureus strains (MRSA252, RN4282 and T1). 
 
Figure 11. A 1.5% agarose gel image showing PCR products of 4 lipoprotein genes 
fragments 
PCR Products were stained with GelRed. (M) 50 bp Hyperladder II was used as molecular 
weight marker (Bioline), lane 1, 2, 3: SAR0730 gene (390 bp), lane 4, 5, 6: SAR0390 gene 
(573 bp), lane 7, 8, 9: SAR0174 gene (975 bp), lane 10, 11, 12: SAR0201 gene (1776 bp), 
fragments for S. aureus strains (MRSA252, RN4282 and T1). 
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3.2.2 S. aureus lipoprotein nucleotide diversity (π), mutation rate and distribution 
DNA variation information can be used to study genetic diversity within and between 
strains, and to conclude the population genetics parameters in statistic figures, also to 
investigate the mechanisms of nucleotide changes. The total 50 lipoprotein genes for 20 S. 
aureus strains were subjected to statistical calculations by DnaSP program for the analysis 
of nucleotide polymorphism from aligned DNA data, including the noncoding and 
synonymous or nonsynonymous sites. Genetic diversity analysis among examined 
lipoprotein genes for 20 S. aureus strains search has showed considerable high similarity 
between the majorities of these sequenced genes, data are summarized in table 8. The 
available information about these genes in UniProt database give a strong probability for a 
similar biological relationship between large number of these genes, however table 9 
outlines some potential lipoprotein functions in S. aureus MRSA252 and function of 
similar genes in other S. aureus strains, these proteomics data were obtained from UniProt 
database (Consortium, 2014). BLAST searches for each lipoprotein gene gives a relative 
idea about their amino acid sequences, estimates of molecular variation and identifying 
individual gene sequence similarities with other appropriate lipoprotein of S. aureus 
strains.  
As noted above, DNA analysis revealed variable sequence variation between S. aureus 
lipoprotein, BLAST alignment of 50 lipoprotein gene sequence of S. aureus MRSA252 
against another 19 S. aureus strains were performed in an individual basis. There were no 
significant differences in gene sequence of 28/50 genes (56%) SAR0794, SAR0641, 
SAR0618, SAR0463, SAR0390, SAR0340, SAR0216, SAR0201, SAR2496, SAR0872, 
SAR1106, SAR1608, SAR1995, SAR2179, SAR2368, SAR2499, SAR2500, SAR2536, 
SAR2546, SAR0794, SAR1034, SAR0463, SAR0118, SAR0206, SAR0230, SAR1495, 
SAR0396 and SAR0872) which were very highly conserved and have relative similarity 
score among them to show at least 98% nucleotide similarity and 100% query cover of all 
sequences, while the E-value was zero for all of these alignment genes, this low value 
present a great statistical significance of a given pairwise alignment. However, 11 genes 
had nucleotide similarity with a range of 94-97% with E-value was nil and up to 68% 
query cover of gene sequence. The other 11 genes were highly variable in the gene size 
and genetic structures, 5 genes were not detected in most strains (SAR1558, SAR1288, 
SAR0706, SAR1831 and SAR2104), meanwhile 6 genes (SAR0442, SAR0443, SAR1189, 
SAR0438, SAR0444 and SAR0439) exhibited strong genetic variation and showed an 
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extremely changeable structure coupled with low query cover and insignificant E-value for 
some truncated genes, these genes contained a large number of mutations compared with 
the other examined genes, BLAST alignment for all these genes are given in appendix A.    
The number of mutations (SNPs) was highly variable between the examined genes, where 
the lowest mutation number was found in the relatively small size 363bp SAR2500 gene 
with only 3 SNPs, however the highest number was 354 mutations within 737bp of 
SAR0439 gene. In order to better understand of genetic variation in the form of single 
nucleotide polymorphisms (SNPs), nucleotide diversity was assessed by using DnaSP 
software package. The results (table 8) indicate the number of SNPs, mutations number 
and nucleotide diversity per lipoprotein gene for examined S. aureus strains unless the 
lipoprotein gene was not detected in the most strains, the calculations present the 
proportion of synonymous (silent; ds) and non-synonymous (amino acid-changing; dn) 
substitution rates, the mean pairwise percentage nucleotide diversity, number of mutations, 
invariable sites (monomorphic and polymorphic), singleton variable sites and parsimony 
informative sites (2, 3 or 4 nucleotide variants) of common 44 lipoprotein genes.  
To measure the degree of polymorphism within the lipoprotein genes the average pairwise 
nucleotide diversity for the whole concatenated head-to-tail lipoprotein genes was 0.018 
among all sequences, the highest rate of nucleotide diversity of candidate genes was 
detected in SAR0439 gene with 0.1272, while the lowest rate was found within SAR2500 
gene 0.0008. Twenty three lipoprotein genes showed low nucleotide diversity with a value 
less than 0.010, these genes were fairly invariant between all strains. Furthermore BLAST 
searches revealed similar results with high similarity alignment for these genes. Gene 
alignments involved in this study are given in the appendix. Eleven lipoprotein genes were 
found to be highly variant in all strains to indicate extreme nucleotide diversity with value 
range 0.022 and 0.127, also BLAST analyses for these genes indicated a high level of 
DNA variation and large number of synonymous and non-synonymous mutations.      
The results suggest that overall there were 50 different lipoproteins of which 44 were 
common to all examined strains, of these 28 genes had highly conserved sequences, 6 
genes occurred in ~ 8 strains and 5 genes that only appeared in few tested strains, while 11 
genes were highly variable in their size and genetic structures. 
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Table 7. List of 50 lipoprotein genes tested by PCR in three S. aureus strains 
(MRSA252, RN4282 and T1)  
Genes not detected in some strains are indicated with (●). ORF indicates the gene locus in 
MRSA252 strain. 
 
 
 
 
 
 
Gene  
ORF 
MRSA252 RN4282 T1 
Gene  
ORF 
MRSA252 RN4282 T1 
SAR0118    SAR1066    
SAR0174     SAR1106    
SAR0201    SAR1189    
SAR0206     SAR1288    
SAR0216    SAR1494     
SAR0230    SAR1495    
SAR0340    SAR1558    
SAR0390     SAR1608    
SAR0396    SAR1831    
SAR0438    SAR1879    
SAR0439    SAR1881      
SAR0442    SAR1995    
SAR0443    SAR2104     
SAR0444    SAR2179    
SAR0463    SAR2268    
SAR0618    SAR2363    
SAR0641    SAR2368    
SAR0706    SAR2457    
SAR0730    SAR2496    
SAR0790    SAR2499    
SAR0794    SAR2500    
SAR0872    SAR2504    
SAR0953     SAR2536    
SAR1011    SAR2546    
SAR1034      SAR2554    
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Table 8. Phylogenetic analysis of 44 lipoprotein genes for 20 S. aureus strains, calculated by DnaSP program 
*Synonymous (ds), *non-synonymous (dn). 
Gene ORF/ 
size (bp) 
Variable sites 
(polymorphic) 
Number 
of 
mutations 
ds / dn 
mutation 
number 
Singleton variable 
sites (one nucleotide 
variant) 
Parsimony informative 
sites (2, 3 or 4 nucleotide 
variants) 
Nucleotide 
diversity 
(π) 
SAR0118/ 993 15 15 11/4 
2 nucleotide variants: 4 
3 nucleotide variants: 0 
2 nucleotide variants: 11 
3 nucleotide variants: 0 
0.0040 
SAR0174/ 975 54 57 34/23 
2 nucleotide variants: 22 
3 nucleotide variants: 0 
2 nucleotide variants: 29 
3 nucleotide variants: 3 
0.0159 
SAR0201/ 1776 186 189 148/38 
2 nucleotide variants: 157 
3 nucleotide variants: 0 
2 nucleotide variants: 26 
3 nucleotide variants: 3 
0.0157 
SAR0206/ 1272 30 31 25/6 
2 nucleotide variants: 12 
3 nucleotide variants: 0 
2 nucleotide variants: 17 
3 nucleotide variants: 1 
0.0072 
SAR0216/ 969 44 44 25/16 
2 nucleotide variants: 22 
3 nucleotide variants: 0 
2 nucleotide variants: 22 
3 nucleotide variants: 0 
0.0117 
SAR0230/ 1476 57 57 38/19 
2 nucleotide variants: 23 
3 nucleotide variants: 0 
2 nucleotide variants: 34 
3 nucleotide variants: 0 
0.0096 
SAR0340/ 855 23 23 16/7 
2 nucleotide variants: 15 
3 nucleotide variants: 0 
2 nucleotide variants: 8 
3 nucleotide variants: 0 
0.0042 
SAR0390/ 573 44 46 34/12 
2 nucleotide variants: 0 
3 nucleotide variants: 35 
2 nucleotide variants: 7 
3 nucleotide variants: 2 
0.0114 
SAR0396/ 627 15 16 12/4 
2 nucleotide variants: 4 
3 nucleotide variants: 0 
2 nucleotide variants: 10 
3 nucleotide variants: 1 
0.0058 
SAR0438/ 699 193 218 92/73 
2 nucleotide variants: 42 
3 nucleotide variants: 1 
2 nucleotide variants: 129 
3 nucleotide variants: 18 
0.0783 
SAR0439/ 737 291 354 126/98 
2 nucleotide variants: 74 
3 nucleotide variants: 5 
2 nucleotide variants: 160 
3 nucleotide variants: 46 
4 nucleotide variants: 6 
0.1272 
SAR0442/ 771 286 343 129/103 
2 nucleotide variants: 80 
3 nucleotide variants: 0 
2 nucleotide variants:153 
3 nucleotide variants: 49 
4 nucleotide variants: 4 
0.1111 
SAR0443/ 699 240 272 130/89 
2 nucleotide variants: 123 
3 nucleotide variants: 4 
2 nucleotide variants: 87 
3 nucleotide variants: 24 
4 nucleotide variants: 2 
0.0757 
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Table 8-continued 
Gene ORF/ 
size (bp) 
Variable sites 
(polymorphic) 
Number of 
mutations 
ds / dn mutation 
number 
Singleton variable sites (1 
or 2 nucleotide variant) 
Parsimony informative sites 
(2, 3 or 4 nucleotide variants) 
Nucleotide 
diversity 
SAR0444/ 795 177 190 92/73 
2 nucleotide variants: 25 
3 nucleotide variants: 1 
2 nucleotide variants: 139 
3 nucleotide variants: 12 
0.0791 
SAR0463/ 843 50 51 41/10 
2 nucleotide variants: 20 
3 nucleotide variants: 0 
2 nucleotide variants: 29 
3 nucleotide variants: 1 
0.0159 
SAR0618/ 888 22 23 16/7 
2 nucleotide variants: 7 
3 nucleotide variants: 0 
2 nucleotide variants: 14 
3 nucleotide variants: 1 
0.0061 
SAR0641/ 930 8 8 8/0 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
2 nucleotide variants: 5 
3 nucleotide variants: 0 
0.0552 
SAR0730/ 396 48 48 24/24 
2 nucleotide variants: 
3 nucleotide variants: 
2 nucleotide variants: 31 
3 nucleotide variants: 0 
0.0252 
SAR0790/ 1029 88 90 75/15 
2 nucleotide variants: 18 
3 nucleotide variants: 1 
2 nucleotide variants: 68 
3 nucleotide variants: 1 
0.0208 
SAR0794/ 879 12 12 7/5 
2 nucleotide variants: 8 
3 nucleotide variants: 0 
2 nucleotide variants: 4 
3 nucleotide variants: 0 
0.0025 
SAR0872/ 822 28 28 21/7 
2 nucleotide variants: 13 
3 nucleotide variants: 0 
2 nucleotide variants: 15 
3 nucleotide variants: 0 
0.0083 
SAR0953/ 1656 90 91 70/21 
2 nucleotide variants: 29 
3 nucleotide variants: 0 
2 nucleotide variants: 60 
3 nucleotide variants: 1 
0.0146 
SAR1011/ 960 59 59 44/15 
2 nucleotide variants: 18 
3 nucleotide variants: 0 
2 nucleotide variants: 41 
3 nucleotide variants: 0 
0.0173 
SAR1034/ 1101 9 9 7/2 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
2 nucleotide variants: 6 
3 nucleotide variants: 0 
0.0017 
SAR1066/ 627 28 28 20/8 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
2 nucleotide variants: 25 
3 nucleotide variants: 0 
0.0141 
SAR1106/ 879 16 16 12/4 
2 nucleotide variants: 12 
3 nucleotide variants: 0 
2 nucleotide variants: 4 
3 nucleotide variants: 0 
0.0024 
SAR1189/ 954 115 113 48/65 
2 nucleotide variants: 4 
3 nucleotide variants: 0 
2 nucleotide variants: 110 
3 nucleotide variants: 1 
0.0675 
SAR1494/ 909 69 74 48/26 
2 nucleotide variants: 20 
3 nucleotide variants: 1 
2 nucleotide variants: 44 
3 nucleotide variants: 4 
0.0486 
SAR1608/ 582 9 9 4/5 
2 nucleotide variants: 6 
3 nucleotide variants: 0 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
0.0020 
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Table 8-continued 
ORF/ size (bp) 
Variable sites 
(polymorphic) 
Number 
of 
mutations 
ds / dn 
mutation 
number 
Singleton variable 
sites (1 or 2 nucleotide 
variant) 
Parsimony informative 
sites (2, 3 or 4 nucleotide 
variants) 
Nucleotide 
diversity 
SAR1879/ 555 37 38 14/24 
2 nucleotide variants: 5 
3 nucleotide variants: 0 
2 nucleotide variants: 31 
3 nucleotide variants: 1 
0.0222 
SAR1881/ 846 21 21 36/31 
2 nucleotide variants: 18 
3 nucleotide variants: 0 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
0.0415 
SAR1995/ 1200 24 24 18/6 
2 nucleotide variants: 12 
3 nucleotide variants: 0 
2 nucleotide variants: 12 
3 nucleotide variants: 0 
0.0042 
SAR2104/ 465 15 16 9/7 
2 nucleotide variants: 15 
3 nucleotide variants: 0 
2 nucleotide variants: 1 
3 nucleotide variants: 0 
0.0104 
SAR2179/ 873 18 18 15/3 
2 nucleotide variants: 7 
3 nucleotide variants: 0 
2 nucleotide variants: 11 
3 nucleotide variants: 0 
0.0042 
SAR2268/ 984 46 47 37/10 
2 nucleotide variants: 6 
3 nucleotide variants: 0 
2 nucleotide variants: 39 
3 nucleotide variants: 1 
0.0137 
SAR2363/ 783 55 57 57/22 
2 nucleotide variants: 14 
3 nucleotide variants: 0 
2 nucleotide variants: 39 
3 nucleotide variants: 2 
0.0227 
SAR2368/ 909 18 18 15/3 
2 nucleotide variants: 8 
3 nucleotide variants: 0 
2 nucleotide variants: 10 
3 nucleotide variants: 0 
0.0042 
SAR2457/ 630 50 52 24/15 
2 nucleotide variants: 7 
3 nucleotide variants: 0 
2 nucleotide variants: 41 
3 nucleotide variants: 2 
0.0211 
SAR2499/ 600 18 18 14/4 
2 nucleotide variants: 10 
3 nucleotide variants: 0 
2 nucleotide variants: 8 
3 nucleotide variants: 0 
0.0064 
SAR2500/ 363 3 3 1/2 
2 nucleotide variants: 3 
3 nucleotide variants: 0 
2 nucleotide variants: 0 
3 nucleotide variants: 0 
0.0008 
SAR2504/ 780 34 34 26/8 
2 nucleotide variants: 5 
3 nucleotide variants: 0 
2 nucleotide variants: 29 
3 nucleotide variants: 0 
0.0115 
SAR2536/ 942 44 46 34/9 
2 nucleotide variants: 20 
3 nucleotide variants: 1 
2 nucleotide variants: 22 
3 nucleotide variants: 1 
0.0109 
SAR2546/ 456 10 10 5/5 
2 nucleotide variants: 5 
3 nucleotide variants: 0 
2 nucleotide variants: 5 
3 nucleotide variants: 0 
0.0051 
SAR2554/ 1599 55 56 46/10 
2 nucleotide variants: 14 
3 nucleotide variants: 0 
2 nucleotide variants: 40 
3 nucleotide variants: 1 
0.0093 
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Table 9. Comparison of lipoprotein function in S. aureus MRSA252 and other S. aureus strains according to the UniProt database 
Gene Id ORF S. aureus MRSA252 Other S. aureus 
gi|446967868 SAR0118 sirA lipoprotein 
Iron compound ABC transporter iron compound-binding 
protein SirA, periplasmic binding protein 
gi|49240544 SAR0174 Putative lipoprotein 
Sulfonate/nitrate/taurine transport system substrate-binding 
protein 
gi|49240571 SAR0201 RGD-containing lipoprotein ABC transporter, substrate-binding protein, family 5 
gi|49240576 SAR0206 
Putative extracellular sugar-
binding lipoprotein 
Maltose/maltodextrin ABC superfamily ATP binding cassette 
transporter 
gi|49240586 SAR0216 Putative lipoprotein ABC transporter, solute-binding protein 
gi|49240600 SAR0230 
Putative extracellular solute-
binding lipoprotein 
Peptide ABC transporter, ABC transporter, substrate-binding 
protein 
gi|49240702 SAR0340 Putative lipoprotein Lipoprotein, hypothetical protein 
gi|49240750 SAR0390 Putative lipoprotein 
Putative lipoprotein, conserved hypothetical protein, 
propeptide 
gi|49482628 SAR0396 Hypothetical protein Putative lipoprotein, lipoprotein 
gi|49482665 SAR0438 Lipoprotein 
Zn-binding lipoprotein adcA, ribulose-phosphate 3-epimerase, 
Similar to Zn-binding lipoprotein adcA 
gi|49240795 SAR0439 Putative lipoprotein Tandem lipoprotein 
gi|49240796 SAR0442 Putative membrane protein Lipoprotein, tandem lipoprotein 
gi|49240797 SAR0443 Putative lipoprotein Lipoprotein. 
gi|49240798 SAR0444 Putative lipoprotein Tandem lipoprotein, conserved hypothetical protein 
gi|49240817 SAR0463 Putative lipoprotein 
Methionine ABC transporter substrate-binding protein, 
lactococcal lipoprotein 
gi|49240968 SAR0618 
Putative transport system 
lipoprotein 
Vitamin B12 ABC transporter substrate-binding 
gi|49482859 SAR0641 ABC transporter Lipoprotein, hypothetical protein, iron-repressed lipoprotein 
gi|49241045 SAR0706 Putative membrane protein Hypothetical lipoprotein 
gi|49240968 SAR0618 
Putative transport system 
lipoprotein 
Vitamin B12 ABC transporter substrate-binding 
gi|49482859 SAR0641 ABC transporter Lipoprotein, hypothetical protein, iron-repressed lipoprotein 
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Table 9-continued 
Gene Id ORF S. aureus MRSA252 Other S. aureus 
gi|49241045 SAR0706 Putative membrane protein Hypothetical lipoprotein 
gi|49241062 SAR0730 Putative lipoprotein Hypothetical protein 
gi|49482993 SAR0790 Lipoprotein 
Iron (Fe+3) ABC superfamily ATP binding cassette 
transporter, iron complex transport system substrate-
binding protein 
gi|49241126 SAR0794 Putative lipoprotein Conserved hypothetical protein 
gi|49483071 SAR0872 Lipoprotein 
ABC transporter substrate-binding protein, methionine 
ABC transporter substrate-binding protein 
gi|49241280 SAR0953 
Transport system extracellular 
binding lipoprotein 
Ferrichrome ABC transporter lipoprotein, 
gi|49241332 SAR1011 
Transport system extracellular 
binding lipoprotein 
Ferrichrome ABC transporter, putative iron transport 
protein 
gi|49241354 SAR1034 
Putative quinol oxidase polypeptide II 
precursor 
Cytochrome aa3 quinol oxidase, subunit II 
gi|49241384 SAR1066 Putative lipoprotein Cell-wall binding lipoprotein 
gi|49241424 SAR1106 
Putative transport system extracellular 
binding lipoprotein 
Putative iron transport lipoprotein SirF, heme uptake 
system protein IsdE 
gi|49241505 SAR1189 Putative lipoprotein Lipoprotein, hypothetical protein 
gi|49483474 SAR1288 Lipoprotein Hypothetical protein, putative lipoprotein 
gi|49241801 SAR1494 Putative lipoprotein Lipoprotein 
gi|49241802 SAR1495 Putative lipoprotein Lipoprotein, conserved hypothetical protein 
gi|49483736 SAR1558 Lipoprotein Putative lipoprotein 
gi|49483780 SAR1608 Hypothetical protein Lipoprotein 
gi|49242122 SAR1831 Beta-lactamase precursor Beta-lactamase 
gi|49242169 SAR1879 Putative lipoprotein Excalibur calcium-binding domain protein 
gi|49242171 SAR1881 Putative lipoprotein Lipoprotein, tandem lipoprotein 
gi|49484144 SAR1995 Lipoprotein Putative lipoprotein, hypothetical protein 
gi|49242375 SAR2104 Putative lipoprotein Lipoprotein, hypothetical protein 
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Table 9-continued
Gene Id ORF S. aureus MRSA252 Other S. aureus 
gi|49242443 SAR2179 Putative membrane protein 
Lipoprotein precursor, lipoprotein, membrane- 
embedded lipoprotein precursor 
gi|49242526 SAR2268 
Putative transport system binding 
lipoprotein 
Iron citrate ABC transporter substrate-binding 
protein, putative ferrichrome-binding protein FhuD 
gi|49484494 SAR2363 Molybdate-binding lipoprotein 
Molybdate ABC superfamily ATP binding cassette 
transporter, binding protein, putative molybdate-
binding protein 
gi|49484499 SAR2368 Ferrichrome-binding lipoprotein precursor 
Ferrichrome ABC transporter substrate-binding 
protein 
gi|49484586 SAR2457 Hypothetical protein Lipoprotein, conserved hypothetical protein 
gi|49242751 SAR2496 Putative solute binding lipoprotein 
Zn-binding lipoprotein adcA-protein, ribulose-
phosphate 3-epimerase 
gi|49242754 SAR2499 Putative lipoprotein DSBA-like thioredoxine domain protein, lipoprotein 
gi|49484626 SAR2500 Lipoprotein Hypothetical protein 
gi|49242759 SAR2504 Extracellular solute-binding protein  
Extracellular solute-binding protein, family 3, amino 
acid ABC superfamily ATP binding cassette 
transporter 
gi|49242792 SAR2536 
Putative glycine betaine/carnitine/choline-
binding lipoprotein precursor 
Osmoprotectant transport system substrate-binding 
protein 
gi|49242802 SAR2546 Putative lipoprotein Lipoprotein, PF06998 family protein 
gi|49242810 SAR2554 
Oligopeptide transporter putative substrate 
binding domain 
Nickel ABC transporter, nickel/metallophore 
periplasmic binding protein 
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3.2.3 Prediction of promoter sequences and promoters structure 
The promoter sequence of the S. aureus MRSA252 lipoprotein genes are very little 
information are available. The promoter sequences for lipoprotein genes were determined 
by mapping the transcription start site for each gene and compared to E. coli promoter 
consensus -10 and -35 sequences (Hertz and Stormo, 1995). Figure 12, table 10 and 11 
show the location of lipoprotein genes on the reference circular genome of S. aureus 
MRSA252 and labeled according to their position of the strands. Promoter sequences of S. 
aureus MRSA252 lipoproteins, upstream sequences for 100 nucleotides from start codon 
obtained from www.kegg.jp (table 11). Including the coding sequences of fur binding 
sites, the promoter sequences and 4 binding sites were predicted using the BPROM web-
based software (Solovyev and Salamov, 2011). Operons were predicted using Genome 2D 
(genome2D.molgenrig.nl) and Artemis (http://www.sanger.ac.uk/science/tools/artemis) 
(Rutherford et al., 2000). 
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Figure 12. The distribution and location of lipoprotein genes mapped on the 
reference circular genome of S. aureus MRSA252 and labeled according to their 
position of the strands.  
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Table 10. An overview of genes encoding S. aureus lipoprotein and their regulating 
operons description, the promoter sequences and 4 binding sites were predicted using the 
BPROM web-based software (Solovyev and Salamov, 2011). Operons were predicted 
using Genome 2D (genome2D.molgenrig.nl) and Artemis 
(http://www.sanger.ac.uk/science/tools/artemis) (Rutherford et al., 2000).                                                                                                    
ORF Start End Strand Gene Probable operon structure 
SAR0106 110754 111524 +  SAR106-SAR0107 
SAR0118 128926 129918 - SirA 
SAR0116 (Sir B)-SAR0117 (SirC)-
SAR0118 (SirA) Iron regulated 
SAR0145 158898 159854 -  Monocistronic 
SAR0174 191762 192736 +  
SAR0173-SAR0174-SAR0175-
SAR0176 
SAR0201 231906 233681 + rlp 
SAR0199-SAR0200-SAR0201-
SAR0202 
SAR0206 239168 240439 + MalB 
SAR0205 (Mal A)-SAR0206 
(MalA)-SAR0207 (MalC)-
SAR0208 (MalD) 
Maltose transporter 
SAR0216 251020 251988 -  
SAR0214-SAR0215-SAR0216 
sensor receptor/kinase 
SAR0230 271601 273076 -  Substrate binding 
SAR0340 385032 385886 +  
SAR0340-SAR0341-SAR0342 
Fe uptake 
SAR0390 426962 427534 +  Monocistronic 
SAR0396 430210 430836 -  
SAR0396-SAR0397-SAR0398 
(AhpF)-SAR0399 (AhpfC) 
SAR0438 467510 468295 +  
SAR0448-SAR0449-SAR0440-
SAR0441-SAR0442-SAR0443-
SAR0444 
SAR0440 Frameshift after codon 
136 
SAR0439 468343 469116 +  
SAR0440 469147 469949 +  
SAR0442 469987 470757 +  
SAR0443 470789 471589 +  
SAR0444 471608 472402 +  
SAR0445 472568 473389 +  
SAR0445-SAR0446- SAR0447-
SAR0448 
SAR0463 491739 492581 +  SAR0462-SAR0463 
SAR0618 666806 667693 +  Zinc, haem, cobalamin transporter 
SAR0641 687790 688719 - MntC Fe, Zn, Cu transport 
SAR0706 746977 747081 -  
34 amino acids one transmembrane 
region 
SAR0730 766363 766752 +  SAR0730-SAR0731-SAR0732 
SAR0761 796705 797145 -   
SAR0790 828218 829246 + sstD 
SAR0787 (sstA)-SAR0788 (sstB)-
SAR0789 (sstC)-SAR0790 (sstD) 
Fe transporter 
SAR0794 831583 832461 +  Monocistronic 
SAR0839 885498 886186 -  Monocistronic 
SAR0872 910328 911149 +  
Sars007-SAR0870-SAR0871-
SAR0872 
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Table 10-continued 
ORF Start End Strand Gene Probable operon structure 
SAR0953 995948 997603 + OppA 
SAR0949 (OppB)-SAR0950 
(OppC)-SAR0951(OppD)-
SAR0952 (OppF)-SAR0953 
Oligopeptide transporter 
SAR0954 997815 1000604 +  Monocistronic 
SAR1011 1054214 1055173 +  Monocistronic Fe transport 
SAR1034 1079932 1081032 - QoxA 
SAR1031 (Qox D)-SAR1032 
(QoxC)-SAR1033 (QoxB)- 
SAR1034 (QoxA) 
Quinol oxidase 
SAR1066 1112113 1112739 +  Monocistronic 
SAR1106 1152065 1152943 + IsdE 
SAR1104 (IsdC)-SAR1105 (IsdD)-
SAR1106 (IsdE)-SAR1107 (IsdF)-
SAR1108 (SrtB)-SAR1109 
SAR1189 1238170 1239123 +  Monocistronic 
SAR1288 1352458 1352814 -  
SAR1287-SAR1288-SAR1289-
SAR1290 
Fe regulated 
SAR1402 1458802 1458062 -  Monocistronic 
SAR1494 1589460 1590368 -  
SAR1494-SAR1495 
SAR1495 1590426 1591331 -  
SAR1558 1634418 1634852 +  
SAR1557-SAR1558-SAR1559- 
SAR1560 
Monocistronic 
SAR1607-SAR1608 
Monocistronic 
Monocistronic 
SAR1879-SAR1780 
SAR1565 1639484 1640417 -  
SAR1608 1681001 1681582 +  
SAR1831 1913827 1914672 + BlaZ 
SAR1878 1965275 1965757 -  
SAR1879 1966128 1966682 +  
SAR1881 1967834 1968460 +  SAR1881-SAR1882-SAR1883 
SAR1932 2011797 2012759 +  Monocistronic 
SAR1995 2084777 2085976 -  
SAR1995-SAR1996-SAR1997-
SAR1998 
SAR2104 2166873 2167337 +  SAR2103-SAR2104-SAR2105 
SAR2179 2249989 2250861 +  
SAR2179-SAR2180-SAR2181-
SAR2182-SAR2183-sars023 
SAR2268 2349338 2350321 - FhuD SAR2266-SAR2267-SAR2268 
SAR2363 2433026 2433808 - ModA 
Mo transport 
SAR2361 (ModC)-SAR2362 
(ModB)-SAR2363 (ModA) 
SAR2368 2439723 2438831 -  Monocistronic 
SAR2457 2528101 2528730 -  Monocistronic 
SAR2470 2541365 2543521 +  Monocistronic 
SAR2496 2569326 2570873 -  
Monocistronic Zinc 
binding/transport 
SAR2499 2571954 2572553 -  
SAR2499-SAR2500 
SAR2500 2572572 2572934 -  
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Table 10-continued 
ORF Start End Strand Gene Probable operon structure 
SAR2504 2575960 2576739 -  
SAR2502-SAR2503-SAR2504-
SAR2505 
Transporter 
SAR2536 2615364 2616305 - OpucC 
SAR2535 (OpucD)-SAR2536 
(OpucC)-SAR2537 (OpucB), 
SAR2538 (OpucA) 
SAR2546 2627660 2628115 +  Monocistronic 
SAR2554 2635602 2637200 -  
SAR2549-(Opp1F)-SAR2550 
(Opp1C)-SAR2551 (Opp1D)- 
SAR2552 (Opp-1B)-SAR2553 
(Opp1A)-SAR2554 
SAR2573 2652402 2653178 -  Monocistronic 
SAR2736 2844639 2845582 +  SAR2736-SAR2738-SAR2739 
SAR2763 2866243 2867367 -  
SAR2763-SAR2764-SAR2765-
SAR2766-SAR2767-SAR2768 
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Table 11. Promoter sequences of S. aureus MRSA252 lipoproteins  
(Bold ORF gene promoters shown for initial genes in operon marked not lipoprotein), upstream sequences for 100 nucleotides from start codon 
obtained from www.kegg.jp. Key: Coding sequences in blue and underlined, -10 sequences highlighted in yellow, -35 sequences in red, fur 
binding site in blue. Promoter sequences and 4 binding sites were predicted using BPROM (Solovyev and Salamov, 2011). 
   ORF Promoter sequences 
SAR0106 TGTGGAATTTTTGATAATATTAAAGTGAAAAAGTGTTATAAATTGATATTAATATGTAATTTGCAAAAGTAAATCATTTTAAAAAGAAGAGAGTTGTAAGATG 
SAR0118 AAATCATAAATATTTTATTGACTTAGGAAAAAATTTAATTCATACTAAACCGTGATAATGATTCTCATTGTCATACATCACGAAGGAGGCTAATTAGTCAATG 
SAR0118 AAATCATAAATATTTTATTGACTTAGGAAAAAATTTAATTCATACTAAACCGTGATAATGATTCTCATTGTCATACATCACGAAGGAGGCTAATTAGTCAATG 
SAR0145 TTTATAAAATACTTTTTAGCATTTAAATGTGGTACGCTATAAGTGTAATTTCATTGCATACATATTACACGATTAAGAATGTGAAGGGGACAGTTATCAAATG 
SAR0173 TAGATATAACAATTCACGATTTAAGGGCTGTGTTTGGCATAGCCCTTTAGATATACATTTAATTCTTATTAAAATGGTAGGGATTAAAAGGGGGCTTGTCATG 
SAR0174 GATAGCCACCTACTTAAGATTCGTAATGAAATTATGGAAACATTTGCATTGAATCATCATCAAGTTGAACCTGAATATTATTTATAAGGAGTGAGTGACGATG 
SAR0201 GGTATTTGTATTATGTTCGTCGTTTTAGCATTTAATTTTATAGGTGATGCAGTGCGTGATGCGCTAGATCCAAGAATTCATTAAAAAGGTAGGGATAGATGTG 
SAR0206 AGTGATGGCGAACGACAAGATTACACTAGCATTTGATATGAATAAGTGTCACTTTTTTGATGAAAAAACAGGAAATCGTATCGTCTAAGGGGGAGTATTCATG 
SAR0216 ACAAGTCATCTATAAACATTTCTAAATATTTAACATTACTTATGCGTCATTTATTGCTAAAATTATTGTATTAAAATATACATAGAATTGATGGGATATCATG 
SAR0230 TAATTACTGAACTTGAACAACATTTTACTTCAACAAAATAAAGTTTTAAAATATTAATTGTTGGGTTTTACATAGTAATTAGAAAGAGAGTGTTAATGAAATG 
SAR0340 TTTAAGAGCCACGTATTATCTTGGCATTTAGGGAGTGTGAGATAGTACGAATGAGAGCATGTCTATGGGGATAATAGAATTTCTATAATGAGGTGTCAAAATG 
SAR0390 GTAATAATTATGAATAGAATTAAAAACAAGGGGTAATACAATCTATATAGCATATAAGCTTTTGTTATGAGTTTCAAAAAAAGGAAGAGAGAGTGATATTATG 
SAR0396 GCAAGGTCATCGTGACATTCCAAACTAATTCAATGTTACTCTATTAAACATGAATACATATTTTTTCAATTAAAGATAAACTAAGGAGTTATATTACATTATG 
SAR0438 TATATGTATATTTTGGTAACGTAAAAGAGAAATATACAAAATAATTAATTATTTATATGAAAAGAGAATATAAATGAAGTATAAAACAGAGAGACGTGAAATG 
SAR0439 AGACAACATTAAGAGATTATTTAAATTTTGGGCCGTCTGATGAAGATAGCTAAAGTTTATTAGATGTAGAAATAATTCTAAAACAGAGAGACGTGAAACGATG 
SAR0442 GAAACAGCTGTAAGAGATTTTGTGAATTTTGGACCATCTGATGGAGGAGCTAAAGTTTATTAGGTGTAGAAATAATTCTAAAACAGAGAGATGTGAAAAGATG 
SAR0443 GACTTTTCAAAAGAAGATAGGGATATTTCAGTCATTGATTATTTAAGTTATAAGCCAGCGAAAAAATAGTGTTGATAATTAAATATTAGGGTGTGAAATGATG 
SAR0444 TTCAAAAGGTGAAAAAAGCGATTTGTCAGTAATAGATTCTTTGAATTTCCAGCCGGCGAAGGTGAATGAAGATGATGAATGATGAGGATGGTGTGTAACAATG 
SAR0445 AGTTAGTTTTGTTTGATAACATAAAAGTGTAATAATCACTATTTTATTAAGTTGTATGAAATATTCAAATGTGTATAAAAATAAAGCAGAGAGATGTGAAATG 
SAR0463 CGTTATTGTCCAAGTGATTCAAACGCTAGGGAATGTCCTAGCTAGATTCATACGTAGACATTGATGATATATAGTGAAGATTTTGAAAGGAATTGATAGAATG 
SAR0618 AAAGTGGGATTAAAGGAACGCAGTTGGATGTAACCGCACAACTGCATAAAAGCCTCTAATCACTAAAGTTCAAGAGGCTTTAAAAAGGAGATGTGATAATGTG 
SAR0641 TTCCTAGTGGTGCAACAATCGTACTTTGTACGTTTGTAATTTATATCATCACATTATTTTTCACAAAATTTACGAATAGAAAGAAACGAGGAAGTTTAATCATG 
SAR0706 AACAACATTTATTAATATTCATGTTATTTCATGGAAGAAGAGATTTGTTATAATGTGAAGGTCGTCTATCTCTCAGACGTCAATTCGGCGTAGAGAGGAGGTG 
SAR0730 GAGTCATGTAAAAATGTATAAAGATATTGATTAGAATTAGGATTATGTTGCTAATTCATGTTAAAATTAAAAAAGATTTAATGACGTTAAGGAGTTTTATATG 
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Table 11-continued 
ORF Promoter sequences 
SAR0790 GAAAATTAATTTAATCACGATAAAGTCTGGAATACTATAACATAATTCATTTTCATAATAAACATGTTTTTGTATAATGAATCTGTTAAGGAGTGCAATCATG 
SAR0794 TTTAAAGGGGTGATGCGCCAATTAAAGAAGGGTTAACAAGTATTTATTCGTATTTCACATCAAGCACACAGATTAAGCCAAAAGAGGAGAATATTATATTATG 
SAR0872 TATCAACAGTTTTTATTTTAATTATTGTATTTATAATCCAATTCATTGGGGATTGGCTTACAAATAAACTTGATAAACGATAAATTGGGGGTTTCATTTTATG 
SAR0953 AATAAGACCACAGCATTTTGTCTTTAGTACTGAAGAAGAAGCGGCACGACTACGAAAAAATTTGTTGGTAACACAAGATTAAGGGGAAGGGAGAAATGAAATG 
SAR1066 TATACTTAGTAATGAAGATGTGTAATGTAATTGTTTAAAATTGATTTCCAAGCAGATTTTATTTATCATTTAATTTAAATAGCAAGTGGAGGTACAAGTAATG 
SAR1104 ATAATAAATTGATTATAAAATAAATATTGACAATGATAATCATTATTATTTATGATTTTAGTAAAGACTTAAAAGCAATCATAAAAAGGAGGATTATGTTTTG 
SAR1106 ATCATAAAAAGCAATATATGTTATTTGCAGTTGGCATTGTGTTAGCAACCATTTTACTTATTTCGGCACATTTATACAGCAGAAAGAGAGGTAACCAAGTTTG 
SAR1189 AAAATATTGATGGTTAATGTAAAATATCAATATAAATAAGTTTTTTAAATTTATGTATGTTTATTTGATTCAAACAAAATAACTTAAGAGGAGAAAGTTTATG 
SAR1288 ATTGATAATTTAAAACGTTTCAATTTAAAACCTCTAGGACGTTAGTTTGTTTCAAGACGATAGCAATGATATAATTTACGTAAAAAGGAGTGAATTTATCATG 
SAR1402 ACATTTACAGTTTCTAAAGATGAGGTTAATAATTCGAGGTTAAGATAAAGATGTAATCAATACAAATACTATTTGTTGTTCATACAGGGAGGATATTTCAATG 
SAR1494 TAATTACAGTGATAATGAGTCTATAAGGATTGAGGTCGAATGACTTGAAATCAGCTAATTTCTCTATATTCTAAACAAACACATAAATGGGTGATGAGCTATG 
SAR1495 CAGTATACTAATTATTTATTAAAAGCTACTTGTTTTCATTGAGAATAAGTAGCTTTTTCAAACATAAAAGTTTTACAAACACATAAATAGGTGATGAAATATG 
SAR1558 AGATATATGGTATTGGAACTCACTATGGCGAGTATTCGATCACATTTGAGCCGTTGAGAGTTTTTAAATATAAGGAAATATAAACAAAGGAGAGATACATATG 
SAR1608 TTACCTCCTAGTGAAACGTTTGTGCATTTCAACTTTATACATTAAAATAATATCATAATAAGGATAAAAAATAATAGATATTGATTTTAGGGAGATAGTAATG 
SAR1831 ACCTTCTTTCAAATATTTATAATAAACTATTGACACCGATATTACAATTGTAATATTATTGATTTATAAAAATTACAACTGTAATATCGGAGGGTTTATTTTG 
SAR1878 TATTACTGCTTAAAATGACACGAACATGACAATATCATTTAATAAAATAATAAATTTAATTTGATATAATATAGTGTAATTATTTTTAGAGGTGTTGCTTTTG 
SAR1879 AATCATGAAAATAACATATAAATATAGAGGAGATTTACCTTTGAATACAGAGAACAACAAGAATCAAAACCAATCTGCTAAAAATTCTGAAAGACGTGGCATG 
SAR1881 CATGTACGACGCTTCAACAGAATAAAATTTCAGGGTAGCTCGGCTACCCTTCTTTTACGGAAAAATTAATTATACATAATCAAATCAAGGAGATAAAAAAATG 
SAR1995 TTCAAAATTAACAAAAGCACAAAGTTTAGGTATTGAAATTTGGACAGAGCAACAATTTGTAGATAAGCAAAATGAATTAAATAGTTAGAGGGGTATGTCGATG 
SAR2104 ATTTTACTAAACAAAAAAACGCCTACTAGTGTGAAAACGTATTGATTAATAGCGCCTATATGGAGTTTTAATATAAAAAGTAAGCAAAGGAGAAATGAGAATG 
SAR2179 TTTTTTAATAATTAGTTAAATTTTTCCACTTATTGTTTCATACGTACTCATTAATGTGATAGAATAAATCCTATGTGAATATAATGATAGAGGTGGAAAAATG 
SAR2268 CATACATTTTAGTAATATAAAAAGATTGAACGCTACTTGACAATGATAATTGTTATCAATAAAATAATAAATGAAGTTATACATATTAAGGAGTGGAACGATG 
SAR2363 ATTATTTGAATCATTATTTAAAGAGAAAACGCTTCTTTTCAAAAATATTGTTAAGTGTATAATGAGAGTGTAAATATTTAATAATTGGGGGTATTTCATAATG 
SAR2368 TGCGAAAATAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG 
SAR2457 TATTGTTGACGTCTTTGGTAACAATCCATGAAATGATACACATGGTAGATATGTATTTCAAGCTTATTCAATGAATATCGAATTATAGGAGGAGATATGTATG 
SAR2496 ATGATTCGACTTTATATTATTTATAAAAACAGTGCTTGTATTTTAAGTAGCATGAGTATATAATTTTAAAACGTAAAGATTACTATTTAGGAGGGTGACTATG 
SAR2499 ATCATATAAGCAAGATTTTGATTCGAGACGATATTATCAACAACATGATGCGGATTATCATGAAGAAAATATGACGAACTAGATATGAACAGGAGTTATTATG 
SAR2500 TTAAATGTATTGGTAGTAGTTGTAGCGCATTGATGTTTGACGGTGTATAGTATTAATTATATTGAAAGTTAGTTGGAAGTTGATAGTAGGAGTGGGAGCATTG 
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Table 11-continued 
No ORF Promoter sequences 
55 SAR2504 AACGCTTTTTAGCAAAAGTTCAACATATTGACTTATCTGGCGATTCAGATTAAAATATTTTTATTCCGATTAGAATAATAAGAATAAGGAGATATATTCTATG 
56 SAR2536 ACTGCACTAGCATTAGGTGTTGATGCCTTATTAGCTTTAGTTGAAAAATGGGTAGTTCCCAAAGGCTTAAAAGTATCTGGATAATTAGGAGGCTAAGATAATG 
57 SAR2546 TACAAAAAAATTATCAAAATTTAAATTTTTGAATAACATCATTTTTTAGTAAATGTTATAATTTCTTTATAATACAAATATCGAAAGAAGGCGACTGACTTTG 
58 SAR2554 TGTTTGACATTTACATAAAAATAAGCAAATAATTGAGAAAAATAATCATTACGATTTGATTAAGTAATGCAACTTATCAATTTAGAAAGAGGAAAAGCAAATG 
59 SAR2573 ATTAAAAGCCACGAGGATTTAATCATAAAATTTCCTCTAGTATTATTAATATTGGAATTTGAACTTAACTTTGCATCAAAAATAAAAATGGGGATGTGAAATG 
60 SAR2736 TCAAGATTAGCTTATAATAATATTGAATAACATTATTTTAGTTTTTGTATAATTTGCCTATCAACTGAAAAACAGCTAATACAAAGGAGCTAATGAAGATATG 
61 SAR2763 TAAAAAATAAAATTAAAATCCCAACAGTTTCTTAAAAAGTTATGAGCCACATAATAAAAATGTTATAATTGTGCATAATAAAACATAGGGAGAATGTTTAATG 
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3.2.4 Lipobox sequences 
S. aureus lipoprotein lipobox features of 50 lipoprotein genes were examined and were 
found to be highly conserved and showing relatively constant amino acid residues 
frequency among all strains with very low observed changes. The signal sequence divided 
into three regions: n-region, h-region and c-region. The n-region is characterized by 
presence of the positive amino acids lysine and/or arginine, the h-region consists of 
hydrophobic amino acids, and the c-region has a characteristic region of four amino acids 
around the cleavage site that is very well conserved, a so-called lipobox. The search 
criteria for lipobox in this task was as following: methionine at position 1, followed by 2 to 
6 amino acids with at least one positive charge lysine or arginine, followed by a 
hydrophobic stretch of 7 to 15 amino acids followed by the lipobox with 4 amino acids. 
Analysis of lipobox amino acids frequency of an approximately 950 distinct lipoproteins in 
20 S. aureus strains revealed four distinct amino acids sequences at the C-terminal end of 
the signal peptide including the modifiable cysteine. The amino acid in the -3 position was 
the most variable among the lipobox sequences with mainly leucine (71.7%), valine 
(15.1%), then isoleucine (10.9%) and threonine (2%). In contrast the -2 position was 
occupied equally by three amino acids serine (38.7 %), alanine (35.4 %), threonine 
(23.4%) and at low frequencies isoleucine (2.1%), in the -1 position three amino acids 
residues were found with more constant of glycine (47.3%), alanine (44.2%), and serine 
(8.3%), and as expected 100% of +1 residue in lipobox was cysteine and the consensus 
lipobox sequence would be [TIVL][ITSA][SAG][C] as shown in figure 13. The sequence 
results show that the n-terminal 5-7 residues always contained two high positively charged 
residues of (lysine or arginine), while the h-region length varied between 7 and 9 residues. 
Table 12 summarizes the list of 50 lipoproteins S. aureus MRSA252 including details of 
their genes and lipobox structure.    
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Figure 13. Amino acid numbers and position in lipobox of lipoproteins in 20 S. aureus 
strains 
936 lipoproteins were examined for their lipobox properties of 4 amino acid sequences at 
the C-terminal, the lipid modifiable Cysteine (+1 position) was invariant; Glycine, Alanine 
and Serine at (-1 position); Alanine, Threonine, Isoleucine and Serine at the (-2 position); 
Leucine, Valine, Isoleucine and Threonine were occupied at the (-3 position); some minor 
amino acids were not included. 
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Table 12. List of S. aureus MRSA252 lipoproteins including details of their genes and lipoprotein signal peptides, the carboxy-terminal 
region (C-region or lipobox), the hydrophobic (H-) region and amino-terminal (N-) region. 
ORF 
Amino acids 
sequence length 
Gene sequence 
length DNA (bp) 
lipoprotein signal peptides 
Lipobox 
aa length 
Lipobox DNA sequences 
SAR0118 330 993 
n-region: MNKVIK 
h-region: MLVVTLAFLLV 
c-region: LAGC 
21 
TTATTTTGATTGTTTTTCAATATTTAAC
TTTTCATATAAATCGTCAATAAGTTTT
AATGATGA 
SAR0174 324 975 
n-region: MKR 
h-region: LSIIVIIGIFI 
c-region: ITGC 
18 
ATGAAAAGGTTAAGCATAATCGTCAT
CATTGGAATCTTTATAATTACAGGATG
T 
SAR0201 591 1776 
n-region: MKK 
h-region: IISIAIIVLALV 
c-region: LSGC 
19 
GTGAAGAAAATCATTAGTATCGCAAT
TATAGTTTTAGCGTTGGTATTAAGTGG
TTGT 
SAR0206 423 1272 
n-region: MSKILK 
h-region: YITLAVVMLLI 
c-region: VTAC 
21 
ATGTCTAAAATTTTAAAATATATCACG
TTAGCCGTGGTAATGTTATTAATCGTA
ACTGCATGT 
SAR0216 322 969 
n-region: MKSK 
h-region: IYILLLFLIF 
c-region: LSAC 
18 
TCATTGAATCATCTCCAAAAATTTATG
ATGCGGAATGTCCGGTAATTTAGATTT 
SAR0230 491 1476 
n-region: MKFKR 
h-region: LATIFSAVLV 
c-region: LSGC 
19 
TTATCGTTCAATCGTAGTTCGATAATC
GATTAAATAGATACCTTCAGGTGTTAC
TTT 
SAR0340 284 855 
n-region: MKK 
h-region: LTTLLLASTLL 
c-region: IAAC 
18 
ATGAAAAAGTTAACAACGCTATTATT
AGCATCAACGTTATTAATTGCTGCATG
T 
SAR0390 190 573 
n-region: MKLK 
h-region: SLAVLSMSAVV 
c-region: LTAC 
19 
ATGAAATTAAAATCATTAGCAGTGTT
ATCAATGTCAGCGGTGGTGCTTACTGC
ATGT 
SAR0396 208 627 
n-region: MKKR 
h-region: LLLSTFLASTLI 
c-region:LTGC 
20 
TTATTTATCGATAACATCACTCTTGAT
ACCTTTAGATTTTAAGAAATCTTTAAT
TTTATC 
SAR0438 261 786 
n-region: MMGNIK 
h-region: SFALYISILLLIVV 
c-region: VAGC 
24 
ATGATGGGAAATATAAAAAGTTTTGC
ATTGTACATAAGTATCTTGCTTTTAAT
AGTTGTTGTAGCAGGTTGT 
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Table 12-continued 
ORF 
Amino acids 
sequence length 
Gene sequence 
length DNA (bp) 
lipoprotein signal peptides 
Lipobox 
aa length 
Lipobox DNA sequences 
SAR0439 257 774 
n-region: MGYLKR 
h-region: FALYISVMILMFA 
c-region: IAGC 
23 
ATGGGGTATTTAAAAAGGTTTGCATTG
TACATAAGCGTTATGATTTTAATGTTT
GCGATAGCAGGTTGT 
SAR0442 256 771 
n-region: MGYLKR 
h-region: IGMCISLLIVIIF 
c-region: VTSC 
23 
ATGGGATATTTAAAAAGGATTGGAAT
GTGCATAAGCCTATTGATTGTAATTAT
TTTTGTAACATCTTGC 
SAR0443 266 801 
n-region: MRYLNR 
h-region: VVLYIIVMVLSVF 
c-region: IIGC 
23 
ATGAGATATTTAAATAGAGTTGTACTG
TACATAATTGTTATGGTTTTGAGTGTT
TTTATAATAGGTTGT 
SAR0444 264 795 
n-region: MKSIKR 
h-region: IGLCISLLILIIF 
c-region: VTSC 
23 
ATGAAGTCTATAAAAAGGATTGGATT
GTGCATTAGTTTGTTGATTTTAATCAT
CTTTGTTACATCTTGT 
SAR0463 280 843 
n-region: MKR 
h-region: LIGLVIVALVL 
c-region: LAAC 
18 
ATGAAAAGATTGATTGGGTTAGTTATC
GTAGCACTTGTATTATTAGCAGCGTGT 
SAR0618 295 888 
n-region: MKK 
h-region: SLIAFILIFMLV 
c-region: LSGC 
19 
ATGAAAAAAATTGTTATTATCGCTGTT
TTAGCGATTTTATTTGTAGTAATAAGT
GCTTGT 
SAR0641 309 930 
n-region: MKK 
h-region: LVPLLLALLLL 
c-region: VAAC 
18 
TTATTTCATGCTTCCGTGTACAGTTTC
AATATTTGATTTCATCATTTTGTAGTA 
SAR0706 34 105 
n-region: MR 
h-region: FMNEILVHIMTTA 
c-region: ISGC 
19 
TTATTTTTTATCACGTTTATGGAGCCA
ATAACCAAATAACGTAACGAGACAAC
CACT 
SAR0730 129 390 
n-region: MKK 
h-region: LIISIMAIMLF 
c-region: LTGC 
18 
ATGAAGAAATTAATCATCAGCATTAT
GGCGATCATGCTATTTTTAACAGGTTG
T 
SAR0790 342 1029 
n-region: MKK 
h-region: TVLYLVVAVMFL 
c-region: LAAC 
19 
ATGAAGAAAACAGTCTTATATTTAGT
AGTAGCAGTAATGTTTTTATTAGCGGC
ATGC 
 
109 
 
Table 12-continued 
ORF 
Amino acids 
sequence length 
Gene sequence 
length DNA (bp) 
lipoprotein signal peptides 
Lipobox 
aa length 
Lipobox DNA sequences 
SAR0794 292 879 
n-region: MKK 
h-region: IVIIAVLAILFVV 
c-region: ISAC 
20 
ATGAAAAAAATTGTTATTATCGCTGTT
TTAGCGATTTTATTTGTAGTAATAAGT
GCTTGT 
SAR0872 273 822 
n-region: MKK 
h-region: LFGLILVLTFAVV 
c-region: LAAC 
20 
ATGAAAAAATTATTTGGTCTTATTTTA
GTATTAACATTTGCAGTTGTATTAGCA
GCTTGC 
SAR0953 551 1656 
n-region: MTRKLK 
h-region: TLILIFVATIA 
c-region: LSGC 
21 
ATGACAAGAAAGTTAAAAACGCTGAT
TTTAATATTTGTTGCCACAATTGCATT
AAGTGGTTGT 
SAR1011 319 960 
n-region: MNRNIVK 
h-region: LVVFMLILVVA 
c-region: VAGC 
22 
GTGAATAGGAATATCGTTAAATTAGTT
GTGTTTATGCTAATCTTAGTTGTAGCA
GTAGCGGGTTGT 
SAR1034 366 1101 
n-region: MSKFK 
h-region: SLLLLFGTLIL 
c-region: LSGC 
20 
TTAATGTCCACCTCCATGATCATCATT
GTCTTGATCTTGCGCATCTTTTGAAAT
TTTCTT 
SAR1066 208 627 
n-region: MKFGK 
h-region:TIAVVLASSVL 
c-region: LAGC 
20 
ATGAAATTTGGAAAAACAATCGCAGT
AGTATTAGCATCTAGTGTCTTGCTTGC
AGGATGT 
SAR1106 292 879 
n-region: MRIIK 
h-region: YLTILVISVVI 
c-region: LTSC 
20 
TTGAGAATCATAAAGTATTTAACCATT
TTAGTGATAAGCGTCGTTATCTTAACC
AGCTGT 
SAR1189 317 954 
n-region: MKK 
h-region: TLGCLLLIMLLV 
c-region: VAGC 
19 
ATGAAAAAGACACTGGGATGTTTACT
TTTAATTATGCTTTTAGTCGTAGCAGG
TTGT 
SAR1288 118 357 
n-region: MRR 
h-region: WFVLILGLVIL 
c-region: LSAC 
18 
TTATTTTTTCATATTATTTTCTTCATAA
ACTGGTTTATTATCTTTCTCAAACTT 
SAR1494 302 909 
n-region: MFKRTK 
h-region: LILIATLL 
c-region: LSGC 
18 
TTAGTCAAACACACCATATTCTGAAGT
GCTTTTACCGTTATAATTTGGTTTAAC 
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Table 12-continued 
ORF 
Amino acids 
sequence length 
Gene sequence 
length DNA (bp) 
lipoprotein signal peptide 
Lipobox 
aa length 
Lipobox DNA sequences 
SAR1495 301 906 
n-region: MLKKAK 
h-region: LILIATLL 
c-region: LSGC 
18 
TCATTCGACCTCAATCCTTATAGACTC
ATTATCACTGTAATTAACTCGATTAGT 
SAR1558 144 435 
n-region: MKK 
h-region: VIGLLLVSTLA 
c-region: LTAC 
18 
ATGAAAAAAGTAATCGGACTGCTACT
AGTAAGTACATTAGCTTTAACAGCTTG
T 
SAR1608 193 582 
n-region: MKK 
h-region: LVSIVGATLL 
c-region: LAGC 
17 
ATGAAAAAATTGGTTTCAATTGTTGGC
GCAACATTATTGTTAGCTGGATGT 
SAR1831 281 846 
n-region: MKK 
h-region: LIFLIVIALV 
c-region: LSAC 
17 
TTGAAAAAGTTAATATTTTTAATTGTA
ATTGCTTTAGTTTTAAGTGCATGT 
SAR1879 184 555 
n-region: MLK 
h-region: GCGGCLISFIILIIL 
c-region: LSAC 
22 
ATGTTAAAAGGATGCGGCGGTTGCCTT
ATTTCTTTTATTATATTAATTATCTTAT
TATCAGCCTGT 
SAR1881 208 627 
n-region: MKFK 
h-region: AIVAITLSLSL 
c-region: LTAC 
19 
ATGAAATTCAAAGCTATCGTTGCAATC
ACATTATCATTGTCACTATTAACCGCC
TGT 
SAR1995 399 1200 
n-region: MKR 
h-region: TLVLLITAIFI 
c-region: LAAC 
18 
TTAATTACTGTAAATATGAACTTGCGG
TTCTTTGTCATCTTTTGTCTTACTAAT 
SAR2104 154 465 
n-region: MKR 
h-region: LLGLLLVSTLV 
c-region: LSAC 
18 
ATGAAAAGATTGTTAGGTTTATTATTA
GTGAGCACGTTAGTGTTAAGTGCATGT 
SAR2179 290 873 
n-region:MKKK 
h-region: TLLPLFLGIMVF 
c-region: LAGC 
20 
TTATTTCTTTTTCTTTTTAGACACTACT
TGTGTGTTTTTGCCTTTTTTATTGCTGC
CGCC 
SAR2268 327 984 
n-region: MRGLK 
h-region: TFSILGLIVALFL 
c-region: VAAC 
22 
TTACTTTTGTTCTTTTTTTGATAATTCA
ACAAGTTCTTTAGCCATTTCTTCAGAA
GAAATTAAGCC 
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Table 12-continued 
ORF 
Amino acids 
sequence length 
Gene sequence 
length DNA (bp) 
lipoprotein signal peptides 
Lipobox 
aa length 
Lipobox DNA sequences 
SAR2363 260 783 
n-region: MKMKR 
h-region: FIAIVMALFLV 
c-region: LAGC 
20 
TTATGCTGTAAAGTGGTATTCTTTTAA
TATTTCTTTAGCTTTATCTGATTTTAAG
AATTC 
SAR2368 302 909 
n-region: MKK 
h-region: LLLPLIIMLLV 
c-region: LAAC 
18 
TTATTTTGCAGCTTTAATTAATTTTTCT
TTTAAATCTTTACGCATGAAATCTAA 
SAR2457 209 630 
n-region: MKK 
h-region: LVTGLLALSLF 
c-region: LAAC 
18 
TTATTGTTGGTAGTTTGGATCAGTAACC
ATTGCTTGTCCAGTATAATCAACCGT 
SAR2496 515 1548 
n-region: MKKK 
h-region: LGMLLLVPAVTLS 
c-region: LAAC 
21 
TTAATGCGCTAACATTTCTTCTTTGATT
TGGTCTTTATTTAATTTTGAAGGATAAT
ATGTTGG 
SAR2499 199 600 
n-region: MTKK 
h-region: LLTLFIVSMLI 
c-region: LTAC 
19 
CTATTTGATTTTATCTTTTAATAATTTTT
CATAACTTTCATAATCATATGGATCTTC 
SAR2500 120 363 
n-region: MKR 
h-region: FVATVLLLLVF 
c-region: ISGC 
18 
CTAGTTCGTCATATTTTCTTCATGATAAT
CCGCATCATGTTGTTGATAATATCG 
SAR2504 259 780 
n-region: MKR 
h-region: LLFVVIAFVFI 
c-region: LAAC 
18 
CTATTTAGATTTAGAAACATCTTGACCA
AACCATTTCTTACCTATTTTAGCTAA 
SAR2536 313 942 
n-region: MKKIK 
h-region: YILVVLVLSLTV 
c-region: LSGC 
21 
TTACTTATGACCACCTTTCTGTTTATCA
AAATAGTGGTGTTTTTTCAAAAATTCT
TCTGCGAC 
SAR2546 151 456 
n-region: MKK 
h-region LCSLIVVALVCVIA 
c-region: LSAC 
21 
TTGAAAAAATTATGTTCATTAATTGTAG
TAGCATTAGTTTGTGTCATTGCATTATC
AGCTTGT 
SAR2554 532 1599 
n-region: MRKLTK 
h-region: MSAMLLASGLI 
c-region: LTGC 
21 
TTATTTATACTGCATTTCATTGAATGGTA
ATTCATACTGTGATTGTGTGAATGCTAC
TTTTTC 
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3.2.5 Phylogenetic analysis 
The phylogenetic trees generated with both analytical programs package (Seaview 4 and 
MEGA 6) using the lipoprotein sequence data revealed very similar results to confirm the 
accuracy of these analyses. Concatenated sequences were used to construct a Bayesian 
phylogenetic tree of the 44 common lipoprotein genes (figure 14 A and B). Six genes were 
identified as not occurring in most strains or with truncated sizes (SAR1558, SAR1288, 
SAR0439, SAR0706, SAR1831 and SAR2104) were excluded in the phylogenetic analysis. 
Phylogenetic analysis was completed by using a Neighbor-Joining (NJ) method, based on 
pairwise nucleotide sequence alignments for the 44 S. aureus lipoproteins. Both trees in 
figure 14 had similar distributions of 20 S. aureus strains according to their lipoproteins, 
based on the genetic diverse and lipoproteins variations. The clusters of these strains were 
highly concordant with BLAST alignment data of individual genes. There were two main 
branches for both trees dividing to two separate groups of strains (8 and 12 strains for each 
group) figure 14 A and B, these strains showed clear relation between their lipoprotein 
genetic structure, each group had two or three sub-groups of more closely related strains. 
The first group of lipoprotein in both trees has sub-groups were almost distributed in pairs 
to show more close related strains, three groups of pair strain are generated (MRSA252 
and T1), (MSSA476 and MW2) and (RF122 and M013) these strains shared almost 
identical genetic features for lipoprotein genes.     
RF122 bovine strain and M013 MRSA strain showed more than 98% average identity of 
examined genes nucleotide sequences, but SAR0438 shared only 88% of DNA identity, 
also 96% of the SAR0444 and SAR0730 sequence was identical in both strains. MSSA476 
and MW2 strains displayed homologous lipoprotein genes, this high similarity sequence 
were found in all genes. The related MRSA252 and T1 strains have shown a strong genetic 
structure similarity for the tested genes to suggest the common genomic features, 
meanwhile, LGA251 and ST398 strains are possess less nucleotides identity with 
MRSA252 to show earlier diversion according to the percentage of similarity as shown in 
figure 14.      
On the other hand, the trees in figure 14 A and B has second branch of were distributed 
into on other two main divisions one of them were contains three HA-MRSA strains (Mu3, 
Mu50 and N315) with highly related lipoprotein primery sequence, the three strains were 
sharing the similar nucleotide identity with ~100% identity, there were three lipoprotein 
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genes (SAR0439, SAR0438 and SAR1011) have very minor nucleotide differences in Mu3 
strain, for this reason there is a slight variations in this cluster. The second sub-branch 
consisting of 9 strains distributed in individual and pairs, HA-MRSA strains T0131, 
BMB9393 and TW20 has similar nucleotides properties close to 98%, however T0131 and 
BMB9393 were more closely related to each other, by cause of few variable genes 
(SAR0439, SAR0444, SAR0790, SAR042 and SAR0443) that contains more nucleotides 
variation to generate this differences. The laboratory strain NCTC8325 and vancomycin 
resistant VC40 strain were shown conserved relative nucleotides structure, both strains 
were identified with 100% identitical in 44 lipoprotein genes, while the MRSA strain COL 
had two diverse genes (SAR0439 and SAR0442) with 2% and 8% nucleotides variability 
amongb these genes, this nucleotides variability produce a slight alteration in this small 
cluster group. Additionally, MRSA S. aureus M1 have almost the similar nucleotides 
features of this cluster but had a few further genetic differences in SAR0438 and SAR0442 
genes with some variant SNPs. Unlike most other strains, S. aureus str. Newman and 
RN4282 had a different trend were branched in an individual manner to show less 
nucleotides identity to the other groups.
114 
 
(A)                                                                                                          (B) 
 
Figure 14. Phylogenetic relationships of lipoprotein among 20 S. aureus strain                                                                                      
Bayesian phylogram indicating the evolutionary relationships of lipoprotein, sequences were aligned using Clustal W2. NJ tree with 
bootstrapping consensus inferred from 1,000 replicates was constructed using sequences of concatenated 44 lipoprotein genes for each S. aureus 
strain representing 37670 bp by two different software (A) MEGA 6, and (B) Seaview 4 were used to generate the concatenated trees.
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3.2.6 Antibiotic susceptibility test 
In this study S. aureus strains has been used in the proteomics and genomics analysis were 
investigated to determinate their methicillin resistance using oxacillin/cefoxitin disc 
diffusion test on Iso-Sensitest agar. The variability of MICs of S. aureus strains could help 
to explain the differences in some genetics structures and expression levels during the 
growth stages. Results are presented in table 13. Three strains (MRSA252, RN4282 and 
8325-4) were resistant to cefoxitin according to current criteria and were therefore 
probably MRSA strains, while only 1 strain (T1) was susceptible oxacillin/cefoxitin 
antibiotics. Also the full antibiotic susceptibility test images for each strain prepared in 
agar plates are available in appendix B. 
 
Table 13. Zone diameter and MIC interpretive for S. aureus tested with 30 μg of 
cefoxitin 
MIC breakpoints to determined inhibition zone: susceptible = ≥ 22 mm diameter, resistant 
= ≤ 21 mm diameter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. aureus strain 
Zone diameter interpretive criteria 
(nearest whole mm) 
MRSA252 0 mm 
T1 25mm 
RN4282 21mm 
ACTC8325 21mm 
NCTC12493 (control strain) 10mm 
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3.3 Discussion 
3.3.1 Lipoprotein relatedness of S. aureus strains and their genetic diversity  
S. aureus strains have a genome ranging in size from 2,799,802 to 3,075,806 base pairs 
containing regions of small and large difference. Small genetic variation is defined as 
changes that affect few individual genes, while the large variation is related to horizontally 
acquired DNA segments. Different predictive algorithms rules have been used to predict 
the unique N-terminal lipid modification. The absence of some genes gives a clear 
indication that these genes are not common to all S. aureus strains, furthermore the 
functions for most of them were not well identified to be named as putative lipoproteins. 
Also the comparative analysis search for lipoproteins in protein database showed the 
numbers of bacterial lipoproteins were not similar between strains (Sutcliffe and 
Harrington, 2002). The BLAST search results in this study have revealed certain variation 
in the lipoprotein repertoire among examined strains. Six genes were absent in some tested 
strains. Lipoprotein genes of T1 strain which has revealed to be closely related to other 
lipoprotein genes of MRSA252, but SAR1881 was not found in T1 S. aureus. Also, small 
number of genes (SAR2104, SAR1881, SAR1494 and SAR0953) in RN4282 and T1 strains 
were absent from MRSA252.  
Gene sequence analysis of nucleotide polymorphism was used to detect SNPs between 
lipoprotein of S. aureus, revealed 11 genes with strong nucleotides changes leading to 
many amino acids variations, these variant genes have a strong impact on the phylogenetic 
trees as some strains was more related to each other based on the sequence variation of 
these genes. From molecular analysis, the great majority of mutations among lipoprotein 
genes are represented within a limited number of genes to reveal considerable variation 
among analogous genes encoding lipoproteins, 11 highly variable genes with considerable 
numbers of non-synonymous residues. 
3.3.2 Phylogenetic analysis 
The most reliable markers genes used in epidemiological or population studies encode 
essential housekeeping functions (Case et al., 2007). A study in population and 
epidemiological investigation based on ~17.8 kb of intra-species tree sequence of 
individual genes using multilocus sequence typing (MLST) suggested that the candidate 
marker loci used in S. aureus phylogeny should have at least >1 % mean pairwise diversity 
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for all genes in the genome, also there was no strong relation between gene function and 
phylogenetic reliability (Cooper and Feil, 2006). The neighbour joining tree of S. aureus 
strains investigated in this study indicates a pattern of genetic diversity of lipoprotein, the 
distribution of this diversity was generated and displayed in phylogenetic trees, S. aureus 
lipoprotein differed from one another among 20 strains, also it has revealed several 
common features in the majority of examined genes. To illustrate the value of variety in 
compared lipoprotein sequences with related genes sequences, both analyses trees formed 
distinct clusters of strains with similarity of 100%. The main two branches of phylogenetic 
tree has a consistent structure among their sub-branches, 8 strains were trend to share more 
genetic features and exposed to less mutation changes. Comparisons between UK hospital-
acquired epidemic MRSA252 and T1 strains by using BLAST search for the lipoprotein 
genes, the two strains had an identical genetic identity, lipoprotein genes identity were 
found 100% identical in each strain, MRSA252 has proved a high methicillin resistance 
while T1 were methicillin susceptible. LGA251 and ST398 strains have shown more 
genetics identity related to MRSA252 strain with few minor varability in some genes. 
Lipoprotein genes sequence of MSSA476 and MW2 strains were highly identical, these 
results are consistent with previous study which find that both strains was related to each 
other (Holden et al., 2004). Based on the generated phylogeny comparative analysis in this 
study the genetic structure relationship between MSSA476 and MW2 strains the genetic 
elements of lipoprotein were highly identical. The sequence and order of most of the open 
reading frames in the genomes M013 and MW2 were conserved (Huang et al., 2012). 
Lipoprotein genes of bovine strains RF122 was similar to genes content to human strain 
M013, this finding suggests that similar strains may cause cross infection between human 
and animals.  
NCTC 8325 and VC40 strains have shown major paired nucleotides structures in all tested 
genes, this high similarity were proved in other genetic study were genomic tree based on 
average nucleotide identity (ANI) calculation of homologous genes among five S. aureus 
genomes has shown that VC40 strain were closely related to strains NCTC 8325 (Kim et 
al., 2014). A previous study using an amplicon-based microarray technique found that 
COL and 8325 stains were clustered closely to show very identical related genomically 
features (Cassat et al., 2005). MRSA N315, Mu3 and VRSA Mu50 strains genome content 
share common characteristics, complete comparative analyses of whole genome sequences 
of three strains found 213 ORFs diverse between Mu50 and N315, and 9 ORFs between 
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Mu50 and Mu3 (Ohta et al., 2004). N315 and Mu50 strains share 96% nucleotide sequence 
identity (Kuroda et al., 2001). TW20 strain that is highly resistant to a range of antibiotics 
shares close average nucleotide identity with T0131and BMB9393 strains. Comparative 
study on the genomes of these S. aureus shown that BMB9393 has 142 unique ORFs, also 
BMB9393 and TW20 strains sharing 2,555 CDS and 2,541 with strain T0131 (Costa et al., 
2013). T0131 shares 2,573 orthologous coding sequences CDSs with TW20, moreover 
T0131 has 85 definite genes compared with TW20 genomes (Li et al., 2011).  
Baba et al., 2008 examined the diversity and clonal relationships between the S. aureus 
strains to investigate the differential success of these strains based on sequence of seven 
housekeeping genes and the distribution of the genomic islands (Baba et al., 2008), data 
has revealed phylogenetic analyses identical to the overall results of phylogenetic trees in 
this study, the shared tested strains in both studies were grouped in the same pattern and 
groups. The sequence variation of lipoproteins within virulent strains may have a value as 
an epidemiological marker among related isolates, but the results for most lipoprotein 
genes in this study had <1 % mean pairwise diversity to indicate their low significance as 
genetic markers.    
The lipoprotein genes SAR0439 putative lipoprotein and SAR0442 putative membrane 
protein have shown the highest nucleotide diversity value but it is still insufficient to use 
as epidemiological marker, as the marker loci used in S. aureus phylogeny should have at 
least >1 % mean pairwise diversity for all genes in the genome. 
3.3.3 Lipobox features 
The lipobox was identified as a consensus sequence in prolipoproteins, this signature can 
help to differentiate lipoproteins and non-lipoproteins (Babu and Sankaran, 2002). The 
lipoprotein signal sequences are characterized with an n-region including 5 to 7 amino 
acids with at least one or two positively charged amino acid Lys and Arg residues, C-
terminal signal recognition sequence containing conserved lipid-modified Cys at +1 
position, while the length of uncharged h-region ranges between 7-22 amino acids. 
Lipobox motif composition of examined 20 S. aureus strains did not display major 
differences and also showed only a small number of varations (29 mutations in 936 distinct 
lipoboxes) among their amino acids residues. Comparison of the main lipobox features for 
tested S. aureus strains comprised [TIVL][ITSA][SAG][C], in contrast lipobox from other 
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bacteria [ILV][ASTVI][GAS][C] (Babu and Sankaran, 2002), this residues specifying few 
amino acids sequences variability, the results showing a slight changes in the amino acids 
frequency order, lipobox of S. aureus have some diverse amino acids residues with a low 
frequency that were present in some lipoproteins. SNPs occurred in a few lipoprotein 
genes but only twenty nine amino acids mutations were reported in 8 lipoproteins to show 
less than 0.85% of all examined lipoboxes. Also a few amino acid residues were minor 
components in the lipobox as this was noted in SAR1558 the -3 position was threonine, 
while in SAR0443 the -2 position was isoleucine.   
3.3.4 Antibiotic susceptibility test 
Cefoxitin is recommended to detect the methicillin resistance in S. aureus (MRSA), the 
aim was to evaluate the S. aureus strains methicillin resistance for the five strains that been 
used in this study to assess any possible relation of methicillin resistance and lipoprotein 
features of the tested strains. Relating to cell wall biosynthesis, multiple genes appear to be 
significantly induced by different cell wall-active drugs or antibiotics. In general, beta-
lactam antibiotics targeting the transpeptidase of PBPs, this action decreases the cell wall 
cross-linking and hence the lack of cell wall integrity (Mallorquí-Fernández et al., 2004). 
Lipoprotein genes of MRSA252 and T1 strains were highly similar in the primary 
sequence, however MRSA252 has proved a highest cefoxitin resistance in the same time 
T1 strain was highly susceptible. T1 strain was isolated from a case of menstrual TSS in 
the early 1990’s, at that time the methicillin-resistant S. aureus strains had not spread so 
widely. The data shows that the lipoproteins of the two strains are similar suggesting that 
MRSA252 may have originated from the same lineage as T1. Mobile accessory genetic 
elements containing virulence genes possibly move between isolates, these acquired 
elements could explain the relatedness between S. aureus strains to shown relative variable 
MIC breakpoints of inhibition zone for different antibiotics (Moore and Lindsay, 2002). 
Many transcriptomic experiments on S. aureus have defined the existence of different 
genes whose expression is changed after exposure to a range of antimicrobial agents that 
target cell wall biosynthesis (Dengler et al., 2011, Drummelsmith et al., 2007, McAleese et 
al., 2006). Genetic and biochemical examinations carried out on 30-kDa lipoprotein prsA 
of methicillin resistant S. aureus showed that a prsA deletion led to changes in the 
susceptibility of S. aureus COL (MRSA) to show decreases the resistance to oxacillin 
(Jousselin et al., 2012).  
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4. Proteomics identification of S. aureus lipoproteins under different 
growth conditions 
4.1 Introduction  
Understanding of the lipoprotein properties in S. aureus is needed for better definition of 
their pathogenesis and development of potential therapeutic strategies to reduce S. aureus 
infections. Lipoproteins have been described that are very important virulence factors as 
they are involved in many processes of S. aureus pathogenesis, but fulfil diverse functions. 
The roles of individual lipoproteins have not been fully characterized. Although some 
lipoproteins are involved in Fe transport and are regulated by Fe via fur, the regulation of 
expression of the majority is not understood. Initial studies therefore aimed to determine 
whether the lipoprotein genes were expressed in different growth phases. Investigation of 
lipoproteins could help to understand mechanisms of virulence and antibiotic resistance of 
S. aureus. Many transcriptional analyses of proteins expressed on S. aureus have provided 
views on the virulence factors expression under different conditions, but these results 
cannot explain the proteome changes during host infection as production of various 
proteins can be regulated post-translationally. Just because the gene is present and 
transcribed does not prove that the protein is synthesised. A detailed proteomic proﬁling of 
S. aureus lipoproteins is important to confirm their expression from the genes and to 
determine their potential roles as virulence factors and antigens. This proteomic 
information could help to identify the differences and similarity of lipoprotein constituents 
and provide helpful information to develop a vaccine and/or treatment of S. aureus 
infections.   
There are two major approaches to convert proteins extracted from a biological specimen 
to peptides prior to mass spectrometry and proteome analysis. The first approach is to treat 
proteins with detergents, separate them by sodium dodecyl sulfate (SDS) poly acrylamide 
gel electrophoresis (PAGE) followed by in-gel digestion of proteins (Gorg et al., 2004). 
The second approach is treating the protein mixture with strong chaotropic substances e.g. 
urea. Protein digestion under detergent-free conditions is known as in-solution digestion 
gel-free proteomic approaches can be also divided as bottom-up and top-down, the bottom-
up is to identify corresponding proteins by analysis of peptides obtained via specific 
proteolysis. While, the top-down proteomics is based on using MALDI-based tandem 
mass spectrometry of fragments or intact protein for identification (Yates et al., 2009). 
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Hecker et al. summarized the impact of proteomic methodology and mass spectrometry 
approaches to understand the S. aureus mechanisms of pathogenesis and virulence (Hecker 
et al., 2010). The classical methods mass spectrometry (MS) or tandem mass spectrometry 
(MS/MS) for quantitative analysis of primary sequence and posttranslational modifications 
have shown successful results when applied to small amount of proteins (Mann and 
Jensen, 2003). Mass spectrometry is a powerful technique for high-throughput proteome 
analysis based on the mass of peptides subjected to trypsin digestion (Aebersold and 
Mann, 2003). The qualitative two-dimensional gel electrophoresis 2-DE in combination 
with protein and peptide analysis mass spectrometry methods can identify individual 
protein spots. This method is based on protease digestion of protein mixtures and 
subsequent peptides separated and identified by LC-MS/MS (Lim et al., 2003).   
The development of non-gel based proteomic techniques has provided powerful tools to 
investigate protein quantification on a large-scale and characterisation of proteins in 
complex biological models (Cravatt et al., 2007). Label-free quantification methods 
correlate the MS signal of peptides obtained by trypsin digestion of proteins or number of 
peptides sequenced with the relative or absolute protein quantity. These quantitative 
approaches can measure significant proteomic changes within a complex proteins mixture 
of multiple samples within a single experiment with a high analytical depth and dynamic 
range. Each sample is prepared separately then individual samples subjected to LC-
MS/MS runs and data analysis including peptide/ protein identification, quantification and 
statistical analysis (Old et al., 2005). The label-free shotgun proteomics techniques for 
quantitative proteomics methods provide higher dynamic range of proteins quantification. 
There are two different label-free quantification strategies have been used, the first one is 
measuring and comparing MS signal intensity of particular peptide precursor ions 
belonging to a specific protein, while the second strategy of label-free LC-MS 
quantification measurements to perform an individual LC-MS/MS runs and protein 
abundance changes are calculated by counting and comparing the number of each spectra 
between different experiments (Chelius and Bondarenko, 2002).    
The aim of this section of the study was initially to identify and characterise all expressed 
lipoproteins of S. aureus MRSA252 an epidemic MRSA strain causing hospital-acquired 
infections in United Kingdom. In this chapter, the first step was proteomic profiling 
analyses of S. aureus lipoproteins by determining and identifying the lipoproteins via 
matrix-assisted laser desorption ionization-time of flight MALDI/TOF and liquid 
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chromatography-mass spectrometry LC-MS/MS analysis methods. Furthermore, an 
analytical quantitative experiment was performed to present a comprehensive quantitative 
proteome profiling of S. aureus MRSA252 lipoproteins, complementing the method of 
gel-free/in-solution trypsin digestion proteins. 
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4.2 Results 
4.2.1 1D and 2D protein separation (procedure 1)  
In order to identify and characterise the lipoprotein complement of S. aureus MRSA252, 
bacteria were grown in tryptone soya broth under non-infection conditions and proteins 
extracted were in time different times of bacterial growth. Proteins separation was 
performed by two approaches, 1D and 2D gel electrophoresis. The first step was to 
separate complex protein mixtures extracted from cells treated with 2% Triton X-114 
detergent followed by fractionation by 1D SDS-PAGE gel electrophoresis using 12% 
acrylamide gel as described in section 2.3.2.1. The gel was sliced into sections containing 
individual bands. Proteins in gel were then reduced, alkylated and digested using trypsin 
and peptides identified by LC-MS/MS. By the procedure of using 1D SDS-PAGE in 
combination with in-gel trypsin digestion of proteins in excised gel pieces revealed that 
few of the identified proteins were lipoproteins, peptide masses were searched by applying 
Mascot software using a protein database comprising of S. aureus MRSA252 protein 
sequences extracted from the UniProt KB/Swiss-Prot database, 1D gel-based proteomics 
detected only 6 lipoproteins of the most highly abundant proteins based on the number of 
identified peptides, lipoproteins identified are presented in table 14 together with other 
identified proteins detected in this experiment which were not lipoproteins. From the 
Mascot search results the detected protein scores were presented with the sequence 
coverage method which correlate the identified peptides to proteins by using the MOWSE 
(Molecular Weight Search) databases, proteins which fell under the p-value level of 
(p<0.05) were not considered as statistically significant. Overall there were 6 lipoproteins 
with a high significant p-value and matches to limit individual score (table 14).    
Some modifications to the isolation procedure were made to the isolation protocol to try to 
improve the recovery of lipoproteins including the addition of the non-ionic Triton X-114 
detergent before the phase separation, (initially the Triton X-114 was added to the bacterial 
mixture before the centrifugation at 4°C for 10 min) and discarding the insoluble materials 
and unbreakable bacterial cells, the modified method used was designed to spin and 
discard the insoluble materials before the Triton X-114 mixing.     
Two-dimensional gel electrophoresis (2-DE) was performed using isoelectric focusing 
(IEF) with immobilized pH gradients (IPGs) in the first dimension and sodium dodecyl 
sulfate (SDS-PAGE) for the second dimension and was used to separate lipoprotein 
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preparations. Individual protein spots in gels were subjected to in-gel trypsin digestion 
followed by analyses on peptide mass fingerprinting MALDI/ TOF- MS. The results from 
2-DE approach once again showed insufficient separation of lipoproteins and only three 
lipoproteins were detected in the majority of gels as presented in table 15. These were 
different to the lipoproteins detected by the previous method. The probability that the 
observed match is a random event and protein scores greater than 82 are significant 
(p<0.05), Mascot threshold was set at P<0.05, threshold Mascot score given corresponds to 
probability of 95% of the identified protein is not a random match.  
Six of these lipoproteins showed a high abundance during all three times of label-free 
relative protein quantification experiment. On the other hand, the 2-DE gel approach 
showed a similar poor efficiency of both quantity and quality of lipoprotein detection. In 
this procedure the lipoprotein spots in the second dimension gels were not stable in the 
same distribution arrangement in the different sizes of immobilized pH gradients (IPGs) 
strips, both sizes pH 3.5-10 NL 18 cm and pH 3,5 -6 NL 7 cm IPGs strips had a different 
pattern of proteins separation which made it hard to differentiate between the identical 
spots in different gels sizes.  
Only three lipoproteins (SAR0641, SAR2457 and SAR2504) were identified in high 
abundance with the 2-DE gel approach, these proteins were detected in individual spots in 
different gel sizes.  
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Table 14. List of identified lipoprotein of S. aureus MRSA252 in 1D SDS-PAGE 1D 
SDS-PAGE combined with in-gel trypsin digestion followed proteomic analysis by LC-
MS/MS and Mascot search. 
 
Table 15. List of identified lipoprotein of S. aureus MRSA252 in 2-DE 
2-DE combined with in-gel trypsin digestion followed by proteomic analysis via LC-
MS/MS and Mascot search. 
Gene ORF 
UniProtKB 
accession 
MW 
(kDa) 
Total 
score 
Calculated 
pI 
Sequence 
coverage 
(%) 
SAR0641 Q6GJ39 34.75 267 8.3 83% 
SAR2457 Q6GE63 23.33 299 6.06 89% 
SAR2504 Q6GE19 28.82 251 9.2 79% 
 
Gene 
ORF 
UniProtKB 
accession 
No 
Protein description 
MW 
(kDa) 
Total 
score 
Sequence 
coverage 
% 
Sequence 
matches 
SAR0390 Q6GJS7 
Hypothetical 
lipoprotein 
21.35 328 37 8 
SAR0641 Q6GJ39 ABC transporter 34.77 421 29 23 
SAR2504 Q6GE19 
Extracellular solute-
binding lipoprotein 
28.85 317 43 14 
SAR0872 Q6GIH7 Lipoprotein 30.36 302 25 13 
SAR2368 Q6GEF0 
Ferrichrome-
binding lipoprotein 
34.04 290 29 14 
SAR0216 Q6GK91 Putative lipoprotein 38.21 187 24 8 
 
Proteins detected in this experiment were not lipoprotein 
SAR1157 Q6GHQ4 
Penicillin-binding 
protein 
82.72 216 29 11 
SAR0566 Q6GJA7 
Putative surface-
anchored protein 
98.62 311 21 19 
SAR2580 Q6GDU5 
Fibronectin-binding 
protein precursor 
105.7 201 31 7 
SAR0553 Q6GJC0 
Translation 
elongation factor Tu 
43.11 189 33 10 
SAR2544 Q6GDX8 
ABC transporter 
amino acid-binding 
protein 
25.16 299 26 15 
SAR1232 Q6GHH9 
Ribosomal protein 
S2 
29.1 170 24 11 
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4.2.2 Protein and peptide quantitation using LC-MS/MS methods  
To investigate the expression of lipoproteins in various bacterial growth stages a 
comprehensive proteomic analysis of S. aureus MRSA252 lipoprotein was performed. 
Bacteria were grown in tryptone soya broth and incubated at 37°C with constant shaking at 
150 rpm. Cultured bacterial cells were harvested after 15 h (late exponential growth phase) 
then subjected to detergent extraction by using the non-ionic Triton X-114 phase 
separation to solubilize lipidated proteins, followed by gel-free in-solution protein 
digestion with trypsin and analysis of generated peptides via combining approach of C18 
ion pair of peptide chromatographic separation with MS/MS analyses, the data is based on 
analysis of two biological replicates. In this experiment, mass spectrometric analysis using 
the Mascot software and UniProtKB database revealed the identification of a total of 38 
distinct lipoproteins as listed in table 16. Twenty three of these proteins were identified as 
putative lipoproteins. Thirty two lipoprotein detected were in the 50 DOLOP database 
lipoprotein list of S. aureus MRSA252 and 6 lipoproteins were not. Protein scores were 
different among the detected lipoproteins with the highest score of 4122 was a 21.3 kDa 
putative lipoprotein SAR0390, while the lower-protein-score of 83 was a 29.7 kDa 
putative lipoprotein SAR0106.  
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Table 16. List of S. aureus MRSA252 lipoproteins identified in gel-free in-solution 
proteins digestion method and analysed by LC-MS/MS 
Peptide identification was accepted if established at >95% probability. 
Gene 
ORF 
Protein description 
MW 
(kDa) 
Protein 
score 
Protein 
matches 
significance 
Protein 
sequences 
significance 
SAR2457 Putative lipoprotein 23.36 1052 28 8 
SAR0445 Putative lipoprotein 31.66 431 11 9 
SAR0443 Putative lipoprotein 30.90 201 5 4 
SAR0438 Putative lipoprotein 30.32 237 6 5 
SAR0340 
Efem/EfeO family 
lipoprotein 
32.28 158 4 5 
SAR0106 Putative lipoprotein 29.78 83 3 3 
SAR2763 Putative lipoprotein 43.37 517 18 11 
SAR2546 Putative lipoprotein 17.30 641 15 11 
SAR2504 
Extracellular solute-
binding lipoprotein 
28.85 3652 87 25 
SAR2500 Putative lipoprotein 14.37 453 16 8 
SAR2499 Putative lipoprotein 23.11 168 7 4 
SAR2496 
Putative solute-
binding lipoprotein 
59.16 217 5 3 
SAR2368 
Putative 
ferrichrome-binding 
lipoprotein 
33.98 1714 44 20 
SAR2268 
Putative transport  
binding lipoprotein 
36.64 492 20 15 
SAR1995 Putative lipoprotein 45.43 789 21 16 
SAR1881 Putative lipoprotein 23.80 240 6 4 
SAR1608 Putative lipoprotein 21.51 414 9 7 
SAR1558 Putative lipoprotein 16.04 257 4 2 
SAR1494 Putative lipoprotein 34.48 352 7 5 
SAR1288 Putative lipoprotein 14.17 1406 45 11 
SAR1189 Putative lipoprotein 35.99 507 13 10 
SAR1066 Putative lipoprotein 23.90 332 7 6 
SAR0953 
Transport 
extracellular 
binding lipoprotein 
61.52 119 7 5 
SAR0872 Lipoprotein 30.36 2141 79 22 
SAR0839 Putative lipoprotein 28.44 355 16 13 
SAR0794 Putative lipoprotein 34.09 435 14 10 
SAR0761 Putative lipoprotein 16.14 560 20 11 
SAR0730 Putative lipoprotein 14.99 627 42 21 
SAR0641 
ABC transporter 
extracellular 
binding protein 
34.77 3695 138 31 
SAR0618 
Putative transport 
system lipoprotein 
33.27 109 2 2 
SAR0463 Lipoprotein 30.49 817 33 17 
SAR0396 Putative lipoprotein 23.70 414 10 7 
SAR0390 Putative lipoprotein 21.35 4122 121 28 
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Table 16-continued 
Gene 
ORF 
Protein description 
MW 
(kDa) 
Protein 
score 
Protein 
matches 
significance 
Protein 
sequences 
significance 
SAR0230 
Extracellular solute-
binding lipoprotein 
55.51 114 9 8 
SAR0216 Putative lipoprotein 36.89 425 29 16 
SAR0206 
Extracellular sugar-
binding lipoprotein 
47.92 148 8 6 
SAR0174 Putative lipoprotein 36.54 341 18 12 
SAR0145 Putative lipoprotein 35.08 682 14 9 
 
 
4.2.3 Differential lipoprotein expression changes (procedure 2) 
As the gel-free in-solution digestion followed by LC-MS/MS was able to resolve the 
lipoproteins a second set of experiments was performed to quantify and differentiate 
lipoproteins of S. aureus grown in 3 different culture conditions using both quantitative 
and qualitative techniques to compare the different samples. The relative quantification 
method based on simple data analysis of expression fold changes ratio was used. This gel-
free proteomics provides an overview on the comparative quantitative lipoprotein of S. 
aureus MRSA252. The abundance of peptides in the label-free approach was measured 
based on the identification of peptides by LC-MS/MS and used the total number of tandem 
mass spectra that matched peptides to a particular protein to quantify the abundance of 
lipoproteins in the samples. Samples were then statistically compared to evaluate the 
differences between the three conditions. In order to illustrate the possible expression 
similarities between the lipoprotein of S. aureus a comparative analysis was performed for 
three different bacterial growth phases early exponential (6h), late exponential (15 h) and 
stationary phase (24 h) as shown in figure 15, the data was based on analyses of two 
biological replicates. Identification and analyses of peptides quantitation revealed a 
quantitative expression level for 38 lipoproteins of S. aureus MRSA252. Detection and 
comparison of 38 lipoproteins corresponds to coverage of approx. 70% of predicted S. 
aureus MRSA252 lipoproteins. The detected lipoproteins and their regulation expression 
ratios are summarized in table 17. There were some differences in lipoprotein expression 
between the late exponential and stationary phases, 17 lipoproteins showed lower 
production in the stationary phase, the expression comparison between the stationary and 
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late exponential phases showed that SAR0443, SAR0106, SAR2546, SAR2504, 
SAR2499, SAR2496, SAR1608, SAR1189, SAR1066, SAR0953, SAR0839, SAR0794, 
SAR0618, SAR0396, SAR0216, SAR0206 and SAR0174 were down-regulated after 15 h 
growth. SAR0206 and SAR2763 lipoproteins were not produced at 6 h but at the late 
exponential phase had a moderate expression level. Lipoproteins synthesized in the 
stationary phase showed down-regulation for 14 lipoproteins, SAR2763 lipoprotein was 
not expressed in the stationary phase, however, 20 lipoproteins displayed different levels 
of high production and up-regulation, 10 lipoproteins were significantly up-regulated 
during the exponential phase and only SAR0230 lipoprotein had significant down-
expression level in this growth phase, whilst 14 lipoproteins were significantly up-
regulated in the stationary phase. SAR0206 was among the lipoproteins that showed a 
decreased quantity during the stationary phase also this protein had no expression in early 
exponential phase. SAR2457, SAR1881, SAR1288, SAR0872 and SAR0761 showed a 
constant level of production during all three times of bacterial growth, these 4 lipoproteins 
displayed up to 6 fold up-regulation over the times of experiment.  
 
 
Figure 15. The growth curves of S. aureus MRSA252 at 37°C in Tryptone soya broth  
The growth curve was plotted following the OD600 measured every 30 min. 
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Table 17. Comparison of the lipoprotein expression in S. aureus MRSA252 
List of lipoprotein detected by LC-MS/MS in different bacterial culture conditions (6 h, 15 h and 24 h), label-free relative protein quantification 
were calculated to show the fold changes levels of up and down regulation, with a fold changes ratio above and below the threshold of ±2. 
Annotation 
UniProtKB 
accession 
ROF 6 h 15 h 24 h 
up/down regulation expression 
ratio 
15/6 h 24/6 h 24/15 h 
Extracellular solute-
binding lipoprotein 
Q6GK77 SAR0230 2.52E+09 7.50E+08 9.61E+08 -2.98 -0.38 1.28 
Putative lipoprotein Q6GIW5 SAR0730 3.52E+09 3.25E+09 8.76E+09 -0.92 2.49 2.70 
Putative ferrichrome-
binding lipoprotein 
Q6GEF0 SAR2368 1.31E+11 1.20E+11 2.00E+11 -0.91 1.54 1.67 
Efem/EfeO family 
lipoprotein 
Q6GJX5 SAR0340 6.39E+08 4.81E+08 8.36E+08 -0.75 1.31 1.74 
Putative lipoprotein Q6GE23 SAR2500 8.06E+09 6.04E+09 2.55E+10 -0.75 3.16 4.22 
Putative lipoprotein Q6GJS0 SAR0396 7.58E+10 4.92E+10 4.02E+10 -0.64 -0.53 -0.81 
Putative lipoprotein Q6GGG8 SAR1608 4.17E+10 2.57E+10 1.44E+10 -0.61 -0.34 -0.56 
Putative lipoprotein Q6GFF4 SAR1995 5.81E+10 3.12E+10 3.71E+10 -0.53 -0.64 1.19 
Transport system 
binding lipoprotein 
Q6GEQ2 SAR2268 3.42E+10 3.54E+10 6.15E+10 1.04 1.80 1.74 
Extracellular solute-
binding lipoprotein 
Q6GE19 SAR2504 6.94E+11 7.42E+11 5.26E+11 1.07 -0.75 -0.7 
Putative lipoprotein Q6GJS7 SAR0390 2.18E+11 2.56E+11 5.11E+11 1.17 2.34 2 
Putative lipoprotein Q6GJM8 SAR0445 3.22E+09 3.94E+09 4.78E+09 1.22 1.48 1.21 
Putative lipoprotein Q6GJN3 SAR0438 5.46E+08 6.91E+08 1.97E+09 1.27 3.61 2.85 
Putative lipoprotein Q6GKD3 SAR0174 1.23E+09 1.60E+09 1.93E+08 1.30 -0.15 -0.12 
Putative lipoprotein Q6GHM2 SAR1189 4.17E+09 5.61E+09 5.41E+09 1.35 1.3 -0.96 
Lipoprotein Q6GIH7 SAR0872 1.28E+11 1.76E+11 5.47E+11 1.39 4.31 3.11 
Putative solute-
binding lipoprotein 
Q6GE27 SAR2496 3.97E+10 5.68E+10 1.48E+10 1.43 -0.37 -0.26 
Putative lipoprotein Q6GGS6 SAR1494 2.55E+08 3.73E+08 8.55E+08 1.46 3.36 2.29 
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Table 17-continued 
Annotation 
UniProtKB 
Accession 
ROF 6 h 15 h 24 h 
Up & down regulation expression ratio 
15/6 h 24/6 h 24/15 h 
Putative lipoprotein Q6GJN0 SAR0443 3.39E+08 5.15E+08 3.27E+08 1.52 -0.96 -0.63 
ABC extracellular 
binding  
Q6GJ39 SAR0641 2.72E+11 4.11E+11 8.95E+11 1.52 3.31 2.18 
Putative lipoprotein Q6GGL2 SAR1558 6.28E+09 9.80E+09 1.75E+10 1.56 2.78 1.78 
Putative lipoprotein Q6GKG2 SAR0145 3.07E+09 4.80E+09 1.58E+10 1.57 5.11 3.27 
Putative transport 
system lipoprotein 
Q6GJ59 SAR0618 3.16E+10 5.49E+10 4.93E+09 1.74 -0.15 -0.89 
Putative lipoprotein Q6GIQ1 SAR0794 1.22E+09 2.32E+09 5.41E+08 1.91 -0.44 -0.23 
Putative lipoprotein Q6GE24 SAR2499 9.33E+09 1.79E+10 1.92E+09 1.92 -0.21 -0.10 
Lipoprotein Q6GJL0 SAR0463 4.73E+10 9.12E+10 2.02E+11 1.93 4.27 2.21 
Putative lipoprotein Q6GFQ6 SAR1881 5.80E+08 1.19E+09 2.45E+09 2.05 4.22 2.06 
Putative lipoprotein Q6GDX6 SAR2546 4.87E+09 1.02E+10 2.00E+09 2.11 -0.41 -0.19 
Putative lipoprotein Q6GK91 SAR0216 2.11E+09 4.78E+09 4.46E+08 2.27 -0.21 -0.93 
Putative lipoprotein Q6GHC4 SAR1288 1.32E+10 3.10E+10 7.51E+10 2.34 5.71 2.43 
Putative lipoprotein Q6GHZ3 SAR1066 8.67E+09 2.06E+10 2.16E+09 2.37 -0.24 -0.11 
Putative lipoprotein Q6GE63 SAR2457 5.92E+10 1.43E+11 3.22E+11 2.43 5.45 2.25 
Putative lipoprotein Q6GIK7 SAR0839 1.40E+10 3.41E+10 2.61E+10 2.44 1.86 -0.76 
Putative lipoprotein Q6GKK2 SAR0106 8.05E+08 1.99E+09 8.81E+08 2.47 1.10 -0.44 
Putative lipoprotein Q6GIT4 SAR0761 7.76E+09 2.39E+10 5.13E+10 3.07 6.61 2.15 
Transport extracellular 
binding protein 
Q6GI97 SAR0953 9.60E+07 5.18E+08 1.21E+08 5.41 1.26 -0.23 
Putative lipoprotein Q6GDC3 SAR2763 0.00E+00 1.75E+08 0.00E+00 ------ ------ ------ 
Extracellular sugar-
binding lipoprotein 
Q6GKA1 SAR0206 0.00E+00 6.10E+08 1.37E+08 ------ ------ -0.22 
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4.3 Discussion 
Few studies have investigated the characterisation of S. aureus lipoproteins and their 
biological and pathological roles. S. aureus genome codes ~ 2700 proteins in total with 
almost half of them with unknown or predicted functions. S. aureus genome has at least 50 
genes that harbour the type II signal sequence for lipoprotein and approx. 35 of them are 
associated with a known or predicted function. Also, some of them are employed in ABC 
transporters and in acquiring nutrients from the environment (Stoll et al., 2005). However 
just because a gene is present it is not necessarily expressed. In order to visualise the 
complete proteome of S. aureus lipoproteins, one of the main objectives of this study was 
to perform a highly comprehensive proteomic analysis of S. aureus lipoprotein, first step 
was employing gel-based proteomics techniques by using classical 1D and 2-DE protein 
separation complemented by LC-MS/MS method as it has been extensively used in several 
studies. Secondly, the gel-free approach of large scale proteome quantification by in-
solution proteins digestion and LC-MS/MS analysis was used. In order to analyse 
lipoproteins of S. aureus the SDS-PAGE gel based method combined with LC-MS/MS 
was used to determine the lipoprotein quantitation. This has showed a low sensitivity to 
detect the low abundance lipoproteins as only the highly abundant lipoproteins but the 
majority of lipoproteins could not be detected after in-gel trypsin digestion. There were 
only 6 lipoproteins that were detected at the extraction at late exponential phase of 
bacterial growth.   
The failure and low producibility of SDS-PAGE efficiency may due to different reasons 
including the manual selection of protein band sizes that has a considerable disadvantage 
which makes it difficult to differentiate between the band sizes. In addition, many reports 
have reported some of the SDS-PAGE gel limitations including the detergents used in cell 
solubilisation which can give rise to problems during enzymatic digestion and in the 
subsequent LC-MS analysis (Hustoft et al., 2012). Detergents such as sodium dodecyl 
sulfate (SDS) can inhibit the peptide digestion and dominate mass spectra according to 
their ionizability and great abundance compared to target peptides (Yeung et al., 2008). 
The six lipoproteins detected by SDS-PAGE were the most abundant lipoproteins, which 
was confirmed by their abundance in the large scale protein quantification by LC-MS/MS. 
The reason for this was not clear as the 2-DE gel approach is usually subject to some 
restrictions of detecting proteins of high molecular weights proteins and pI values. The 
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method is also limited dynamic range of IPGs strips and handling of hydrophobic proteins 
(Rabilloud et al., 2009). 2-DE protein spots patterns derived from all samples of different 
sizes immobilized pH gradients (IPGs) strips were not similar to each other due to the high 
abundance of some contaminating non-lipoproteins. During in-gel trypsin digestion 
preparation prior to LC-MS analysis, the tryptic peptide digests were not treated with Zip-
Tips to concentrate and purify the samples for further analysis. In the 2-DE method 
the intensity of protein spots stain was used to determinate the quantity of an individual 
protein, this quantification technique were inaccurate and unreliable to determine the 
protein abundance in examined samples, the differences between the protein spots were a 
result of the failure of the software to identify the spots or were not detected when the 
unexperienced user during the gel quantification. Spots on 2D gels often contain more than 
one protein (Kondo, 2008). Becher et al. also demonstrated that 2-D gels cover only 25% 
of the S. aureus cytosolic proteome (Becher et al., 2009a). However, due to the poor 
ability of both 1D and 2D gel electrophoresis to cover the all targeted lipoproteins, these 
approaches were replaced by a higher resolution and more powerful gel-free quantitative 
proteome LC-MS/MS methods for better protein quantitation. In addition, the 
MALDI/TOF machine that had been used in the beginning of this study was out of order 
for a long time for these reasons the electrophoretic separations by 2-DE approach was 
terminated.   
In recent years there has been more interest to use the label-free approaches for large scale 
protein mixtures quantitative analysis by LC-MS/MS, in this procedure samples are 
compared to each other after independent analyses to show a high proteome coverage 
results. This technique avoids the weaknesses of gel electrophoresis. In-solution protein 
digestion is a single step method in a single buffer which is more automatable and reduces 
sample handling during the whole procedure, also to avoid the difficulties during the 
process of peptide recovery from gels. The main challenge in investigating bacterial 
proteome is the recoveries of a sufficient amount of proteins from bacterial cells, as 
different proteins are variable in concentration during the growth phases. Protein 
abundance usually correlates with the gene expression level, but this correlation between 
protein and mRNA abundance may differ due to different biological changes of 
translation, protein degradation and many post-translational modifications (Greenbaum et 
al., 2002). Label-free approaches are the most accurate mass spectrometric techniques that 
provide higher dynamic range of proteins quantification (Neilson et al., 2011).  
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Analytical study to investigate the relationship between transcription, translation and 
cellular protein turnover in the yeast Saccharomyces cerevisiae by comparing protein to 
mRNA ratios and the translational activity revealed a clear correlation between protein 
abundance and mRNA are significantly related to biological functional e.g. cellular 
metabolism and energy (Beyer et al., 2004). 
Different expression patterns were observed for the 38 lipoproteins of S. aureus were 
detected. The high accuracy of label-free approach showed the lipoproteins were produced 
in variable amount during the course of experiment. The undefined functions for most of 
these lipoproteins it was difficult to find out a reasonable answer for the changeable 
expression levels. Lipoproteins responsible for iron uptake were intensely over-expressed 
under iron limitation conditions in vitro and in vivo suggested their importance in bacterial 
growth and survival (Allard et al., 2006). In this experiment of non-infection conditions 
the majorities of these lipoproteins were not significantly induced. This observation can 
conclude the function of iron uptake by lipoproteins may improve under the nutrients and 
iron restriction conditions. Up-regulated expression of iron regulation genes in low iron 
conditions in vitro and in vivo signifying their important role in iron acquisition (Allard et 
al., 2006).   
Comprehensive gel-free and LC-MS/MS-based quantitative proteome relative quantitative 
analyses of S. aureus COL relative quantitative analyses of surface-associated proteins 
under infection-relevant situation using three complementing approaches (trypsin shaving, 
biotinylation and precipitation of the supernatant approaches) identified more than 75% of 
expressed lipoproteins, both biotinylation and trypsin shaving methods identified 42 
lipoproteins, including 23 lipoproteins were identiﬁed by biotinylation, whereas 
precipitation of the supernatant approach was able to identiﬁed 18 lipoproteins, these 
methods were successful for the identiﬁcation of cell surface and secreted lipoprotein 
fraction of S. aureus (Hempel et al., 2011). 
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5. Transcription of S. aureus lipoprotein genes studied using 
quantitative RT-PCR, RNA sequencing and during pathogenesis in C. 
elegans  
5.1 Introduction  
Little is known about the expression of lipoprotein genes in S. aureus during infection 
conditions in human or any mammalian hosts. Several studies on S. aureus gene 
expression on in vitro and in vivo conditions including transcriptome analysis during 
infection have revealed many features of S. aureus virulence and pathogenesis. The 
transcriptome has provided powerful and effective tools for the comprehensive 
investigation of gene expression profiles and transcriptional levels in bacterial cells 
(Gilbert et al., 2008).  
Quantitative real-time PCR is a useful technique used in both research and diagnostic 
fields, which provide an absolute copy number of particular target genes (Mullis, 1990). 
RNA sequencing is a high throughput tool that has been used for transcriptomic research 
to provide whole genome coverage and is able to analyse all of the expressed transcripts of 
the tested organism (Oshlack et al., 2010). Both approaches were used in this study to 
identify and evaluate the expression of the S. aureus lipoprotein genes. 
Initially, the simplicity of invertebrates as animal models of infection present them as a 
perfect choice to overcome the logistical limitations of animal models. The nematode C. 
elegans has proved an excellent and useful model of S. aureus infection assays to identify 
host innate immune response and for the screening of pathogen/host-specific pathogenicity 
factors (Irazoqui et al., 2010a, JebaMercy and Balamurugan, 2012). The percentage of 
human genes found to be homologous to C. elegans genes was 55%, this high homology 
makes C. elegans a good model to discover the roles of some human proteins (Lodish et 
al., 2000). C. elegans has no cell-mediated immunity system, while it has a set of complex 
innate immune mechanisms in their response against infections including the avoidance 
behaviours (Pradel et al., 2007, Pujol et al., 2001). The immunity system of C. elegans 
mainly depends on the secretion and action of antimicrobial molecules based on 
production of antimicrobial proteins as a part of the immune response against bacterial 
infections (Wong et al., 2007). The accumulation of S. aureus within the nematodes 
digestive tracts kills the C. elegans over the course of few days (Garsin et al., 2001, 
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Irazoqui et al., 2010a, Sifri et al., 2003). One of the objectives of this part of study was to 
evaluate the lipoprotein genes expression levels during different growth phases by qRT 
PCR, the analysis was carried out for some selected genes and transcript data were 
expressed as fold change values.  
In order to gain a better understanding of the mechanisms used by S. aureus to survive in 
host and cause diseases, the transcriptome especially for lipoprotein genes in S. aureus was 
studied during infection and non-infection conditions. RNA sequencing analysis 
performed by a colleague provides an opportunity to study lipoprotein genes expression of 
S. aureus 8325-4 strain. Secondly; RNA was isolated from S. aureus MRSA252 during 
infection of C. elegans and subjected to RNA-seq transcriptome analyses to identify the 
expression of lipoprotein genes levels within an infected host after establishment of 
infection and to obtain a comprehensive view for the transcriptional response of S. aureus 
during host infection. Additionally, in this study the expression of C. elegans genes was 
also investigated to show the global transcriptional changes for up-and down-regulation of 
host genes including innate immune responses.    
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5.2 Results 
5.2.1 Detection of lipoprotein genes expression level of S. aureus strains in-vitro by 
qRT-PCR 
In order to investigate whether lipoproteins were differentially expressed in S. aureus at 
different levels during the growth phases, expression patterns for 5 lipoprotein genes of 
different sizes were randomly selected and examined by quantitative reverse-transcriptase 
PCR (qRT-PCR) for three S. aureus strains (MRSA252, RN4282 and T1) and expression 
levels of each gene between the examined S. aureus strains were determined as shown in 
figures 16, 17 and table 18. The results showed a different pattern of up-or-down 
regulation for each gene within different stages of growth. Gene expression levels were 
calculated by both Pfaffl and Livak methods and gave the same results, MRSA252 at 4 h 
incubation time (early exponential phase) was chosen as calibrator. SAR0444 gene in S. 
aureus MRSA252 and T1 showed a similar expression level at both time-points of 
measurement, both strains had a slight up-regulation level for SAR0444 gene after 8 h 
(exponential phase), while SAR0444 gene in RN4282 strain had a constant expression level 
with 1 fold level up-regulation during the experiment time-point of 4 and 8h. SAR0216 
gene had a different expression level among RN4282 strain to show expression level at 
both time-points with ~1 fold up-regulation, while MRSA252 and T1 strains had parallel 
expression levels during the growth phases. SAR0390 lipoprotein gene was the most stable 
gene with more similar expression level in tested strains in examined growth stages, but 
slight variance in the expression level was observed in RN4282 and T1 strains at 8 h time-
point. SAR0340 lipoprotein transcript showed a equal level of expression in the tested 
strains in different growth stages, this gene had a slight higher expression level in the 
examined strains at 8 h. SAR0730 gene expression patterns among the 3 tested strains had 
almost identical expression levels in the different growth phases and the expression levels 
were similar at 4 and 8 h in all strains. Figure 15 in section 4.2.3 are shown the growth 
curves of S. aureus MRSA252 culture at 37°C in Tryptone soya broth used in the 
experiments.  
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Table 18. Expression fold level of 5 lipoprotein genes in 3 S. aureus strains examined 
by quantitative real-time PCR 
Results were calculated with two different methods, 2–∆∆CT (Livak) method and the ∆CT 
method, S. aureus MRSA252 at 4 h incubation time was chosen as calibrator. The two 
methods been used have given the same results. 
 
Gene  
ORF 
Predicted function 
Gene expression levels of different S. aureus strains 
MRSA252 
8h 
RN4282 
4h 
RN4282 
8h 
T1  
4h 
T1  
8h 
SAR0444 putative lipoprotein 0.1 1.16 1 0 0.1 
SAR0216 putative lipoprotein 0.1 0.81 1.02 0 0.35 
SAR0390 putative lipoprotein 0.15 0 0.33 0.1 0.20 
SAR0340 putative lipoprotein 0.55 -0.2 0 -0.1 0.51 
SAR0730 putative lipoprotein 0.36 0.39 0.60 0 0.5 
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     C                                                         
Three S. aureus strains (RN4282, MRSA252 and T1) were cultivated separately in the same conditions and RNA was extracted in different 
incubation times (4 and 8 h), A: qPCR fold change of SAR0390 gene, B: qPCR fold change of SAR0444 gene, C: qPCR fold change of 
SAR0216gene, Ct values (triplicate) for each lipoprotein gene were plotted against each strain and the incubation times. The relative expression 
levels of selected genes were calculated using both Pfaffl and Livak methods. Error bars represent standard deviation of mean expression values. 
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Figure 16. Comparisons of differential expression fold patterns of lipoprotein genes as determined by real-time quantitative PCR assay 
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Three S. aureus strains (RN4282, MRSA252 and T1) were cultivated separately in the same conditions then RNA was extracted in different 
incubation times (4 and 8 h), A: qPCR fold change of SAR0340 gene, B: qPCR fold change of SAR0730 gene, Ct values (triplicate) for each 
lipoprotein gene were plotted against each strain and the incubation times. The relative expression levels of selected genes were calculated using 
both Pfaffl and Livak methods. Error bars represent standard deviation of mean expression value.
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Figure 17. Comparisons of differential expression patterns of lipoprotein genes as determined by real-time quantitative PCR 
assay 
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5.2.2 Transcriptome comparison of S. aureus 8325-4 lipoprotein genes  
The first experiment to compare the transcriptome of lipoprotein genes in S. aureus 8325-4 
was to compare gene expression at three growth time-points (1, 12 and 24 h), bacteria were 
inoculated into Iso-sensitest broth then the RNA was extracted. These time-points of 
grown culture have been chosen as a control samples in other expermints of investigation 
the effect of mupirocin on S. aureus 8325-4. The RNA was subjected to RNA-seq and the 
data analysis was performed to examine the differences between samples groups in order 
to evaluate the differential expression of genes at the three times. The results showed that 
54 lipoprotein genes were detected and transcriptome comparisons to evaluate the 
expression differences are summarized in table 19. Transcription of 54 genes showed that 
genes were up and down regulated differently during the course of experiment. The 
comparison of gene expression between the 1 and 12 h growth showed that no lipoprotein 
genes were down-regulated and 20 genes were significantly up-regulated, while the ratio 
comparison between 1 h and the stationary phase at 24 h showed that 35 lipoprotein genes 
were down-regulated and 14 genes were up-regulated. Additionally the ratio of 
transcription of the genes changed between the exponential (12 h) and stationary phase (24 
h) showed 5 genes were significant down-regulated and 4 genes were significant up-
regulated.   
The transcriptome compression of lipoprotein genes in S. aureus 8325-4 strain under non-
infection condition and the transcripts comparison for three growth time-points (1, 12 and 
24 h), the results obtained showed that 23 lipoprotein transcripts analogues for S. aureus 
MRSA252 including SAR1189, SAR0953, SAR0438, SAR0439, SAR2363, SAR1495, 
SAR2536, SAR1494, SAR2554, SAR0444, SAR0390, SAR0872 and SAR1066 were 
significantly up-regulated with 2 to 13 fold in different patterns. 
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Table 19. Transcriptome comparison of lipoprotein genes in S. aureus 8325-4 at 
different phases of growth 
Three growth time-points (1, 12 and 24 h) were compared and the ratios of transcripts up 
and down-regulation between the times, determined with a fold change ratio above and 
below the threshold of ±2, significantly differentially expressed genes were defined with 
FDR-adjusted P-value < 5%. 
 
Homologous 
S. aureus 
MRSA252 
ORF 
S. aureus 8325-4 
locus tag 
Reads per kilobase 
of transcript per 
million 
Ratio 
12h/1h 
Ratio 
24h/12h 
Ratio 
24h/1h 
1h 12h 24h 
SAR1402 SAOUHSC_01389 4081 53630 1659 13.14 -32.32 -2.45 
SAR1189 SAOUHSC_01180 1430 14700 1740 10.3 -0.12 1.22 
SAR0839 SAOUHSC_00808 1139 10191 956 8.94 -10.66 -1.19 
SAR0953 SAOUHSC_00927 4300 26600 2190 6.19 -0.08 -0.51 
SAR0145 SAOUHSC_00105 265 1454 526 5.47 2.76 -0.50 
SAR1878 SAOUHSC_01917 1171 6241 1025 5.32 -6.08 -1.14 
SAR0438 SAOUHSC_00405 1690 8980 2130 5.31 -0.24 1.26 
SAR0438 SAOUHSC_00405 1688 8980 2128 5.31 4.21 0.79 
SAR0439 SAOUHSC_00402 704 2380 819 3.38 -0.34 1.16 
SAR0443 SAOUHSC_00402 704 2382 819 3.38 2.90 0.85 
SAR2363 SAOUHSC_02549 9040 29000 4520 3.21 -0.16 -0.51 
SAR0761 SAOUHSC_00717 2604 7835 3191 3.00 -2.45 0.81 
SAR0954 SAOUHSC_00928 373 1059 805 2.83 -1.31 0.46 
SAR1495 SAOUHSC_01512 1820 4840 1770 2.66 -0.37 -0.97 
SAR2536 SAOUHSC_02742 1180 3030 1940 2.57 -0.64 1.64 
SAR1494 SAOUHSC_01508 2180 4980 3170 2.28 -0.64 1.45 
SAR2763 SAOUHSC_03016 1092 2450 2821 2.24 0.86 0.38 
SAR2554 SAOUHSC_02767 1990 4280 1500 2.15 -0.35 -0.75 
SAR0444 SAOUHSC_00404 1500 3180 1360 2.12 -0.43 -0.91 
SAR0872 SAOUHSC_00844 2490 5050 932 2.03 -0.19 -0.37 
SAR0201 SAOUHSC_00170 873 1700 1360 1.95 -0.8 1.56 
SAR0106 SAOUHSC_00054 2051 3980 1438 1.94 2.76 -1.42 
SAR0390 SAOUHSC_00356 1260 2420 2620 1.92 1.08 2.08 
SAR0340 SAOUHSC_00325 565 1060 1040 1.88 -0.98 1.84 
SAR0641 SAOUHSC_00634 3330 6050 2650 1.82 -0.44 -0.8 
SAR0463 SAOUHSC_00426 6060 10900 2420 1.80 -0.22 -0.4 
SAR0230 SAOUHSC_00201 3030 5330 2360 1.76 -0.44 -0.78 
SAR2268 SAOUHSC_02430 5100 8790 777 1.72 -0.09 -0.15 
SAR1011 SAOUHSC_00976 1690 2890 1910 1.71 -0.66 1.13 
SAR1106 SAOUHSC_01084 462 702 431 1.52 -0.61 -0.93 
SAR1879 SAOUHSC_01918 10400 14800 2410 1.42 -0.16 -0.23 
SAR0794 SAOUHSC_00754 4140 5740 3520 1.39 -0.61 -0.85 
SAR0174 SAOUHSC_00137 171 236 218 1.38 -0.92 1.27 
SAR2457 SAOUHSC_02650 5600 7410 2570 1.32 -0.35 -0.46 
SAR0118 SAOUHSC_00074 821 1040 360 1.27 -0.35 -0.44 
SAR1881 SAOUHSC_01920 1490 1870 1440 1.26 -0.77 -0.97 
SAR2573 SAOUHSC_02789 873 1067 395 1.22 - 2.70 -2.21 
SAR2504 SAOUHSC_02698 7390 8600 7160 1.16 -0.83 -0.97 
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Table 19-continued 
Homologous 
S. aureus 
MRSA252 
ORF 
S. aureus 8325-4 
locus tag 
Reads per kilobase of 
transcript per million Ratio 
12h/1h 
Ratio 
24h/12h 
Ratio 
24h/1h 
1h 12h 24h 
SAR0730 SAOUHSC_00685 7810 8660 7010 1.11 -0.81 -0.9 
SAR2496 SAOUHSC_02690 13600 13900 4340 1.02 -0.31 -0.32 
SAR2499 SAOUHSC_02694 24800 8180 2560 -0.33 -0.31 -0.1 
SAR0206 SAOUHSC_00176 1850 664 814 -0.36 1.23 -0.44 
SAR1066 SAOUHSC_01039 32500 13500 101000 -0.42 7.48 3.11 
SAR0790 SAOUHSC_00749 2460 1240 816 -0.51 -0.66 -0.33 
SAR2546 SAOUHSC_02759 28600 17000 2340 -0.59 -0.14 -0.08 
SAR2500 SAOUHSC_02695 2670 1600 418 -0.62 -0.26 -0.16 
SAR1034 SAOUHSC_01002 374000 286000 28600 -0.77 -0.11 -0.08 
SAR0396 SAOUHSC_00362 4700 3830 3010 -0.82 -0.79 -0.64 
SAR0618 SAOUHSC_00613 4470 3720 857 -0.83 -0.23 -0.19 
SAR2368 SAOUHSC_02554 49200 41200 6860 -0.84 -0.17 -0.14 
SAR0216 SAOUHSC_00185 3890 3400 1500 -0.87 -0.44 -0.39 
SAR2179 SAOUHSC_02327 32300 30000 28900 -0.93 -0.96 -0.9 
SAR1995 SAOUHSC_02121 30900 29800 17300 -0.96 -0.58 -0.56 
SAR1608 SAOUHSC_01627 2550 2520 2950 -0.99 1.17 1.16 
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5.2.3 Changes in gene expression during infection using C. elegans as a model 
C. elegans killing assay was performed using S. aureus MRSA252. Nematodes were 
incubated at 20°C on TS agar and the nematodes were observed and scored as alive or 
dead on a daily basis. The killing assay results revealed that exposure to S. aureus led to a 
significant decrease in life span with ~ 2 d required for half of the nematodes to die (figure 
18) compared with nematodes grown on non-pathogenic E. coli OP50 which  had a mean 
life span of ~ 17 d (figure 19). S. aureus infected nematodes were examined under a 
Nomarski differential interference contrast microscope showed that the nematodes 
incubated with MRSA252 were smaller in size as a result of starvation unlike the non-
infected worms fed on E. coli OP50. Nematodes displayed a distended intestinal tract that 
was presumable colonized with S. aureus; this was particularly evident in the anterior gut. 
In contrast, nematodes fed on E. coli had normal intestinal lumens (figure 21 A and B). 
The newly matured self-fertilizing hermaphrodite nematodes can produce a few hundred of 
progeny in the normal conditions but under the influence of infection this process was 
affected and led to the accumulation of fertilized eggs inside the body (figure 20 A), 
resulting in the appearance of the “bag-of-worms” phenotype.   
 
Figure 18. C. elegans survival in TS agar at 20°C with S. aureus MRSA252 
Kaplan-Meier survival curve of N2 Bristol wild-type (WT) C. elegans, the graph shows 
survival curve of C. elegans cultivated in S. aureus MRSA252. The arrows to show the 
sampling times (16 and 40 h). 
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Figure 19. N2 Bristol wild-type (WT) C. elegans survival in NGM agar at 20°C with 
E. coli OP50 
The graph shows survival curve of C. elegans cultivated in non-pathogenic E. coli OP50, 
Kaplan-Meier survival curve of C. elegans fed on E. coli OP50 was used as a control. 
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Figure 20. Images of C. elegans fed on S. aureus 
The cellular structures were visualized under Nomarski differential interference contrast 
(DIC) microscope after 24 h of feeding are shown in images A and B, S. aureus colonizes 
the entire intestine of the worms and killed them within a few days. 
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Figure 21. Images of healthy C. elegans fed on E. coli OP50 
The cellular structures were visualized under Nomarski differential interference contrast 
(DIC) microscope after 24 h of feeding are shown in images A and B, the standard 
laboratory food E. coli OP50 of C. elegans does not colonize and cause any mortality.
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5.2.4 Transcriptomics of S. aureus MRSA252 lipoprotein genes obtained from C. 
elegans infection model  
To show the molecular features of the S. aureus response to infection and to profile the 
transcriptional pattern of S. aureus lipoprotein genes expression levels during C. elegans 
infection challenge, RNA sequencing was used to quantify total genes expression and in 
particular the lipoprotein genes transcripts from S. aureus RNA isolated from infected C. 
elegans after different times of infection. The results were obtained from three independent 
experiments. The common method of heatmap was used to present the gene expression 
level for a number of comparable samples by assigning different colours to each transcript, 
thus groups of transcripts of similar or different expression values can be easily visible. A 
correlation heatmap matrix for RNA-seq samples based on genes that up-regulated were 
coloured differently than genes that were down-regulated, consequently providing a 
simultaneous visual representation of genes expression levels among different samples. 
Also to show the differentially expressed profile in each transcript of S. aureus MRSA252 
during the C. elegans infection stages used to comparatively illustrate gene expression 
levels across a number of different samples as shown in figure 22. Figure 23 shows the 
correlation heatmap matrix for RNA-seq of C. elegans samples. The first step was to 
compare the levels of lipoprotein genes transcripts of S. aureus at each time (16 and 40 h). 
To evaluate the relative gene expression levels, transcript data were calculated as fold 
change values for RNA from the samples of C. elegans infection model and compared 
relatively to S. aureus MRSA252 transcripts from 16 h in vitro culture as a control. Results 
of the lipoprotein transcriptome are presented in table 20. Tables containing the number of 
significantly expressed genes were defined as those with FDR-adjusted P-value < 5%, P-
values associated with fold change FC were adjusted for multiple testing using the False 
Discovery Rate (FDR) approach (Benjamini and Hochberg, 1995). Gene expressions 
levels of individual transcripts were estimated from reads alignment files by using 
Cufflinks corresponding FPKM values were converted from count numbers and reported 
in this analysis. The number of fragments per kilobase per million base (FPKM) was used 
to show the gene expression levels. The table shows how many of these genes were up-
regulated and how many of them were down-regulated. The overall transcription of 
lipoprotein genes from infected samples in the two points of evaluation showed the total 
number of lipoprotein genes expressed during the time of infection were 62 genes. At the 
early stage of bacterial infection no gene showed up-regulated transcripts and 8 genes 
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(13%) were down-regulated (table 20). Three lipoprotein genes expressed at the late stage 
of infection (5%) were up-regulated and 17 genes (28%) were significantly down-
regulated. In contrast, the relative gene expression levels between the two time-points of 
post-infection showed that 3 lipoprotein genes were up-regulated in this time of evaluation. 
Lipoprotein genes that were significantly down-regulated at the early and late stages of 
infection was 6 and 14 lipoprotein genes respectively, they showed significant down 
expression after the nemato-bacterial infection. The most strongly up-regulated 
lipoproteins at the two points of 16 and 40 h were 2 and 3 respectively lipoprotein genes as 
showed ~2 fold change of significant high production.  Among the down-regulated set, 
only two lipoproteins SAR1878 and SAR1402 that involved and associated with the 
inflammatory responses during the early stage of C. elegans infection to show >2 fold of 
significant down-regulation. SAR2736 and SAR1565 putative lipoprotein both of them 
were annotated as (pseudogene) in S. aureus transcriptome meta-database (SATMD), but 
their expression levels during the C. elegans challenge course proved their ability to 
expressed as lipoprotein.  
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Figure 22. Correlation heatmap matrix for RNA-seq samples 
The heatmap based on the genes that up-regulated were coloured differently than genes 
that were down-regulated  to show the differentially expressed profile in each transcript of 
S. aureus  MRSA252 during the C. elegans infection stages, P-value less than <0.05, 
colour code values in the heatmap are shown in the side (blue to brown colour scale).  
 
 
Figure 23. Correlation heatmap matrix for RNA-seq C. elegans samples 
The heatmap based on the genes that up-regulated were coloured differently than genes 
that were down-regulated to displaygene expressions at different time points transcript of 
C. elegans RNA-seq sample during the C. elegans infection model, P-value less than 
<0.05, colour code values in the heatmap are shown on the side.   
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Table 20. Comparison of S. aureus MRSA252 lipoprotein genes transcriptome in the C. elegans infection model at 16 and 40 h 
The transcriptome of two conditions were compared with 16 h in vitro control culture to show the ratio fold change, also the two treated samples 
were compared to show the changes occurred, fold change ratio above and below the threshold of ±2, significantly differentially expressed genes 
were defined with FDR-adjusted P-value < 5%. ORF’s in bold were detected in lipoprotein proteomics experiment.   
MRSA252 
ORF 
Description 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C1
6 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0106 Putative lipoprotein 3.935536 -0.13 7.99E-01 -1.28 9.14E-02 -1.16 1.43E-01 
SAR0118 Lipoprotein 5.362675 0.73 7.47E-02 1.08 2.69E-02 0.35 4.84E-01 
SAR0145 Putative lipoprotein 2.864657 -0.91 1.65E-01 -0.29 7.30E-01 0.62 5.08E-01 
SAR0174 Putative lipoprotein 2.067345 -0.63 4.25E-01 -5.98 1.27E-02 -5.35 4.26E-02 
SAR0201 
RGD-containing 
lipoprotein 
2.228918 0.09 9.19E-01 -1.83 2.05E-01 -1.91 1.93E-01 
SAR0206 
Putative extracellular 
sugar-binding 
lipoprotein 
5.81876 -0.75 9.19E-02 -2.18 6.27E-04 -1.43 2.92E-02 
SAR0216 Putative lipoprotein 3.974462 -1.09 3.82E-02 -1.46 4.41E-02 -0.37 6.36E-01 
SAR0230 
Putative extracellular 
solute-binding 
lipoprotein 
5.679551 -2 3.18E-06 -1.9 2.70E-04 0.1 8.57E-01 
SAR0340 Putative lipoprotein 2.712954 -3.57 5.40E-06 -3.38 2.52E-03 0.19 9.04E-01 
SAR0390 Putative lipoprotein 11.86024 -1.28 1.10E-03 -0.6 1.25E-01 0.68 8.26E-02 
SAR0396 Putative lipoprotein 5.674911 -0.1 8.11E-01 0.02 9.71E-01 0.12 8.18E-01 
SAR0438 Putative lipoprotein -3.71531 -1.77 3.34E-01 -1.77 5.83E-01 0 1.00E+00 
SAR0439 Putative lipoprotein 0.15784 -1.83 2.20E-01 -4.76 1.28E-01 -2.93 3.90E-01 
SAR0442 Tandem lipoprotein 1.716093 0.62 6.26E-01 1.05 4.82E-01 0.43 7.80E-01 
SAR0443 Putative lipoprotein 2.690094 0.51 5.60E-01 0.34 7.60E-01 -0.17 8.82E-01 
SAR0444 Putative lipoprotein 3.291042 -0.88 1.09E-01 -2.36 1.29E-02 -1.48 1.57E-01 
SAR0445 Putative lipoprotein 6.229949 0.77 6.02E-02 0.92 4.77E-02 0.15 7.56E-01 
SAR0463 Putative lipoprotein 6.099396 -1.81 1.56E-04 -1.91 2.55E-03 -0.1 8.84E-01 
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Table 20-continued 
MRSA252 
ORF 
Description 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0618 
transport system 
lipoprotein 
5.46572 -1.37 5.57E-04 -2.6 5.57E-06 -1.22 4.60E-02 
SAR0641 
ABC transporter 
extracellular 
binding 
10.74544 -0.83 8.38E-02 -4.58 2.84E-14 -3.75 1.81E-10 
SAR0706 Putative protein -1.16517 0 - 3.94 4.25E-02 3.94 1.12E-01 
SAR0730 Putative lipoprotein 7.813473 -0.25 4.32E-01 0.21 5.60E-01 0.46 2.05E-01 
SAR0761 Putative lipoprotein 6.68203 0.74 1.27E-01 0.97 6.49E-02 0.22 6.71E-01 
SAR0790 Lipoprotein 6.137203 0.49 3.69E-01 -1.2 7.05E-02 -1.69 1.15E-02 
SAR0794 Putative lipoprotein 8.006958 -0.01 9.80E-01 -0.25 4.69E-01 -0.24 4.88E-01 
SAR0839 Putative lipoprotein 5.259353 0.16 7.65E-01 -1.43 4.08E-02 -1.59 2.56E-02 
SAR0872 Putative lipoprotein 7.612778 0.55 1.81E-01 0.18 7.09E-01 -0.37 4.46E-01 
SAR0953 
Extracellular 
binding lipoprotein 
9.61191 1.43 1.25E-03 1.46 1.47E-03 0.03 9.45E-01 
SAR1011 
Transport 
extracellular 
binding lipoprotein 
5.972712 -0.69 2.90E-01 1.58 3.03E-02 2.27 3.34E-03 
SAR1034 
Putative quinol 
oxidase polypeptide 
II precursor 
13.41435 -0.98 2.79E-02 -1.4 1.90E-03 -0.42 3.42E-01 
SAR1066 Putative lipoprotein 8.718441 -0.58 6.82E-02 -1.15 9.70E-04 -0.57 1.04E-01 
SAR1106 
Transport 
extracellular 
binding lipoprotein 
-0.64547 -1.95 2.35E-01 -4.1 2.07E-01 -2.15 5.24E-01 
SAR1189 Putative lipoprotein 5.218548 1.76 1.05E-05 -0.39 5.33E-01 -2.15 2.56E-04 
SAR1288 Putative lipoprotein 8.244903 -1.52 1.07E-05 -1.64 2.81E-05 -0.12 7.68E-01 
SAR1402 
Phosphate-binding 
lipoprotein 
7.665538 -2.14 5.93E-04 2.71 6.47E-06 4.85 1.35E-12 
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Table 20-continued 
MRSA252 
ORF 
Description 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR1494 Putative lipoprotein 1.53716 -0.58 5.59E-01 -1.43 3.52E-01 -0.85 6.00E-01 
SAR1495 Putative lipoprotein 1.1517 -0.09 9.26E-01 0.55 6.74E-01 0.64 6.48E-01 
SAR1558 Putative lipoprotein 7.435479 -1.12 2.07E-03 -2.28 3.38E-07 -1.16 9.56E-03 
SAR1565 
Putative lipoprotein 
(pseudogene) 
7.23253 0.4 3.16E-01 0.16 7.10E-01 -0.24 5.90E-01 
SAR1608 Putative lipoprotein 6.520394 -0.89 1.27E-02 0.07 8.65E-01 0.96 2.10E-02 
SAR1831 
beta-lactamase 
precursor 
11.39788 -2.69 4.84E-10 -2.19 3.86E-07 0.49 2.32E-01 
SAR1878 Putative lipoprotein 1.912886 -2.34 8.43E-03 -1.16 2.90E-01 1.18 4.01E-01 
SAR1879 Putative lipoprotein 11.07714 -1.54 3.07E-03 -1.32 1.13E-02 0.22 6.71E-01 
SAR1881 Putative lipoprotein 4.332287 -0.35 5.01E-01 -1.26 7.97E-02 -0.91 2.24E-01 
SAR1932 
Peptidyl-prolyl cis-
isomerase 
11.57265 -3.48 1.10E-14 -3.87 1.71E-16 -0.39 3.60E-01 
SAR1995 Putative lipoprotein 8.782224 -0.41 2.05E-01 0.24 4.74E-01 0.65 5.77E-02 
SAR2179 
Putative membrane 
protein 
8.760973 0.65 5.83E-02 0.69 5.92E-02 0.04 9.24E-01 
SAR2268 
Putative transport 
system binding 
lipoprotein 
6.969823 -0.25 5.71E-01 -2.14 8.66E-05 -1.89 5.52E-04 
SAR2363 
Putative molybdate-
binding lipoprotein 
precursor 
6.671393 -2.09 4.39E-08 -3.1 4.16E-10 -1.01 5.07E-02 
SAR2368 
Putative ferrichrome-
binding lipoprotein 
7.031337 -0.24 4.78E-01 -2.62 7.08E-08 -2.38 1.30E-06 
SAR2457 Putative lipoprotein 11.99348 1.95 6.63E-07 2.58 1.60E-10 0.63 1.01E-01 
SAR2470 
Putative exported 
protein 
4.535592 -0.28 4.82E-01 -2.02 2.55E-03 -1.74 1.30E-02 
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Table 20-continued 
MRSA252 
ORF 
Description 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR2496 Putative lipoprotein 6.852125 -1.39 2.02E-04 -1.5 5.94E-04 -0.11 8.00E-01 
SAR2499 Putative lipoprotein 8.001797 -1.4 2.41E-04 -0.98 1.93E-02 0.42 3.16E-01 
SAR2500 Putative lipoprotein 4.258847 -0.85 1.14E-01 -1.26 7.83E-02 -0.41 5.90E-01 
SAR2504 
Extracellular solute 
binding lipoprotein 
9.306613 -0.19 5.27E-01 -0.62 6.32E-02 -0.42 2.05E-01 
SAR2536 
Glycine/carnitine/ 
binding lipoprotein 
6.857105 -3.67 9.48E-15 -3.36 6.30E-10 0.31 5.90E-01 
SAR2546 Putative lipoprotein 7.586737 -1.21 3.55E-04 -2.99 2.05E-11 -1.78 7.37E-05 
SAR2554 
Putative substrate 
binding lipoprotein 
6.289847 -0.28 5.06E-01 -1.83 1.04E-03 -1.55 6.07E-03 
SAR2573 Putative lipoprotein 4.205983 -0.45 4.15E-01 -0.73 2.98E-01 -0.29 6.99E-01 
SAR2546 Putative lipoprotein 7.586737 -1.21 3.55E-04 -2.99 2.05E-11 -1.78 7.37E-05 
SAR2736 
Putative lipoprotein 
(pseudogene) 
4.018851 1.33 5.66E-02 1.22 1.37E-01 -0.11 8.87E-01 
SAR2763 Putative lipoprotein 4.879761 0.79 5.01E-02 -0.01 9.82E-01 -0.8 1.48E-01 
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5.2.5 Transcriptome analysis of S. aureus MRSA252 genes  
From the analysis of 2620 genes that were detected in the transcriptome profile of S. 
aureus MRSA252 during the course of C. elegans infection, the top one hundred genes up 
and down-regulated of each infection condition were selected and analysed to show the 
most induced S. aureus genes during infection model. Table 21 summarises the main 
groups of up-regulated genes of S. aureus after 16 h of infection and their predicted 
function and the top 100 up-regulated genes are shown in table 22. After 16 h of infection 
the S. aureus showed a significant up-regulation expression change in the capsular 
polysaccharide synthesis enzymes and membrane protein production. Thirty-one of the 
most affected 100 genes were related to cell wall synthesis proteins, while the predominant 
produced proteins were enzymes related to biosynthesis of the essential amino acids and 
enzymes belongs to oxidoreductases (table 22). The major groups of down-regulated genes 
after 16 h are summarised in table 23 and details are given in table 24. Down-regulated 
genes during the early infection stage were related to the cell membrane transport systems, 
and there were a high number of proteins related to metabolism, hypothetical proteins and 
some transporting ATPase enzymes (table 23). The top down-regulated genes included 
membrane transporters, enzymes of arginine and ornithine metabolism (table 24). 
At the late stage of infection the transcriptome profile showed the most up-regulated genes 
of S. aureus at 40 h were similar to that of early stage of infection including up-regulation 
of capsular polysaccharide synthesis enzymes, membrane protein synthesis and amino acid 
transport (tables 25 and 26). The down-regulated genes at 40 h of infection had no clear 
trends but showed that some hypothetical phage proteins were among the most affected 
genes, cell wall metabolism protein and exotoxin were also detected in the late stage as 
shown in tables 27 and 28. The two points of infection (16 and 40 h) were compared to 
find out the most affected genes as presented in table 29 and 30, among the up-regulated 
protein were 34 hypothetical protein, 13 membrane protein and several ABC transporter 
ATP-binding proteins, while the second most up-regulated was SAR1402 a phosphate-
binding lipoprotein which also had a high level of expression during the early infection 
stage.    
Tables 31 and 32 shows the most down-regulated genes at 40 h comparing to 16 h of 
infection, 11 phage protein, 34 hypothetical proteins and 4 exotoxins were significantly 
down-expressed in this period between the two stages of infection.    
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5.2.5.1 S. aureus metabolism regulated pathways  
Oxygen is one of the most essential growth-limiting factors for most bacterial,  both Gram-
positive and Gram-negative bacteria regulate their gene expression in response to carbon 
availability, many bacteria have evolved sophisticated mechanisms to use different 
carbohydrates to allow a rapid growth; the induction of specific carbohydrate transport and 
utilization systems in the presence of the carbon source and their repression when a more 
efficiently utilizable carbohydrate is present, this mechanisms is known as carbon 
catabolite repression, In many low-GC Gram-positive bacteria carbon catabolite regulation 
is mediated by the Catabolite control protein A CcpA.CcpA regulates more than 100 genes 
in S. aureus (Seidl, Muller et al. 2009). Characteristics of metabolic profiles of S. aureus 
are still unclear and very little information was identified about the affect of different 
growth conditions on metabolic profiles, especially during anaerobic growth. S. aureus is a 
facultative anaerobic bacterium and can sirvive in a low oxygen condation by fermentation 
or nitrate respiration and can adaptate to different levels of oxygen (Burke and Lascelles, 
1975). The key regulatory system that responsible for anaerobic gene regulation is the two-
component Staphylococcal respiratory response AB system (Pragman, Yarwood et al. 
2004). Also, S. aureus has another system of two-component system that regulates 
nitrogen metabolism NreABC it has a role in anaerobic gene regulation and virulence 
factor expression (Schlag et al., 2008). While, redox-dependent transcription repressor 
(Rex) also playing a crucial role in the regulation of anaerobic metabolism in S. aureus 
which employing the mechanism of sensing redox status through responding to 
NADH/NAD+ ratio (Pagels et al., 2010). In this study the arcR gene encoding ArcR with 
the arginine deiminase pathway, genes arcABDC that control the use of arginine as a 
source of energy for growth under anaerobic conditions was significantly down-regulated 
after 16 h of infection. Exposure of C. elegans to MRSA252 has shown to down-
regulationsome genes such as the acpD gene that involved in fatty acid and phospholipid 
metabolism, also putative pyruvate formate-lyase activating enzyme taht been reported to 
up-regulated under anaerobic conditions this enzyme is essential for energy supply when 
pyruvate is available (Fuchs et al., 2007). 
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Table 21. Major groups of up-regulated genes in S. aureus at 16 h of C. elegans 
infection model and their predicted function   
Number of genes Predicted function 
16 
Capsular polysaccharide 
synthesis enzyme 
15 Putative membrane protein 
36 Synthesis enzyme protein 
20 Hypothetical protein 
 
 
Table 22. Top 100 up-regulated genes in S. aureus infection of C. elegans at 16 h 
comparing to 16 h control sample 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR2762 ATP phosphoribosyl transferase regulatory  7.34 3.27E-14 
SAR0159 Capsular polysaccharide synthesis enzyme 6.01 4.30E-34 
SAR0160 Capsular polysaccharide synthesis enzyme 5.76 7.97E-19 
SAR0742 Putative membrane protein 5.68 4.67E-05 
SAR0415 Hypothetical protein  5.67 2.82E-04 
SAR0316 Putative membrane protein 5.37 1.54E-09 
SAR0158 Capsular polysaccharide synthesis enzyme 5.23 9.03E-29 
SAR2449 Hypothetical protein 5.19 1.91E-18 
SAR0155 Capsular polysaccharide synthesis enzyme 5.05 4.81E-21 
SAR0157 Capsular polysaccharide synthesis enzyme 5.01 2.13E-24 
SAR0156 Capsular polysaccharide synthesis enzyme 5.00 1.50E-23 
SAR0031b Hypothetical protein 4.98 4.76E-04 
SAR0161 Capsular polysaccharide synthesis enzyme 4.90 1.29E-17 
SAR0154 Capsular polysaccharide synthesis enzyme 4.87 2.12E-16 
SAR2144 2-isopropylmalate synthase 4.58 1.87E-12 
SAR0162 Capsular polysaccharide synthesis enzyme 4.53 5.60E-21 
SAR2143 Ketol-acid reductoisomerase 4.45 1.13E-08 
SAR2147 3-isopropylmalate dehydratase subunit 4.32 1.43E-10 
SAR0458 Sodium neurotransmitter symporter protein 4.32 4.60E-11 
SAR1000 Hypothetical protein 4.19 8.58E-03 
SAR0250 Hypothetical protein 4.13 1.36E-02 
SAR2648 Secretory antigen precursor 4.11 2.53E-19 
SAR1405 Aspartokinase I 4.11 2.69E-17 
SAR0153 Capsular polysaccharide synthesis enzyme 4.10 1.45E-14 
SAR1383 Indole-3-glycerol phosphate synthase 3.95 5.93E-03 
SAR0165 Capsular polysaccharide synthesis enzyme 3.94 1.13E-14 
SAR0151 Capsular polysaccharide synthesis enzyme 3.92 8.22E-16 
SAR1273a Hypothetical protein 3.91 8.57E-03 
SAR0152 Capsular polysaccharide synthesis enzyme 3.89 3.96E-17 
SAR2450 Putative membrane protein 3.85 6.00E-16 
SAR0241 Putative PTS transport system 3.80 1.04E-02 
SAR2141 Acetolactate synthase large subunit 3.76 1.98E-07 
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Table 22-continued 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR0996 Conserved hypothetical protein 3.74 8.19E-14 
SAR2145 3-isopropylmalate dehydrogenase 3.70 6.69E-08 
SAR0164 
Capsular polysaccharide synthesis 
enzyme 
3.69 8.62E-14 
SAR2140 Putative dihydroxy-acid dehydratase 3.67 2.03E-05 
SAR1325 Hypothetical protein 3.64 2.14E-02 
SAR1459a Hypothetical protein 3.52 3.31E-02 
SAR0166 
Capsular polysaccharide synthesis 
enzyme 
3.49 5.24E-12 
SAR1407 Dihydrodipicolinate synthase 3.48 1.55E-11 
SAR0639 
Putative halo-acid dehydrogenase- 
Hydrolase 
3.43 4.76E-13 
SAR2146 
Isopropyl malate dehydratase large 
subunit 
3.42 1.98E-08 
SAR2599 Putative dioxygenase 3.42 1.57E-07 
SAR0163 
Capsular polysaccharide synthesis 
enzyme 
3.38 4.95E-11 
SAR1408 Dihydrodipicolinate reductase 3.18 1.10E-11 
SAR0030 Hypothetical protein 3.12 4.73E-02 
SAR0244 Hypothetical protein 3.07 5.33E-02 
SAR1620 Putative membrane protein 3.04 4.56E-02 
SAR0356 
Cys/Met metabolism PLP-dependent 
enzyme 
3.04 2.39E-03 
SAR0117 Putative siderophore transport permease 2.98 1.87E-03 
SAR2761 Putative ATP phosphoribosyltransferase 2.94 2.22E-03 
SAR2148 Threonine dehydratase biosynthetic 2.93 9.00E-05 
SAR1406 Aspartate semialdehyde dehydrogenase 2.89 6.73E-11 
SAR0455 Putative membrane protein 2.88 1.29E-04 
SAR1381 Anthranilate synthase component I 2.87 1.70E-02 
SAR0171 Hypothetical protein 2.83 4.32E-05 
SAR2752 conserved hypothetical protein 2.83 6.13E-02 
SAR0731 Hypothetical protein 2.81 2.50E-12 
SAR2642 Squalene synthase 2.79 1.94E-12 
SAR0212 Putative membrane protein 2.74 9.53E-04 
SAR1384 N-(5'phosphoribosyl) anthranilate (PRA) 2.71 9.82E-04 
SAR2738 Conserved hypothetical protein 2.70 2.05E-02 
SAR0495 Conserved hypothetical protein 2.70 1.09E-09 
SAR0471 Glutamate synthase, large subunit 2.67 5.65E-06 
SAR1411 Putative alanine racemase 2.67 7.07E-08 
SAR2681 Amino acid permease family protein 2.66 4.78E-08 
SAR2598 Putative phospholipase/carboxylesterase 2.61 6.04E-05 
SAR2512 Putative membrane protein 2.61 4.36E-02 
SAR2645 Putative glycosyl transferase 2.60 1.32E-11 
SAR0238 Putative PTS multi-domain regulator 2.60 8.74E-03 
SAR2682 Putative aminotransferase 2.58 1.55E-06 
SAR0042 Hypothetical protein 2.53 1.13E-01 
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Table 22-continued 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR0638 Putative membrane protein 2.52 6.38E-07 
SAR1800 Putative soluble hydrogenase subunit 2.52 1.39E-06 
SAR1108 Sortase 2.51 1.08E-01 
SAR2551 
Oligopeptide transporter putative 
ATPase 
2.50 3.22E-03 
SAR2651 Putative membrane protein 2.46 5.51E-04 
SAR1677 Putative membrane protein 2.46 7.66E-02 
SAR1380 Anthranilate synthase component 2.43 1.74E-02 
SAR2507 Cation efflux family protein 2.42 1.11E-08 
SAR0745 Putative membrane protein 2.41 7.32E-05 
SAR1409 
Putative tetrahydrodipicolinate 
acetyltransferase 
2.39 4.23E-06 
SAR2562 Putative membrane protein 2.39 2.04E-02 
SAR2384 Hypothetical protein 2.38 3.56E-06 
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Table 23. Major groups of down-regulated genes in S. aureus at 16 h of C. elegans 
infection compared to non-infected control sample and their predicted function   
Number of genes Predicted function 
34 Different activating enzymes 
8 Membrane proteins 
32 Transport ATP-binding proteins 
25 Hypothetical proteins 
 
 
Table 24. Top 100 down-regulated genes in S. aureus infection of C. elegans at 16 h 
comparing to to non-infected control sample 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR2621 Putative membrane protein -7.54 6.58E-17 
SAR2714 Arginine deiminase -7.49 2.34E-47 
SAR2713 Putative ornithine carbamoyl-transferase -6.74 4.94E-51 
SAR1450 Putative threonine dehydratase -6.46 6.37E-08 
SAR0203 Putative phosphodiesterase -6.28 9.82E-13 
SAR2712 Arginine/ornithine antiporter -6.18 3.58E-31 
SAR2605 D-specific D-2-hydroxyacid dehydrogenase -6.17 1.23E-23 
SAR0218 
Putative pyruvate formate-lyase activating 
enzyme 
-6.15 7.44E-23 
SAR0217 Formate acetyltransferase -6.14 9.48E-15 
SAR1007 Hypothetical protein -6.09 1.16E-04 
SAR2455 Putative L-lactate permease -6.01 1.64E-22 
SAR2628 
Putative ATP-dependent protease ATP-
binding subunit Clp 
-5.85 3.26E-18 
SAR2066 Hypothetical phage protein -5.77 4.02E-04 
SAR1142 Ornithine carbamoyl-transferase -5.73 2.14E-17 
SAR1832 Hypothetical protein -5.52 3.77E-04 
SAR0613 Alcohol dehydrogenase -5.48 4.25E-16 
SAR2372 Urease gamma subunit -5.46 1.71E-03 
SAR0309 Putative membrane protein -5.08 2.54E-06 
SAR0234 L-lactate dehydrogenase -5.03 1.88E-11 
SAR2711 Carbamate kinase -5.00 8.59E-26 
SAR1143 Putative carbamate kinase -4.97 1.92E-16 
SAR2569 Hypothetical protein -4.96 9.91E-19 
SAR0256 Cell wall metabolism protein -4.95 5.85E-26 
SAR2068 Putative exported protein -4.80 2.77E-07 
SAR2691 Putative betaine aldehyde dehydrogenase -4.76 2.41E-16 
SAR2071 Hypothetical phage protein -4.75 1.14E-02 
SAR0584 Hypothetical protein -4.72 9.37E-13 
SAR1451 Alanine dehydrogenase -4.72 1.91E-05 
SAR2285 Galactose-6-phosphate isomerase LacB -4.71 1.88E-20 
SAR0317 Lipase precursor -4.70 3.50E-08 
SAR2280 6-phospho-beta-galactosidas -4.53 1.20E-16 
SAR0219 Hypothetical protein -4.51 1.12E-02 
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Table 24-continued 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR2286 Galactose-6-phosphate isomerase LacA -4.49 1.76E-15 
SAR2710 Putative regulatory protein -4.48 3.90E-19 
SAR1302 Conserved hypothetical protein -4.38 1.37E-02 
SAR2284 Tagatose-6-phosphate kinas -4.37 2.70E-16 
SAR2488 Assimilatory nitrite reductase subunit -4.36 1.52E-05 
SAR1909 Hypothetical protein -4.25 1.57E-02 
SAR1136 Alpha-hemolysin precursor  -4.25 1.17E-09 
SAR2296 Conserved hypothetical protein -4.24 9.95E-11 
SAR2122 Delta-hemolysin precursor -4.17 4.15E-04 
SAR2283 Tagatose 1,6-diphosphate aldolase -4.17 2.45E-16 
SAR2282 
PTS system, lactose-specific IIA 
component 
-4.14 2.68E-09 
SAR0070 Potassium-transporting ATPase A -4.13 3.06E-04 
SAR2536 
Glycine betaine/carnitine/choline-
binding lipoprotein precursor 
-3.67 9.48E-15 
SAR2523 Putative membrane protein -3.61 1.28E-12 
SAR1320 Hypothetical protein -3.61 8.38E-02 
SAR0340 Putative lipoprotein -3.57 5.40E-06 
SAR1987 Putative membrane protein -3.55 4.90E-14 
SAR2695 
Anaerobic ribonucleoside-triphosphate 
reductase 
-3.55 1.07E-08 
SAR2067 Hypothetical phage protein -3.53 1.26E-13 
SAR2281 PTS system, lactose-specific IIBC -3.51 7.30E-11 
SAR1932 Putative peptidyl-prolyl cis-isomerase -3.48 1.10E-14 
SAR1150 Antibacterial protein -3.47 1.58E-02 
SAR0182 Putative membrane protein -3.47 2.88E-07 
SAR0308 PfkB family carbohydrate kinas -3.46 4.18E-06 
SAR2539 Conserved hypothetical protein -3.45 7.91E-21 
SAR0528 Putative stress response Clp ATPase -3.42 1.27E-12 
SAR2535 
Putative glycine betaine/carnitine/choline 
transport system permease protein 
-3.38 6.40E-11 
SAR2099 DNA-binding protein -3.37 7.59E-09 
SAR0072 Potassium-transporting ATPase C chain -3.36 1.83E-04 
SAR2072 Putative dUTP pyro-phosphatase -3.36 1.12E-07 
SAR2095 Hypothetical phage protein -3.35 3.33E-11 
SAR2519a Hypothetical protein -3.35 1.45E-04 
SAR1974 Putative response regulator -3.33 1.38E-17 
SAR0232 Putative membrane protein -3.33 3.55E-03 
SAR0261 Putative nitric oxide reductase -3.33 4.26E-07 
SAR0419 Hypothetical protein -3.33 1.01E-01 
SAR1658 GrpE protein- Hsp-70 cofactor -3.33 2.16E-10 
SAR1657 Chaperone protein -3.32 1.88E-09 
SAR0369 Conserved hypothetical protein -3.27 1.51E-01 
SAR2715 Arginine repressor family protein -3.25 1.63E-06 
SAR2694 
Putative anaerobic ribonucleotide 
reductase activating protein 
-3.24 6.28E-06 
SAR2091 Putative exported protein -3.24 1.07E-01 
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Table 24-continued 
ORF Annotation 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
SAR1322 Hypothetical protein -3.24 1.00E-01 
SAR2094 Hypothetical phage protein -3.23 1.50E-05 
SAR0233 Flavohemo protein -3.22 7.28E-13 
SAR1709 Hypothetical protein -3.22 1.05E-12 
SAR2117 10 kDa chaperonin -3.21 1.38E-15 
SAR2096 Putative anti repressor -3.21 1.61E-19 
SAR2089 Hypothetical phage protein -3.20 7.98E-09 
SAR1659 Heat-inducible transcription repressor -3.20 2.95E-08 
SAR0130 
NAD dependent epimerase/dehydratase 
family protein 
-3.18 2.39E-02 
SAR0525 Putative DNA-binding protein -3.16 2.19E-17 
SAR2074 Hypothetical phage protein -3.16 1.42E-01 
SAR0526 Conserved hypothetical protein -3.16 4.15E-13 
SAR1975 Histidine kinase sensor -3.16 9.92E-16 
SAR2538 
Glycine betaine/carnitine/choline 
Transport ATP-binding protein 
-3.15 2.50E-15 
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Table 25. Major groups of up-regulated genes of S. aureus at 40 h of C. elegans 
infection comparing to non-infected control sample and their predicted function  
Number of genes Predicted function 
19 Hypothetical protein 
16 
Capsular polysaccharide 
synthesis enzyme 
11 Putative membrane protein 
3 Membrane lipoprotein 
 
Table 26. List of the most up-regulated genes of S. aureus at 40 h after infection of C. 
elegans comparing to 16 h control sample 
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR2762 ATP phosphoribosyltransferase regulatory  8.83 9.62E-20 
SAR0159 Capsular polysaccharide synthesis enzyme 6.59 2.76E-38 
SAR0154 Capsular polysaccharide synthesis enzyme 6.50 3.34E-24 
SAR0984 Transposase 6.38 1.14E-04 
SAR0160 Capsular polysaccharide synthesis enzyme 6.33 6.02E-21 
SAR0155 Capsular polysaccharide synthesis enzyme 6.31 1.52E-28 
SAR0158 Capsular polysaccharide synthesis enzyme 6.14 7.29E-36 
SAR0156 Capsular polysaccharide synthesis enzyme 6.10 5.88E-31 
SAR0157 Capsular polysaccharide synthesis enzyme 6.05 1.23E-31 
SAR0742 Putative membrane protein 5.84 1.79E-04 
SAR0153 Capsular polysaccharide synthesis enzyme 5.83 6.76E-24 
SAR2648 Secretory antigen precursor 5.81 2.07E-32 
SAR0152 Capsular polysaccharide synthesis enzyme 5.62 4.09E-29 
SAR0151 Capsular polysaccharide synthesis enzyme 5.44 2.57E-25 
SAR0451 Hypothetical protein 4.92 1.87E-02 
SAR2761 Putative ATP phosphoribosyltransferase 4.90 1.15E-06 
SAR0161 Capsular polysaccharide synthesis enzyme 4.83 6.97E-17 
SAR1273a Hypothetical protein 4.81 5.69E-03 
SAR0393 Hypothetical protein 4.78 9.59E-03 
SAR0162 Capsular polysaccharide synthesis enzyme 4.77 2.64E-22 
SAR0471 Glutamate synthase, large subunit 4.50 2.74E-12 
SAR0011 Putative membrane protein 4.39 1.30E-02 
SAR0165 Capsular polysaccharide synthesis enzyme 4.37 1.00E-16 
SAR1380 Anthranilate synthase component 4.35 9.68E-05 
SAR1381 Anthranilate synthase component I 4.26 8.16E-04 
SAR1383 Indole-3-glycerol phosphate synthase 4.25 9.83E-03 
SAR0166 Capsular polysaccharide synthesis enzyme 4.24 1.45E-15 
SAR2683 Putative membrane protein 4.09 6.63E-21 
SAR1325 Hypothetical protein 3.94 4.00E-02 
SAR0706 Putative membrane lipoprotein 3.94 4.25E-02 
SAR0458 Sodium: neurotransmitter symporter  3.92 2.85E-09 
SAR0164 Capsular polysaccharide synthesis enzyme 3.90 2.53E-14 
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Table 26-continued 
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR0415 Hypothetical protein 3.88 3.73E-02 
SAR0055 DNA repair protein RadC 3.87 4.48E-02 
SAR1866 CrcB-like protein 3.87 4.48E-02 
SAR2517 Putative dethiobiotin synthetase 3.87 4.48E-02 
SAR0472 Glutamate synthase, small subunit 3.80 3.91E-09 
SAR2745 Putative capsule synthesis protein 3.70 4.60E-02 
SAR0731 Hypothetical protein 3.66 2.89E-18 
SAR2643 Squalene desaturase 3.65 1.44E-16 
SAR1040 
Putative phosphor 
ribosylaminoimidazole succino-
carboxamide synthase 
3.62 6.05E-08 
SAR2384 Hypothetical protein 3.54 6.55E-11 
SAR1401 ABC transporter permease protein 3.54 2.23E-08 
SAR1283 Putative membrane protein 3.94 3.44E-14 
SAR2645 Putative glycosyl transferase 3.04 2.75E-14 
SAR0675 Putative exported protein 3.03 2.11E-14 
SAR0010 Putative membrane protein 3.03 4.06E-02 
SAR2758 
Putative imidazole glycerol-phosphate 
dehydratase 
3.02 1.87E-03 
SAR1284 Glutamine synthetase 3.01 6.26E-09 
SAR1041 Conserved hypothetical protein 3.00 1.25E-07 
SAR1337 Putative aspartate kinas 2.96 1.36E-05 
SAR1855 Arsenical resistance operon repressor 2.94 1.22E-01 
SAR0316 Putative membrane protein 2.93 1.30E-03 
SAR1922 Hypothetical protein 2.91 2.68E-02 
SAR0171 Hypothetical protein 2.88 3.22E-04 
SAR2145 3-isopropylmalate dehydrogenase 2.86 4.55E-05 
SAR1382 Anthranilate phosphoribosyltransferase 2.85 1.11E-04 
SAR0241 Putative PTS transport system 2.85 1.54E-01 
SAR2143 Ketol-acid reductoisomerase 2.82 2.40E-04 
SAR2647 Putative membrane protein 2.82 5.97E-10 
SAR0200 Putative transport system permease 2.80 2.42E-02 
SAR1910 Putative membrane protein 2.79 1.76E-01 
SAR0356 Cys/Met metabolism PLP enzyme 2.78 1.44E-02 
SAR0117 Putative siderophore transport permease 2.78 1.58E-02 
SAR0066 Putative transposase 2.77 1.38E-01 
SAR1285 Hypothetical protein 2.75 1.79E-06 
SAR0589 Putative amino acid permease 2.74 6.54E-13 
SAR2144 2-isopropylmalate synthase 2.74 3.46E-05 
SAR1402 Phosphate-binding lipoprotein 2.71 6.47E-06 
SAR2147 3-isopropylmalate dehydratase subunit 2.71 2.89E-03 
SAR1400 ABC transporter permease protein 2.69 1.70E-05 
SAR2750 Intercellular adhesion protein 2.68 5.70E-02 
SAR2059 Hypothetical phage protein 2.67 9.91E-02 
SAR0854 Hypothetical protein 2.67 4.69E-04 
SAR0142 
Binding-protein-dependent transport 
systems membrane component 
2.66 6.44E-03 
SAR1800 Putative soluble hydrogenase subunit 2.65 1.90E-06 
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Table 26-continued 
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR1930a Hypothetical protein 2.62 1.06E-01 
SAR0128 Putative membrane protein 2.59 1.22E-03 
SAR2457 Putative lipoprotein 2.58 1.60E-10 
SAR1921 Enterotoxin 2.57 6.79E-02 
SAR1000 Hypothetical protein 2.56 2.02E-01 
SAR2781 ABC transporter ATP-binding protein 2.55 3.64E-02 
SAR0282 Conserved hypothetical protein 2.54 2.18E-01 
SAR1598 Arginine repressor 2.53 4.36E-11 
SAR1943 Putative membrane protein 2.51 3.10E-05 
SAR0036 Putative membrane protein 2.47 1.34E-01 
SAR2646 
Putative phytoene dehydrogenase 
related protein 
2.47 2.57E-08 
SAR2681 Amino acid permease family protein 2.42 1.81E-06 
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Table 27. Major groups of down-regulated genes in S. aureus at 40 h of C. elegans 
infection comparing to 16 h control sample model and their predicted function  
Number of genes Predicted function 
35 Hypothetical protein 
10 ATP-binding transporter protein 
10 Amino acids metabolic enzymes  
8 Putative membrane protein 
 
 
Table 28. The most down-regulated genes in S. aureus at 40h of C. elegans infection 
comparing to 16 h control sample  
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR2621 Putative membrane protein -9.80 3.70E-10 
SAR2132 Putative membrane protein -8.88 8.65E-09 
SAR2715 Arginine repressor family protein -8.83 3.28E-07 
SAR2070 Hypothetical phage protein -8.72 4.47E-09 
SAR1451 Alanine dehydrogenase -8.26 1.62E-04 
SAR2055 Hypothetical phage protein -7.53 7.38E-05 
SAR2793 Putative membrane protein -7.52 1.77E-04 
SAR2054 Hypothetical phage protein -7.51 4.61E-04 
SAR2605 D-specific D-2-hydroxyacid dehydrogenase -7.34 9.41E-25 
SAR2052 Hypothetical phage protein -7.31 1.98E-04 
SAR0173 
Putative ABC transporter ATP-binding 
protein 
-7.22 2.95E-04 
SAR2061 Hypothetical phage protein -7.20 1.85E-04 
SAR0989 Hypothetical protein -7.17 4.01E-04 
SAR2068 Putative exported protein -7.10 3.00E-04 
SAR2040 Autolysis -7.01 4.12E-04 
SAR2714 Arginine deiminase -6.74 2.33E-33 
SAR2373 Urease beta subunit -6.69 4.07E-03 
SAR2088 Hypothetical phage protein -6.60 2.75E-03 
SAR2488 Assimilatory nitrite reductase small subunit -6.59 2.16E-03 
SAR2053 Hypothetical phage protein -6.42 6.21E-03 
SAR0907 Hypothetical protein -6.31 1.45E-02 
SAR0423 Exotoxin -6.25 1.11E-02 
SAR0047 Conserved hypothetical protein -6.22 5.85E-03 
SAR0787 FecCD transport family protein -6.20 9.82E-03 
SAR2076 Hypothetical phage protein -6.19 1.07E-02 
SAR1007 Hypothetical protein -6.09 1.43E-02 
SAR2163 Putative potassium-transporting ATPase -6.06 1.04E-02 
SAR0174 Putative lipoprotein -5.98 1.27E-02 
SAR2712 Arginine/ornithine antiporter -5.94 7.47E-23 
SAR2711 Carbamate kinas -5.94 3.06E-27 
SAR0788 FecCD transport family protein -5.92 1.97E-02 
SAR1141 Exotoxin -5.89 2.44E-02 
SAR0218 Putative pyruvate formate-lyase enzyme -5.89 2.12E-19 
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Table 28-continued 
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR2066 Hypothetical phage protein -5.77 2.59E-02 
SAR2631 Hypothetical protein -5.74 3.97E-02 
SAR0294 Conserved hypothetical protein -5.72 3.08E-02 
SAR2046 Hypothetical phage protein -5.69 3.40E-02 
SAR0428 Exotoxin -5.69 2.21E-02 
SAR2628 
Putative ATP-dependent protease ATP-
binding subunit Clp 
-5.66 2.51E-16 
SAR0435 Exotoxin -5.52 2.55E-02 
SAR1832 Hypothetical protein -5.52 3.04E-02 
SAR2058 Hypothetical phage protein -5.50 2.70E-02 
SAR2372 Urease gamma subunit -5.46 4.75E-02 
SAR0256 Cell wall metabolism protein -5.45 4.88E-22 
SAR2710 Putative regulatory protein -4.88 4.73E-18 
SAR1079 Putative manganese transport protein -4.86 2.54E-23 
SAR2569 Hypothetical protein -4.79 2.55E-15 
SAR0439 Putative lipoprotein -4.76 1.28E-01 
SAR1450 Putative threonine dehydratase -4.75 3.50E-04 
SAR2071 Hypothetical phage protein -4.75 1.14E-01 
SAR2731 Conserved hypothetical protein  -4.71 9.30E-06 
SAR0613 Alcohol dehydrogenase -4.71 2.51E-11 
SAR2117 10 kDa chaperonin -4.64 1.30E-21 
SAR1907 Serine protease  -4.63 1.08E-01 
SAR2742 Acetyltransferase (GNAT) family protein -4.63 1.16E-01 
SAR0416 Putative transposes -4.63 1.05E-01 
SAR2691 Putative betaine aldehyde dehydrogenase -4.63 6.09E-14 
SAR0122 Putative transport protein -4.63 1.21E-01 
SAR1657 Chaperone protein -4.62 7.12E-15 
SAR2743 Putative capsule synthesis protein -4.59 1.23E-01 
SAR1686 
Putative biotin carboxyl carrier protein of 
acetyl-CoA carboxylase 
-4.58 1.30E-01 
SAR0641 ABC transporter extracellular binding  -4.58 2.84E-14 
SAR2044 Hypothetical protein -4.57 1.23E-01 
SAR1350 Putative membrane protein -4.57 7.37E-05 
SAR0361 Hypothetical protein -4.56 4.14E-07 
SAR0120 Putative ornithine cyclodeaminase -4.55 1.16E-01 
SAR1449 Amino acid permease -4.55 2.30E-04 
SAR2768 Conserved hypothetical protein -4.54 1.37E-01 
SAR1143 Putative carbamate kinas -4.53 5.18E-10 
SAR2085 Hypothetical phage protein -4.49 4.72E-18 
SAR0119 Pyridoxal-phosphate dependent enzyme -4.49 1.33E-01 
SAR1625 Conserved hypothetical protein -4.46 1.59E-01 
SAR0941 Hypothetical protein -4.46 1.21E-01 
SAR1658 GrpE protein (Hsp-70 cofactor) -4.45 7.64E-15 
SAR0111 Putative myosin-crossreactive antigen -4.44 7.44E-12 
SAR2051 Hypothetical phage protein -4.44 1.53E-01 
SAR1330 Putative membrane protein -4.43 1.31E-01 
SAR0286 Hypothetical protein -4.41 1.51E-01 
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Table 28-continued 
ORF Annotation 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
SAR2072 Putative dUTP pyrophosphatase -4.41 1.31E-01 
SAR2694 
Putative anaerobic ribonucleotide reductase 
Activating protein 
-4.37 1.51E-01 
SAR2658 TetR family regulatory protein -4.36 1.79E-05 
SAR0635 Putative membrane protein -4.36 4.23E-07 
SAR0114 
Immunoglobulin G binding protein A 
precursor 
-4.34 9.50E-05 
SAR1109 Conserved hypothetical protein -4.33 1.42E-01 
SAR2087 Hypothetical phage protein -4.31 6.47E-08 
SAR1909 Hypothetical protein -4.25 1.45E-01 
SAR0642 ABC transporter permease protein -4.25 4.72E-05 
SAR0209 Putative oxidoreductase -4.23 1.53E-01 
SAR2537 
Putative glycine betaine/carnitine/choline 
Transport system permease protein 
-4.21 4.34E-13 
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Table 29. Major groups of up-regulated genes in S. aureus at 40 h of C. elegans 
infection compared to 16 h of infection sample and their predicted function  
Number of genes Predicted function 
25 Metabolic enzyme 
10 Transport system proteins 
9 Putative membrane protein 
4 Capsule synthesis protein 
 
 
Table 30. Top 100 up-regulated genes in S. aureus infection of C. elegans at 40 h 
comparing to 16 h of infection sample 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0451 Hypothetical protein 6.79 7.54E-03 
SAR1402 Phosphate-binding lipoprotein 4.85 1.35E-12 
SAR1302 Conserved hypothetical protein 4.83 2.21E-02 
SAR0219 Hypothetical protein 4.83 2.23E-02 
SAR0393 Hypothetical protein 4.78 4.25E-02 
SAR1126 Hypothetical protein 4.75 5.78E-02 
SAR1401 ABC transporter permease protein 4.71 3.06E-10 
SAR1399 ABC transporter ATP-binding protein 4.40 3.09E-11 
SAR2354 Putative molybdopterin-synthase 4.32 8.65E-03 
SAR0984 Transposase 4.22 1.36E-02 
SAR0203 Putative phosphodiesterase 4.15 8.55E-04 
SAR1400 ABC transporter permease protein 3.95 3.90E-08 
SAR1320 Hypothetical protein 3.94 1.10E-01 
SAR0706 Putative membrane protein 3.94 1.12E-01 
SAR2519 ABC transporter ATP-binding protein 3.90 3.43E-04 
SAR0419 Hypothetical protein 3.87 1.10E-01 
SAR2613 Putative membrane protein 3.87 4.08E-05 
SAR0062 Hypothetical protein 3.87 1.14E-01 
SAR2243 Hypothetical protein 3.87 1.14E-01 
SAR0282 Conserved hypothetical protein 3.87 1.16E-01 
SAR0055 DNA repair protein RadC 3.87 1.18E-01 
SAR1866 CrcB-like protein 3.87 1.18E-01 
SAR2517 Putative dethiobiotin synthetase 3.87 1.18E-01 
SAR1398 Putative phosphate transport protein 3.85 4.22E-09 
SAR0317 Lipase precursor 3.84 3.30E-06 
SAR0309 Putative membrane protein 3.60 1.19E-02 
SAR0070 Potassium-transporting ATPase A chai 3.47 1.69E-02 
SAR1896 Hypothetical protein 3.42 6.85E-03 
SAR0766 Glutamine amidotransferase protein 3.29 6.93E-02 
SAR0105 Phosphatidylinositol phosphodiesterase 3.01 6.24E-02 
SAR0142 
Binding-protein-dependent transport 
systems membrane component 
2.98 7.18E-03 
SAR1038 
Putative phosphoribosylaminoimidazole 
carboxylase catalytic subunit 
2.95 4.69E-04 
 
173 
 
Table 30-continued 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0011 Putative membrane protein 2.91 8.94E-02 
SAR0431 Exotoxin 2.83 1.44E-03 
SAR0308 PfkB family carbohydrate kinas 2.81 5.38E-03 
SAR0228 Putative glutamine amidotransferase 2.68 1.22E-03 
SAR2745 Putative capsule synthesis protein 2.65 1.92E-01 
SAR2349 MarR family regulatory protein 2.63 6.60E-03 
SAR0580 Putative AMP-binding enzyme 2.61 2.93E-02 
SAR1012 Hypothetical protein 2.60 1.27E-01 
SAR1930a Hypothetical protein 2.58 1.59E-01 
SAR1132 Hypothetical protein 2.56 7.47E-02 
SAR0437 Putative exported protein 2.54 4.31E-05 
SAR1041 Conserved hypothetical protein 2.45 3.64E-05 
SAR1294 Putative membrane protein 2.25 8.40E-02 
SAR0327 Putative PTS transport system protein 2.21 1.05E-01 
SAR1855 Arsenical resistance operon repressor 2.18 2.81E-01 
SAR2477 Conserved hypothetical protein 2.17 8.27E-02 
SAR2285 Galactose-6-phosphate isomerase LacB  2.14 1.00E-03 
SAR2758 
Putative imidazole glycerol-phosphate 
dehydratase 
2.11 3.36E-02 
SAR0411 Hypothetical protein 2.11 4.16E-04 
SAR0617 Putative DNA repair protein 2.10 5.02E-02 
SAR1042 
Putative phosphoribosyl formyl 
Glycinamidine synthase 
2.08 5.18E-03 
SAR0335 Putative luciferase-like monooxygenase 2.06 1.20E-06 
SAR1289 Putative exported protein 2.05 7.89E-03 
SAR0336 NADH-dependent FMN reductase  1.99 5.16E-04 
SAR0626 Putative membrane protein 1.99 7.46E-02 
SAR0934 Halo-acid dehalogenase-like hydrolase 1.96 2.02E-07 
SAR2761 ATP phosphoribosyltransferase 1.96 3.64E-02 
SAR1380 Anthranilate synthase component 1.93 6.69E-02 
SAR1225 SMF family protein 1.91 3.76E-03 
SAR2162 Conserved hypothetical protein 1.91 9.05E-03 
SAR2792 Putative membrane protein 1.91 6.13E-02 
SAR2289a Hypothetical protein 1.91 2.11E-01 
SAR0146 Putative exported protein 1.91 2.35E-02 
SAR2744 Putative capsule synthesis protein 1.90 1.85E-01 
SAR0846 Putative exported protein 1.89 1.50E-01 
SAR0185 
Putative N-acetyl-gamma-glutamyl-
phosphate reductase 
1.88 1.23E-01 
SAR1772 
Alkaline phosphatase synthesis 
Transcriptional regulatory protein 
1.88 1.21E-06 
SAR1142 Ornithine carbamoyl transferase 1.87 2.87E-02 
SAR0967 Hypothetical protein 1.87 3.07E-01 
SAR2509 
Gamma-hemolysin component A 
precursor 
1.84 7.69E-03 
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Table 30-continued 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0471 Glutamate synthase, large subunit 1.83 9.57E-02 
SAR0200 Putative transport system permease 1.83 9.75E-02 
SAR2251 Putative transposase 1.81 1.68E-01 
SAR2122 Delta-hemolysin precursor 1.79 6.32E-06 
SAR2478 MerR family regulatory protein  1.78 7.12E-03 
SAR2624 Putative exported protein 1.76 2.80E-01 
SAR0961 Putative transposase 1.75 8.16E-03 
SAR2297b Hypothetical protein 1.74 4.40E-01 
SAR1910 Putative membrane protein 1.74 3.50E-04 
SAR0153 
Capsular polysaccharide synthesis 
enzyme 
1.73 4.63E-05 
SAR0152 
Capsular polysaccharide synthesis 
enzyme 
1.73 4.20E-01 
SAR0131 Putative sugar transferase 1.73 3.88E-01 
SAR1450 Putative threonine dehydratase 1.71 3.76E-05 
SAR2648 Secretory antigen precursor 1.70 3.56E-02 
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Table 31. Major groups of down-regulated genes in S. aureus at 40 h of C. elegans 
infection comparing to 16 h of infection sample and their predicted function  
Number of genes Predicted function 
46 Hypothetical proteins 
14  Different enzymes 
15 Putative membrane proteins 
13 Transport family proteins 
 
 
Table 32. Top 100 down-regulated genes in S. aureus infection of C. elegans at 40 h 
comparing to 16 h of infection sample 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0788 FecCD transport family protein -6.91 3.41E-03 
SAR0047 Conserved hypothetical protein -6.71 2.01E-03 
SAR2061 Hypothetical phage protein -6.70 1.46E-03 
SAR0787 FecCD transport family protein -6.68 3.97E-03 
SAR0989 Hypothetical protein -6.64 2.40E-03 
SAR2132 Putative membrane protein -6.51 2.27E-03 
SAR2046 Hypothetical phage protein -6.20 1.80E-02 
SAR2054 Hypothetical phage protein -6.08 1.47E-02 
SAR2055 Hypothetical phage protein -5.78 1.69E-02 
SAR2557 Conserved hypothetical protein -5.73 2.11E-02 
SAR0173 
Putative ABC transporter ATP-binding 
protein 
-5.70 2.10E-02 
SAR0122 Putative transport protein -5.66 4.46E-02 
SAR1298 Hypothetical protein -5.65 4.98E-02 
SAR2715 Arginine repressor family protein -5.58 2.62E-02 
SAR0936 Hypothetical protein -5.43 1.20E-01 
SAR0174 Putative lipoprotein -5.35 4.26E-02 
SAR0143 
Binding-protein-dependent transport 
system membrane component 
-5.33 7.66E-02 
SAR1677 Putative membrane protein -5.32 8.55E-02 
SAR2163 Putative potassium-transporting ATPase C  -5.27 4.65E-02 
SAR2562 Putative membrane protein -5.23 5.83E-02 
SAR2631 Hypothetical protein -5.22 7.48E-02 
SAR0250 Hypothetical protein -5.21 1.09E-01 
SAR1912 Transposase  -5.21 1.18E-01 
SAR0793 Hypothetical protein -5.20 7.52E-02 
SAR2230 Putative membrane protein -5.18 8.88E-02 
SAR2391a Putative membrane protein -5.17 9.75E-02 
SAR2058 Hypothetical phage protein -5.14 5.39E-02 
SAR0428 Exotoxin -5.03 6.52E-02 
SAR2373 Urease beta subunit -5.02 7.15E-02 
SAR0031b Hypothetical protein -4.98 9.53E-02 
SAR2552 
Oligopeptide transporter putative 
membrane permease 
-4.96 1.21E-01 
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Table 32-continued 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR2070 Hypothetical phage protein -4.95 6.01E-02 
SAR0090 Hypothetical protein -4.92 1.09E-01 
SAR0120 Putative ornithine cyclodeaminase -4.92 8.60E-02 
SAR1620 Putative membrane protein -4.90 1.26E-01 
SAR0242 Putative PTS transport system, IIC  -4.89 8.70E-02 
SAR2752 Conserved hypothetical protein -4.87 1.29E-01 
SAR1625 Conserved hypothetical protein -4.85 1.24E-01 
SAR1107 Iron/heme permease -4.75 1.25E-01 
SAR1619 Putative exported protein -4.74 1.42E-01 
SAR2768 Conserved hypothetical protein -4.72 1.23E-01 
SAR2040 Autolysin -4.71 8.74E-02 
SAR0907 Hypothetical protein -4.70 1.17E-01 
SAR0057 Hypothetical protein -4.68 1.49E-01 
SAR0423 Exotoxin -4.40 1.42E-01 
SAR2450 Putative membrane protein -4.38 3.05E-12 
SAR1108 Sortase -4.36 1.89E-01 
SAR0100 Putative membrane protein -4.33 1.78E-01 
SAR1981 Hypothetical protein -4.32 2.12E-01 
SAR0941 Hypothetical protein -4.23 1.60E-01 
SAR0244 Hypothetical protein -4.16 2.13E-01 
SAR2041 Holi -4.15 2.02E-01 
SAR1907 Serine protease -4.10 1.87E-01 
SAR2060 Hypothetical phage protein -4.07 1.92E-01 
SAR0285 Hypothetical protein -4.06 1.92E-01 
SAR0435 Exotoxin -4.01 1.84E-01 
SAR2053 Hypothetical phage protein -3.98 1.95E-01 
SAR2741 Hypothetical protein -3.91 2.08E-01 
SAR0643 ABC transporter ATP-binding protein -3.91 7.11E-13 
SAR0642 ABC transporter permease protein -3.84 5.15E-11 
SAR2520 Hypothetical protein -3.81 2.37E-01 
SAR2088 Hypothetical phage protein -3.79 2.25E-01 
SAR0209 Putative oxidoreductase -3.78 1.04E-08 
SAR0133 Putative membrane protein -3.76 2.50E-01 
SAR0641 
ABC transporter extracellular binding 
protein 
-3.75 1.81E-10 
SAR2112 Putative transposase -3.68 2.53E-01 
SAR1330 Putative membrane protein -3.68 2.51E-01 
SAR0208 Putative sugar transport system permease -3.60 8.69E-05 
SAR0376 Hypothetical protein -3.59 2.71E-01 
SAR0460 
Putative Cys/Met metabolism PLP-
dependent enzyme 
-3.58 2.21E-07 
SAR1451 Alanine dehydrogenase -3.54 2.70E-01 
SAR1109 Conserved hypothetical protein -3.54 2.73E-01 
SAR0627 Hypothetical protein -3.53 3.19E-01 
SAR1459a Hypothetical protein -3.52 3.18E-01 
SAR2449 Hypothetical protein -3.44 1.50E-06 
SAR0805 Conserved hypothetical protein -3.41 3.16E-01 
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Table 32-continued 
ORF Annotation 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
SAR0286 Hypothetical protein -3.40 3.16E-01 
SAR2582 Putative gluconate permease -3.33 2.52E-12 
SAR1873 Conserved hypothetical protein -3.31 2.93E-03 
SAR0459 Pyridoxal-phosphate dependent enzyme -3.27 1.36E-04 
SAR1317 Hypothetical protein -3.27 3.38E-01 
SAR2076 Hypothetical phage protein -3.26 3.22E-01 
SAR2266 FecCD transport family protein -3.25 4.10E-03 
SAR0260 Holin-like protein -3.22 1.88E-06 
SAR2466 
PTS system, sucrose-specific IIBC 
component 
-3.21 1.94E-07 
SAR1141 Exotoxin -3.15 3.43E-01 
SAR0259 Holin-like protein -3.13 2.82E-04 
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5.2.6 Differential expression analysis 
Approx. 50 million reads were obtained from the mixture of each RNA sample, reads were 
aligned to the combined genome sequences using Tophat (version 2.1.0), then gene 
expressions were calculated from reads alignment files. The count data were split into two 
sub sets: one containing transcripts belong to S. aureus, other containing transcripts for C. 
elegans. The two sub data sets were analysed separately. The differential genes expression 
analyses were applied to the two sub count data sets, respectively. The estimated Fold 
Changes (FC) was tested in edgeR using a Likelihood-Ratios (LR) test. P-values 
associated with FC were adjusted for multiple testing using the False Discovery Rate 
(FDR) approach (Benjamini and Hochberg, 1995). Significantly differentially expressed 
genes were defined as those with FDR-adjusted P-value < 5%.  
5.2.6.1 Identification of differentially expressed (DE) genes of S. aureus MRSA252 in 
C. elegans infection model by using RNA-seq technology  
The transcriptome analyses of the three conditions in this experiment showed a group of S. 
aureus MRSA252 genes that were expressed during infection of C. elegans, the three 
times shared many genes that were expressed with different levels, the samples of early 
and late stages of infection have shared 307 expressed genes. However, 44 genes similar in 
expression between the three transcriptome conditions. The early time-point of post-
infection (16 h) revealed that 799 genes were expressed in total in this condition, 349 
transcripts up-regulation and 450 transcripts were down-regulation. At the late stage of 
infection the S. aureus transcriptome had 782 transcripts differentially expressed with 324 
transcripts up-regulation and 458 transcripts were down-regulation. Seventy-five 
transcripts were expressed only during 16 and 40 h. The number of DE genes for S. aureus 
are listed in table 33; also differentially expressed genes common to the different sampling 
times are summarized in a Venn diagram (figure 24) which produced by Venny 2.1 
software from http://bioinfogp.cnb.csic.es/tools/venny/.     
Table 33. Number of Differentially Expressed genes of S. aureus MRSA252 during 
the C. elegans infection model 
Regulation T16.vs.C16 T40.vs.C16 T40.vs.T16 
Differentially Expressed 799 782 307 
Up-regulated DE 349 324 118 
Down- regulated DE 450 458 189 
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Figure 24. Proportional Venn diagram summarizing common differentially expressed 
genes of S. aureus MRSA252 during the infection model of C. elegans                      
Samples taken 16 and 40 h post-infection conditions compared with the 16 h control, the 
overlap area indicates the common differentially expressed genes among three conditions. 
Venn diagram produced by Venny 2.1 software from http://bioinfogp.cnb.csic.es/tools/ 
venny/.     
 
 
Figure 25. Proportional Venn diagram summarizing common differentially expressed 
genes of C. elegans during the infection model  
Analysis of RNA-Sequencing data of 16 and 40 h post-infection conditions compared with 
the 16 h control; the overlap area indicates the common differentially expressed genes 
among three conditions. 
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5.2.6.2 Differentially expressed genes of C. elegans during the infection model  
Expression levels of C. elegans transcripts were calculated to find out the differentially 
expressed genes, C. elegans transcriptional profiling reveals ~ 18,000 transcripts were 
identified. Initially, in the 16 h of infection condition compared with the non-infected 
nematodes 3629 differentially expressed genes were profiled in total, including 1776 
transcripts that were down-regulated and 1853 transcripts that were up-regulated, while 
1880 transcripts were up-regulated and 1311 transcripts down-regulated in the late stage of 
infection (40h). Meanwhile, 231 differentially expressed genes were expressed in both 
times of infection with 53 most down-regulated and 178 up-regulated transcripts. The 
number of C. elegans DE genes is listed in table 34, also the differentially expressed genes 
common to different times of infection are summarized in a Venn diagram (figure 25).   
 
Table 34. Number of Differentially Expressed genes of C. elegans 
Regulation T16.vs.C16 T40.vs.C16 T40.vs.T16 
Differentially Expressed 3629 3191 231 
Up-regulated DE 1853 1880 178 
Down- regulated DE 1776 1311 53 
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5.2.8 Analysis of C. elegans gene expression changes induced by S. aureus infection  
The bacterial pathogen S. aureus colonize the intestine of nematodes and caused the 
alteration of expressed genes, over 2,000 transcripts were expressed in up and down-
regulated manner, the top 100 genes up and down-regulated in the C. elegans transcripts 
were identified to investigate the transcriptome complexity changes that accompany 
infection and show the innate immune response of C. elegans. Both infection times 
showed detailed transcriptional response of C. elegans to S. aureus infection, the 
comparison of this transcriptome data characterize the most transcriptional changes in C. 
elegans genes that accompany infection, quantitative transcript levels of the top 100 down 
and up regulated genes are summarized in tables 35-46. The biological variation for 16 h 
time-point of infection were compared to 16 h of non-infected sample, 40 h of infection 
compared to 16 h of non-infected sample and 16 h of infection were compared to 40 h of 
infection sample. 
Among the 100 genes most up-regulated after 16 h (tables 35 and 36) there were a group 
of cuticle collagen protein genes which are a common component of C. elegans response 
to the infection. Several protein-protein interaction genes are known to be involved in the 
enzyme activities and antibody antigen interaction were identified in significant up-
regulated levels. Also 6 zygotic transcript proteins were identified as up-regulated in the 
early stage of infection.    
In the late stage of C. elegans infection (40h) the cellular activities of nematodes was 
decreased as most of metabolic and developments process responsible genes were showed 
to be down-regulated compared with the early stage activities of those genes. Three cuticle 
collagen genes were activated during the late time of infection, also few of protein-protein 
interactions fbxa genes were upregulated after 40 h (tables 37 and 38). The transcriptional 
changes between the two time-points of infection revealed the unknown protein functions 
were the most up-regulated transcripts as 38 expressed genes of hypothetical or unknown 
function proteins (table 39 and 40). Thirty protein-protein interaction genes were up-
regulated and 6 zygotic transcript transcripts showed up-regulated level at the late phase of 
bacterial infection.    
The early phase of infection showed several down-regulated genes (tables 41 and 42), 30 
of cuticle collagen transcripts had reduced levels of expression, 2 C-type lectin genes were 
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among the down-regulated transcripts and several genes of unknown function were 
decreased. In table 44, among the top 100 C. elegans down-regulated genes after 40 h of 
infection the transcriptome showed decline in the metabolic enzymes activities and metals 
ions binding proteins biosynthesis, 13 signaling receptor genes were among the most 
down-regulated transcripts, also 2 C-type lectin transcripts had low level of expression in 
late infection stage comparing with non-infected control.             
The top 100 up-or-down-regulated genes of C. elegans after 16 and 40 h of infection with 
S. aureus MRSA252 are summarized in table 47. The majority of these induced genes 
were predicted as undefined function but their induction in this particular time of infection 
suggests an important role in the C. elegans innate immune system. The up-regulation 
levels for ~ 90% of them were during the early infection stage, while these genes had no 
down-regulation in the late infection stages. Fourteen embryogenesis and growth factor 
genes were highly induced and showed high level of up-regulation at the early infection 
time and down-regulation during the late stage of infection. A set of heat shock protein had 
a high level of transcripts during the course of S. aureus infection stages. Two cytochrome 
P450s encoding genes had a low expression level as they showed down-regulation in the 
early time of C. elegans infection.      
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Table 35. Major groups of up-regulated genes in C. elegans at 16 h of infection model 
compared with the non-infected 16 h control sample their predicted function  
Number of genes Predicted function 
36 Protein-protein interactions 
23 Hypothetical proteins 
6 Zygotic transcripts 
5 Unknown 
3 Zinc ion binding activity 
 
 
Table 36. Top 100 C. elegans genes up-regulated after 16 h of infection compared 
with the non-infected 16 h control sample 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
sdz-4 Zygotic transcript 9.25 1.53E-11 
hnd-1 Transcription factor 9.10 1.66E-12 
sdz-5 Zygotic transcript 8.98 1.00E-10 
T04C12.1 Hypothetical protein 8.93 2.18E-13 
ZK899.6 Hypothetical protein 8.86 1.49E-10 
F57G9.3 Hypothetical protein 8.82 8.70E-09 
ins-19 Insulin related 8.75 1.06E-15 
fbxb-3 Protein-protein interactions 8.70 1.64E-08 
dsl-1 Postembryonic development 8.64 3.89E-09 
fbxb-42 F-box B protein 8.56 2.92E-09 
C40A11.6 Tumour necrosis factor 8.50 3.34E-09 
fbxc-34 F-box C protein 8.48 2.30E-08 
fbxb-13 F-box C protein 8.43 3.79E-09 
F21H7.10 Hypothetical protein 8.26 3.00E-09 
F45D11.5 Hypothetical protein 8.24 9.17E-08 
C29G2.3 Hypothetical protein 8.24 8.70E-09 
fbxb-10 Protein-protein interactions 8.17 1.07E-08 
C17E4.19 Hypothetical protein 8.08 8.19E-08 
lys-10 Lysozyme 8.04 1.63E-07 
fbxb-44 Paraoxonase-like protein 8.02 5.21E-08 
fbxb-40 Protein-protein interactions 8.01 1.59E-08 
ins-2 Insulin related 7.93 1.93E-07 
nlp-39 Neuropeptide-Like Protein 7.92 7.30E-08 
fbxb-43 Protein-protein interactions 7.89 6.53E-08 
fbxb-1 Protein-protein interactions 7.79 4.66E-07 
Y73C8C.8 Zinc ion binding activity 7.76 6.00E-11 
scl-12 SCP-extracellular protein 7.76 3.92E-03 
C08F8.15 Hypothetical protein 7.76 4.53E-06 
C24H12.3 Unknown 7.66 2.74E-07 
T26E3.8 Hypothetical protein 7.62 1.36E-07 
fbxb-108 Protein-protein interactions 7.59 6.89E-06 
fbxb-22 Protein-protein interactions 7.59 6.36E-06 
fbxb-65 Protein-protein interactions 7.56 1.46E-06 
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Table 36-continued 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
Y45G5AM.5 Hypothetical protein 7.53 5.04E-07 
fbxb-47 Protein-protein interactions 7.53 8.95E-05 
fbxb-91 Protein-protein interactions 7.49 6.09E-12 
fbxb-66 Protein-protein interactions 7.44 1.94E-16 
clec-196 killer cell lectin-like receptor 7.38 3.02E-11 
fbxc-22 Protein-protein interactions 7.37 2.31E-06 
fbxb-95 Protein-protein interactions 7.35 1.52E-06 
F38C2.7 RNA-binding protein 7.31 5.36E-04 
col-121 Cuticle collagen 7.31 9.41E-19 
C32B5.15 Protein-protein interactions 7.31 4.18E-06 
T08B6.5 Nucleotide binding activity 7.30 2.02E-05 
fbxb-19 Protein-protein interactions 7.30 1.83E-05 
pes-10 
Patterned expression site 
protein 10 
7.29 4.14E-08 
dct-13 RNA-binding protein 7.11 5.39E-05 
tbx-43 DNA binding transcription 7.10 1.16E-03 
21ur-14519 21U-RNA gene 7.09 2.89E-05 
F36H5.4 Hypothetical protein 7.07 2.36E-05 
hch-1 Epidermal growth factor 7.07 3.49E-19 
sdz-11 Zygotic transcript 7.06 3.79E-04 
fbxb-61 Protein-protein interactions 7.05 8.86E-06 
T26E3.5 Protein-protein interactions 6.99 2.42E-05 
R05D8.11 Hypothetical protein 6.98 7.04E-06 
fbxb-52 Protein-protein interactions 6.97 6.59E-05 
fbxb-46 Protein-protein interactions 6.97 4.51E-06 
fbxb-50 Protein-protein interactions 6.95 6.62E-05 
fbxb-60 Protein-protein interactions 6.94 7.95E-05 
ZK816.4 Hypothetical protein 6.93 3.90E-05 
fbxb-82 Protein-protein interactions 6.93 5.47E-05 
ZK250.15 Unknown 6.88 7.11E-05 
clec-266 Lectin domain family 6.87 1.86E-39 
T02G6.11 Hypothetical protein 6.86 5.48E-05 
fbxb-6 Protein-protein interactions 6.85 1.50E-05 
F21D9.5 Unknown 6.85 1.55E-04 
C54F6.5 Hypothetical protein 6.85 2.95E-05 
sdz-31 Zygotic transcript 6.83 1.18E-04 
fbxc-30 Protein-protein interactions 6.79 1.01E-03 
F30A10.15 Hypothetical protein 6.75 5.48E-05 
fbxc-29 Protein-protein interactions 6.72 1.86E-11 
C32B5.7 Cysteine-peptidase activity 6.69 3.46E-04 
ZK899.5 Hypothetical protein 6.66 1.35E-04 
Y7A5A.6 Unknown 6.66 6.09E-05 
ZC239.21 Hypothetical protein 6.65 7.53E-05 
fbxb-33 Protein-protein interactions 6.64 5.33E-04 
T24E12.13 Hypothetical protein 6.61 2.61E-04 
fbxb-32 Protein-protein interactions 6.60 8.42E-05 
fbxb-116 Protein-protein interactions 6.59 7.74E-05 
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Table 36-continued 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
sdz-18 Zygotic transcript 6.59 1.67E-03 
K08H2.2 Hypothetical protein 6.59 1.20E-07 
C35D6.4 RNA-binding protein 6.58 1.99E-03 
dsl-6 Putative transmembrane 6.58 4.91E-09 
Y38H6A.3 Hypothetical protein 6.57 8.79E-04 
fbxc-18 Protein-protein interactions 6.57 1.38E-11 
fbxb-30 Protein-protein interactions 6.55 7.00E-04 
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Table 37. Major groups of up-regulated genes in C. elegans at 40 h of infection model 
compared with the non-infected 16 h control sample and their predicted function  
Number of genes Predicted function 
26 Hypothetical proteins 
12 Unknown 
30 Protein-protein interactions 
6 Zygotic transcripts 
 
 
Table 38. Top 100 C. elegans genes up-regulated after 40 h of infection compared 
with the non-infected 16 h control sample 
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
ins-19 Insulin related 10.27 8.05E-21 
sdz-4 Zygotic transcript 8.78 3.69E-10 
fbxb-3 Protein-protein interactions 8.60 2.83E-08 
lys-10 Lysozyme 8.57 9.22E-09 
sdz-5 Zygotic transcript 8.52 2.11E-09 
cyp-14A3 Cytochrome P450 8.35 5.35E-06 
cpr-2 cysteine-type peptidase 8.34 3.84E-07 
nlp-39 Neuropeptide-Like Protein 8.33 6.25E-09 
C40A11.6 Tumour necrosis factor 8.22 1.78E-08 
fbxc-34 Protein-protein interactions 8.19 1.05E-07 
hnd-1 Transcription factor 8.14 2.64E-09 
fbxb-10 Protein-protein interactions 8.13 1.42E-08 
fbxb-44 Protein-protein interactions 8.11 3.10E-08 
F57G9.3 Hypothetical protein 8.09 3.37E-07 
T04C12.1 Unknown 8.05 6.64E-10 
fbxb-42 Protein-protein interactions 8.01 7.20E-08 
ZK899.6 Protein-protein interactions 7.99 4.01E-08 
fbxb-13 Hypothetical protein 7.92 8.58E-08 
dsl-1 Postembryonic development 7.89 2.56E-07 
fbxb-108 Protein-protein interactions 7.87 2.19E-06 
fbxb-40 Protein-protein interactions 7.84 4.89E-08 
ins-2 ATP binding activity 7.82 3.55E-07 
C17E4.19 Unknown 7.74 5.24E-07 
fbxb-107 Hypothetical protein 7.72 6.03E-07 
F45D11.5 Unknown 7.58 2.42E-06 
C08F8.15 Transcription-binding Zn 7.50 1.30E-05 
fbxb-22 Protein-protein interactions 7.35 1.73E-05 
F36H5.4 Unknown 7.34 7.53E-06 
C32B5.15 Hypothetical protein 7.33 3.87E-06 
Y73C8C.8 Hypothetical protein 7.26 1.31E-09 
Y57A10C.1 Cuticlin-Like 7.20 3.50E-04 
Y45G5AM.5 Hypothetical protein 7.17 3.92E-06 
fbxb-1 Protein-protein interactions 7.16 1.07E-05 
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 Table 38-continued  
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
ZK822.9 Unknown 7.13 5.44E-04 
tbx-43 DNA binding transcription 7.10 1.17E-03 
C54F6.5 Hypothetical protein 7.07 1.10E-05 
F38C2.7 RNA-binding protein 7.02 1.06E-03 
T26E3.8 Hypothetical protein 7.02 4.91E-06 
T08B6.5 Nucleotide binding activity 7.01 6.40E-05 
fbxb-50 Protein-protein interactions 7.01 5.37E-05 
fbxb-65 Protein-protein interactions 6.99 2.22E-05 
F21H7.10 Hypothetical protein 6.99 6.73E-06 
C24H12.9 Hypothetical protein 6.96 1.85E-05 
F21D9.5 Hypothetical protein 6.92 1.21E-04 
nspe-5 Nematode Specific Peptide 6.88 2.08E-04 
clec-266 C-type lectin 6.69 6.39E-38 
fbxb-95 Protein-protein interactions 6.66 5.17E-05 
fbxb-82 Protein-protein interactions 6.65 1.63E-04 
C24H12.3 Unknown 6.65 5.43E-05 
ZK250.15 Unknown 6.65 1.82E-04 
W08F4.13 Hypothetical protein 6.64 1.55E-04 
fbxb-91 Hypothetical protein 6.62 3.38E-09 
fbxc-22 Protein-protein interactions 6.60 9.00E-05 
ZK816.4 Hypothetical protein 6.57 1.78E-04 
fbxb-47 Protein-protein interactions 6.55 1.40E-03 
fbxb-46 Protein-protein interactions 6.54 4.57E-05 
C02B4.3 Unknown 6.52 1.94E-02 
col-121 Cuticle collagen 6.51 3.33E-15 
F21D9.11 Hypothetical protein 6.48 2.64E-03 
C54C8.12 Hypothetical protein 6.47 2.20E-07 
T02G6.11 Hypothetical protein 6.47 2.66E-04 
Y7A5A.6 Unknown 6.45 1.53E-04 
fbxb-62 Protein-protein interactions 6.45 7.96E-04 
nhx-6 Sodium/proton exchanger 6.44 1.06E-04 
C29G2.3 Hypothetical protein 6.44 1.38E-04 
T24E12.13 Hypothetical protein 6.43 5.02E-04 
Y46H3A.5 Hypothetical protein 6.43 2.84E-23 
fbxb-18 Protein-protein interactions 6.43 1.02E-04 
dct-13 RNA-binding protein 6.42 6.18E-04 
sdz-11 Zygotic transcript 6.36 2.38E-03 
fbxc-15 Protein-protein interactions 6.36 5.13E-04 
fbxb-30 Protein-protein interactions 6.35 1.26E-03 
dsl-6 Postembryonic development 6.35 1.89E-08 
sdz-31 Zygotic transcript 6.30 7.99E-04 
B0391.14 Unknown 6.29 8.62E-04 
fbxb-61 Protein-protein interactions 6.27 3.15E-04 
fbxc-30 Protein-protein interactions 6.26 3.63E-03 
sdz-30 Zygotic transcript 6.26 1.28E-09 
F35E12.2 Hypothetical protein 6.25 4.63E-04 
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Table 38-continued 
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
sdz-18 Zygotic transcript 6.23 3.95E-03 
T04B8.2 Protein-protein interactions 6.20 3.10E-08 
H25K10.4 Hypothetical protein 6.19 1.61E-02 
F54F7.9 Hypothetical protein 6.15 1.86E-03 
fbxb-116 Protein-protein interactions 6.14 5.30E-04 
R05D8.11 Hypothetical protein 6.14 3.91E-04 
fbxb-90 Protein-protein interactions 6.14 2.06E-06 
F43C11.10 Unknown 6.13 2.87E-03 
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Table 39. Major groups of up-regulated genes in C. elegans at 40 h of infection model 
comparing to 16 h of infection sample and their predicted function  
Number of genes Predicted function 
35 Unknown 
27 Hypothetical proteins 
8 Signaling receptors 
4 Lectin proteins 
3 Cytochrome P450 
2 Collagen proteins 
 
 
Table 40. Top 100 C. elegans genes up-regulated after 40 h of infection comparing 
with 16 h of infected sample 
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
C02E7.10 Hypothetical protein 7.05 2.30E-03 
C54C8.2 Hypothetical protein 6.46 3.84E-03 
C32H11.6 Hypothetical protein 6.18 2.99E-03 
Y39G8B.7 Hypothetical protein 6.18 5.17E-03 
T22B2.6 Hypothetical protein 6.18 2.85E-03 
catp-2 Metal ion binding 6.16 1.76E-03 
F14D7.10 Hypothetical protein 6.05 1.39E-03 
B0563.10 Hypothetical protein 5.73 3.16E-02 
C37A5.5 Hypothetical protein 5.70 4.67E-02 
F07C6.6 Hypothetical protein 5.60 4.24E-03 
T25G12.13 Oxidoreductase activity 5.42 6.04E-04 
gba-2 Glucosyl ceramidase 5.29 9.11E-04 
nhr-259 DNA transcription 5.21 1.70E-02 
B0507.4 Hypothetical protein 5.20 1.34E-01 
ZK563.10 Unknown 5.18 7.10E-02 
nhx-6 Sodium/proton exchanger 5.17 8.90E-04 
cyp-35A1 Cytochrome P450s 5.15 1.62E-03 
R05A10.7 Hypothetical protein 5.10 5.98E-02 
clec-206 C-type lectin 5.07 2.30E-03 
F52B10.16 Unknown 4.99 1.10E-02 
Y60A3A.23 Hypothetical protein 4.98 5.74E-02 
nhr-74 Nuclear hormone receptor 4.90 8.13E-03 
H06H21.36 Unknown 4.87 3.60E-02 
C32H11.8 Hypothetical protein 4.85 8.88E-03 
C32H11.9 Hypothetical protein 4.76 1.23E-02 
C05E4.12 Hypothetical protein 4.74 2.93E-02 
cyp-13A9 Cytochrome P450 4.73 3.51E-02 
ZK1025.5 Unknown 4.73 4.00E-02 
H39E23.3 
Chloride intracellular 
channel 
4.67 5.74E-07 
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Table 40-continued 
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
Y105C5B.1420 Unknown 4.62 5.24E-02 
dao-4 Dauer Overexpression 4.61 1.38E-02 
Y57G11C.41 Hypothetical protein 4.60 5.59E-02 
W01B6.4 Hypothetical protein 4.59 5.67E-02 
K02A2.9 Unknown 4.58 5.26E-02 
C13A2.9 Hypothetical protein 4.57 6.21E-02 
C17F3.4 Hypothetical protein 4.52 2.47E-01 
F49C5.11 Unknown 4.48 1.25E-02 
F36H1.17 Unknown 4.48 1.26E-01 
nhr-222 Steroid hormone receptor 4.46 1.26E-01 
sls-2.3 Unknown 4.46 1.21E-01 
F17B5.4 Sulfotransferase activity 4.45 8.49E-02 
C02H6.3 Hypothetical protein 4.45 1.69E-01 
clec-247 C-type lectin 4.42 6.27E-02 
C05A9.8 Unknown 4.42 1.46E-01 
D1086.3 Hypothetical protein 4.24 4.46E-05 
21ur-9901 Unknown 4.24 1.38E-01 
E02C12.11 Transferase activity 4.23 8.30E-02 
nhr-234 
DNA binding 
transcription 
4.23 1.33E-01 
F48C5.3 Unknown 4.21 1.46E-01 
math-29 Meprin-associated Traf 4.20 1.87E-01 
C06E4.6 Oxidoreductase activity 4.17 4.16E-02 
srz-15 Serpentine receptor 4.17 2.88E-01 
srh-167 Serpentine receptor 4.13 3.07E-01 
srz-55 Unknown 4.13 3.06E-01 
col-163 Collagen 4.12 7.14E-03 
B0495.21 Unknown 4.09 1.81E-01 
K08B5.3 Unknown 4.09 1.81E-01 
T26H10.6 Unknown 4.09 1.81E-01 
cyp-13A11 Cytochrome P450 family 4.08 5.11E-03 
T28C12.13 Unknown 4.07 9.41E-02 
C34E7.5 Unknown 4.07 1.83E-01 
F49F1.11 
Lectin, galactoside-
binding 
4.07 1.73E-01 
21ur-6449 Unknown 4.07 1.15E-01 
F40F9.11 Unknown 4.07 1.30E-01 
clec-2 C-type lectin 4.05 9.39E-02 
C12C8.6 Unknown 4.05 1.11E-01 
C52G5.7 Unknown 4.05 1.24E-01 
ZK228.10 Hypothetical protein 4.04 2.10E-01 
T07C12.10 Hypothetical protein 4.04 2.04E-01 
R144.19 Hypothetical protein 4.04 1.73E-01 
C26F1.13 Unknown 4.04 1.67E-01 
hpa-2 Aging-associated changes 4.04 1.73E-01 
C47E8.14 Unknown 4.03 1.81E-01 
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Table 40-continued 
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
F08H9.14 Unknown 4.03 3.12E-01 
F33D4.13 Unknown 4.03 3.12E-01 
F41G3.20 Unknown 4.03 1.21E-01 
srh-188 Serpentine receptor 4.02 7.61E-02 
F47B7.4 Unknown 4.02 1.31E-01 
col-114 Collagen 4.02 8.21E-02 
C27A12.11 Unknown 4.01 1.81E-01 
T03G11.19 Unknown 4.01 1.29E-01 
srg-38 Signaling receptor 4.00 1.73E-01 
21ur-9425 Unknown 4.00 1.73E-01 
cnc-1 Antimicrobial peptide 3.98 2.13E-01 
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Table 41. Major groups of down-regulated genes in C. elegans at 16 h of infection 
model comparing to 16 h control sample and their predicted function  
Number of genes Predicted function 
39 Hypothetical protein 
30 Cuticle collagen 
7 Synthesize cuticle 
6 Unknown 
 
 
Table 42. Top 100 C. elegans genes down-regulated after 16 h of infection compared 
with the non-infected 16 h control sample 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
C54C8.2 Hypothetical protein -8.74 4.70E-05 
Y39G8B.7 Hypothetical protein -8.74 2.97E-05 
T22B2.6 Hypothetical protein -8.50 1.11E-05 
C32H11.6 Hypothetical protein -8.43 1.54E-05 
nhr-74 Nuclear hormone receptor -7.95 5.68E-06 
cyp-13A9 Cytochrome P450s -7.62 4.45E-05 
clec-206 C-type lectin -7.61 3.31E-06 
ZK1025.5 Hypothetical protein -7.39 1.53E-04 
ZK1025.4 Hypothetical protein -7.31 1.06E-05 
F49C5.11 Hypothetical protein -7.28 8.76E-06 
dao-4 Aging adult Overexpression -7.13 1.65E-04 
nhr-259 Nuclear hormone receptor -7.04 3.09E-04 
T06G6.6 Hypothetical protein -6.99 1.61E-06 
pud-3 Protein Up-regulated Daf-2 -6.98 3.04E-06 
bli-2 Cuticle collagen -6.85 3.78E-03 
nhr-113 Nuclear hormone receptor -6.81 1.31E-04 
clec-247 C-type lectin -6.79 7.03E-04 
pqn-57 Prion-like protein -6.76 3.21E-06 
W01B6.4 Hypothetical protein -6.74 1.34E-03 
C32H11.8 Hypothetical protein -6.73 1.21E-04 
bah-1 Nematode cuticle -6.68 1.30E-04 
col-49 Cuticle collagen -6.65 5.21E-04 
R166.8 Unknown -6.65 4.32E-04 
str-131 Seven TM Receptor -6.64 7.11E-05 
F07E5.7 Hypothetical protein -6.62 4.83E-04 
ZK1025.3 Hypothetical protein -6.61 1.49E-04 
E01G4.6 Hypothetical protein -6.59 5.07E-04 
D1014.6 Hypothetical protein -6.52 1.44E-04 
col-175 Cuticle collagen -6.51 1.57E-03 
C04G6.2 Hypothetical protein -6.51 3.24E-07 
rol-1 Synthesize adult cuticle -6.50 2.68E-03 
F26F2.10 Hypothetical protein -6.46 1.20E-04 
nhr-73 Seam cell development -6.34 6.56E-05 
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Table 42-continued 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
C33G8.13 Hypothetical protein -6.30 5.25E-04 
col-79 Cuticle collagen -6.30 8.52E-04 
dpy-4 Larval development -6.30 2.77E-06 
Y47G6A.15 Hypothetical protein -6.29 8.50E-04 
col-138 Cuticle collagen -6.29 9.11E-04 
F35F10.5 Hypothetical protein -6.29 1.69E-06 
col-71 Cuticle collagen -6.29 2.24E-05 
col-163 Cuticle collagen -6.28 1.39E-06 
sqt-1 Cuticle collagen -6.27 1.24E-06 
col-133 Constituent of cuticle -6.27 3.29E-03 
K02E11.10 Hypothetical protein -6.26 1.70E-05 
F28A10.4 Hypothetical protein -6.05 6.66E-04 
sqt-2 Cuticle collagen -6.01 3.71E-07 
col-137 Cuticle collagen -6.01 4.16E-04 
bli-6 Cuticular collagens -6.00 1.24E-03 
F31B9.4 Hypothetical protein -6.00 1.88E-05 
bli-1 Cuticular collagens -5.99 5.94E-03 
R05A10.7 Hypothetical protein -5.97 2.34E-02 
pqn-2 Prion-like protein -5.96 8.98E-05 
col-88 Collagen superfamily -5.96 2.88E-03 
ZC411.1 Hypothetical protein -5.95 3.07E-03 
col-176 Cuticle collagen -5.95 1.99E-05 
col-60 Collagen superfamily -5.89 1.59E-03 
col-149 Collagen superfamily -5.88 1.88E-05 
C11H1.5 Hypothetical protein -5.88 3.59E-05 
col-17 Cuticle collagen -5.86 1.29E-04 
C13A2.9 Hypothetical protein -5.86 9.12E-03 
dpy-13 Collagen superfamily -5.84 1.24E-05 
T08G3.13 Unknown -5.84 9.58E-03 
col-114 Cuticle collagen -5.83 1.77E-03 
C05A9.8 Unknown -5.82 4.68E-02 
F55C10.4 Hypothetical protein -5.82 1.86E-04 
col-145 Collagen superfamily -5.82 9.44E-08 
F57H12.6 Hypothetical protein -5.82 4.53E-08 
W05B10.3 Hypothetical protein -5.81 1.87E-03 
ZK1025.8 Sulfotransferase activity -5.80 4.96E-04 
Y46H3D.1 Hypothetical protein -5.78 2.20E-03 
abu-9 Transmembrane protein -5.74 6.04E-04 
lon-3 Cuticle collagen -5.71 4.33E-06 
D1086.3 Hypothetical protein -5.71 4.84E-08 
col-157 Cuticle collagen -5.70 8.30E-08 
ZK354.9 Hydrolase activity -5.69 1.96E-02 
dpy-20 BED zinc finger protein -5.68 9.58E-04 
Y47D7A.18 Hypothetical protein -5.66 1.63E-02 
col-41 Collagen superfamily -5.64 2.04E-07 
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Table 42-continued 
Name Function 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
C05G5.7 Hypothetical protein -5.62 2.51E-07 
Y47D7A.11 Hypothetical protein -5.61 5.81E-03 
rol-6 Cuticle collagen -5.59 1.01E-05 
F47B7.4 Unknown -5.59 1.91E-02 
ZK381.8 Hypothetical protein -5.59 5.01E-03 
col-38 Collagen superfamily -5.57 2.21E-05 
Y60A3A.23 Hypothetical protein -5.55 3.03E-02 
col-120 Constituent of cuticle -5.51 8.68E-04 
T06E4.12 Constituent of cuticle -5.50 8.04E-05 
Y51H7C.13 Hypothetical protein -5.50 1.41E-03 
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Table 43. Major groups of down-regulated genes in C. elegans at 40 h of infection 
model comparing to 16 h control sample and their predicted function  
Number of genes Predicted function 
46 Hypothetical protein 
29 Unknown 
13 Signaling receptor 
4 Metabolic enzymes 
 
Table 44. Top 100 C. elegans genes down-regulated after 40 h of infection compared 
with the non-infected 16 h control sample 
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
D1014.6 Hypothetical protein -6.52 2.23E-04 
F02C9.1 Hypothetical protein -5.99 5.42E-03 
clec-245 C-type lectin -5.99 6.66E-04 
Y4C6A.4 Hypothetical protein -5.85 4.95E-03 
Y54E5B.6 Hypothetical protein -5.84 2.03E-02 
Y102A5C.38 Unknown -5.79 3.72E-03 
Y73B3A.7 Hypothetical protein -5.71 5.08E-02 
ZK643.7 Hypothetical protein -5.69 6.59E-03 
Y47D7A.11 Hypothetical protein -5.61 7.60E-03 
F47F6.9 Hypothetical protein -5.54 1.12E-02 
Y47D7A.17 Hypothetical protein -5.53 8.82E-03 
Y32G9A.3 Transcript Isoform -5.53 4.15E-02 
ZK328.10 Unknown -5.53 9.97E-03 
srw-121 Serpentine receptor -5.45 5.18E-03 
Y116A8C.8 Hypothetical protein -5.42 6.11E-03 
Y116A8C.44 Hypothetical protein -5.39 1.20E-02 
srh-18 Serpentine receptor -5.32 2.36E-02 
R07H5.14 Hypothetical protein -5.31 6.89E-02 
AC3.16 Hypothetical protein -5.31 1.12E-02 
C29F5.5 Hypothetical protein -5.30 5.24E-02 
W04E12.10 Hypothetical protein -5.24 7.13E-02 
T26H10.2 Unknown -5.24 2.45E-02 
Y26D4A.12 Protease inhibitor -5.24 2.61E-02 
Y41C4A.21 Hypothetical protein -5.24 1.53E-02 
F49C5.10 Hypothetical protein -5.20 4.18E-02 
C06E8.7 Unknown -5.20 1.67E-02 
F56A6.7 Hypothetical protein -5.20 1.37E-02 
C24D10.2 Hypothetical protein -5.19 8.53E-05 
C13C4.8 Hypodermal syncytia -5.15 3.00E-02 
F20D12.7 Unknown -5.09 4.74E-02 
21ur-2482 Unknown -5.08 8.39E-02 
F14F7.t1 Hypothetical protein -5.06 4.28E-02 
Y47D9A.4 Unknown -5.02 4.90E-02 
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Table 44-continued 
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
T16D1.1 hypothetical protein -4.98 6.85E-02 
21ur-11873 Hypothetical protein -4.97 1.27E-01 
str-24 Seven TM receptor -4.97 8.32E-02 
F35C12.5 Hypothetical protein -4.95 8.65E-02 
F47B10.4 Unknown -4.93 7.62E-02 
21ur-9702 Unknown -4.93 7.93E-02 
T05A8.6 Hypothetical protein -4.93 1.04E-01 
Y76B12C.10 Unknown -4.93 1.04E-01 
Y32F6B.6 Unknown -4.92 1.70E-02 
C08H9.8 Hypothetical protein -4.88 5.84E-02 
K01D12.18 Unknown -4.88 1.91E-03 
K02E11.8 
RNA pseudouridylate 
synthase 
-4.70 1.03E-01 
srx-64 Serpentine receptor -4.69 2.48E-01 
21ur-11492 Unknown -4.69 2.27E-01 
R02D5.20 Hypothetical protein -4.68 1.27E-01 
21ur-6527 Hypothetical protein -4.67 1.33E-01 
C54H2.6 Unknown -4.64 2.07E-01 
cwp-2 
Co-expressed With 
Polycystins 
-4.64 2.10E-01 
21ur-13468 Hypothetical protein -4.64 2.16E-01 
R01E6.5 Hypothetical protein -4.62 3.32E-02 
K11H12.10 Hypothetical protein -4.62 8.70E-02 
W02H5.14 Unknown -4.61 4.84E-02 
sra-34 Serpentine receptor -4.60 1.29E-01 
oac-41 Hypothetical protein -4.60 9.10E-02 
stdh-4 
Putative steroid 
dehydrogenase 
-4.59 1.41E-01 
21ur-15088 Hypothetical protein -4.57 1.42E-01 
21ur-7901 Hypothetical protein -4.55 1.32E-01 
Y26G10.3 Unknown -4.54 1.55E-01 
srh-149 Serpentine receptor -4.54 1.44E-01 
W01B6.11 Hypothetical protein -4.52 5.98E-02 
Y116A8C.51 Hypothetical protein -4.52 1.41E-01 
C17B7.14 Hypothetical protein -4.51 1.80E-01 
anr-47 Unknown -4.51 1.67E-01 
C13A2.4 Hypothetical protein -4.50 1.55E-01 
F17E5.5 Unknown -4.50 1.74E-01 
nspd-2 Nematode Specific Peptide -4.49 2.14E-03 
R31.5 Unknown -4.48 2.23E-01 
F57B7.9 Unknown -4.48 2.23E-01 
srj-19 Serpentine receptor -4.48 2.23E-01 
21ur-11874 Hypothetical protein -4.48 9.72E-02 
F48G7.7 Unknown -4.48 2.41E-01 
21ur-11197 Hypothetical protein -4.48 2.78E-01 
ZC477.15 G-protein receptor -4.48 2.70E-01 
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Table 44-continued 
Name Function 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
F57B10.17 Hypothetical protein -4.47 2.02E-01 
str-188 Seven TM receptor -4.45 8.30E-02 
F56D6.12 Hypothetical protein -4.43 1.13E-03 
srx-21 Serpentine receptor -4.42 1.81E-01 
sru-25 Serpentine receptor -4.41 1.70E-01 
Y38F1A.13 Unknown -4.40 8.17E-02 
C36F7.25 Unknown -4.39 8.09E-02 
Y69A2AR.23 Hypothetical protein -4.39 2.32E-03 
T05B4.12 Hypothetical protein -4.38 1.30E-01 
C18H7.4 Tyrosine-protein kinase -4.36 9.36E-03 
clec-58 C-type lectin -4.36 1.14E-01 
F36H12.9 Unknown -4.36 3.67E-04 
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Table 45. Major groups of down-regulated genes in C. elegans at 40 h of infection 
model comparing to 16 h of infection sample and their predicted function  
Number of genes Predicted function 
50 Unknown 
22 Hypothetical proteins 
11 Signaling receptors 
4 C-type lectin 
 
 
Table 46. Top 100 C. elegans genes down-regulated after 40 h of infection compared 
with the 16 h of infection samples  
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
scl-12 SCP- extracellular protein -7.76 2.41E-03 
scl-13 SCP- extracellular protein -6.46 3.43E-02 
clec-134 C-type lectin -6.20 1.19E-02 
ZK381.57 Hypothetical protein -5.45 7.20E-03 
F49H6.3 Hypothetical protein -5.33 6.03E-02 
21ur-6059 Unknown -5.05 6.78E-02 
C06E8.7 Unknown -5.04 2.06E-02 
K01C8.11 Hypothetical protein -4.99 2.37E-02 
C06A12.8 Hypothetical protein -4.98 6.98E-02 
mir-44 Posttranscriptional regulation -4.98 4.07E-02 
21ur-15231 Unknown -4.94 7.99E-02 
Y60C6A.2 Hypothetical protein -4.85 2.62E-02 
F48A9.4 Unknown -4.85 1.03E-01 
F49C5.7 Hypothetical protein -4.84 4.18E-02 
F26C11.4 Unknown -4.79 9.81E-02 
ZK381.51 Hypothetical protein -4.79 9.81E-02 
clec-107 C-type lectin -4.77 1.01E-01 
T23D5.5 Unknown -4.74 1.95E-02 
Y4C6A.4 Hypothetical protein -4.73 3.97E-02 
B0334.17 Unknown -4.72 1.07E-01 
21ur-10725 Unknown -4.70 5.66E-02 
F02C9.1 Hypothetical protein -4.70 4.88E-02 
21ur-11874 Unknown -4.66 7.62E-02 
K10H10.9 Hypothetical protein -4.66 1.34E-01 
nhr-81 Nuclear Hormone Receptor -4.64 1.29E-01 
srh-279 Serpentine Receptor -4.62 7.99E-02 
21ur-6987 Unknown -4.61 1.15E-01 
srg-25 Signaling receptor -4.60 7.43E-02 
F10G8.11 Unknown -4.60 9.09E-02 
srg-24 Signaling receptor -4.59 4.92E-02 
sru-38 Neuronal cell -4.57 1.16E-01 
21ur-15668 Unknown -4.52 2.43E-01 
F11H8.6 Unknown -4.50 1.41E-01 
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Table 46-continued 
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
srg-9 Signaling receptor -4.49 1.08E-01 
K01A2.12 Protease inhibitor -4.48 1.16E-01 
srh-22 Serpentine Receptor -4.48 6.25E-02 
Y26D4A.12 Protease inhibitor -4.48 7.28E-02 
K09C4.2 
Transmembrane 
transporter 
-4.48 7.34E-02 
W09G10.t3 Unknown -4.47 6.05E-02 
F11D11.19 Unknown -4.47 5.90E-02 
F47G4.13 Unknown -4.47 4.95E-02 
Y116A8C.44 Hypothetical protein -4.47 5.71E-02 
F12F6.13 Unknown -4.46 4.80E-02 
F58H1.14 Unknown -4.45 7.20E-02 
math-11 Meprin-associated Traf -4.32 1.44E-01 
B0457.15 Unknown -4.30 9.66E-02 
C31H2.13 Unknown -4.29 5.95E-02 
21ur-14670 Unknown -4.29 1.43E-01 
C06E7.93 Unknown -4.26 1.71E-01 
srbc-39 Serpentine Receptor -4.24 1.57E-01 
21ur-14969 Unknown -4.23 1.98E-01 
gmd-2 
GDP-mannose 4, 
dehydratase 2 
-4.20 3.08E-01 
F13A2.9 Hypothetical protein -4.20 3.08E-01 
K10F12.10 Hypothetical protein -4.17 2.18E-01 
21ur-213 Unknown -4.17 2.18E-01 
C08E8.11 Hypothetical protein -4.17 1.77E-01 
21ur-6455 Unknown -4.17 1.64E-01 
T27F7.7 Unknown -4.16 1.80E-01 
H22K11.9 Hypothetical protein -4.16 1.55E-01 
F52B10.11 Unknown -4.16 1.30E-01 
sre-21 Serpentine receptor -4.15 1.92E-01 
21ur-10289 Unknown -4.15 1.92E-01 
21ur-11377 Unknown -4.15 1.12E-01 
F32B4.6 Hypothetical protein -4.14 1.92E-01 
21ur-12971 Unknown -4.14 2.19E-01 
F57G12.7 Unknown -4.14 1.11E-01 
C35B1.3 Hypothetical protein -4.13 1.73E-01 
Y57E12B.7 Unknown -4.13 1.11E-01 
K04D7.8 Unknown -4.13 1.10E-01 
21ur-7340 Unknown -4.13 1.80E-01 
clec-253 C-type lectin -4.13 3.16E-01 
sri-42 Serpentine chemoreceptor -4.13 8.33E-02 
K06C4.7 Hypothetical protein -4.12 1.39E-01 
C04E7.1 Hypothetical protein -4.12 8.24E-02 
srab-13 Serpentine receptor -4.11 2.04E-01 
R13H4.11 Unknown -4.11 8.10E-02 
21ur-4829 Unknown -4.11 1.80E-01 
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Table 46-continued 
Name Function 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
T05A8.1 Hypothetical protein -4.10 1.01E-01 
M153.7 Unknown -4.10 1.09E-01 
anr-42 Hypothetical protein -4.09 1.46E-01 
Y116A8C.8 Unknown -4.09 7.92E-02 
clec-252 C-type lectin -4.09 1.80E-01 
Y57A10C.12 Unknown -4.08 1.38E-01 
F01E11.14 Unknown -4.08 1.74E-01 
C06E7.89 Unknown -4.08 1.80E-01 
F09F9.16 Unknown -4.08 1.80E-01 
F55A8.5 Unknown -4.06 1.93E-01 
21ur-13160 Unknown -4.06 1.93E-01 
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Table 47. Top 100 up and down-regulated genes of C. elegans at different times during the infection model 
Fold change ratio above and below the threshold of ±2, significantly differentially expressed genes were defined with FDR-adjusted P-value < 
5%. 
Name Annotation 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
clec-266 Lectin domain 5.558241 6.87 1.86E-39 6.69 6.39E-38 -0.19 8.65E-01 
cav-1 Embryogenesis 7.014377 6.00 3.57E-36 5.47 3.28E-31 -0.53 4.35E-01 
C35E7.5 Unknown 6.962521 5.25 5.69E-30 4.76 1.83E-25 -0.50 4.80E-01 
cht-1 Embryogenesis 6.907533 4.95 1.07E-28 4.46 4.58E-24 -0.50 4.67E-01 
ttr-50 Keratin 5.198313 4.96 7.79E-25 4.37 5.07E-20 -0.60 3.80E-01 
Y46H3A.5 Unknown 3.682821 6.24 5.77E-22 6.43 2.84E-23 0.20 8.85E-01 
H29C22.1 Unknown 5.383573 3.89 3.60E-17 4.65 3.64E-23 0.76 2.10E-01 
T24C4.2 Unknown 4.644558 4.73 1.78E-21 4.33 2.02E-18 -0.40 6.18E-01 
K02B12.2 Unknown 4.069439 5.73 1.71E-21 5.07 2.02E-17 -0.66 4.02E-01 
ins-19 Unknown 4.304115 8.75 1.06E-15 10.30 8.05E-21 1.53 8.90E-02 
Y82E9BR Unknown 4.36591 6.16 7.58E-20 5.64 3.60E-17 -0.52 5.96E-01 
fbxc-51 Unknown 5.093167 5.26 4.39E-20 4.67 1.26E-16 -0.59 4.84E-01 
hch-1 Epidermal growth 3.64563 7.07 3.49E-19 6.82 6.05E-18 -0.25 8.69E-01 
cht-3 
Constituent of 
cuticle 
8.192169 2.82 2.45E-16 3.13 1.31E-19 0.31 6.22E-01 
col-165 Collagen  6.017185 6.14 2.35E-20 4.58 7.81E-13 -1.57 2.21E-02 
ces-2 Apoptosis 3.762572 5.95 4.44E-18 5.79 2.94E-17 -0.16 9.40E-01 
cut-3 Unknown 4.945543 5.53 4.45E-20 4.22 8.68E-13 -1.31 4.12E-02 
T05E12.3 
Tumour necrosis 
factor 
5.013994 3.93 8.75E-18 3.84 3.60E-17 -0.09 9.82E-01 
col-121 Cuticle collagen 3.358249 7.31 9.41E-19 6.51 3.33E-15 -0.80 3.98E-01 
W03F11.1 
Eggshell 
synthesis 
6.012397 3.42 7.99E-13 4.41 9.94E-20 0.98 9.10E-02 
R09E10.5 
Cell surface 
mucin 
5.709052 3.08 5.46E-20 2.39 1.95E-12 -0.70 1.07E-01 
sepa-1 Embryogenesis 4.457864 6.22 8.80E-18 5.76 9.35E-16 -0.45 6.61E-01 
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Table 47-continued 
Name Annotation 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
EEED8.15 Unknown 4.359395 4.77 8.80E-18 4.44 9.11E-16 -0.33 7.27E-01 
dpy-14 Embryogenesis 6.979845 6.03 1.33E-17 5.15 7.69E-14 -0.88 3.49E-01 
F10E9.12 Unknown 4.972003 3.68 1.53E-14 4.05 3.60E-17 0.37 6.32E-01 
skpo-1 Unknown 7.148056 2.23 2.47E-15 2.33 1.20E-16 0.10 9.18E-01 
T04G9.7 Unknown 5.985112 2.55 7.27E-14 2.88 2.70E-17 0.33 5.93E-01 
ZK1053.4 Embryogenesis 4.583162 4.05 5.13E-16 3.83 1.65E-14 -0.22 8.43E-01 
fbxb-66 Unknown 2.579982 7.44 1.94E-16 6.75 1.76E-13 -0.69 5.04E-01 
F48E3.4 
Serine-type 
endopeptidase 
6.735226 2.26 8.86E-13 2.63 5.26E-17 0.37 4.80E-01 
C08F1.10 Unknown 3.315901 6.44 5.77E-16 5.88 1.41E-13 -0.56 6.16E-01 
C01G6.3 Unknown 7.276837 3.01 3.41E-15 2.95 1.04E-14 -0.05 1.00E+00 
ifa-3 
Constituent of 
cuticle 
3.68215 4.90 8.67E-16 4.39 6.09E-13 -0.51 5.80E-01 
ZK813.1 Unknown 7.010004 2.89 1.64E-15 2.66 2.81E-13 -0.23 7.41E-01 
C44B7.5 Unknown 8.060923 2.50 1.32E-13 2.63 5.10E-15 0.14 8.88E-01 
hsp-70 Unknown 7.43764 5.14 1.05E-12 5.67 8.59E-15 0.53 6.32E-01 
Y110A2AL.4 Unknown 4.292483 3.56 1.47E-15 3.05 1.26E-11 -0.52 4.45E-01 
his-1 H4 histone 8.002064 3.15 3.71E-17 2.02 1.09E-07 -1.13 8.17E-03 
Y45F10C.2 Unknown 4.207213 2.90 2.59E-07 4.63 1.20E-16 1.73 2.25E-03 
dpy-17 
Constituent of 
cuticle 
6.231157 5.62 1.10E-14 4.75 2.83E-11 -0.87 3.82E-01 
Y82E9BR.1 Unknown 2.813558 5.35 4.25E-14 4.91 5.66E-12 -0.44 6.46E-01 
col-74 
Constituent 
cuticle 
6.038969 6.02 5.98E-15 4.49 1.90E-09 -1.53 6.70E-02 
zeel-1 
Constituent of 
cuticle 
2.597211 5.86 1.32E-13 5.52 3.93E-12 -0.34 7.92E-01 
F44F1.6 Unknown 3.290147 5.28 1.02E-13 4.89 5.92E-12 -0.39 7.23E-01 
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Table 47-continued 
Name Annotation 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
T05H10.3 Unknown 3.085155 5.77 3.24E-14 4.71 7.05E-10 -1.06 2.20E-01 
T21C9.13 Unknown 6.305646 2.33 7.94E-12 2.47 3.11E-13 0.14 8.75E-01 
C34C6.7 Unknown 5.409637 2.96 1.44E-12 2.93 2.26E-12 -0.03 1.00E+00 
jmjd-3.2 
Putative histone 
H3 
3.312448 5.03 2.56E-13 4.49 6.79E-11 -0.54 6.00E-01 
B0281.5 
Tumour necrosis 
factor 
3.626724 4.68 8.20E-13 4.40 1.71E-11 -0.28 8.34E-01 
ZK675.4 Unknown 3.726333 6.02 1.36E-13 4.96 8.71E-10 -1.06 2.70E-01 
Y46G5A.7 
Protein-protein 
interactio 
3.123447 4.63 1.86E-13 3.97 3.69E-10 -0.66 4.51E-01 
T04C12.1 Unknown 1.133165 8.93 2.18E-13 8.05 6.64E-10 -0.89 3.49E-01 
pes-2.1 Embryogenesis 3.371121 5.72 2.45E-12 5.56 9.02E-12 -0.15 9.68E-01 
pes-2.2 
Ubiquitin-
mediated protein 
degradation 
3.252341 5.52 3.22E-12 5.32 1.86E-11 -0.20 9.32E-01 
ttr-51 Unknown 7.14365 1.78 4.84E-09 2.20 1.69E-13 0.43 3.66E-01 
hnd-1 
Transcription 
factor 
1.27087 9.10 1.66E-12 8.14 2.64E-09 -0.96 3.51E-01 
his-38 
Packaging of 
DNA 
5.680307 3.31 4.30E-14 1.87 4.63E-05 -1.44 2.31E-03 
dct-18 
Germline tumour 
affecting 
6.827166 -2.06 5.47E-11 -2.10 2.16E-11 -0.04 1.00E+00 
F28D1.2 Unknown 3.381882 4.24 2.12E-12 3.59 3.14E-09 -0.65 4.53E-01 
sdz-30 Embryogenesis 3.189749 7.13 5.20E-12 6.26 1.28E-09 -0.88 4.92E-01 
D1054.10 Unknown 7.85303 2.50 4.20E-11 2.51 3.78E-11 0.01 1.00E+00 
sdz-4 Embryogenesis 1.589117 9.25 1.53E-11 8.78 3.69E-10 -0.47 7.42E-01 
fbxb-41 
Protein-protein 
interactio 
2.173568 6.48 5.68E-12 5.66 3.14E-09 -0.82 4.51E-01 
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Table 47-continued 
Name Annotation 
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
fbxb-91 
Protein-protein 
interactions 
1.797952 7.49 6.09E-12 6.62 3.38E-09 -0.87 4.32E-01 
hsp-16.11 Heat shock proteins 7.019073 3.98 5.73E-10 4.28 3.10E-11 0.30 8.29E-01 
ilys-2 Lysozyme activity 4.027286 5.92 4.40E-12 4.50 8.37E-08 -1.41 1.34E-01 
clec-196 C-type lectin 2.639523 7.38 3.02E-11 6.82 9.56E-10 -0.56 6.83E-01 
epg-2 Autophagy 7.326239 2.65 5.68E-12 0.03 1.04E-08 2.22 5.02E-01 
fbxc-29 
Protein-protein 
interactions 
1.927203 6.72 1.86E-11 0.07 3.14E-09 6.02 5.64E-01 
T27A1.3 
Protein-protein 
interactions 
1.65513 6.47 1.27E-11 5.70 6.25E-09 -0.77 4.70E-01 
skr-7 Embryogenesis 2.777746 4.58 2.95E-10 4.72 7.30E-11 0.15 9.64E-01 
cutl-2 Cuticlin-like protein 2.252654 5.51 3.10E-11 5.06 1.41E-09 -0.45 7.01E-01 
tbh-1 
Tyramine 
Hydroxylase 
7.093627 1.77 2.16E-09 1.96 2.16E-11 0.19 7.42E-01 
D1054.11 Unknown 8.485427 2.37 6.15E-10 2.50 5.69E-11 0.13 9.18E-01 
inx-3 Embryogenesis 6.733508 2.82 8.11E-11 2.72 4.10E-10 -0.10 9.66E-01 
vet-6 Embryogenesis 4.164211 6.03 3.33E-11 5.33 2.93E-09 -0.69 5.99E-01 
clec-88 Lectin like 7.594933 2.22 6.02E-11 2.09 8.95E-10 -0.13 8.96E-01 
Y73C8C.8 Zinc ion binding 2.192917 7.76 6.00E-11 7.26 1.31E-09 -0.50 7.33E-01 
F44E5.4 Heat shock proteins 9.782001 4.50 3.24E-10 4.57 1.89E-10 0.06 1.00E+00 
arrd-1 
AR Restin Domain 
protein 
3.141409 5.57 1.77E-10 5.38 7.04E-10 -0.19 9.53E-01 
hsp-16.48 
Embryogenesis/ 
Constituent of cuticle 
6.52384 3.42 2.74E-09 3.75 7.30E-11 0.34 7.59E-01 
sdz-5 Embryogenesis 1.324043 8.98 1.00E-10 8.52 2.11E-09 -0.47 7.48E-01 
C08F1.6 Unknown 2.663316 5.91 6.03E-11 5.26 5.71E-09 -0.65 6.08E-01 
F44E5.5 Heat shock proteins 9.874649 4.51 5.75E-10 4.59 3.13E-10 0.07 1.00E+00 
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Table 47-continued 
Name Annotation  
Log 
CPM 
FC 
T16.vs.C16 
FDR 
T16.vs.C16 
FC 
T40.vs.C16 
FDR 
T40.vs.C16 
FC 
T40.vs.T16 
FDR 
T40.vs.T16 
nhr-17 
transcriptional 
regulators 
6.205633 3.06 1.36E-08 3.57 3.78E-11 0.51 5.71E-01 
Y41D4B.26 Unknown 2.199906 6.02 1.06E-10 5.53 3.80E-09 -0.49 6.93E-01 
F54D5.5 Unknown 5.592415 2.74 1.56E-10 2.57 2.05E-09 -0.17 8.88E-01 
T25E12.6 Unknown 2.958206 4.61 8.85E-11 4.14 6.45E-09 -0.47 6.41E-01 
hsp-16.49 
Heat shock 
proteins 
6.479764 3.57 3.51E-09 3.90 1.38E-10 0.33 7.86E-01 
pqn-73 
Prion-like 
protein 
4.773582 2.82 1.92E-11 2.21 2.59E-07 -0.62 3.12E-01 
fmo-2 
Oxidative 
metabolism 
6.793298 2.71 3.02E-06 3.93 1.14E-11 1.22 7.51E-02 
cyp-35A3 
Encodes 
cytochrome 
P450s 
5.971488 -4.82 9.55E-12 -1.97 0.007816 2.85 5.17E-05 
cyp-35A2 
Encodes 
cytochrome 
P450s 
7.178269 -2.47 2.17E-12 -1.26 0.001063 1.21 1.93E-03 
col-10 Cuticle collagen 7.346566 -3.01 2.18E-08 -3.48 1.06E-10 -0.47 6.13E-01 
ZK899.6 Unknown 1.056743 8.86 1.49E-10 7.99 4.01E-08 -0.87 4.67E-01 
C28G1.4 
Zinc finger 
protein 
2.472117 5.17 6.51E-10 4.98 2.64E-09 -0.18 9.48E-01 
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5.3 Discussion  
The expression of S. aureus virulence genes was measured in different types of studies, but 
few have investigated the overall patterns of lipoprotein genes expression in in vitro and in 
vivo conditions in the same time, this study focused on lipoprotein genes expression levels 
in some S. aureus strains. Furthermore the transcriptome analysis in this study provides the 
ﬁrst analysis of S. aureus lipoprotein proteomics in response to C. elegans infection 
challenge and enables an investigation of the roles lipoproteins may play in pathogenicity 
during infection.   
5.3.1 Investigation the S. aureus lipoprotein genes expression in-vitro by qRT-PCR 
Many studies have used the qRT-PCR technique to detect the presence of particular S. 
aureus lipoprotein genes (Hashimoto et al., 2006a). Expression levels of the examined 
lipoprotein genes were observed in each growth condition were in different pattern of up 
or down-regulation of expression. The examined lipoprotein genes were selected at the 
beginning of this study did not have well-defined functions and in sequence annotations 
were predicted as putative lipoprotein. Some transcriptional profile differences were 
observed despite the identical growth conditions used. These variations in expression 
suggest that lipoprotein gene roles may not be similar in all strains.   
Notably, these 5 lipoproteins were down-regulated during infection of C. elegans, apart 
from SAR0740 gene which was up-regulated in the early time of C. elegans infection with 
S. aureus MRSA252. S. aureus transcriptional analyses during the growth in in vitro 
conditions did not correlate with gene expression in in vivo mammalian models or in 
human infections, therefore investigations to characterize S. aureus virulence genes 
regulation in vivo are preferred (Pragman and Schlievert, 2004). 
In the current study, two approaches were used to detect lipoprotein gene expression 
levels, the first was qRT-PCR and the second was RNA sequencing. The plan for this 
study was to evaluate the majority of lipoprotein genes expression patterns using the qRT-
PCR but using qRT PCR was replaced by the whole RNA sequencing due to the high-
throughput of RNA sequencing and also their ability to determine gene expression level 
changes during the infection course.     
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5.3.2 Transcriptome of S. aureus 8325-4 lipoprotein genes in vitro under non-infection 
condition  
The ratio of fold up-regulation for 5 cell wall-associated transporter binding lipoprotein 
transcripts strongly induced during the early stationary phase including peptide ABC 
transporter and ABC-type metal ion transporter had up-regulated expression level during 
the exponential growth phase. These types of transporter lipoproteins are involved in the 
uptake of different nutrients and antimicrobial resistance through the cytoplasmic 
membrane, also playing a role in peptidoglycan synthesis and maintenance and virulence 
of pathogenic bacteria, therefore, mutation of a few lipoprotein genes does not affect high-
affinity different nutrients uptake but mutants are attenuated in virulence (Schmaler et al., 
2009).  
Lipoprotein genes for iron uptake are over-expressed under iron deficiency conditions in 
vitro and in vivo indicating their roles in bacterial growth and survival (Allard et al., 2006). 
Transcriptome of S. aureus 8325-4 at exponential growth phase had two up-regulated 
lipoprotein transcripts for cell-wall binding lipoprotein SAR1066 and hypothetical 
lipoprotein SAR0390 with different expression patterns observed during this phase, 
transcription of cell-wall binding lipoprotein SAR1066 up-regulation level was continued 
in the stationary growth phase. Genome-wide transcriptional proﬁling of S. aureus 8325-4 
has identified ~100 transcripts been up-regulated in response to the cell-wall-active 
antibiotics, this up-regulation in gene expression suggested the bacterial attempt to defend 
against the antibiotics activities (Utaida et al., 2003). Proteomics study on S. aureus 
MRSA USA300 based on murine infection model revealed that the majority of surface 
proteome post- infection is proteins involved in nutrient acquisition and iron uptake 
including the lipoproteins of ABC-type transport systems (Diep et al., 2014b). The oligo-
peptide permease lipoprotein (OppA) SAR0953 which is assist in protein folding (Stoll et 
al., 2005), was among the up-regulated lipoproteins with ~ 6 fold change in the early time 
of growth.   
The genes found to be down-regulated in all three time-points of evaluation in this study 
were not significant, as a result of no stress was applied on the bacterial growth conditions 
the bacterial growth curve was in the normal pattern and at the stationary phase the rate of 
growth decreased because of the lack of nutrients in the medium. The results indicate that 
up-regulated lipoproteins under non-infection condition were not associated with the C. 
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elegans defence functions, these observations suggest that these lipoprotein genes are not 
required for S. aureus pathogenesis and survival during infection. 
5.3.3 C. elegans life span assay 
This assay demonstrates that S. aureus MRSA252 exposed to C. elegans able to complete 
killing of C. elegans at 3 d in solid plates. However, earlier report by JebaMercy et al. 
indicated that 8 h of exposure to penicillin-resistant S. aureus ATCC 11632 was sufficient 
to kill C. elegans, also the accumulation of S. aureus in C. elegans intestine was found to 
be significantly increased from 24 to 48 h of exposures (JebaMercy et al., 2011). In this 
study, the C. elegans exposed to S. aureus MRSA252 displayed abnormal movement and 
pharyngeal pumping, however the nematodes became immobile and the mortality rate was 
significant high as worms died after ~18 h of infection. Sifri et al., have examined the 
accumulation and proliferation of S. aureus inside the intestinal lumen of C. elegans by 
feeding worms with a lawn of S. aureus containing a shuttle vector which expresses 
Aequorea victoria green fluorescent protein (GFP), after 1 d of feeding the confocal 
fluorescence microscopy showed a considerable number of fluorescent cocci in the 
distended intestinal lumen (Sifri et al., 2003). The infected nematodes become excessively 
weak to lay eggs normally then eggs of a gravid hermaphrodite hatched inside the worms 
and the “bag-of-worms” phenotype was observed.  
5.3.4 Changes in lipoprotein transcriptome of S. aureus MRSA252 caused by C. 
elegans infection model 
The lipoprotein gene up-or down-regulation in this experiment was basis on the fold 
change in expression between two in vivo growth conditions. A total of 62 lipoprotein 
transcripts were identified, these lipoproteins were divided into two main groups (up-or 
down-regulated) based on their response to the C. elegans infection and how they 
responded to the infection at different time-points.  
During S. aureus infection the data of C. elegans transcriptome showed that different 
genes induced by infection were affected from one stage to another. The correlation 
between bacterial virulence factors in invertebrate and mammals has been reported as 
different genes have been shown to be involved in in vivo pathogenicity including many 
surface proteins such as capsular polysaccharide genes (Cheung et al., 2004), in this study 
the expression of capsular polysaccharide synthesis enzymes of S. aureus were highly 
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significant as 16 transcripts of these enzymes had up-regulation fold changes at the early 
post-infection stage. S. aureus global virulence regulators agr and sarA promote 
production of many extracellular and cell wall-associated proteins and have been found to 
have a role in nematocidal activity (Sifri et al., 2003).   
In another experiment of murine systemic infection with S. aureus USA300 MRSA 
performed by Diep et al., 15 putative lipoproteins genes analogous to S. aureus MRSA252 
SAR2457, SAR0118, SAR0761, SAR0872, SAR0390, SAR0790, SAR0839, SAR1288, 
SAR2545, SAR2470, SAR2368, SAR2546, SAR2563, SAR1932, SAR0641 were involved 
and showed high up-regulation during the course of the murine infection, only one of these 
lipoproteins SAR2457 was involved in the C. elegans infection model and displayed 
significant response, while the other 14 genes had a different pattern of expression during 
the C. elegans infection, 6 transcripts of surface-associated lipoproteins SAR2470, 
SAR2368, SAR2563, SAR2546, SAR1932 and SAR0641 which are involved mainly in 
nutrients uptake and metal ions acquisition were down-regulated at the late stage of 
infection.   However, a search on the S. aureus MRSA252 genome for the lipobox motif 
confirmed that SAR2545 and SAR2563 do not contains the lipobox sequence in their first 
35 amino acids and in particular the invariant C was missing, these proteins were wrongly 
annotated as lipoproteins. 
Seven lipoproteins genes including SAR0230 putative extracellular solute-binding 
lipoprotein, SAR2363 putative molybdate-binding lipoprotein precursor, SAR2536 glycine 
betaine/ carnitine/ binding lipoprotein precursor, SAR1878 and SAR0340 putative 
lipoproteins, SAR1402 phosphate-binding lipoprotein and SAR1932 peptidyl-prolyl cis-
isomerase have showed low expression during the early point of evaluation at 16 h, these 
lipoproteins remains to be in low expressed at the late stage of C. elegans infection model 
except SAR1402 which showed ~ 5 fold up-regulation. The analogues of SAR2368 
SAR2470, SAR1932, SAR2546 and SAR0641 in the murine infection model had over-
expression levels, but in this study these genes were significantly down-expressed to 
suggest that they had no functions in C. elegans infection conditions.      
In the late phase of infection 16 lipoproteins including 10 genes involved in uptake of 
metal ions and ABC transporter extracellular binding were identified to be down-regulated, 
these proteomics data indicate that the main down-expressed lipoprotein genes of 
MRSA252 during the C. elegans infection were lipoproteins that are related to nutrient 
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acquisition. MntC ABC transporter extracellular binding lipoprotein SAR0641 a part of 
MntABC operon is involved in the manganese acquisition was among the transcripts with 
a low production level during the late infection stage. SAR1932 peptidyl-prolyl cis-/trans-
isomerase (PrsA) this lipoprotein involved in protein folding including formation of the 
cell wall and toxins (Heikkinen et al., 2009), PrsA transcript had repressed level at the all 
points of evaluation in the infection model, the reason for this down-expression remain 
unclear. SAR2104 putative lipoprotein was not found in clinical isolate RN4282 strain, this 
gene was inactive during the C. elegans infection model experiment as shown zero read 
transcript in the all period of infections. 
Nematodes do not have an adaptive immune system or mobile phagocytic cells, and relies 
mainly on the innate immune system, the intestinal epithelial cells have a significant to 
defend the worms against pathogenic bacteria. While, vertebrates have more sophisticated 
immunity systems that participate the innate responses, phagocytic cells and antimicrobial 
peptides. For this reasons the comparison between the innate immunity response of C. 
elegans against S. aureus infection will not be similar to the vertebrates immunity response 
to an invading pathogens.       
5.3.5 C. elegans transcriptional changes induced by infection with MRSA252  
Although not part of the main study, the innate immune response of C. elegans is an 
important model for host defences against pathogens such as S. aureus which are capable 
of infecting and killing C. elegans. The detailed mechanisms of immune responses of C. 
elegans against invading pathogens are generally unknown, the general changes in genes 
transcription of C. elegans after infection with S. aureus showed that many genes were 
involved in the immune response of nematode in different levels to infection. This study 
determined lists of ~18,000 transcripts that were up or downregulated in various infection 
stages in response to bacterial pathogenicity.  
The expression of cuticle collagen genes which are involved in many vital roles in the C. 
elegans body structure and secretions. Collagen deficiency can result in a series of defects 
from abnormal morphology of adults and larval death (Page and Johnstone, 2007). Cuticle 
collagen transcripts in early phase of infection had been down regulated as many of cuticle 
collagen transcripts showed low level of expression, the explanation for this down-
expression are not clear, but the C. elegans in general at this stage of growth does not 
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require abundant cuticle collagen production as the full size of adult nematodes are 
reached after 3 d of growth. 
Another observation from the RNA-seq data was the level of expression among the large 
gene family of C-type lectins in C. elegans, many suggestions that C-type lectins play a 
role in immune recognition of pathogens and general stress response functions 
(Schulenburg et al., 2008). C-type lectin family genes expression in C. elegans during the 
S. aureus exposures showed up-regulation in sequentially post-infected conditions 
(JebaMercy and Balamurugan, 2012). There were also 13 F-box containing proteins were 
up-regulated in different phases of infection, to suggested ubiquitin ligases involvement in 
host defense (Thomas, 2006). One of the important innate immune system proteins were 
found among the up-regulated transcripts is the lysozyme genes, infected C. elegans with 
bacterial pathogens subjected to many changes in gene regulation of antimicrobial peptides 
and proteins include the lysozyme encoding genes (Mallo et al., 2002).     
The transcripts of G-protein-coupled receptor that sense molecules outside the cell and 
activate the signal transduction pathways were over-expressed at many stages of infection. 
The genetic features of sensory neuron specific G-proteins shows that olfaction, 
nociception and pheromone responses in C. elegans are controlled by G protein-coupled 
receptor (Jansen et al., 2002). On the other hand, RNA-seq data showed that signaling 
receptor during the infection period were highly expressed, the chemoreceptor families of 
C. elegans mediated by members of seven-transmembrane G-protein-coupled receptor 
including the large family of str genes, the prospective function of these receptors are 
based on transgene expression patterns in the known pairs of chemosensory neurons 
(Robertson and Thomas, 2006).  
Transcription factors (sequence-specific DNA-binding factors) are involved in C. elegans 
embryogenesis and many of these genes function as a key regulators of early blastomere 
divisions, but how these genes are up-regulated to regulated zygotic developments is not 
understandable (Maduro and Rothman, 2002). The early mature hermaphrodite nematodes 
used in this experiment have a large number of cells and contain eggs/embryos under 
development stages this would contribute to the RNA-seq results as many embryogenesis 
transcripts will be observed.  
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Also, a set of the apoptotic germline cells genes was induced by the S. aureus infection, 
these genes is a part of the oogenesis program in C. elegans, the physiological germline 
apoptosis occurs in the absence of any known stress and is initiated by the core apoptotic 
machinery, besides it can be initiated by infection with pathogenic bacteria (Lettre and 
Hengartner, 2006). The bacteria invasion led to an up-regulation of 32 F-box B protein 
genes, the physiological function of F-box B protein control apoptotic cell death and the 
stability of some antiapoptotic proteins (Chiorazzi et al., 2013). Over-expression of insulin 
related gene (ins) is remains unclear whether this effect was directly related to the early 
infection phase, the overexpression of ins genes were reported to enhance dauer arrest in 
certain stages (Pierce et al., 2001).  
Cysteine protease genes in RNA-seq results of C. elegans were up-regulated after 16 h of 
infection, cysteine protease has reported a role in innate immunity against S. aureus which 
act in the degradation of proteins and antigen processing (Irazoqui et al., 2010a). Several 
genes of prion-like Q/N proteins known to be involved in C. elegans stress response 
comprised were down-regulated in the late stage of bacterial exposure (Golden and Melov, 
2007). Transcriptome results revealed some cellular biological effects of S. aureus 
infection on the host innate immunity including detoxification factors cytochrome P450 
genes which are expected to function in the detoxification of xeniobiotics (Werck-
Reichhart and Feyereisen, 2000), these genes displayed over-expression at different time 
points of infection. 
This experiment showed significant down-regulation of ~ 3000 transcripts at 40 h post-
infection influenced the physiological and behavioural activities of the nematodes with the 
majority of metabolic enzymes and signalling receptor transcripts as the nematodes 
showed visible signs of illness and starvation. Nine metabolic enzyme genes known to be 
involved in glycoprotein biosynthesis in C. elegans were down-regulated in the late stage 
of bacterial infection experiment. Microarrays transcription proﬁling differences for the 
dauer state/non-dauer state and after feeding of starved L1 C. elegans showed changes in 
expression levels for large number of genes involved in the metabolism process (Wang and 
Kim, 2003). 
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5.3.6 Post-infection differentially-regulated genes of S. aureus MRSA252 in C. elegans 
infection model  
Investigation of time-based changes of genes expression using an RNA-seq approach to 
identified S. aureus response to C. elegans infection has identified markedly different 
response of S. aureus to host innate immune mechanisms, the overall transcriptomic data 
showed that 25% of differentially transcribed genes observed in the post-infection course, 
after 40 h of infection course 1274 identified transcripts known to be significantly 
differentially-expressed in response to the C. elegans challenge, 799 transcripts were 
differentially-expressed at 16 h post-infection including 349 up-regulated and 450 down-
regulated, the number of transcripts up-or-down expressed that report as differentially 
expressed shown similar number of transcripts at the both stages of infection, the rapid 
dynamics in over-expression of some genes after short time of C. elegans challenge and  
suggesting their roles in pathogenicity and virulence of S. aureus.      
Differentially expressed transcripts in both 16 and 40 h post-infection stages showed 118 
up-regulated and 189 down-regulated transcripts. The large-scale transcriptome of S. 
aureus pathogenicity are highly dependent on the infection conditions to show the 
interaction between host response and pathogen. The continuation of bacterial exposure 
has revealed 307 genes were conserved in expression post-infection indicating 
their importance for host pathogenesis.   
5.3.7 Changes in expressed genes of nematodes during the infection of C. elegans  
To understand the nature of C. elegans response to S. aureus infection, differentially 
expressed genes (up-or-down) displays the impact of infection on C. elegans and to show 
genes involved during infection. Transcriptomic data showed that 14% of differentially 
transcribed genes were observed in different abundance at the time-course of infection. 
The differentially expressed genes of C. elegans that observed in the early exposure time-
point have showed that transcripts number were almost similar as 1853 up-expressed genes 
than 1776 down-expressed genes with average of 1:1 expressed in response to the S. 
aureus challenge. However, C. elegans transcripts at 40 h were quite different; there were 
more up-expressed genes than down-expressed genes in the late stage of S. aureus 
exposure as showed differentially expressed 1880 genes were up-regulated and 1311 genes 
down-regulated, those genes showed lower expression level in this stage were less than the 
over-expressed genes.       
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In order to find out the genes expression profile comparisons between the 16 and 40 h 
post-infection to evaluate the changes in genes expression, 231 transcripts were observed 
to be expressed in both conditions and may play a part in the immunity response, while 53 
down-regulated transcripts to suggests that their expression may not be involved in host 
resistance against bacterial infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
215 
 
 
 
 
 
 
 
 
 
Chapter six 
General summary and discussion 
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6. General summary and discussion 
The main objective of this study was to try to clarify the number and genetics of S. aureus 
lipoproteins and to determine whether the genes were expressed under different conditions. 
The results generally extended the information of the molecular variation of lipoprotein 
genes by examining and comparing the genetic background of lipoproteins in some S. 
aureus strains that are involved in human and animal infection. The BLAST searches and 
PCR results revealed certain variation in the lipoproteins among the examined strains, six 
genes were identified in only few strains also a number of lipoprotein genes in RN4282 
and T1 strains were not detected in MRSA252. The majority of mutations in the 
lipoprotein genes were represented within a limited number of highly variable genes to 
reveal significant variation among S. aureus strains, there were 11 highly variable genes 
with considerable value of non-synonymous residues. Whereas, almost half of the genes 
showed low nucleotide diversity, these genes were fairly invariant in examined S. aureus 
strains. The numbers of lipoprotein genes were variant in these strains as the predictive 
algorithms rules used to predict the unique N-terminal lipid modification, N-acyl-S-
diacylglyceryl-Cys in the complete genome of S. aureus have revealed different number of 
lipoprotein genes. One confounding factor was that lipoproteins were sometimes wrongly 
annotated of genes in the gene prediction and functions in different genetic sequence 
database and collection of publicly available DNA sequences which could lead to incorrect 
analysis. Some assigned genes sequences in different databases were annotated as 
lipoprotein but were missing the C-region end of signal peptides with Cysteine (+1 
position) which is the lipid-modification site. SAR2104 (putative lipoprotein) was not 
detected in RN4282 S. aureus strain, this gene was inactive during the C. elegans infection 
model experiment as shown RNA zero read for the all period of infections. In the PCR 
approach to detect the lipoprotein genes of S. aureus were limited to 50 genes at the 
beginning of this study, while the RNA sequencing analysis has identified 62 lipoprotein 
transcripts in total, the extra 12 lipoprotein genes need to be investigated for their genetic 
diversity and the number of mutations. Lipoprotein genes sequence detected variable SNPs 
between S. aureus strains including 10 genes with intense nucleotides changes leading to 
excessive amino acids variations, the phylogenetic trees were more effective by the genes 
with a highly number of variable SNPs. A detailed proteomic proﬁling of S. aureus 
lipoproteins is important to confirm the translation of their mRNA’s and to determine their 
potential roles as virulence factors and antigens. This information could help to identify 
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the differences and similarities of lipoprotein constituents and provide helpful information 
to develop a vaccine and/or treatment of S. aureus infections. Proteomic analysis using the 
application of gel-free proteomic technique to identify the lipoproteins within S. aureus 
MRSA252 identified 38 lipoproteins that were expressed in the non-infection condition 
representing approx. two-thirds of the S. aureus MRSA252 lipoproteins. Meanwhile, in the 
S. aureus-mediated infections with C. elegans showed involvement of 62 lipoprotein 
genes, identification of some lipoproteins in the infection condition that were not detected 
in the proteomic proﬁle in non-infected samples suggest that these lipoproteins might be 
associated with bacterial virulence. Also, detection of transcripts of some lipoproteins does 
not prove they are translated and synthesized into final active lipoprotein form, as several 
steps in the protein expression process and many factors can affect the processes of protein 
translation and post-translational modification. An analytical study to investigate the 
relation of transcription, translation, and cellular protein turnover in the yeast 
Saccharomyces cerevisiae by comparing protein to mRNA ratios and the translational 
activity revealed a clear correlation between protein abundance and mRNA are 
significantly related to biological functional e.g. cellular metabolism and energy (Beyer et 
al., 2004).  
S. aureus infection of C. elegans induced strong transcriptional immunity host response to 
support the view that S. aureus infection stimulates the innate immune system of C. 
elegans to regulating and produce more antimicrobial products during the invasion, 
confirming previous studies on knowledge of the molecular biology of the C. elegans 
genes that are involved in the transcriptional response to S. aureus infection (Irazoqui et 
al., 2010a). The up-or down-regulated changes in genes transcription in C. elegans after 
infection with S. aureus shown expression of immune-related genes and virulence factors 
that were involved in the post-infection virulence of the nematode, these genes needs to be 
subjected to further investigation as many of them were determined to be important in 
mammalian pathogenesis (Irazoqui et al., 2010b). In the other hand, the C. elegans 
infection model is not directly comparable to animals and virulence factors also vary 
between different species and tissues, therefore the pathogenesis models are variable in the 
assessment of the host response and bacterial virulence factors. Also, the time of RNA 
extraction and the age of worms are very critical to detect and evaluated some important 
transcripts level, C. elegans has a short generation time which is 3 days cycle at 25°C to 
produce progeny, RNA isolation from mature worms may contain some RNA of 
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developed eggs and new progenies that may hatched inside the worms. High level of some 
zygotic and embryonic transcripts have been detected during the early stages of C. elegans 
infection which is more likely linked to development of eggs into infected C. elegans as a 
result of egg-laying behaviour was affected by S. aureus infection (Gardner et al., 2013).  
However, funding was only available to analyse samples from three times of infection. The 
results demonstrate that S. aureus MRSA252 was able to infect and kill C. elegans under 
the examined conditions of in vitro infection model, the C. elegans infection experiment 
showed prospective interactions of S. aureus antigen expression and antibody response to 
antigens in early and late stages of infection, but the mechanisms of host-pathogen 
interaction still to be clarified. Transcriptome observation showed that the C. elegans host 
response post-infection shares important factors with the mammalians innate immunity 
response to suggest their importance in human innate responses.   
Some lipoproteins shown to be involved in experimental infection of mice experiment 
done by Diep et al. (Diep et al., 2014a) were not involved in pathogenesis in C. elegans in 
this study, while putative membrane protein SAR0706 and phosphate-binding lipoprotein 
SAR1402 lipoprotein genes were significantly up-regulated in C. elegans infection 
experiment and identified as virulence factors, these lipoproteins promising to be an 
effective component of vaccine candidates against S. aureus but require further 
investigation. Approx. 60 lipoprotein genes expressed in the clinically important S. aureus 
MRSA252 some of them were known as factors of pathogenicity, transcriptional profiling 
of S. aureus post-infection showed that C. elegans infection model elicits changes in 
expression of the majority of the total genome of ~ 2,600 genes. The up-regulation of 
capsule synthesis proteins during infection stages was the most significant virulence factor 
that was related to S. aureus infection. 
Label-free shotgun proteomics techniques based on the identification of peptides by LC-
MS/MS has provided a high dynamic range of lipoproteins to cover almost two-thirds of 
the S. aureus MRSA252 predicted lipoproteins, while, the detected lipoprotein transcripts 
in RNA-seq of C. elegans infection experiment identified 62 transcripts, the two methods 
have been performed in two different conditions and showed a higher number of 
lipoprotein transcripts that may not have been expressed in the non-infection quantification 
method, 24 lipoprotein transcripts including two significantly up-regulated SAR0706 and 
SAR1402 transcripts that expressed under the infection condition did not show a detectable 
level of translated lipoproteins in the non-infection condition. This may reflect the real life 
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situation but may also be due to the different sensitivities of the two techniques and low 
levels of expression may not have been detected in the proteomics experiments.  One of 
the important functions of lipoproteins is as transporters for many nutrients or chaperones, 
therefore it is not unexpected that the lgt mutation bacterium showed affected high-affinity 
metal ion uptake and also attenuated virulence (Schmaler et al., 2009). S. aureus USA300 
mutant in νSaα genomic island which containing tandem lipoprotein-like genes lpl were 
lacking in the stimulation of pro-inflammatory cytokines of human monocytes, 
macrophages and keratinocytes (Nguyen et al., 2015). νSaα was not annotated on the 
MRSA252 chromosome from Genbank that was used here but the tandem lipoproteins 
SAR0438-0445 may represent a similar cluster. The potential roles of lipoproteins in 
infection and innate immune response was not obvious in the C. elegans infection 
experiment, ~ 4 fold increase in SAR0706 and an almost 2 fold increase in SAR1402 and 
SAR2457 expression were the only observed lipoproteins transcripts the involved in the 
innate immune stimulation which comprise 5% of all lipoproteins of S. aureus MRSA252, 
however the significantly down-regulated lipoprotein genes were comprise ~18%, to 
suggest that these genes do not contributes in innate immune stimulation activity. Two 
lipoprotein genes SAR2736 and SAR1565 were annotated as pseudogene in the genomes 
and protein NCBI database, but both genes were expressed and detected in the RNA 
Sequencing procedure to suggest that these genes are real genes.    
Most of the investigation on S. aureus aimed to identify particular virulence factors and 
novel therapeutic targets for the S. aureus infections, this study has focused on the 
important epidemic strains EMRSA-16 S. aureus that cause nosocomial infections in the 
UK and around the world. Lipoproteins are effective vaccine candidates and proved 
protective immunity against S. aureus (Mishra et al., 2012; Mariotti et al., 2013). There is 
high demand for new treatment in order to treat S. aureus infections as only few antibiotics 
have a proved an effectiveness to treat the MRSA strains in the last decades. Although the 
results presented here have demonstrated some variation of lipoproteins genes structure 
and expression, further work is needed to investigate the remaining lipoproteins and their 
expression levels. It would also be valuable to evaluate lipoprotein expression at different 
times of infection of C. elegans this would lead to a better understanding of S. 
aureus infection mechanisms and how the infections occur. It will also be necessary to 
determine their roles in pathogenesis in a model system that involves cell-mediated 
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immunity unlike C. elegans and find new approaches to prevent infection, develop new 
and more effective treatments. 
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Appendix 1 
Table 1. SAR0443 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0443 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1480 100% 0.0 100% 801/801 
S. aureus RN4282 1153 90% 0.0 99% 699/699 
S. aureus T1 1480 100% 0.0 100% 801/801 
S. aureus COL 1133 99% 0.0 96% 669/697 
S. aureus MSSA476 1153 99% 0.0 97% 668/690 
S. aureus MW2 1153 99% 0.0 97% 668/690 
S. aureus N315 1125 100% 0.0 94% 755/801 
S. aureus Mu50 1225 100% 0.0 94% 755/801 
S. aureus T0131 1133 99% 0.0 96% 669/697 
S. aureus TW20 344 78% 0.0 77% 492/638 
S. aureus BMB9393 933 99% 0.0 88% 698/794 
S. aureus LGA251 1149 87% 0.0 96% 672/697 
S. aureus RF122 678 90% 0.0 86% 539/625 
S. aureus ST398 1153 99% 0.0 97% 668/690 
S. aureus M013 601 90% 0.0 87% 469/541 
S. aureus M1 1133 99% 0.0 96% 669/697 
S. aureus Mu3 1225 100% 0.0 94% 755/801 
S. aureus str. Newman 1133 100% 0.0 96% 669/697 
S. aureus NCTC8325 1129 87% 0.0 96% 673/704 
S. aureus VC40 1129 87% 0.0 96% 673/704 
 
Table 2. SAR1189 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1189 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1762 100% 0.0 100% 954/954 
S. aureus RN4282 1679 100% 0.0 98% 939/954 
S. aureus T1 1762 100% 0.0 100% 954/954 
S. aureus COL 1679 100% 0.0 98% 939/954 
S. aureus MSSA476 1679 100% 0.0 98% 939/954 
S. aureus MW2 1679 100% 0.0 98% 939/954 
S. aureus N315 1679 100% 0.0 98% 939/954 
S. aureus Mu50 1679 100% 0.0 98% 939/954 
S. aureus T0131 1679 100% 0.0 98% 939/954 
S. aureus TW20 1679 100% 0.0 98% 939/954 
S. aureus BMB9393 1679 100% 0.0 98% 939/954 
S. aureus LGA251 448 58% 0.0 81% 453/557 
S. aureus RF122 440 58% 0.0 81% 452/557 
S. aureus ST398 436 58% 0.0 98% 939/954 
S. aureus M013 1679 58% 0.0 81% 452/558 
S. aureus M1 1679 100% 0.0 98% 939/954 
S. aureus Mu3 1679 100% 0.0 98% 939/954 
S. aureus str. Newman 1679 100% 0.0 98% 939/954 
S. aureus NCTC8325 1679 100% 0.0 98% 939/954 
S. aureus VC40 1679 100% 0.0 98% 939/954 
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Table 3. SAR0439 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0439 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1430 100% 0.0 100% 774/774 
S. aureus RN4282 1236 100% 0.0 97% 776/765 
S. aureus T1 1430 100% 0.0 99% 774/772 
S. aureus COL 773 100% 0.0 85% 659/777 
S. aureus MSSA476 723 100% 0.0 84% 651/778 
S. aureus MW2 723 100% 0.0 84% 651/778 
S. aureus N315 1236 100% 0.0 96% 735/768 
S. aureus Mu50 1236 100% 0.0 96% 735/768 
S. aureus T0131 1029 100% 0.0 92% 678/738 
S. aureus TW20 315 100% 0.0 76% 472/625 
S. aureus BMB9393 1029 100% 0.0 92% 678/738 
S. aureus LGA251 1099 99% 0.0 96% 656/686 
S. aureus RF122 623 100% 0.0 83% 573/688 
S. aureus ST398 649 99% 0.0 95% 547/644 
S. aureus M013 529 100% 0.0 83% 499/603 
S. aureus M1 747 100% 0.0 85% 630/741 
S. aureus Mu3 1236 100% 0.0 96% 774/768 
S. aureus str. Newman 1280 100% 0.0 97% 774/747 
S. aureus NCTC8325 813 95% 0.0 87% 639/738 
S. aureus VC40 813 95% 0.0 87% 679/738 
 
Table 4. SAR0442 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0442 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base 
pairs) 
S. aureus MRSA252 1424 100% 0.0 100% 771/771 
S. aureus RN4282 1214 100% 0.0 93% 708/771 
S. aureus T1 1424 100% 0.0 100% 771/771 
S. aureus COL 1075 100% 0.0 92% 709/771 
S. aureus MSSA476 1214 100% 0.0 95% 733/771 
S. aureus MW2 1214 100% 0.0 95% 733/771 
S. aureus N315 756 100% 0.0 89% 553/624 
S. aureus Mu50 756 100% 0.0 89% 553/624 
S. aureus T0131 1173 100% 0.0 94% 719/761 
S. aureus TW20 313 80% 0.0 76% 482/634 
S. aureus BMB9393 1173 100% 0.0 94% 719/761 
S. aureus LGA251 669 87% 0.0 85% 576/680 
S. aureus RF122 1173 100% 0.0 98% 668/684 
S. aureus ST398 741 99% 0.0 88% 549/623 
S. aureus M013 1042 100% 0.0 98% 584/594 
S. aureus M1 1173 100% 0.0 94% 719/761 
S. aureus Mu3 756 100% 0.0 89% 553/624 
S. aureus str. Newman 1162 100% 0.0 94% 718/762 
S. aureus NCTC8325 684 92% 0.0 84% 601/716 
S. aureus VC40 684 92% 0.0 84% 601/716 
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Table 5. SAR0206 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0206 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2350 100% 0.0 100% 1272/1272 
S. aureus RN4282 2272 100% 0.0 99% 1258/1272 
S. aureus T1 2350 100% 0.0 100% 1272/1272 
S. aureus COL 2272 100% 0.0 99% 1258/1272 
S. aureus MSSA476 2272 100% 0.0 99% 1258/1272 
S. aureus MW2 2266 100% 0.0 99% 1257/1272 
S. aureus N315 2261 100% 0.0 99% 1256/1272 
S. aureus Mu50 2350 100% 0.0 99% 1256/1272 
S. aureus T0131 2338 100% 0.0 100% 1272/1272 
S. aureus TW20 2350 100% 0.0 99% 1270/1272 
S. aureus BMB9393 2350 100% 0.0 100% 1272/1272 
S. aureus LGA251 2305 100% 0.0 99% 1264/1272 
S. aureus RF122 2289 100% 0.0 99% 1261/1272 
S. aureus ST398 2311 100% 0.0 99% 1265/1272 
S. aureus M013 2278 100% 0.0 99% 1259/1272 
S. aureus M1 2272 100% 0.0 99% 1258/1272 
S. aureus Mu3 2261 100% 0.0 99% 1256/1272 
S. aureus str. Newman 2272 100% 0.0 99% 1258/1272 
S. aureus NCTC8325 2272 100% 0.0 99% 1258/1272 
S. aureus VC40 2272 100% 0.0 99% 1258/1272 
 
Table 6. SAR0396 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0396 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1158 100% 0.0 100% 627/627 
S. aureus RN4282 1125 100% 0.0 99% 621/627 
S. aureus T1 1158 100% 0.0 100% 627/627 
S. aureus COL 1125 100% 0.0 99% 621/627 
S. aureus MSSA476 1120 100% 0.0 99% 620/627 
S. aureus MW2 1120 100% 0.0 99% 621/627 
S. aureus N315 1125 100% 0.0 99% 621/627 
S. aureus Mu50 1125 100% 0.0 99% 621/627 
S. aureus T0131 1125 100% 0.0 99% 621/627 
S. aureus TW20 1125 100% 0.0 99% 621/627 
S. aureus BMB9393 1125 100% 0.0 99% 621/627 
S. aureus LGA251 1114 100% 0.0 99% 619/627 
S. aureus RF122 1114 100% 0.0 99% 619/627 
S. aureus ST398 1131 100% 0.0 99% 622/627 
S. aureus M013 1125 100% 0.0 99% 621/627 
S. aureus M1 1125 100% 0.0 99% 621/627 
S. aureus Mu3 1125 100% 0.0 99% 621/627 
S. aureus str. Newman 1125 100% 0.0 99% 621/627 
S. aureus NCTC8325 1125 100% 0.0 99% 621/627 
S. aureus VC40 1125 100% 0.0 99% 621/627 
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Table 7. SAR0118 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0118 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1834 100% 0.0 100% 993/993 
S. aureus RN4282 1801 100% 0.0 99% 987/993 
S. aureus T1 1834 100% 0.0 100% 993/993 
S. aureus COL 1801 100% 0.0 99% 987/993 
S. aureus MSSA476 1784 100% 0.0 99% 984/993 
S. aureus MW2 1784 100% 0.0 99% 987/993 
S. aureus N315 1801 100% 0.0 89% 987/993 
S. aureus Mu50 1801 100% 0.0 89% 987/993 
S. aureus T0131 1834 100% 0.0 100% 993/993 
S. aureus TW20 1834 100% 0.0 100% 993/993 
S. aureus BMB9393 1834 100% 0.0 100% 993/993 
S. aureus LGA251 1801 100% 0.0 99% 987/993 
S. aureus RF122 1801 100% 0.0 99% 987/993 
S. aureus ST398 1801 100% 0.0 99% 988/993 
S. aureus M013 1807 100% 0.0 99% 988/993 
S. aureus M1 1807 100% 0.0 99% 987/993 
S. aureus Mu3 1801 100% 0.0 99% 987/993 
S. aureus str. Newman 1801 100% 0.0 99% 987/993 
S. aureus NCTC8325 1801 100% 0.0 99% 987/993 
S. aureus VC40 1801 100% 0.0 99% 986/993 
 
Table 8. SAR0438 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0438 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1452 100% 0.0 100% 786/786 
S. aureus RN4282 1452 100% 0.0 100% 786/786 
S. aureus T1 1452 100% 0.0 100% 786/786 
S. aureus COL 937 98% 0.0 92% 623/680 
S. aureus MSSA476 545 80% 0.0 83% 506/609 
S. aureus MW2 545 80% 0.0 83% 506/609 
S. aureus N315 1181 100% 0.0 97% 682/703 
S. aureus Mu50 1181 100% 0.0 97% 682/703 
S. aureus T0131 931 98% 0.0 91% 622/680 
S. aureus TW20 931 98% 0.0 91% 622/680 
S. aureus BMB9393 931 98% 0.0 91% 622/680 
S. aureus LGA251 1286 100% 0.0 96% 756/786 
S. aureus RF122 1194 99% 0.0 94% 739/785 
S. aureus ST398 1315 99% 0.0 97% 760/784 
S. aureus M013 911 99% 0.0 88% 690/787 
S. aureus M1 931 98% 0.0 91% 622/680 
S. aureus Mu3 1181 100% 0.0 97% 682/703 
S. aureus str. Newman 937 98% 0.0 92% 623/680 
S. aureus NCTC8325 937 98% 0.0 92% 623/680 
S. aureus VC40 937 98% 0.0 92% 623/680 
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Table 9. SAR1034 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1034 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2034 100% 0.0 100% 1101/1101 
S. aureus RN4282 2017 100% 0.0 99% 1098/1101 
S. aureus T1 2034 100% 0.0 100% 1101/1101 
S. aureus COL 2017 100% 0.0 99% 1098/1101 
S. aureus MSSA476 2012 100% 0.0 99% 1097/1101 
S. aureus MW2 2012 100% 0.0 99% 1097/1101 
S. aureus N315 2012 100% 0.0 99% 1097/1101 
S. aureus Mu50 2012 100% 0.0 99% 1097/1101 
S. aureus T0131 2017 100% 0.0 99% 1098/1101 
S. aureus TW20 2017 100% 0.0 99% 1098/1101 
S. aureus BMB9393 2017 100% 0.0 99% 1098/1101 
S. aureus LGA251 2017 100% 0.0 99% 1098/1101 
S. aureus RF122 2006 100% 0.0 99% 1096/1101 
S. aureus ST398 2028 100% 0.0 99% 1100/1101 
S. aureus M013 2017 100% 0.0 99% 1098/1101 
S. aureus M1 2017 100% 0.0 99% 1098/1101 
S. aureus Mu3 2017 100% 0.0 99% 1097/1101 
S. aureus str. Newman 2017 100% 0.0 99% 1098/1101 
S. aureus NCTC8325 2017 100% 0.0 99% 1098/1101 
S. aureus VC40 2017 100% 0.0 99% 1097/1101 
Table 10. SAR1879 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1879 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1026 100% 0.0 100% 555/555 
S. aureus RN4282 898 100% 0.0 96% 532/555 
S. aureus T1 898 100% 0.0 100% 555/555 
S. aureus COL 898 100% 0.0 96% 532/555 
S. aureus MSSA476 915 100% 0.0 96% 535/555 
S. aureus MW2 915 100% 0.0 96% 535/555 
S. aureus N315 893 100% 0.0 96% 531/555 
S. aureus Mu50 893 100% 0.0 96% 531/555 
S. aureus T0131 898 100% 0.0 96% 531/555 
S. aureus TW20 898 100% 0.0 96% 532/555 
S. aureus BMB9393 893 100% 0.0 96% 532/555 
S. aureus LGA251 891 100% 0.0 96% 531/555 
S. aureus RF122 1003 100% 0.0 96% 547/555 
S. aureus ST398 715 100% 0.0 96% 551/555 
S. aureus M013 898 100% 0.0 96% 425/555 
S. aureus M1 898 100% 0.0 96% 550/555 
S. aureus Mu3 893 100% 0.0 96% 532/555 
S. aureus str. Newman 893 100% 0.0 96% 531/555 
S. aureus NCTC8325 898 100% 0.0 96% 532/555 
S. aureus VC40 898 100% 0.0 96% 532/555 
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Table 11. SAR0230 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0230 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2726 100% 0.0 100% 1476/1476 
S. aureus RN4282 2621 100% 0.0 99% 1457/1476 
S. aureus T1 2726 100% 0.0 100% 1476/1476 
S. aureus COL 2621 100% 0.0 99% 1457/1476 
S. aureus MSSA476 2588 100% 0.0 98% 1451/1476 
S. aureus MW2 2588 100% 0.0 98% 1451/1476 
S. aureus N315 2599 100% 0.0 98% 1453/1476 
S. aureus Mu50 2599 100% 0.0 98% 1453/1476 
S. aureus T0131 2715 100% 0.0 99% 1474/1476 
S. aureus TW20 2715 100% 0.0 99% 1476/1476 
S. aureus BMB9393 2715 100% 0.0 99% 1474/1476 
S. aureus LGA251 2588 100% 0.0 98% 1451/1476 
S. aureus RF122 2615 100% 0.0 99% 1456/1476 
S. aureus ST398 2649 100% 0.0 99% 1462/1476 
S. aureus M013 2610 100% 0.0 99% 1455/1476 
S. aureus M1 2621 100% 0.0 99% 1457/1476 
S. aureus Mu3 2599 100% 0.0 98% 1453/1476 
S. aureus str. Newman 2621 100% 0.0 99% 1457/1476 
S. aureus NCTC8325 2621 100% 0.0 99% 1457/1476 
S. aureus VC40 2621 100% 0.0 99% 1457/1476 
 
Table 12. SAR1066 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1066 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1158 100% 0.0 100% 627/627 
S. aureus RN4282 1109 100% 0.0 99% 618/627 
S. aureus T1 1158 100% 0.0 100% 627/627 
S. aureus COL 1109 100% 0.0 99% 618/627 
S. aureus MSSA476 1114 100% 0.0 99% 619/627 
S. aureus MW2 1114 100% 0.0 99% 619/627 
S. aureus N315 1103 100% 0.0 98% 617/627 
S. aureus Mu50 1103 100% 0.0 98% 617/627 
S. aureus T0131 1109 100% 0.0 99% 618/627 
S. aureus TW20 1103 100% 0.0 98% 617/627 
S. aureus BMB9393 1109 100% 0.0 99% 618/627 
S. aureus LGA251 1048 100% 0.0 97% 607/627 
S. aureus RF122 1042 100% 0.0 97% 606/627 
S. aureus ST398 1131 100% 0.0 99% 622/627 
S. aureus M013 1053 100% 0.0 97% 608/627 
S. aureus M1 1109 100% 0.0 99% 618/627 
S. aureus Mu3 1103 100% 0.0 98% 617/627 
S. aureus str. Newman 1109 100% 0.0 99% 618/627 
S. aureus NCTC8325 1109 100% 0.0 99% 618/627 
S. aureus VC40 1109 100% 0.0 99% 618/627 
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Table 13. SAR1881 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1881 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1158 100% 0.0 100% 627/627 
S. aureus RN4282 959 100% 0.0 94% 591/627 
S. aureus T1 1158 100% 0.0 100% 627/627 
S. aureus COL 959 100% 0.0 94% 591/627 
S. aureus MSSA476 987 100% 0.0 95% 596/627 
S. aureus MW2 987 100% 0.0 95% 596/627 
S. aureus N315 981 100% 0.0 95% 595/627 
S. aureus Mu50 981 100% 0.0 95% 595/627 
S. aureus T0131 953 100% 0.0 94% 590/627 
S. aureus TW20 959 100% 0.0 94% 591/627 
S. aureus BMB9393 959 100% 0.0 94% 591/627 
S. aureus LGA251  
S. aureus RF122 1055 100% 0.0 97% 607/627 
S. aureus ST398 1064 100% 0.0 97% 610/627 
S. aureus M013 981 100% 0.0 98% 616/627 
S. aureus M1 959 100% 0.0 94% 591/627 
S. aureus Mu3 981 100% 0.0 95% 595/627 
S. aureus str. Newman 959 100% 0.0 94% 591/627 
S. aureus NCTC8325 959 100% 0.0 94% 591/627 
S. aureus VC40 959 100% 0.0 94% 591/627 
 
Table 14. SAR0794 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0794 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1624 100% 0.0 100% 879/879 
S. aureus RN4282 1613 100% 0.0 99% 877/879 
S. aureus T1 1624 100% 0.0 100% 879/879 
S. aureus COL 1613 100% 0.0 99% 877/879 
S. aureus MSSA476 1613 100% 0.0 99% 877/879 
S. aureus MW2 1613 100% 0.0 99% 877/879 
S. aureus N315 1618 100% 0.0 99% 878/879 
S. aureus Mu50 1618 100% 0.0 99% 878/879 
S. aureus T0131 1596 100% 0.0 99% 878/879 
S. aureus TW20 1613 100% 0.0 99% 877/879 
S. aureus BMB9393 1613 100% 0.0 99% 877/879 
S. aureus LGA251 1596 100% 0.0 99% 874/879 
S. aureus RF122 1594 100% 0.0 99% 874/879 
S. aureus ST398 1613 100% 0.0 99% 877/879 
S. aureus M013 1613 100% 0.0 99% 877/879 
S. aureus M1 1613 100% 0.0 99% 877/879 
S. aureus Mu3 1618 100% 0.0 99% 878/879 
S. aureus str. Newman 1613 100% 0.0 99% 877/879 
S. aureus NCTC8325 1613 100% 0.0 99% 877/879 
S. aureus VC40 1613 100% 0.0 99% 877/879 
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Table 15. SAR2104 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2104 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252  100% 0.0 100%  
S. aureus RN4282  100% 0.0 93%  
S. aureus T1  100% 0.0 100%  
S. aureus COL  
S. aureus MSSA476  
S. aureus MW2  
S. aureus N315  
S. aureus Mu50  100% 0.0 89%  
S. aureus T0131  
S. aureus TW20  100% 0.0 76%  
S. aureus BMB9393  
S. aureus LGA251  
S. aureus RF122  
S. aureus ST398  100% 0.0 88%  
S. aureus M013  
S. aureus M1  
S. aureus Mu3  100% 0.0 89%  
S. aureus str. Newman  100% 0.0 94%  
S. aureus NCTC8325  
S. aureus VC40  
 
Table 16. SAR0872 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0872 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1519 100% 0.0 100% 822/822 
S. aureus RN4282 1519 100% 0.0 99% 813/822 
S. aureus T1 1519 100% 0.0 100% 822/822 
S. aureus COL 1519 100% 0.0 99% 813/822 
S. aureus MSSA476 1463 100% 0.0 99% 812/822 
S. aureus MW2 1469 100% 0.0 99% 813/822 
S. aureus N315 1488 100% 0.0 99% 815/822 
S. aureus Mu50 1488 100% 0.0 99% 815/822 
S. aureus T0131 1469 100% 0.0 99% 813/822 
S. aureus TW20 1469 100% 0.0 99% 813/822 
S. aureus BMB9393 1469 100% 0.0 99% 813/822 
S. aureus LGA251 1452 100% 0.0 99% 810/822 
S. aureus RF122 1458 100% 0.0 99% 811/822 
S. aureus ST398 1519 100% 0.0 100% 822/822 
S. aureus M013 1485 100% 0.0 99% 816/822 
S. aureus M1 1469 100% 0.0 99% 813/822 
S. aureus Mu3 1480 100% 0.0 99% 815/822 
S. aureus str. Newman 1463 100% 0.0 99% 812/822 
S. aureus NCTC8325 1469 100% 0.0 99% 813/822 
S. aureus VC40 1469 100% 0.0 99% 813/822 
263 
 
Table 17. SAR0790 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0790 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1901 100% 0.0 100% 1029/1029 
S. aureus RN4282 1557 100% 0.0 94% 967/1029 
S. aureus T1 1901 100% 0.0 100% 1029/1029 
S. aureus COL 1550 100% 0.0 94% 967/1029 
S. aureus MSSA476 1563 100% 0.0 99% 968/1029 
S. aureus MW2 1563 100% 0.0 99% 968/1029 
S. aureus N315 1563 100% 0.0 99% 968/1029 
S. aureus Mu50 1563 100% 0.0 99% 968/1029 
S. aureus T0131 1557 100% 0.0 94% 967/1029 
S. aureus TW20 1557 100% 0.0 94% 967/1029 
S. aureus BMB9393 1557 100% 0.0 94% 967/1029 
S. aureus LGA251 1507 100% 0.0 93% 958/1029 
S. aureus RF122 1360 100% 0.0 91% 936/1029 
S. aureus ST398 1840 100% 0.0 99% 968/1029 
S. aureus M013 1602 100% 0.0 95% 975/1029 
S. aureus M1 1552 100% 0.0 94% 966/1029 
S. aureus Mu3 1563 100% 0.0 99% 968/1029 
S. aureus str. Newman 1557 100% 0.0 94% 967/1029 
S. aureus NCTC8325 1557 100% 0.0 94% 967/1029 
S. aureus VC40 1557 100% 0.0 94% 967/1029 
Table 18. SAR1106 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1106 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1624 100% 0.0 100% 879/789 
S. aureus RN4282 1613 100% 0.0 99% 877/789 
S. aureus T1 1624 100% 0.0 100% 879/789 
S. aureus COL 1613 100% 0.0 99% 877/789 
S. aureus MSSA476 1596 100% 0.0 99% 874/789 
S. aureus MW2 1596 100% 0.0 99% 874/789 
S. aureus N315 1613 100% 0.0 99% 877/789 
S. aureus Mu50 1613 100% 0.0 99% 877/789 
S. aureus T0131 1607 100% 0.0 99% 876/789 
S. aureus TW20 1613 100% 0.0 99% 877/789 
S. aureus BMB9393 1613 100% 0.0 99% 877/789 
S. aureus LGA251 1613 100% 0.0 99% 877/789 
S. aureus RF122 1591 100% 0.0 99% 873/789 
S. aureus ST398 1602 100% 0.0 99% 875/789 
S. aureus M013 1602 100% 0.0 99% 875/789 
S. aureus M1 1613 100% 0.0 99% 877/789 
S. aureus Mu3 1613 100% 0.0 99% 877/789 
S. aureus str. Newman 1613 100% 0.0 99% 877/789 
S. aureus NCTC8325 1613 100% 0.0 99% 877/789 
S. aureus VC40 1613 100% 0.0 99% 877/789 
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Table 19. SAR0953 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0953 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 3059 100% 0.0 100% 1657/1657 
S. aureus RN4282 2809 100% 0.0 97% 1612/1657 
S. aureus T1 3059 100% 0.0 100% 1657/1657 
S. aureus COL 2809 100% 0.0 97% 1612/1657 
S. aureus MSSA476 2826 100% 0.0 97% 1615/1657 
S. aureus MW2 2820 100% 0.0 97% 1614/1657 
S. aureus N315 2804 100% 0.0 97% 1611/1657 
S. aureus Mu50 2804 100% 0.0 97% 1611/1657 
S. aureus T0131 2809 100% 0.0 97% 1612/1657 
S. aureus TW20 2809 100% 0.0 97% 1612/1657 
S. aureus BMB9393 2809 100% 0.0 97% 1612/1657 
S. aureus LGA251 2865 100% 0.0 98% 1621/1656 
S. aureus RF122 2854 100% 0.0 98% 1640/1656 
S. aureus ST398 2970 100% 0.0 99% 1618/1657 
S. aureus M013 2809 100% 0.0 98% 1618/1656 
S. aureus M1 2809 100% 0.0 97% 1612/1657 
S. aureus Mu3 2804 100% 0.0 97% 1611/1657 
S. aureus str. Newman 2809 100% 0.0 97% 1612/1657 
S. aureus NCTC8325 2809 100% 0.0 97% 1612/1657 
S. aureus VC40 2809 100% 0.0 97% 1612/1657 
 
Table 20. SAR1011 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1011 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1773 100% 0.0 100% 960/960 
S. aureus RN4282 1585 100% 0.0 96% 926/960 
S. aureus T1 1773 100% 0.0 100% 960/960 
S. aureus COL 1585 100% 0.0 96% 926/960 
S. aureus MSSA476 1580 100% 0.0 96% 925/960 
S. aureus MW2 1580 100% 0.0 96% 925/960 
S. aureus N315 1602 100% 0.0 97% 929/960 
S. aureus Mu50 1602 100% 0.0 97% 929/960 
S. aureus T0131 1585 100% 0.0 96% 926/960 
S. aureus TW20 1585 100% 0.0 96% 926/960 
S. aureus BMB9393 1585 100% 0.0 96% 926/960 
S. aureus LGA251 1640 100% 0.0 98% 936/960 
S. aureus RF122 1554 100% 0.0 96% 921/960 
S. aureus ST398 1657 100% 0.0 98% 939/960 
S. aureus M013 1568 100% 0.0 96% 923/960 
S. aureus M1 1585 100% 0.0 96% 926/960 
S. aureus Mu3 1602 100% 0.0 98% 929/960 
S. aureus str. Newman 1585 100% 0.0 96% 926/960 
S. aureus NCTC8325 1585 100% 0.0 96% 926/960 
S. aureus VC40 1585 100% 0.0 96% 926/960 
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Table 21. SAR1995 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1995 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2217 100% 0.0 100% 1200/1200 
S. aureus RN4282 2178 100% 0.0 99% 1193/1200 
S. aureus T1 2217 100% 0.0 100% 1200/1200 
S. aureus COL 2178 100% 0.0 99% 1193/1200 
S. aureus MSSA476 2178 100% 0.0 99% 1193/1200 
S. aureus MW2 2178 100% 0.0 99% 1193/1200 
S. aureus N315 2178 100% 0.0 99% 1193/1200 
S. aureus Mu50 2178 100% 0.0 99% 1193/1200 
S. aureus T0131 2178 100% 0.0 99% 1193/1200 
S. aureus TW20 2178 100% 0.0 99% 1193/1200 
S. aureus BMB9393 2178 100% 0.0 99% 1193/1200 
S. aureus LGA251 2172 100% 0.0 99% 1192/1200 
S. aureus RF122 2178 100% 0.0 99% 1193/1200 
S. aureus ST398 2206 100% 0.0 99% 1198/1200 
S. aureus M013 2167 100% 0.0 99% 1191/1200 
S. aureus M1 2178 100% 0.0 99% 1193/1200 
S. aureus Mu3 2178 100% 0.0 99% 1193/1200 
S. aureus str. Newman 2178 100% 0.0 99% 1193/1200 
S. aureus NCTC8325 2178 100% 0.0 99% 1193/1200 
S. aureus VC40 2178 100% 0.0 99% 1193/1200 
Table 22. SAR2179 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2179 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1613 100% 0.0 100% 873/873 
S. aureus RN4282 1568 100% 0.0 99% 865/873 
S. aureus T1 1613 100% 0.0 100% 873/873 
S. aureus COL 1568 100% 0.0 99% 865/873 
S. aureus MSSA476 1580 100% 0.0 99% 867/873 
S. aureus MW2 1580 100% 0.0 99% 867/873 
S. aureus N315 1568 100% 0.0 99% 865/873 
S. aureus Mu50 1568 100% 0.0 99% 865/873 
S. aureus T0131 1555 100% 0.0 99% 863/873 
S. aureus TW20 1568 100% 0.0 99% 865/873 
S. aureus BMB9393 1568 100% 0.0 99% 863/873 
S. aureus LGA251 1563 100% 0.0 99% 865/873 
S. aureus RF122 1574 100% 0.0 99% 865/873 
S. aureus ST398 1574 100% 0.0 99% 866/873 
S. aureus M013 1563 100% 0.0 99% 866/873 
S. aureus M1 1563 100% 0.0 99% 864/873 
S. aureus Mu3 1568 100% 0.0 99% 865/873 
S. aureus str. Newman 1568 100% 0.0 99% 865/873 
S. aureus NCTC8325 1568 100% 0.0 99% 865/873 
S. aureus VC40 1568 100% 0.0 99% 865/873 
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Table 23. SAR1494 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1494 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1679 100% 0.0 100% 909/909 
S. aureus RN4282 1392 100% 0.0 94% 851/909 
S. aureus T1 1679 100% 0.0 100% 909/909 
S. aureus COL 1373 100% 0.0 94% 851/905 
S. aureus MSSA476 929 70% 0.0 96% 549/572 
S. aureus MW2 924 70% 0.0 96% 548/572 
S. aureus N315 918 68% 0.0 96% 547/572 
S. aureus Mu50 918 68% 0.0 96% 852/905 
S. aureus T0131 1378 100% 0.0 94% 850/905 
S. aureus TW20 1367 100% 0.0 94% 851/905 
S. aureus BMB9393 1373 99% 0.0 94% 851/905 
S. aureus LGA251 1469 91% 0.0 99% 817/828 
S. aureus RF122 1395 100% 0.0 94% 858/909 
S. aureus ST398 732 71% 0.0 94% 851/905 
S. aureus M013 941 68% 0.0 96% 552/573 
S. aureus M1 1373 99% 0.0 94% 851/905 
S. aureus Mu3 918 68% 0.0 96% 547/572 
S. aureus str. Newman 1373 99% 0.0 94% 851/909 
S. aureus NCTC8325 1373 99% 0.0 94% 851/909 
S. aureus VC40 1373 99% 0.0 94% 851/909 
 
Table 24. SAR1608 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1608 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1075 100% 0.0 100% 582/582 
S. aureus RN4282 1059 100% 0.0 99% 579/582 
S. aureus T1 1075 100% 0.0 100% 582/582 
S. aureus COL 1059 100% 0.0 99% 579/582 
S. aureus MSSA476 1044 100% 0.0 99% 579/582 
S. aureus MW2 1044 100% 0.0 99% 579/582 
S. aureus N315 1059 100% 0.0 99% 579/582 
S. aureus Mu50 1059 100% 0.0 99% 579/582 
S. aureus T0131 1059 100% 0.0 99% 579/582 
S. aureus TW20 1059 100% 0.0 99% 579/582 
S. aureus BMB9393 1059 100% 0.0 99% 579/582 
S. aureus LGA251 1059 100% 0.0 99% 579/582 
S. aureus RF122 1048 100% 0.0 99% 577/582 
S. aureus ST398 1053 100% 0.0 99% 578/582 
S. aureus M013 1042 100% 0.0 99% 576/582 
S. aureus M1 1059 100% 0.0 99% 579/582 
S. aureus Mu3 1059 100% 0.0 99% 579/582 
S. aureus str. Newman 1059 100% 0.0 99% 579/582 
S. aureus NCTC8325 1059 100% 0.0 99% 579/582 
S. aureus VC40 1059 100% 0.0 99% 579/582 
267 
 
Table 25. SAR2368 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2368 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1674 100% 0.0 100% 909/909 
S. aureus RN4282 1629 100% 0.0 99% 900/909 
S. aureus T1 1674 100% 0.0 100% 909/909 
S. aureus COL 1629 100% 0.0 99% 900/909 
S. aureus MSSA476 1629 100% 0.0 99% 900/909 
S. aureus MW2 1629 100% 0.0 99% 900/909 
S. aureus N315 1624 100% 0.0 99% 899/909 
S. aureus Mu50 1624 100% 0.0 99% 899/909 
S. aureus T0131 1629 100% 0.0 99% 900/909 
S. aureus TW20 1629 100% 0.0 99% 900/909 
S. aureus BMB9393 1629 100% 0.0 99% 900/909 
S. aureus LGA251 1629 100% 0.0 99% 900/909 
S. aureus RF122 1618 100% 0.0 99% 898/909 
S. aureus ST398 1646 100% 0.0 99% 903/909 
S. aureus M013 1629 100% 0.0 99% 900/909 
S. aureus M1 1629 100% 0.0 99% 900/909 
S. aureus Mu3 1624 100% 0.0 99% 899/909 
S. aureus str. Newman 1629 100% 0.0 99% 900/909 
S. aureus NCTC8325 1629 100% 0.0 99% 900/909 
S. aureus VC40 1629 100% 0.0 99% 900/909 
 
Table 26. SAR2457 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2457 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1164 100% 0.0 100% 630/630 
S. aureus RN4282 931 100% 0.0 93% 588/630 
S. aureus T1 1164 100% 0.0 100% 630/630 
S. aureus COL 931 100% 0.0 93% 588/630 
S. aureus MSSA476 883 100% 0.0 92% 582/630 
S. aureus MW2 883 100% 0.0 92% 582/630 
S. aureus N315 900 100% 0.0 93% 585/630 
S. aureus Mu50 900 100% 0.0 93% 585/630 
S. aureus T0131 931 100% 0.0 93% 588/630 
S. aureus TW20 931 100% 0.0 93% 588/630 
S. aureus BMB9393 931 100% 0.0 93% 588/630 
S. aureus LGA251 942 100% 0.0 94% 590/630 
S. aureus RF122 931 100% 0.0 93% 585/630 
S. aureus ST398 1153 100% 0.0 99% 628/630 
S. aureus M013 948 100% 0.0 93% 588/630 
S. aureus M1 931 100% 0.0 93% 588/630 
S. aureus Mu3 900 100% 0.0 93% 585/630 
S. aureus str. Newman 931 100% 0.0 93% 588/630 
S. aureus NCTC8325 931 100% 0.0 93% 588/630 
S. aureus VC40 931 100% 0.0 93% 588/630 
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Table 27. SAR2268 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2268 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1818 100% 0.0 100% 984/984 
S. aureus RN4282 1657 100% 0.0 97% 955/984 
S. aureus T1 1818 100% 0.0 100% 984/984 
S. aureus COL 1657 100% 0.0 97% 955/984 
S. aureus MSSA476 1635 100% 0.0 97% 951/984 
S. aureus MW2 1635 100% 0.0 97% 951/984 
S. aureus N315 1663 100% 0.0 97% 959/984 
S. aureus Mu50 1663 100% 0.0 97% 956/984 
S. aureus T0131 1657 100% 0.0 97% 955/984 
S. aureus TW20 1657 100% 0.0 97% 955/984 
S. aureus BMB9393 1657 100% 0.0 97% 955/984 
S. aureus LGA251 1696 100% 0.0 99% 962/984 
S. aureus RF122 1696 100% 0.0 99% 962/984 
S. aureus ST398 1779 100% 0.0 99% 977/984 
S. aureus M013 1690 100% 0.0 97% 961/984 
S. aureus M1 1657 100% 0.0 97% 955/984 
S. aureus Mu3 1663 100% 0.0 97% 956/984 
S. aureus str. Newman 1657 100% 0.0 97% 955/984 
S. aureus NCTC8325 1657 100% 0.0 97% 955/984 
S. aureus VC40 1657 100% 0.0 97% 955/984 
 
Table 28. SAR2363 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2363 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1447 100% 0.0 100% 783/783 
S. aureus RN4282 1225 100% 0.0 97% 743/783 
S. aureus T1 1447 100% 0.0 100% 783/783 
S. aureus COL 1225 100% 0.0 95% 743/783 
S. aureus MSSA476 1286 100% 0.0 96% 754/783 
S. aureus MW2 1286 100% 0.0 96% 754/783 
S. aureus N315 1286 100% 0.0 96% 754/783 
S. aureus Mu50 1286 100% 0.0 96% 754/783 
S. aureus T0131 1225 100% 0.0 95% 743/783 
S. aureus TW20 1219 100% 0.0 95% 742/783 
S. aureus BMB9393 1225 100% 0.0 95% 743/783 
S. aureus LGA251 1236 100% 0.0 95% 745/783 
S. aureus RF122 1236 100% 0.0 95% 746/783 
S. aureus ST398 1424 100% 0.0 99% 779/783 
S. aureus M013 1225 100% 0.0 95% 743/783 
S. aureus M1 1225 100% 0.0 95% 743/783 
S. aureus Mu3 1286 100% 0.0 96% 754/783 
S. aureus str. Newman 1225 100% 0.0 95% 743/783 
S. aureus NCTC8325 1225 100% 0.0 95% 743/783 
S. aureus VC40 1218 100% 0.0 95% 742/783 
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Table 29. SAR2500 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2500 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 671 100% 0.0 100% 363/363 
S. aureus RN4282 671 100% 0.0 100% 363/363 
S. aureus T1 671 100% 0.0 100% 363/363 
S. aureus COL 671 100% 0.0 100% 363/363 
S. aureus MSSA476 671 100% 0.0 100% 363/363 
S. aureus MW2 671 100% 0.0 100% 363/363 
S. aureus N315 671 100% 0.0 100% 363/363 
S. aureus Mu50 671 100% 0.0 100% 363/363 
S. aureus T0131 671 100% 0.0 100% 363/363 
S. aureus TW20 671 100% 0.0 100% 363/363 
S. aureus BMB9393 671 100% 0.0 100% 363/363 
S. aureus LGA251 671 100% 0.0 100% 363/363 
S. aureus RF122 671 100% 0.0 100% 363/363 
S. aureus ST398 660 100% 0.0 99% 362/363 
S. aureus M013 660 100% 0.0 99% 362/363 
S. aureus M1 671 100% 0.0 100% 363/363 
S. aureus Mu3 671 100% 0.0 100% 363/363 
S. aureus str. Newman 671 100% 0.0 100% 363/363 
S. aureus NCTC8325 671 100% 0.0 100% 363/363 
S. aureus VC40 671 100% 0.0 100% 363/363 
 
Table 30. SAR2536 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2536 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1740 100% 0.0 100% 942/942 
S. aureus RN4282 1663 100% 0.0 99% 932/942 
S. aureus T1 1740 100% 0.0 100% 942/942 
S. aureus COL 1663 100% 0.0 99% 932/942 
S. aureus MSSA476 1663 100% 0.0 99% 932/942 
S. aureus MW2 1685 100% 0.0 99% 932/942 
S. aureus N315 1685 100% 0.0 99% 932/942 
S. aureus Mu50 1685 100% 0.0 99% 932/942 
S. aureus T0131 1663 100% 0.0 99% 932/942 
S. aureus TW20 1663 100% 0.0 99% 932/942 
S. aureus BMB9393 1663 100% 0.0 99% 932/942 
S. aureus LGA251 1657 100% 0.0 98% 927/942 
S. aureus RF122 1646 100% 0.0 98% 927/942 
S. aureus ST398 1657 100% 0.0 98% 927/942 
S. aureus M013 1640 100% 0.0 98% 927/942 
S. aureus M1 1663 100% 0.0 99% 932/942 
S. aureus Mu3 1685 100% 0.0 99% 932/942 
S. aureus str. Newman 1663 100% 0.0 99% 932/942 
S. aureus NCTC8325 1663 100% 0.0 99% 932/942 
S. aureus VC40 1663 100% 0.0 99% 932/942 
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Table 31. SAR2504 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2504 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1441 100% 0.0 100% 780/780 
S. aureus RN4282 1291 100% 0.0 97% 753/780 
S. aureus T1 1441 100% 0.0 100% 780/780 
S. aureus COL 1291 100% 0.0 97% 753/780 
S. aureus MSSA476 1291 100% 0.0 97% 753/780 
S. aureus MW2 1291 100% 0.0 97% 753/780 
S. aureus N315 1303 100% 0.0 97% 755/780 
S. aureus Mu50 1303 100% 0.0 97% 755/780 
S. aureus T0131 1291 100% 0.0 97% 753/780 
S. aureus TW20 1291 100% 0.0 97% 753/780 
S. aureus BMB9393 1291 100% 0.0 97% 753/780 
S. aureus LGA251 1314 100% 0.0 97% 757/780 
S. aureus RF122 1286 100% 0.0 96% 752/780 
S. aureus ST398 1408 100% 0.0 99% 774/780 
S. aureus M013 1291 100% 0.0 97% 753/780 
S. aureus M1 1291 100% 0.0 97% 753/780 
S. aureus Mu3 1303 100% 0.0 97% 753/780 
S. aureus str. Newman 1291 100% 0.0 97% 753/780 
S. aureus NCTC8325 1291 100% 0.0 97% 753/780 
S. aureus VC40 1291 100% 0.0 97% 753/780 
 
Table 32. SAR2499 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2499 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1109 100% 0.0 100% 600/600 
S. aureus RN4282 1075 100% 0.0 99% 594/600 
S. aureus T1 1109 100% 0.0 100% 600/600 
S. aureus COL 1075 100% 0.0 99% 594/600 
S. aureus MSSA476 1070 100% 0.0 99% 593/600 
S. aureus MW2 1070 100% 0.0 99% 593/600 
S. aureus N315 1070 100% 0.0 99% 593/600 
S. aureus Mu50 1070 100% 0.0 99% 593/600 
S. aureus T0131 1075 100% 0.0 99% 594/600 
S. aureus TW20 1075 100% 0.0 99% 594/600 
S. aureus BMB9393 1075 100% 0.0 99% 594/600 
S. aureus LGA251 1075 100% 0.0 99% 594/600 
S. aureus RF122 1092 100% 0.0 99% 597/600 
S. aureus ST398 1064 100% 0.0 99% 592/600 
S. aureus M013 1075 100% 0.0 99% 594/600 
S. aureus M1 1075 100% 0.0 99% 594/600 
S. aureus Mu3 1070 100% 0.0 99% 593/600 
S. aureus str. Newman 1075 100% 0.0 99% 594/600 
S. aureus NCTC8325 1075 100% 0.0 99% 594/600 
S. aureus VC40 1075 100% 0.0 99% 594/600 
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Table 33. SAR2546 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2546 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 843 100% 0.0 100% 456/456 
S. aureus RN4282 826 100% 0.0 99% 453/456 
S. aureus T1 843 100% 0.0 100% 456/456 
S. aureus COL 826 100% 0.0 99% 453/456 
S. aureus MSSA476 837 100% 0.0 99% 455/456 
S. aureus MW2 837 100% 0.0 99% 455/456 
S. aureus N315 821 100% 0.0 99% 452/456 
S. aureus Mu50 821  100% 0.0 99% 452/456 
S. aureus T0131 286 100% 0.0 99% 453/456 
S. aureus TW20 821 100% 0.0 99% 452/456 
S. aureus BMB9393 826 100% 0.0 99% 453/456 
S. aureus LGA251 832 100% 0.0 99% 454/456 
S. aureus RF122 832 100% 0.0 99% 454/456 
S. aureus ST398 837 100% 0.0 99% 455/456 
S. aureus M013 832 100% 0.0 99% 454/456 
S. aureus M1 826 100% 0.0 99% 453/456 
S. aureus Mu3 821 100% 0.0 99% 452/456 
S. aureus str. Newman 826 100% 0.0 99% 453/456 
S. aureus NCTC8325 826 100% 0.0 99% 453/456 
S. aureus VC40 826 100% 0.0 99% 453/456 
 
Table 34. SAR2554 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2554 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2953 100% 0.0 100% 1599/1599 
S. aureus RN4282 2854 100% 0.0 99% 1580/1599 
S. aureus T1 2953 100% 0.0 100% 1599/1599 
S. aureus COL 2854 100% 0.0 99% 1575/1599 
S. aureus MSSA476 2820 100% 0.0 98% 1575/1599 
S. aureus MW2 2820 100% 0.0 98% 1575/1599 
S. aureus N315 2798 100% 0.0 98% 1571/1599 
S. aureus Mu50 2798 100% 0.0 98% 1571/1599 
S. aureus T0131 2854 100% 0.0 99% 1581/1599 
S. aureus TW20 2854 100% 0.0 99% 1581/1599 
S. aureus BMB9393 2854 100% 0.0 99% 1581/1599 
S. aureus LGA251 2870 100% 0.0 99% 1584/1599 
S. aureus RF122 2843 100% 0.0 99% 1579/1599 
S. aureus ST398 2915 100% 0.0 99% 1592/1599 
S. aureus M013 2865 100% 0.0 99% 1583/1599 
S. aureus M1 2854 100% 0.0 99% 1581/1599 
S. aureus Mu3 2798 100% 0.0 98% 1571/1599 
S. aureus str. Newman 2854 100% 0.0 99% 1580/1599 
S. aureus NCTC8325 2845 100% 0.0 99% 1580/1599 
S. aureus VC40 2845 100% 0.0 99% 1580/1599 
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Table 35. SAR0463 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0463 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1557 100% 0.0 100% 843/843 
S. aureus RN4282 1458 100% 0.0 98% 825/843 
S. aureus T1 1552 100% 0.0 99% 842/843 
S. aureus COL 1458 100% 0.0 98% 825/843 
S. aureus MSSA476 1435 100% 0.0 98% 821/843 
S. aureus MW2 1441 100% 0.0 98% 822/843 
S. aureus N315 1452 100% 0.0 98% 824/843 
S. aureus Mu50 1452 100% 0.0 98% 824/843 
S. aureus T0131 1452 100% 0.0 98% 824/843 
S. aureus TW20 1458 100% 0.0 98% 825/843 
S. aureus BMB9393 1458 100% 0.0 98% 825/843 
S. aureus LGA251 1458 100% 0.0 98% 830/843 
S. aureus RF122 1458 100% 0.0 98% 830/843 
S. aureus ST398 1474 100% 0.0 98% 828/843 
S. aureus M013 1480 100% 0.0 98% 829/843 
S. aureus M1 1458 100% 0.0 98% 825/843 
S. aureus Mu3 1452 100% 0.0 98% 824/843 
S. aureus str. Newman 1458 100% 0.0 98% 825/843 
S. aureus NCTC8325 1458 100% 0.0 98% 825/843 
S. aureus VC40 1458 100% 0.0 98% 825/843 
 
Table 36. SAR0444 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0444 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1469 100% 0.0 100% 795/795 
S. aureus RN4282 1208 100% 0.0 94% 749/795 
S. aureus T1 1469 100% 0.0 100% 795/795 
S. aureus COL 1190 100% 0.0 94% 742/790 
S. aureus MSSA476 802 100% 0.0 88% 613/700 
S. aureus MW2 802 100% 0.0 88% 613/700 
S. aureus N315 1164 100% 0.0 94% 735/795 
S. aureus Mu50 1164 100% 0.0 94% 735/795 
S. aureus T0131 1190 100% 0.0 94% 742/790 
S. aureus TW20 1026 100% 0.0 93% 651/698 
S. aureus BMB9393 734 100% 0.0 86% 592/686 
S. aureus LGA251 1120 100% 0.0 93% 723/780 
S. aureus RF122 710 100% 0.0 95% 611/720 
S. aureus ST398 1397 100% 0.0 98% 783/795 
S. aureus M013 771 100% 0.0 86% 623/723 
S. aureus M1 1190 100% 0.0 94% 742/790 
S. aureus Mu3 1164 100% 0.0 94% 735/786 
S. aureus str. Newman 1190 100% 0.0 94% 742/790 
S. aureus NCTC8325 1190 100% 0.0 94% 742/790 
S. aureus VC40 1190 100% 0.0 94% 742/790 
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Table 37. SAR0618 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0618 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1640 100% 0.0 100% 888/888 
S. aureus RN4282 1602 100% 0.0 99% 881/888 
S. aureus T1 1640 100% 0.0 100% 888/888 
S. aureus COL 1596 100% 0.0 99% 880/888 
S. aureus MSSA476 1585 100% 0.0 99% 878/888 
S. aureus MW2 1585 100% 0.0 99% 878/888 
S. aureus N315 1591 100% 0.0 99% 879/888 
S. aureus Mu50 1591 100% 0.0 99% 879/888 
S. aureus T0131 1596 100% 0.0 99% 880/888 
S. aureus TW20 1596 100% 0.0 99% 880/888 
S. aureus BMB9393 1596 100% 0.0 99% 880/888 
S. aureus LGA251 1607 100% 0.0 99% 882/888 
S. aureus RF122 1607 100% 0.0 99% 882/888 
S. aureus ST398 1591 100% 0.0 99% 879/888 
S. aureus M013 1607 100% 0.0 99% 882/888 
S. aureus M1 1591 100% 0.0 99% 879/888 
S. aureus Mu3 1591 100% 0.0 99% 879/888 
S. aureus str. Newman 1596 100% 0.0 99% 880/888 
S. aureus NCTC8325 1596 100% 0.0 99% 880/888 
S. aureus VC40 1596 100% 0.0 99% 880/888 
 
Table 38. SAR0641 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0641 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1718 100% 0.0 100% 930/930 
S. aureus RN4282 1696 100% 0.0 99% 926/930 
S. aureus T1 1718 100% 0.0 100% 930/930 
S. aureus COL 1696 100% 0.0 99% 926/930 
S. aureus MSSA476 1696 100% 0.0 99% 926/930 
S. aureus MW2 1696 100% 0.0 99% 926/930 
S. aureus N315 1690 100% 0.0 99% 925/930 
S. aureus Mu50 1690 100% 0.0 99% 925/930 
S. aureus T0131 1696 100% 0.0 99% 926/930 
S. aureus TW20 1696 100% 0.0 99% 926/930 
S. aureus BMB9393 1696 100% 0.0 99% 926/930 
S. aureus LGA251 1690 100% 0.0 99% 925/930 
S. aureus RF122 1701 100% 0.0 99% 927/930 
S. aureus ST398 1701 100% 0.0 99% 927/930 
S. aureus M013 1701 100% 0.0 99% 927/930 
S. aureus M1 1696 100% 0.0 99% 926/930 
S. aureus Mu3 1690 100% 0.0 99% 925/930 
S. aureus str. Newman 1696 100% 0.0 99% 926/930 
S. aureus NCTC8325 1659 100% 0.0 99% 927/930 
S. aureus VC40 1659 100% 0.0 99% 927/930 
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Table 39. SAR0730 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0730 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 721 100% 0.0 100% 573/573 
S. aureus RN4282 693 100% 0.0 99% 566/573 
S. aureus T1 721 100% 0.0 100% 573/573 
S. aureus COL 660 100% 0.0 97% 566/573 
S. aureus MSSA476 660 100% 0.0 97% 567/573 
S. aureus MW2 654 100% 0.0 97% 567/573 
S. aureus N315 665 100% 0.0 97% 566/573 
S. aureus Mu50 665 100% 0.0 97% 566/573 
S. aureus T0131 660 100% 0.0 97% 566/573 
S. aureus TW20 660 100% 0.0 97% 566/573 
S. aureus BMB9393 660 100% 0.0 97% 566/573 
S. aureus LGA251 521 100% 0.0 91% 567/573 
S. aureus RF122 688 100% 0.0 98% 567/573 
S. aureus ST398 499 100% 0.0 90% 530/573 
S. aureus M013 593 100% 0.0 94% 540/573 
S. aureus M1 660 100% 0.0 97% 566/573 
S. aureus Mu3 665 100% 0.0 97% 566/573 
S. aureus str. Newman 660 100% 0.0 97% 566/573 
S. aureus NCTC8325 660 100% 0.0 97% 566/573 
S. aureus VC40 660 100% 0.0 97% 566/573 
 
Table 40. SAR0390 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0390 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1059 100% 0.0 100% 573/573 
S. aureus RN4282 1020 100% 0.0 99% 566/573 
S. aureus T1 1059 100% 0.0 100% 573/573 
S. aureus COL 1020 100% 0.0 99% 566/573 
S. aureus MSSA476 1026 100% 0.0 99% 567/573 
S. aureus MW2 1020 100% 0.0 99% 567/573 
S. aureus N315 1020 100% 0.0 99% 566/573 
S. aureus Mu50 1020 100% 0.0 99% 566/573 
S. aureus T0131 1020 100% 0.0 99% 566/573 
S. aureus TW20 1020 100% 0.0 99% 566/573 
S. aureus BMB9393 1020 100% 0.0 99% 566/573 
S. aureus LGA251 1026 100% 0.0 99% 567/573 
S. aureus RF122 1014 100% 0.0 99% 566/573 
S. aureus ST398 1020 100% 0.0 99% 566/573 
S. aureus M013 1020 100% 0.0 99% 566/573 
S. aureus M1 1020 100% 0.0 99% 566/573 
S. aureus Mu3 1020 100% 0.0 99% 566/573 
S. aureus str. Newman 1020 100% 0.0 99% 566/573 
S. aureus NCTC8325 1020 100% 0.0 99% 566/573 
S. aureus VC40 1020 100% 0.0 99% 566/573 
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Table 41. SAR0340 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0340 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1580 100% 0.0 100% 855/855 
S. aureus RN4282 1546 100% 0.0 99% 849/855 
S. aureus T1 1574 100% 0.0 99% 854/855 
S. aureus COL 1552 100% 0.0 99% 850/855 
S. aureus MSSA476 1535 100% 0.0 99% 847/855 
S. aureus MW2 1535 100% 0.0 99% 847/855 
S. aureus N315 1557 100% 0.0 99% 851/855 
S. aureus Mu50 1557 100% 0.0 99% 851/855 
S. aureus T0131 1552 100% 0.0 99% 850/855 
S. aureus TW20 1544 100% 0.0 99% 849/855 
S. aureus BMB9393 1552 100% 0.0 99% 850/855 
S. aureus LGA251 1541 100% 0.0 99% 848/855 
S. aureus RF122 1541 100% 0.0 99% 848/855 
S. aureus ST398 1530 100% 0.0 99% 846/855 
S. aureus M013 1546 100% 0.0 99% 849/855 
S. aureus M1 1527 100% 0.0 99% 850/855 
S. aureus Mu3 1527 100% 0.0 99% 851/855 
S. aureus str. Newman 1522 100% 0.0 99% 850/855 
S. aureus NCTC8325 1522 100% 0.0 99% 850/855 
S. aureus VC40 1522 100% 0.0 99% 850/855 
 
Table 42. SAR0216 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0216 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1790 100% 0.0 100% 969/969 
S. aureus RN4282 1690 100% 0.0 98% 951/969 
S. aureus T1 1790 100% 0.0 100% 969/969 
S. aureus COL 1707 100% 0.0 98% 954/969 
S. aureus MSSA476 1701 100% 0.0 98% 953/969 
S. aureus MW2 1701 100% 0.0 98% 953/969 
S. aureus N315 1696 100% 0.0 98% 952/969 
S. aureus Mu50 1696 100% 0.0 98% 952/969 
S. aureus T0131 1784 100% 0.0 99% 968/969 
S. aureus TW20 1790 100% 0.0 100% 969/969 
S. aureus BMB9393 1790 100% 0.0 100% 969/969 
S. aureus LGA251 1724 100% 0.0 99% 957/969 
S. aureus RF122 1685 100% 0.0 98% 950/969 
S. aureus ST398 1735 100% 0.0 99% 959/969 
S. aureus M013 1701 100% 0.0 98% 953/969 
S. aureus M1 1707 100% 0.0 98% 954/969 
S. aureus Mu3 1696 100% 0.0 98% 952/969 
S. aureus str. Newman 1707 100% 0.0 98% 954/969 
S. aureus NCTC8325 1707 100% 0.0 98% 954/969 
S. aureus VC40 1707 100% 0.0 98% 954/969 
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Table 43. SAR0201 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0201 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 3280 100% 0.0 100% 1776/1776 
S. aureus RN4282 3164 100% 0.0 99% 1755/1776 
S. aureus T1 3280 100% 0.0 100% 1776/1776 
S. aureus COL 3169 100% 0.0 99% 1756/1776 
S. aureus MSSA476 3164 100% 0.0 99% 1755/1776 
S. aureus MW2 3164 100% 0.0 99% 1755/1776 
S. aureus N315 3169 100% 0.0 99% 1756/1776 
S. aureus Mu50 3169 100% 0.0 99% 1756/1776 
S. aureus T0131 3280 100% 0.0 100% 1776/1776 
S. aureus TW20 3280 100% 0.0 100% 1776/1776 
S. aureus BMB9393 3275 100% 0.0 99% 1775/1776 
S. aureus LGA251 3208 100% 0.0 99% 1763/1776 
S. aureus RF122 3197 100% 0.0 99% 1761/1776 
S. aureus ST398 3192 100% 0.0 99% 1760/1776 
S. aureus M013 3181 100% 0.0 99% 1758/1776 
S. aureus M1 3169 100% 0.0 99% 1756/1776 
S. aureus Mu3 3169 100% 0.0 99% 1756/1776 
S. aureus str. Newman 3169 100% 0.0 99% 1756/1776 
S. aureus NCTC8325 3169 100% 0.0 99% 1756/1776 
S. aureus VC40 3169 100% 0.0 99% 1756/1776 
 
Table 44. SAR0174 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0174 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1801 100% 0.0 100% 975/975 
S. aureus RN4282 1679 100% 0.0 98% 953/975 
S. aureus T1 1801 100% 0.0 100% 975/975 
S. aureus COL 1674 100% 0.0 98% 952/975 
S. aureus MSSA476 1679 100% 0.0 98% 953/975 
S. aureus MW2 1679 100% 0.0 98% 953/975 
S. aureus N315 1659 100% 0.0 97% 950/975 
S. aureus Mu50 1659 100% 0.0 97% 950/975 
S. aureus T0131 1790 100% 0.0 99% 974/975 
S. aureus TW20 1796 100% 0.0 99% 974/975 
S. aureus BMB9393 1796 100% 0.0 99% 974/975 
S. aureus LGA251 1652 100% 0.0 99% 948/975 
S. aureus RF122 1668 100% 0.0 98% 981/975 
S. aureus ST398 1768 100% 0.0 99% 969/975 
S. aureus M013 1638 100% 0.0 97% 945/975 
S. aureus M1 1674 100% 0.0 98% 952/975 
S. aureus Mu3 1659 100% 0.0 97% 950/975 
S. aureus str. Newman 1674 100% 0.0 98% 952/975 
S. aureus NCTC8325 1674 100% 0.0 98% 952/975 
S. aureus VC40 1674 100% 0.0 98% 952/975 
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Table 45. SAR1495 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1495 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1647 100% 0.0 100% 906/906 
S. aureus RN4282 1647 100% 0.0 100% 906/906 
S. aureus T1 1647 100% 0.0 100% 906/906 
S. aureus COL 846 74% 0.0 99% 524/557 
S. aureus MSSA476 1452 98% 0.0 99% 855/891 
S. aureus MW2 1447 98% 0.0 99% 855/891 
S. aureus N315 1419 100% 0.0 99% 860/906 
S. aureus Mu50 1419 100% 0.0 99% 860/906 
S. aureus T0131 846 74% 0.0 99% 537/572 
S. aureus TW20 486 74% 0.0 99% 524/557 
S. aureus BMB9393 846 74% 0.0 99% 524/557 
S. aureus LGA251 846 74% 0.0 99% 480/497 
S. aureus RF122 863 61% 0.0 99% 527/557 
S. aureus ST398 713 63% 0.0 99% 520/584 
S. aureus M013 1447 98% 0.0 99% 855/891 
S. aureus M1 846 74% 0.0 99% 524/557 
S. aureus Mu3 1419 100% 0.0 99% 860/906 
S. aureus str. Newman 486 74% 0.0 99% 524/557 
S. aureus NCTC8325 846 74% 0.0 99% 524/557 
S. aureus VC40 846 74% 0.0 99% 524/557 
Table 46. SAR0706 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR0706 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 195 100% 0.0 100% 105/105 
S. aureus RN4282 195 100% 0.0 100% 105/105 
S. aureus T1 195 100% 0.0 100% 105/105 
S. aureus COL  
S. aureus MSSA476 191 100% 0.0 99% 101/105 
S. aureus MW2  
S. aureus N315  
S. aureus Mu50  
S. aureus T0131  
S. aureus TW20  
S. aureus BMB9393  
S. aureus LGA251  
S. aureus RF122  
S. aureus ST398  
S. aureus M013  
S. aureus M1  
S. aureus Mu3  
S. aureus str. Newman  
S. aureus NCTC8325  
S. aureus VC40  
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Table 47. SAR1288 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1288 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 660 100% 0.0 100% 357/357 
S. aureus RN4282 649 100% 0.0 100% 357/357 
S. aureus T1 660 100% 0.0 100% 357/357 
S. aureus COL 154 41% 0.0 92% 101/110 
S. aureus MSSA476  
S. aureus MW2  
S. aureus N315  
S. aureus Mu50  
S. aureus T0131 649 100% 0.0 99% 355/357 
S. aureus TW20 649 100% 0.0 99% 355/357 
S. aureus BMB9393 649 100% 0.0 99% 355/357 
S. aureus LGA251  
S. aureus RF122  
S. aureus ST398 649 100% 0.0 99% 355/357 
S. aureus M013  
S. aureus M1 154 41% 0.0 992% 101/110 
S. aureus Mu3  
S. aureus str. Newman  
S. aureus NCTC8325  
S. aureus VC40  
 
Table 48. SAR1558 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1558 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 804 100% 0.0 100% 435/435 
S. aureus RN4282 654 100% 0.0 94% 408/438 
S. aureus T1 654 100% 0.0 94% 408/438 
S. aureus COL  
S. aureus MSSA476 654 100% 0.0 94% 408/438 
S. aureus MW2 793 100% 0.0 99% 433/435 
S. aureus N315  
S. aureus Mu50  
S. aureus T0131  
S. aureus TW20  
S. aureus BMB9393  
S. aureus LGA251  
S. aureus RF122  
S. aureus ST398  
S. aureus M013  
S. aureus M1  
S. aureus Mu3  
S. aureus str. Newman  
S. aureus NCTC8325  
S. aureus VC40  
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Table 49. SAR2496 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR2496 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 2859 100% 0.0 100% 1548/1548 
S. aureus RN4282 2772 100% 0.0 99% 1551/1548 
S. aureus T1 2859 100% 0.0 100% 1548/1548 
S. aureus COL 2772 100% 0.0 99% 1535/1551 
S. aureus MSSA476 2772 100% 0.0 99% 1535/1551 
S. aureus MW2 2787 100% 0.0 99% 1535/1548 
S. aureus N315 2771 100% 0.0 99% 1532/1548 
S. aureus Mu50 2771 100% 0.0 99% 1532/1548 
S. aureus T0131 2772 100% 0.0 99% 1535/1551 
S. aureus TW20 2772 100% 0.0 99% 1535/1551 
S. aureus BMB9393 2772 100% 0.0 99% 1535/1551 
S. aureus LGA251 2782 100% 0.0 99% 1534/1548 
S. aureus RF122 2798 100% 0.0 99% 1537/1548 
S. aureus ST398 2809 100% 0.0 99% 1539/1548 
S. aureus M013 2782 100% 0.0 99% 1534/1548 
S. aureus M1 2772 100% 0.0 99% 1535/1551 
S. aureus Mu3 2771 100% 0.0 99% 1532/1548 
S. aureus str. Newman 2743 100% 0.0 99% 1529/1550 
S. aureus NCTC8325 2772 100% 0.0 99% 1535/1548 
S. aureus VC40 2772 100% 0.0 99% 1535/1548 
Table 50. SAR1831 gene multiple sequence BLAST, pairwise alignment parameters and 
comparisons for S. aureus MRSA252 sequence with another 19 S. aureus strains. 
SAR1831 
Max 
score 
Query 
cover 
E-value 
Similarity 
(%) 
Similarity 
(base pairs) 
S. aureus MRSA252 1563 100% 0.0 100% 846/846 
S. aureus RN4282 1502 100% 0.0 99% 835/846 
S. aureus T1 1563 100% 0.0 100% 846/846 
S. aureus COL  
S. aureus MSSA476  
S. aureus MW2  
S. aureus N315 1502 100% 0.0 99% 835/846 
S. aureus Mu50      
S. aureus T0131 1550 100% 0.0 99% 844/846 
S. aureus TW20 1557 100% 0.0 99% 845/846 
S. aureus BMB9393 1563 100% 0.0 100% 846/846 
S. aureus LGA251  
S. aureus RF122  
S. aureus ST398  
S. aureus M013  
S. aureus M1  
S. aureus Mu3  
S. aureus str. Newman  
S. aureus NCTC8325  
S. aureus VC40  
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Appendix 2. 
 
Figure 1. Cefoxitin disk diffusion plate test showing methicillin-resistance in S. aureus strains 
Test was performed with 30 μg of cefoxitin per disk on 25 ml Iso-Sensitest agar incubation at 35°C for 18-20 h. Zone size was interpreted 
according to the CLSI as follows, susceptible, ≥ 22 mm; and resistant, ≤ 21 mm. 1. S. aureus RN4282: 21mm, 2. S. aureus ACTC8325: 21mm, 
3. S. aureus T1: 25mm, 4. S. aureus MRSA252: 0 mm, 5. S. aureus NCTC12493 (control strain): 10mm. 
